ketamine has been researched along with Depression in 808 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous racemic ketamine is a promising treatment for treatment-resistant depression." | 9.94 | Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis ( Endo, K; Kodama, W; Terao, I; Tsuge, T, 2024) |
| " We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD)." | 9.69 | Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. ( Bandeira, ID; Beanes, G; Caliman-Fontes, AT; Cardoso, TA; Carvalho, LP; Carvalho, MS; Correia-Melo, FS; Echegaray, M; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Machado, P; Magnavita, G; Mello, RP; Paixão, CS; Quarantini, LC; Sampaio, AS; Silva, SS; Vieira, F, 2023) |
| "Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression." | 9.69 | Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. ( Achtyes, E; Ahearn, E; Frye, M; Goes, FS; Greden, J; Lapidos, A; Lopez-Vives, D; Parikh, SV; Senic, I; Sera, CE; Vande Voort, JL; Vest, E, 2023) |
| "This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD." | 9.69 | Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition. ( Brown, PJ; Butters, MA; Ciarleglio, A; Farber, NB; Flint, AJ; Gebara, MA; Karp, JF; Lavretsky, H; Lenze, EJ; Mulsant, BH; Oughli, HA; Reynolds, CF; Roose, SP; Yang, L, 2023) |
| "To evaluate the effects of ketamine treatment on depression and suicidal ideation in treatment resistant depression (TRD) and to determine whether they are influenced by other psychiatric and personality comorbidities." | 9.69 | Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. ( Ahmed, GK; Ali, MA; Elfadl, GMA; Elserogy, YM; Ghada Abdelsalam, K, 2023) |
| "The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation." | 9.69 | A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. ( Bai, YM; Chen, LF; Chen, MH; Li, CT; Li, WC; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD)." | 9.69 | Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression. ( Al-Sharif, NB; Espinoza, RT; Joshi, SH; Khalil, J; McClintock, SM; Narr, KL; Taraku, B; Zavaliangos-Petropulu, A, 2023) |
| "Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD)." | 9.69 | Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. ( Amarneh, D; Averill, LA; Iqbal, S; Lijffijt, M; Mathew, SJ; Murphy, N; O'Brien, B; Swann, A; Tamman, AJF, 2023) |
| "This secondary analysis of a randomized clinical trial examines whether automated self-association training can prolong the antidepressant effect of a single infusion of ketamine beyond 1 month in patients with treatment-resistant depression." | 9.69 | One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. ( Howland, RH; Mathew, SJ; Price, RB; Wallace, ML, 2023) |
| "Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing neuroplasticity." | 9.69 | Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. ( Bell, E; Cruz, N; Degutis, M; Do-Nguyen, K; Griffo, A; Howland, RH; Keller, TA; Kopelman, J; Mathew, SJ; Panny, B; Price, RB; Spotts, C; Wallace, ML, 2023) |
| "Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear." | 9.69 | Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "To examine whether psychological well-being, sleep, and suicidality improved with treatment with intravenous (IV) ketamine for late-life treatment-resistant depression (TRD)." | 9.69 | Change in patient-centered outcomes of psychological well-being, sleep, and suicidality following treatment with intravenous ketamine for late-life treatment-resistant depression. ( Brown, PJ; Butters, MA; Farber, NB; Flint, AJ; Gebara, MA; Karp, JF; Lavretsky, H; Lenze, EJ; Mulsant, BH; Oughli, HA; Reynolds, CF; Roose, SP; Vanderschelden, B, 2023) |
| "Resting state connectivity studies link ketamine's antidepressant effects with normalisation of the brain connectivity changes that are observed in depression." | 9.69 | Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression. ( Burrows, M; Dipasquale, O; Kotoula, V; Mehta, MA; Stringaris, A, 2023) |
| " However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown." | 9.69 | Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8." | 9.69 | Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. ( Bitter, I; Buyze, J; Cebulla, K; Frey, R; Fu, DJ; Godinov, Y; Ito, T; Kambarov, Y; Llorca, PM; Messer, T; Mulhern-Haughey, S; Oliveira-Maia, AJ; Reif, A; Rive, B; von Holt, C; Young, AH, 2023) |
| " This trial will provide efficacy, safety and health economic data on serial ketamine infusions and thus help inform clinical practice on the potential role of this treatment in the management of depression." | 9.69 | Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]). ( Igoe, A; Jelovac, A; Loughran, O; McCaffrey, C; McDonagh, K; McDonogh, S; McLoughlin, DM; Mohamed, E; O'Neill, C; Shackleton, E; Shanahan, E; Terao, M; Whooley, E, 2023) |
| "Pretreatment neurocognitive function may predict the treatment response to low-dose ketamine infusion in patients with treatment-resistant depression (TRD)." | 9.51 | Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2022) |
| "Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major depressive disorder (MDD) and clinically significant suicidal ideation examined changes in factor analysis-derived symptom clusters from standard measures of depression (Hamilton Depression Rating Scale, HDRS; Beck Depression Inventory, BDI) and mood disturbance (Profile of Mood States, POMS), and their relationship to severity of suicidal ideation (Beck Scale for Suicidal Ideation; SSI)." | 9.51 | Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. ( Burke, AK; Grunebaum, MF; Hochschild, A; Keilp, JG; Madden, SP; Mann, JJ, 2022) |
| "The objective of this analysis was to determine if there are sex differences with esketamine for treatment-resistant depression (TRD)." | 9.51 | Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. ( Canuso, CM; Cooper, K; Daly, EJ; Freeman, MP; Jones, RR; Kornstein, SG; Nicholson, S, 2022) |
| " Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI)." | 9.51 | mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. ( Abdallah, CG; Ahn, KH; Averill, CL; Averill, LA; D'Souza, DC; Duman, RS; Fouda, S; Gueorguieva, R; Krystal, JH; Ranganathan, M; Sanacora, G; Sherif, M; Southwick, SM, 2022) |
| "The objective of this study was to determine which symptoms measured by the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) improve in those treated with esketamine nasal spray in combination with oral antidepressant (AD) compared with those treated with placebo plus AD for adult patients with treatment-resistant depression (TRD)." | 9.51 | Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. ( Cooper, K; Drevets, WC; Floden, L; Hudgens, S; Jamieson, C; Popova, V; Singh, J, 2022) |
| "Using data from a randomized, double-blind (DB), placebo-controlled trial of esketamine (ESK) in patients with treatment-resistant depression (TRD), we conducted exploratory analyses." | 9.51 | Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression. ( Kobayashi, H; Ohnishi, T; Wakamatsu, A, 2022) |
| "This study examined magnetoencephalographic (MEG) correlates of suicidal ideation (SI) and suicide attempt history in patients with treatment-resistant major depression (TRD) at baseline and following subanesthetic-dose ketamine infusion." | 9.51 | Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression. ( Ballard, ED; Burton, CR; Gerner, JL; Gilbert, JR; Nugent, AC; Zarate, CA, 2022) |
| "Derive and confirm factor structure of the Montgomery-Åsberg Depression Rating Scale (MADRS) in patients with treatment-resistant depression (TRD) and evaluate how the factors evident at baseline change over 4 weeks of esketamine treatment." | 9.51 | Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. ( Borentain, S; Cabrera, P; Carmody, T; Daly, EJ; DiBernardo, A; Gogate, J; Jamieson, C; Popova, V; Trivedi, M; Wajs, E; Williamson, D, 2022) |
| "This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD)." | 9.51 | Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies. ( Bai, YM; Chen, MH; Cheng, CM; Li, CT; Lin, WC; Su, TP; Tsai, SJ, 2022) |
| "Whether the antidepressant effects of low-dose ketamine infusion and the therapeutic impact of Val66Met brain-derived neurotrophic factor (BDNF) polymorphism vary across different depression symptom domains, namely affective, cognitive, and somatic, remains unclear." | 9.41 | Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD)." | 9.41 | Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. ( Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A, 2021) |
| "A total of 78 patients with medication-resistant depression were allocated to receive two ketamine infusions (n = 30; days 1 and 4), a single ketamine infusion (n = 24; only day 1), or normal saline placebo infusion (n = 24; only day 1)." | 9.41 | Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Although results are still preliminary, ketamine and classical hallucinogens have shown promise in recent years as novel, fast-acting antidepressants, especially for the treatment of unipolar treatment-resistant depression (TRD)." | 9.41 | The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials. ( Baker, G; Dos Santos, RG; Dursun, SM; Hallak, JEC; Rossi, GN, 2023) |
| "Studies have demonstrated the beneficial therapeutic effects of sarcosine, benzoate, and ketamine (including esketamine and arketamine) on depression." | 9.41 | Ketamine, benzoate, and sarcosine for treating depression. ( Cheng, YJ; Lane, HY; Lin, CH, 2023) |
| "While previous systematic reviews of trials evaluating conventional antidepressants highlighted inadequacies and inconsistencies in adverse event (AE) reporting, no evaluation is available on esketamine in resistant depression." | 9.41 | Reporting of harms in clinical trials of esketamine in depression: a systematic review. ( Cestac, P; Jullien, A; Montastruc, F; Taillefer de Laportalière, T; Yrondi, A, 2023) |
| "The following review will explore ketamine's antidepressant and antisuicidal properties in adults, review of what is known about ketamine's safety in children, and summarize the limited information we have on ketamine's role in treating depression and suicidal ideation in adolescents with depression." | 9.41 | Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions. ( Hosanagar, A; Ryan, K, 2023) |
| "Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for depression." | 9.41 | Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. ( Esterlis, I; Girgenti, MJ; Jefferson, S; Kaye, AP; Krystal, JH; Sanacora, G; Wilkinson, ST, 2023) |
| "This study aims to investigate the effect of the pretreatment of S-ketamine on postoperative depression (POD) for breast cancer patients with mild/moderate depression." | 9.41 | Effect of Pretreatment of S-Ketamine On Postoperative Depression for Breast Cancer Patients. ( Li, P; Li, Q; Liu, C; Liu, P; Peng, S; Shi, X; Yan, H; Zhang, Y, 2021) |
| "Dissociative symptoms are common, possibly severe, side effects associated with the use of ketamine and esketamine in depression." | 9.41 | Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. ( Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Magnavita, GM; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza-Marques, B; Telles, M; Vieira, F, 2021) |
| "Post hoc data support efficacy of esketamine plus an oral antidepressant in patients with TRD, regardless of comorbid anxiety." | 9.41 | The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. ( Borentain, S; Daly, EJ; Fedgchin, M; Ionescu, DF; Salvadore, G; Singh, JB; Starr, HL; Thase, ME; Trivedi, MH; Turkoz, I, 2021) |
| "Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression." | 9.34 | Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. ( Araújo-de-Freitas, L; Bandeira, ID; Caliman-Fontes, AT; Cavalcanti, DE; Correia-Melo, FS; Del-Porto, JA; Echegaray, MVF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Loo, C; Magnavita, G; Mello, RP; Nakahira, C; Quarantini, LC; Sampaio, AS; Sarin, LM; Silva, SS; Tuena, MA; Turecki, G; Vieira, F, 2020) |
| "This post hoc study assessed the evidence-base for esketamine nasal spray for management of treatment-resistant depression (TRD) using number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH)." | 9.34 | Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. ( Citrome, L; DiBernardo, A; Singh, J, 2020) |
| "BACKGROUND This study investigated the effects of various doses of S-ketamine on depression and pain management of cervical carcinoma patients with mild/moderate depression." | 9.34 | Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression After Laparoscopic Total Hysterectomy. ( Liu, P; Peng, S; Wang, J; Wang, Y; Xu, F; Xu, X, 2020) |
| "The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine." | 9.34 | A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. ( Albott, CS; Erbes, C; Lim, KO; Shiroma, PR; Thuras, P; Tye, S; Wels, J, 2020) |
| "While the psychiatric benefits of ketamine have been verified through clinical trials, there is limited information about ketamine augmentation in patients with treatment-resistant bipolar depression (TRBPD)." | 9.34 | Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study. ( Chen, C; Ji, F; Jia, F; Jiang, D; Lin, X; Tian, H; Wang, L; Zhou, C; Zhu, J; Zhuo, C, 2020) |
| "This study explores responses to ketamine in patients with treatment-resistant depression (TRD) using a wearable forehead electroencephalography (EEG) device." | 9.30 | Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG. ( , 2019) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 9.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| " Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine." | 9.24 | Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. ( Ameli, R; Ballard, ED; Brutsche, NE; Lally, N; Luckenbaugh, DA; Niciu, MJ; Park, L; Richards, EM; Walls, T; Wills, K; Zarate, CA, 2017) |
| "This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer." | 9.24 | Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. ( Fan, W; Li, G; Liu, Y; Sun, Y; Yang, H; Zhang, J; Zheng, Y, 2017) |
| "Ketamine is an NMDAR antagonist and is proven effective in depression for the rapid and sustained antidepressant response, while rapastinel is an NMDAR positive allosteric modulator, producing antidepressant effects like ketamine with no severe side effects." | 9.22 | Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants. ( Chen, NH; Hu, D; Jiang, H; Liu, LJ; Wang, YT; Wang, ZZ; Zhang, NN; Zhang, Y, 2022) |
| " Ketamine, a racemic mixture of the two enantiomers, (R)-ketamine and (S)-ketamine, is an N-methyl-d-aspartate receptor (NMDAR) antagonist and has been shown to have rapid-acting antidepressant properties in patients with treatment-resistant depression (TRD)." | 9.22 | Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers. ( Antqueviezc, B; Colombo, R; Dalpiaz, G; Ferraz Goularte, J; Paul Géa, L; Ribeiro Rosa, A; Scotton, E; Vasconcelos, MF, 2022) |
| " Ketamine, a N-methyl-d-aspartate glutamate receptor antagonist, and its enantiomer esketamine rapidly reduce depressive symptoms in depressed patients with current suicidal ideation." | 9.22 | Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how? ( Courtet, P; Lengvenyte, A; Olié, E; Strumila, R, 2022) |
| "We conducted a PRISMA-guided review for relevant randomized controlled trials of racemic or esketamine for unipolar or bipolar major depression from database inception through 2021." | 9.22 | Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. ( Bahji, A; Vazquez, GH; Zarate, CA, 2022) |
| " Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019." | 9.22 | Long-term safety of ketamine and esketamine in treatment of depression. ( Krystal, JH; Murphy, E; Nikayin, S; Wilkinson, ST, 2022) |
| "Ketamine is a promising therapeutic option in treatment-resistant depression (TRD)." | 9.22 | Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. ( Alnefeesi, Y; Cao, B; Ceban, F; Chen-Li, D; Di Vincenzo, JD; Gill, H; Ho, RCM; Jawad, MY; Krane, E; Lee, Y; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM, 2022) |
| "Ketamine has demonstrated rapid and significant antidepressant effects in patients with treatment resistant depression (TRD)." | 9.22 | The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review. ( Ceban, F; Di Vincenzo, JD; Ho, C; Lee, Y; Levinta, A; Lui, LMW; Mansur, RB; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM, 2022) |
| "Despite a burgeoning body of literature demonstrating that inflammation is linked to TRD, there is still a lack of comprehensive research on the relationship between proinflammatory biomarkers and ketamine's antidepressant effect on TRD patients." | 9.22 | Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review. ( Gu, J; Sukhram, SD; Yilmaz, G, 2022) |
| "The discovery of the robust antidepressant actions of ketamine is regarded as one of the greatest advancements in depression treatment in the past 60 years." | 9.22 | Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota. ( Hua, H; Huang, C; Liu, C; Liu, H; Wang, Y; Wu, Z; Xu, X; Yang, C, 2022) |
| "This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment-psilocybin and esketamine." | 9.22 | Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. ( Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U, 2022) |
| "Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression." | 9.22 | Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. ( Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Spijker, J; Veraart, JK, 2022) |
| "Esketamine is a promising drug which can induce antidepressant effects in Major Depression Disorder (MDD)." | 9.22 | Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials. ( Chen, G; Li, X; Wang, J; Wang, T; Xu, X; Xu, Z; Yang, S; Zhou, X, 2022) |
| " diclofenac monotherapy in reducing symptoms of mild to moderate depression among patients with chronic pain." | 9.22 | Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. ( Afarideh, M; Agah, E; Akhondzadeh, S; Arbabi, M; Ghajar, A; Jafarinia, M; Noorbala, AA; Saravi, MA; Tafakhori, A, 2016) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 9.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| " We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression." | 9.20 | Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. ( Brallier, JW; Charney, DS; Collins, KA; DeWilde, KE; Goodman, WK; Iacoviello, BM; Iosifescu, DV; Kautz, M; Kim, J; Lapidus, KA; Lener, M; Murrough, JW; Perez, AM; Price, RB; Rodriguez, GJ; Soleimani, L; Stern, JB, 2015) |
| " Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that rapidly reduces suicidal ideation as well as depression and anxiety, but the dynamic between these symptoms is not known." | 9.19 | Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. ( Ameli, R; Ballard, ED; Brutsché, NE; Furey, ML; Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Vande Voort, JL; Zarate, CA, 2014) |
| "In this double-blind, randomized, crossover, placebo-controlled study, 15 subjects with DSM-IV bipolar I or II depression maintained on therapeutic levels of lithium or valproate received a single intravenous infusion of either ketamine hydrochloride (." | 9.16 | Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. ( Brutsche, NE; Cravchik, A; Diazgranados, N; Franco-Chaves, J; Ibrahim, L; Liberty, V; Luckenbaugh, DA; Marquardt, CA; Selter, J; Zarate, CA, 2012) |
| "Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine." | 9.14 | Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. ( Charney, DS; Mathew, SJ; Nock, MK; Price, RB, 2009) |
| "The results suggested that it is possible to improve symptoms of depression earlier by using ketamine anesthesia." | 9.14 | Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. ( Higuchi, T; Nagafusa, Y; Nakai, T; Nishikawa, T; Okamoto, N; Sakamoto, K, 2010) |
| "To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with unipolar major depressive disorder." | 9.12 | Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. ( Barnes, A; Cipriani, A; Cowen, PJ; Dean, RL; Hawton, K; Hollingsworth, S; Hurducas, C; Marquardt, T; McShane, R; Smith, R; Spyridi, S; Turner, EH, 2021) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 9.12 | Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. ( Barnes, A; Cipriani, A; Cowen, PJ; Dean, RL; Geddes, J; Hawton, K; Hurducas, C; Malhi, GS; Marquardt, T; McShane, R; Smith, R; Spyridi, S, 2021) |
| "The aim of this paper is to review current studies on the use of ketamine in the treatment of drug-resistant depression, compare results of various administration methods - intravenous, intranasal or oral, as well as compare its effectiveness with that of other antidepressants." | 9.12 | Ketamine as a Novel Drug for Depression Treatment. ( Bogudzińska, B; Kaczmarek, B; Kowalski, K; Piotrowski, P, 2021) |
| "To review the currently available data on the use of ketamine in the treatment of depression among older adults from randomized controlled studies." | 9.12 | A systematic review of ketamine for the treatment of depression among older adults. ( Bhattacharya, G; Dhar, R; Farheen, SA; Funaro, M; Gupta, A; Patadia, P; Tampi, RR, 2021) |
| "Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression." | 9.12 | Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. ( Bahji, A; Vazquez, GH; Zarate, CA, 2021) |
| "The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported." | 9.12 | The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. ( Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J, 2021) |
| "Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects within hours of administration." | 9.12 | Ketamine for depression. ( Jelen, LA; Stone, JM, 2021) |
| "The approval of intranasal esketamine for treatment-resistant depression marks the next step in our understanding of and ability to treat treatment-resistant depression." | 9.12 | Intranasal esketamine: From origins to future implications in treatment-resistant depression. ( Brula, AQ; Sanders, B, 2021) |
| " Ketamine has emerged as a promising new treatment for treatment resistant depression (TRD)." | 9.12 | The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. ( Cao, B; Di Vincenzo, JD; Gill, H; Ho, R; Lin, K; Lipsitz, O; Lui, LMW; McIntyre, RS; Ng, J; Rodrigues, NB; Rosenblat, JD; Siegel, A; Teopiz, KM, 2021) |
| "Ketamine treatment is capable of significant and rapid symptom improvement in adults with treatment-resistant depression (TRD)." | 9.12 | Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. ( Cao, B; Cha, DS; Gill, H; Ho, R; Lee, Y; Lipsitz, O; Lui, LMW; McIntyre, RS; McMullen, EP; Rodrigues, NB; Rosenblat, JD; Teopiz, KM; Vinberg, M, 2021) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 9.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "In recent years, ketamine and esketamine treatment have demonstrated rapid antidepressant effects in adults with treatment-resistant depression (TRD)." | 9.12 | Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. ( Cao, B; Cha, DS; Gill, H; Ho, RC; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Ng, J; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics nationwide that provide this service." | 9.12 | Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. ( Achtyes, E; Bobo, WV; Coryell, W; Drake, K; Frye, MA; Goddard, A; Goes, F; Greden, JF; Kaplin, A; Lopez, D; Maixner, D; Parikh, SV; Rico, J; Riva-Posse, P; Singh, B; Tarnal, V; Vande Voort, JL; Watson, B, 2021) |
| " Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an intranasal formulation for treatment-resistant depression (TRD) and for rapid reduction of depressive symptomatology, including suicidal ideation in MDD patients at imminent risk for suicide." | 9.05 | An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. ( De Berardis, D; Di Giannantonio, M; Fornaro, M; Fraticelli, S; Kim, YK; Martinotti, G; Orsolini, L; Perna, G; Pompili, M; Serafini, G; Tomasetti, C; Valchera, A; Vellante, F; Volpe, U, 2020) |
| "Ketamine is gaining ground as a potential treating depression because it has a distinct mode of action than typical drugs that influence monoamine neurotransmitters including noradrenaline, dopamine, or serotonin." | 9.05 | Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression. ( Cui, YF; Liu, GL; Lu, C; Zhao, P, 2020) |
| "Ketamine has been shown to be efficacious for the treatment of depression, specifically among individuals who do not respond to first-line treatments." | 9.05 | Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement. ( George, TP; Lowe, DJE; Müller, DJ, 2020) |
| "Ketamine is regaining popularity in the field of anesthesia and beyond." | 9.05 | Ketamine: a versatile tool for anesthesia and analgesia. ( Barrett, W; Buxhoeveden, M; Dhillon, S, 2020) |
| " Studies of oral ketamine for depression, from case series to randomized clinical trials, were eligible." | 9.05 | An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. ( Frye, MA; Joseph, B; Kung, S; Nuñez, NA; Pahwa, M; Prokop, LJ; Schak, KM; Seshadri, A; Singh, B; Vande Voort, JL, 2020) |
| "Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades." | 9.01 | Rodent ketamine depression-related research: Finding patterns in a literature of variability. ( Fitzgerald, PJ; Hale, PJ; Polis, AJ; Watson, BO, 2019) |
| "Ketamine is an anaesthetic and analgesic agent that demonstrates the antidepressive effect in major depression." | 9.01 | Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. ( Cubała, WJ; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| "Clinical evidence is accumulating to support the use of ketamine as a powerful, quick-acting intervention for depression." | 9.01 | Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence. ( Andrade, C, 2019) |
| "Recent research demonstrating that the glutamatergic modulator ketamine has rapid, robust, and sustained antidepressant effects has been a turning point in drug discovery for depression." | 9.01 | The influence of ketamine on drug discovery in depression. ( Acevedo-Diaz, E; Henter, ID; Kadriu, B; Kraus, C; Wasserman, D; Zarate, CA, 2019) |
| " The primary outcome measures were the suicide items from clinician-administered (the Montgomery-Åsberg Depression Rating Scale [MADRS] or the Hamilton Depression Rating Scale [HAM-D]) and self-report scales (the Quick Inventory of Depressive Symptomatology-Self Report [QIDS-SR] or the Beck Depression Inventory [BDI]), obtained for up to 1 week after ketamine administration." | 8.98 | The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. ( Ballard, ED; Bloch, MH; Feder, A; Mathew, SJ; Murrough, JW; Sanacora, G; Sos, P; Wang, G; Wilkinson, ST; Zarate, CA, 2018) |
| "We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression." | 8.95 | Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. ( Curran, V; McShane, R; Morgan, C; Nutt, D; Schlag, A; Singh, I, 2017) |
| "There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression." | 8.93 | Should ketamine be used for the clinical treatment of depression? ( Arunogiri, S; Hope, J; Keks, NA, 2016) |
| "Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal ideation." | 8.93 | Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. ( Mallick, F; McCullumsmith, CB, 2016) |
| "Consistent with clinical research on ketamine as a rapid and effective treatment for depression, ketamine has shown early preliminary evidence of a reduction in depressive symptoms, as well as reducing SI, with minimal short-term side effects." | 8.91 | Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. ( Reinstatler, L; Youssef, NA, 2015) |
| "To assess the effects - and review the acceptability - of ketamine and other glutamate receptor modulators in comparison to placebo (or saline placebo), other pharmacologically active agents, or electroconvulsive therapy (ECT) in alleviating the acute symptoms of depression in people with unipolar major depressive disorder." | 8.91 | Ketamine and other glutamate receptor modulators for depression in adults. ( Amit, BH; Caddy, C; Cipriani, A; Furukawa, TA; Hawton, K; McCloud, TL; McShane, R; Rendell, JM, 2015) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 8.91 | Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. ( Amit, BH; Brett, D; Caddy, C; Cipriani, A; Diamond, PR; Hamadi, L; Hawton, K; Jochim, J; McCloud, TL; McShane, R; Rendell, JM; Shuttleworth, C, 2015) |
| "The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and potent antidepressant effects in treatment-resistant major depressive disorder and bipolar depression." | 8.90 | Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. ( Charney, DS; Henter, ID; Luckenbaugh, DA; Niciu, MJ; Zarate, CA, 2014) |
| "Narrative review of the literature on the efficacy and safety of subanaesthetic doses of ketamine for the treatment of depression." | 8.89 | Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. ( Glue, P; Katalinic, N; Lai, R; Loo, CK; Mitchell, PB; Somogyi, A, 2013) |
| "We found that functional connections between the habenula and the substantia nigra, as well as the ventral tegmental area were negatively correlated with depression scores and elevated after ketamine infusions." | 8.84 | Habenular functional connections are associated with depression state and modulated by ketamine. ( Chen, C; Feng, W; Ning, Y; Wang, M; Xu, Y; Yu, T; Zhang, B, 2024) |
| "The antidepressant effects of ketamine in patients with anxious depression (AD) remain unclear." | 8.31 | Functional connectivity differences in the amygdala are related to the antidepressant efficacy of ketamine in patients with anxious depression. ( Chen, X; Hu, Y; Luo, X; Ning, Y; Wang, M; Yuan, S; Zhang, B; Zhou, Y, 2023) |
| "Ketamine is known for its antinociceptive effect and is also used for treatment-resistant depression." | 8.31 | Intranasal (2R, 6R)-hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice. ( Aleem, M; Goswami, N; Manda, K, 2023) |
| "Most research describing ketamine as a treatment for depression has relied on intravenous dosing." | 8.31 | Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis. ( Cheveldae, I; Halpape, K; Peters, EM; Wanson, A, 2023) |
| "Hippocampal functional connectivity (FC) alterations, which may happen following ketamine treatment, play a key role in major depression remission." | 8.31 | Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression. ( Hu, Z; Lan, X; Li, W; Liu, H; Ning, Y; Wang, C; Ye, Y; You, Z; Zhang, F; Zhou, Y, 2023) |
| "Ketamine may work as an anti-inflammatory agent, and it increases the levels of vascular endothelial growth factor (VEGF) in patients with treatment-resistant depression." | 8.31 | Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression. ( Bai, YM; Chen, MH; Hong, CJ; Kao, CF; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC, 2023) |
| " The sucrose consumption test, forced swim test, open field test, elevated plus maze, and Morris water maze were respectively used to assess anhedonia, behavioral despair, general locomotor activity, anxiety-like behavior and spatial reference memory." | 8.31 | Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress. ( Kingir, E; Sevinc, C; Unal, G, 2023) |
| "Ketamine (KA), commonly used as an anesthetic, is now widely studied as an antidepressant for the treatment of depression." | 8.31 | A Multifunctional Nanocarrier System for Highly Efficient and Targeted Delivery of Ketamine to NMDAR Sites for Improved Treatment of Depression. ( Gao, Q; Ge, J; Li, R; Song, H; Tan, R; Wan, Y; Wang, S; Xu, P; Zhou, L, 2023) |
| "In the study, we examined the effects of ketamine and extremely low-frequency electromagnetic fields (ELF-EMF) on depression-like behavior, learning and memory, expression of GFAP, caspase-3, p53, BDNF, and NMDA receptor in animals subjected to chronic unpredictable stress (CUS)." | 8.31 | Impact of ketamine administration on chronic unpredictable stress-induced rat model of depression during extremely low-frequency electromagnetic field exposure: Behavioral, histological and molecular study. ( Ahmadi-Zeidabadi, M; Amiri, M; Asadi-Shekaari, M; Eftekhar-Vaghefi, SH; Esmaeilpour, K; Salari, M; Solhjou, S, 2023) |
| "Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety." | 8.31 | Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. ( Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A, 2023) |
| "Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder." | 8.31 | Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. ( Gan, Y; Hu, Z; Lan, X; Li, N; Li, W; Liu, H; Ning, Y; Wang, C; Wu, Z; Ye, Y; Zhang, F; Zhou, Y, 2023) |
| " In this article, we report the case of a Canadian patient who was actively requesting Medical Assistance in Dying for severe and prolonged treatment-resistant depression until she experienced remarkable benefits from a course of intravenous ketamine infusions." | 8.31 | Ketamine for depression: a potential role in requests for Medical Aid in Dying? ( Garel, N; Greenway, KT; Looper, K; Naghi, K; Nazon, M; Rej, S; Willis, E, 2023) |
| "This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression." | 8.31 | A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression. ( Lan, XF; Ning, YP; Wang, CY; Zheng, W; Zhou, YL, 2023) |
| "Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality." | 8.31 | Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth. ( Arekapudi, A; Chau, E; Chisamore, N; Danayan, K; Di Vincenzo, JD; Doyle, Z; Fancy, F; Kratiuk, K; Mansur, R; McIntyre, RS; Meshkat, S; Phan, L; Rodrigues, NB; Rosenblat, JD; Tabassum, A, 2023) |
| "Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions." | 8.31 | The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. ( Heifets, BD; Hietamies, TM; Klise, AJ; Levine, SP; McInnes, LA; Qian, JJ; Williams, LM; Worley, MJ, 2023) |
| "Ketamine and its enantiomers are widely researched and increasingly used to treat mental disorders, especially treatment-resistant depression." | 8.31 | Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. ( Breeksema, JJ; Kamphuis, J; Kuin, B; Niemeijer, A; Schoevers, R; van den Brink, W; Veraart, J; Vermetten, E, 2023) |
| "Ketamine is a dissociative anesthetic that has been shown to have antidepressant effects in humans and has been proposed as a potential treatment for mood disorders such as posttraumatic stress disorder and aggression." | 8.31 | A single dose of ketamine enhances early life stress-induced aggression with no effect on fear memory, anxiety-like behavior, or depression-like behavior in mice. ( Aaflaq, S; Bartsch, CJ; Jacobs, JT; Li, Z; Nordman, JC; Qasem, E; Skinner, S; Smith, M; Summa, F; Thompson, R, 2023) |
| " We have previously used the chronic mild stress (CMS) model of depression in male rats to show that CMS induces morphological, functional, and molecular changes in the hippocampus of vulnerable animals, the majority of which were recovered using acute subanesthetic ketamine in just 24 h." | 8.31 | Functional and Molecular Changes in the Prefrontal Cortex of the Chronic Mild Stress Rat Model of Depression and Modulation by Acute Ketamine. ( Barbon, A; Bertoli, M; Bonanno, G; Bonifacino, T; La Via, L; Milanese, M; Mingardi, J; Misztak, P; Musazzi, L; Ndoj, E; Popoli, M; Russo, I; Torazza, C, 2023) |
| " Ketamine, known as an anesthetic, is a new treatment option that can be effective in patients with treatment-resistant depression." | 8.31 | [Consider (es)ketamine for treatment-resistant depression]. ( Kramers, CK; Ruhé, HG; Stuiver, S; van Verseveld, M; van Waarde, JA; Vos, CF, 2023) |
| "We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs)." | 8.31 | Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. ( Dinh-Williams, LL; Garel, N; Greenway, KT; Jutras-Aswad, D; Rej, S; Richard-Devantoy, S; Thibault-Levesque, J; Turecki, G, 2023) |
| "We present three patients off-label treated with intravenous (IV) esketamine for treatment-resistant depression (TRD) of whom two (patients A and B, aged 72 and 77 years, respectively) were admitted to the psychiatric unit with depressive symptoms and one outpatient (patient C, aged 66 years)." | 8.31 | [IV esketamine for patients with a treatment-resistant depression]. ( De Wit, NCJ; Koning, MV; Stuiver, S; Van Verseveld, M; Van Waarde, JA, 2023) |
| "This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD)." | 8.31 | Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? ( Anand, A; Jha, MK; Mathew, SJ, 2023) |
| "Whether a single low-dose ketamine infusion may have rapid antidepressant and antisuicidal effects in patients with treatment-resistant double depression remains unclear." | 8.12 | Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2022) |
| " We report the case of a 57-year-old woman diagnosed with treatment-resistant depression (TRD) and comorbid FMD treated with weekly intranasal administrations of esketamine over a six-month follow-up period." | 8.12 | Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. ( Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G, 2022) |
| "In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of esketamine nasal spray (ESK) in treatment-resistant depression (TRD)-short-term study (TRANSFORM-2) and maintenance study (SUSTAIN-1)-were analyzed to evaluate the relationship between dissociation and antidepressant effects of ESK." | 8.12 | Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. ( Chen, G; Chen, L; Daly, EJ; Drevets, WC; Fedgchin, M; Furey, ML; Lane, R; Li, X; Lim, P; Popova, V; Singh, JB; Zhang, Y, 2022) |
| "Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated." | 8.12 | A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. ( DeBattista, C; Gargeya, RS; Heifets, BD; McInnes, LA; Qian, JJ, 2022) |
| "Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression." | 8.12 | Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. ( Haroutounian, S; Lenze, EJ; Palanca, BJA; Subramanian, S, 2022) |
| "Veterans receiving ketamine treatment ( across both IN-(S)-ketamine and IV-(R,S)-ketamine) showed significant reductions in both the Patient Health Questionnaire-9 (PHQ-9), a self-report scale measuring depression symptoms (rm ANOVA F(14,42) = 12." | 8.12 | Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series. ( Artin, H; Baker, DG; Bentley, S; Bismark, A; De Peralta, S; Lee, EE; Liu, F; Martis, B; Mehaffey, E; Mishra, J; Printz, D; Ramanathan, D; Sojourner, K, 2022) |
| "Esketamine was licensed for use in treatment resistant depression by the European Medicines Agency in December 2019." | 8.12 | Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees. ( Curran, HV; Freeman, TP; Grabski, M; van Laar, M; Waldron, J, 2022) |
| "Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression." | 8.12 | Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. ( Brennan, S; Chokka, P; Katzman, MA; Khullar, A; Klassen, LJ; Swainson, J; Tanguay, RL, 2022) |
| "Ketamine has rapid and robust antidepressant effects in adults with treatment-resistant depression (TRD), while its effects on functional outcomes have not been sufficiently evaluated." | 8.12 | The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Zheng, W; Zhou, Y, 2022) |
| "The approval of ketamine for treatment-resistant depression has created a model for a novel class of rapid-acting glutamatergic antidepressants." | 8.12 | Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics. ( Kadriu, B; Kojic, M; Kraus, C; Saelens, J; Zarate, CA, 2022) |
| "Intranasal esketamine has been recently approved for the treatment of resistant depression." | 8.12 | Intranasal esketamine for depression: Not so special K. ( Rosenman, S, 2022) |
| "Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD)." | 8.12 | Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series. ( Budd, GP; Do, A; Fridfinnson, J; Lam, RW; Rafizadeh, R; Siu, JTP; Tham, JCW, 2022) |
| "One hundred thirty-five Chinese individuals with anxious depression (n = 92) and nonanxious depression (n = 43) received six intravenous infusions of ketamine (0." | 8.12 | Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. ( Gu, LM; Ning, YP; Tan, JQ; Wang, CY; Yang, XH; Zheng, W; Zhou, YL, 2022) |
| " The authors set out to investigate the neurotoxicity of S-ketamine, which possesses anesthetic and antidepressant effects and may cause attention deficit hyperactivity disorder (ADHD)- and depression-like behaviors in offspring mice." | 8.12 | S-ketamine administration in pregnant mice induces ADHD- and depression-like behaviors in offspring mice. ( Bai, Y; Bi, XY; Cao, L; Liu, NN; Xin, Y; Xing, BH; Zhang, DX; Zhang, LM; Zhang, W; Zheng, WC, 2022) |
| "Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019." | 8.12 | Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022) |
| "A short course of repeated ketamine infusions did not impair neurocognitive function in patients with treatment-resistant depression." | 8.12 | Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions. ( Batten, LA; Blier, P; Burhunduli, P; Norris, S; Ortiz, A; Owoeye, O; Phillips, JL; Talbot, J; Van Geel, A; Vasudev, D, 2022) |
| " These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression." | 8.12 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. ( Ballard, ED; Bloomfield-Clagett, B; Fava, M; Greenstein, DK; Grunebaum, MF; Mathew, SJ; Murrough, JW; Phillips, JL; Sanacora, G; Wilkinson, ST; Zarate, CA, 2022) |
| "The aim of this study was to estimate the cost-effectiveness of esketamine nasal spray relative to intravenous ketamine for patients with treatment-resistant depression (TRD) in the US." | 8.12 | Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. ( Brendle, M; Malone, DC; Robison, R, 2022) |
| "Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses." | 8.12 | Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression. ( Bottemanne, H; Claret, A; Fossati, P; Morlaas, O; Schmidt, L; Sharot, T, 2022) |
| "Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics." | 8.12 | Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. ( Ahuja, S; Brendle, M; Moore, C; Robison, R; Smart, L; Thielking, P, 2022) |
| "Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits." | 8.12 | Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. ( Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G, 2022) |
| "Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form." | 8.02 | Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. ( Garakani, A, 2021) |
| "Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine's antidepressant actions in rodent models at sub-therapeutic doses." | 8.02 | Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression. ( Butters, K; Frye, MA; McGee, SL; Morath, BA; Price, JB; Tye, SJ; Van De Wakker, SK; Yates, CG; Yates, NJ, 2021) |
| "Τhe Food and Drug Administration (FDA) approval of the use of S-ketamine in the form of nasal spray for the treatment of treatment-resistant depression, launched a new category of therapeutic agents in psychiatry." | 8.02 | [Ketamine infusion therapy in treatment-resistant depression]. ( Christodoulakis, ΤΕ, 2021) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 8.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| "Lay abstract The US FDA recently approved esketamine nasal spray plus an oral antidepressant (AD) as a new treatment for adults with treatment-resistant depression." | 8.02 | Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression. ( Desai, U; Guglielmo, A; Kirson, NY; Le, HH; Shawi, M; Sheehan, JJ; Spittle, T; Tseng-Tham, J, 2021) |
| "This study suggests the possible clinical utility of resting-state functional magnetic resonance imaging for predicting the antidepressant effects of ketamine in treatment-resistant depression patients and implicated resting-state functional connectivity alterations to determine the trait-like pathophysiology underlying treatment response heterogeneity in treatment-resistant depression." | 8.02 | Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression. ( Abe, T; Hiraki, T; Horikawa, N; Ishibashi, M; Nakamura, T; Tomita, M; Uchimura, N; Uematsu, K, 2021) |
| "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response." | 8.02 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Adults with treatment-resistant depression (TRD) receiving intravenous (IV) ketamine had depressive symptoms measured with the 16-Item Quick Inventory Depressive Symptoms Self-Report (QIDS-SR-16) and MARRRS at baseline and as a repeated measure across an acute course of four infusions." | 8.02 | Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "These findings not only suggest that ketamine represents a viable candidate for the treatment of poststroke depression but also that ketamine's lasting antidepressant effects might be achieved through modulation of NMDAR/CaMKII-induced synaptic plasticity in key brain regions." | 8.02 | Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model. ( Abdoulaye, IA; Cao, XJ; Chibaatar, E; Guo, YJ; Le, K; Wu, SS; Yu, DF, 2021) |
| " Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine." | 8.02 | Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? ( Cha, DS; Gill, H; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD)." | 8.02 | Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. ( Abrishami, A; Arekapudi, AK; Chau, EH; Di Vincenzo, JD; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Szpejda, W; Wong, L, 2021) |
| " The treatments with ketamine, guanosine, and ketamine plus guanosine were effective to counteract corticosterone-induced anxiety-like phenotype, but not disturbances in the hippocampal NLRP3 pathway." | 8.02 | Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway. ( Camargo, A; Dalmagro, AP; Fraga, DB; Kaster, MP; Rodrigues, ALS; Rosa, JM; Zeni, ALB, 2021) |
| "Ketamine and related compounds are emerging as rapidly acting therapies for treatment-resistant depression." | 8.02 | Ketamine treatment for depression: A model of care. ( Alonzo, A; Bayes, A; Dong, V; Kabourakis, M; Loo, C; Martin, D, 2021) |
| "Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects." | 7.96 | Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, LT; Zarate, CA, 2020) |
| "The combination of early clinical response and TRP metabolites at the early stage of repeated ketamine treatment could be considered an eligible predictor for acute- and short-term response for treating depression with suicidal ideation." | 7.96 | Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis. ( Lan, X; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zhang, B; Zhang, C; Zheng, W; Zhou, Y, 2020) |
| " Here we aimed to compare the effects of (R)-norketamine ((R)-NK), (S)-NK, (2R,6R)-HNK, and (2S,6S)-HNK in a mouse model of depression induced by chronic corticosterone (CORT) injection." | 7.96 | (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. ( Ago, Y; Chen, L; Hashimoto, H; Hashimoto, K; Higuchi, M; Kasai, A; Naito, M; Nakagawa, S; Nakazawa, T; Seiriki, K; Tanabe, W; Tsukada, S; Yamaguchi, T; Yokoyama, R, 2020) |
| "The present study evaluated the effects of ketamine in rats with the comorbidity of CPSP and depression." | 7.96 | Ketamine relieves depression-like behaviors induced by chronic postsurgical pain in rats through anti-inflammatory, anti-oxidant effects and regulating BDNF expression. ( Liu, Y; Ma, P; Ma, T; Song, Y; Yang, Y; Zhang, H; Zhang, X; Zhao, W; Zhao, Y, 2020) |
| "To investigate the effects of adjunct ketamine treatment on chronic treatment-resistant schizophrenia patients with treatment-resistant depressive symptoms (CTRS-TRD patients), including alterations in brain function." | 7.96 | Adjunct ketamine treatment of depression in treatment-resistant schizophrenia patients is unsatisfactory in pilot and secondary follow-up studies. ( Bian, H; Chen, C; Lin, X; Liu, S; Tian, H; Zhuo, C, 2020) |
| " Ketamine can quickly relieve depression, and its subcutaneous administration appears to be as effective as and probably safer than its standard intravenous administration." | 7.96 | Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: A case report. ( Barbosa, MG; Delfino, RS; Jackowski, AP; Sarin, LM, 2020) |
| "This study aimed to estimate the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant, for patients in the United States with treatment-resistant depression." | 7.96 | Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. ( Ross, EL; Soeteman, DI, 2020) |
| " Considering that ketamine has significant knock-on effects, this study investigated the effects of a single coadministration with subthreshold doses of ketamine plus guanosine in a corticosterone (CORT)-induced animal model of depression and the role of anti-inflammatory and antioxidant pathways." | 7.96 | Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-κB/IDO-1 signaling. ( B Zeni, AL; Camargo, A; Dalmagro, AP; M Rosa, J; P Kaster, M; S Rodrigues, AL; Tasca, CI, 2020) |
| "The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently characterized." | 7.96 | The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. ( Abrishami, A; Arekapudi, AK; Brietzke, E; Carvalho, IP; Chau, EH; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Senyk, O; Siegel, A; Subramaniapillai, M; Szpejda, W, 2020) |
| "Subanesthetic ketamine is found to induce fast-acting and pronounced antidepressant effects, even in treatment resistant depression (TRD)." | 7.96 | Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. ( Congdon, E; Espinoza, R; Joshi, SH; Kubicki, A; Loureiro, JR; Narr, KL; Sahib, AK; Vasavada, MM; Wade, B; Woods, RP, 2020) |
| "Ketamine has been clinically proven to ameliorate depression, including treatment-resistant depression." | 7.96 | Immobility-reducing Effects of Ketamine during the Forced Swim Test on 5-HT1A Receptor Activity in the Medial Prefrontal Cortex in an Intractable Depression Model. ( Kitamura, Y; Sendo, T; Takahashi, K; Ushio, S, 2020) |
| "In CFA-treated mice that exhibited pain behavior and depression-like behavior, ketamine reversed depression-like behavior." | 7.96 | Subanesthetic Dose of Ketamine Improved CFA-induced Inflammatory Pain and Depression-like Behaviors Via Caveolin-1 in Mice. ( Han, R; Han, S; Li, J; Peng, Y; Sun, W; Wang, J; Zhao, Q; Zhou, Y, 2020) |
| " There is a rising promise in a N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, which may be used in the treatment of resistant depression." | 7.91 | Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. ( Cubała, WJ; Małyszko, A; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| "In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults." | 7.91 | Esketamine for treatment resistant depression: a trick of smoke and mirrors? ( Barbui, C; Gastaldon, C; Ostuzzi, G; Papola, D, 2019) |
| "Our findings suggest that skeletal muscular glycine contributes to the antidepressant effects of ketamine in inflammation." | 7.91 | Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression. ( Hua, D; Hua, F; Huang, N; Jiang, R; Li, S; Luo, A; Wang, Y; Wu, Y; Yang, C; Yang, L; Yu, F; Zhan, G; Zhu, B, 2019) |
| "The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication." | 7.88 | Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions. ( Dunlop, BW; Edwards, JA; Galendez, GC; Garlow, SJ; Job, GP; McDonald, WM; Reiff, CM; Riva-Posse, P; Saah, TC, 2018) |
| "Rapid anti-suicidal and antidepressant effects of ketamine have repeatedly been confirmed in unipolar and bipolar depression." | 7.88 | Rapid antidepressant effect of S-ketamine in schizophrenia. ( Bartova, L; Dold, M; Kasper, S; Milenkovic, I; Papageorgiou, K; Weidenauer, A; Willeit, M; Winkler, D, 2018) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 7.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "Chronic ketamine use leads to cognitive and affective deficits including depression." | 7.85 | Depression in chronic ketamine users: Sex differences and neural bases. ( Chen, CM; Duann, JR; Hung, CC; Lee, TS; Li, CR; Lin, CP; Zhang, S, 2017) |
| "Effects of a single bilateral infusion of R-enantiomer of ketamine in rat brain regions of learned helplessness model of depression were examined." | 7.85 | Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. ( Hashimoto, K; Shirayama, Y, 2017) |
| "The acute antidepressant effects of ketamine provide hope for the development of a fast acting approach to treat depression but the consequences of chronic treatment with ketamine are still unclear." | 7.85 | Lack of effect of chronic ketamine administration on depression-like behavior and frontal cortex autophagy in female and male ICR mice. ( Agam, G; Anderson, GW; Einat, H; Kara, NZ; Zitron, N, 2017) |
| "The aim of the present study was to investigate the effects of ketamine, imipramine, and ketamine plus imipramine on chronic depression-like behaviors of Wistar Kyoto (WKY) rats and underlying mechanism." | 7.83 | [Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats]. ( Jin, XJ; Li, QQ; Peng, LC; Ye, K, 2016) |
| "The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression." | 7.83 | Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. ( Chen, QX; Han, M; Hashimoto, K; Ma, M; Ren, Q; Yang, B; Yang, C; Yao, W; Zhang, JC, 2016) |
| "In the present article, we report on the case of a 23-year-old woman with a history of treatment-resistant depression who achieved significant symptom improvement with a novel treatment consisting of ketamine, a dissociative anesthetic, and external neuromodulation with transcranial magnetic stimulation (TMS)." | 7.81 | Combination therapy utilizing ketamine and transcranial magnetic stimulation for treatment-resistant depression: a case report. ( Best, SR; Griffin, B, 2015) |
| "We investigated whether the nitric oxide (NO) precursor, L-arginine, can prevent the antidepressant-like action of the fast-acting antidepressant, ketamine, in a genetic rat model of depression, and/or induce changes in the glutamate (Glu)/N-methyl-D-aspartate receptor (NMDAR)/NO/cyclic guanosine monophosphate (cGMP) signalling pathway." | 7.81 | Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression. ( Joca, S; Liebenberg, N; Wegener, G, 2015) |
| "Studies have suggested that ketamine, a nonselective NMDA receptor antagonist, could be a new drug in the treatment of major depression, but the way ketamine presents such effects remains to be elucidated." | 7.81 | Ketamine treatment partly reverses alterations in brain derived- neurotrophic factor, oxidative stress and energy metabolism parameters induced by an animal model of depression. ( Abelaira, HM; Carlessi, AS; da Luz, JR; dos Santos, MA; Jeremias, GC; Matias, BI; Morais, MO; Nacif, MP; Quevedo, J; Réus, GZ; Scaini, G; Steckert, AV; Streck, EL; Tomaz, DB, 2015) |
| "We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression." | 7.80 | Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. ( Belujon, P; Grace, AA, 2014) |
| "The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid antidepressant effects in treatment-resistant depression (TRD)." | 7.80 | Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. ( Albott, CS; Johns, B; Lim, KO; Shiroma, PR; Thuras, P; Wels, J, 2014) |
| "Genetically modified mice shed new light on how ketamine can target NMDA receptors in the brain to reduce the symptoms of depression." | 7.80 | How ketamine helps to overcome depression. ( Huynh, TN; Klann, E, 2014) |
| "The authors examined whether the spared nerve injury model of neuropathic pain induces depressive behavior in rats, using sucrose preference test and forced swim test, and tested whether a subanesthetic dose of ketamine treats spared nerve injury-induced depression." | 7.77 | A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. ( Blanck, TJ; Eberle, SE; Goffer, Y; Shamir, DB; Tukey, DS; Wang, J; Xu, D; Ziff, EB; Zou, AH, 2011) |
| "For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach." | 7.30 | Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series. ( Desbeaumes Jodoin, V; Elkrief, L; Garel, N; Lespérance, P; Longpré-Poirier, C; Miron, JP; Payette, O; Richard, M, 2023) |
| "Forty-eight patients with treatment-resistant depression and strong suicidal ideation (TRD-SI) were randomly assigned to a single infusion of 0." | 7.30 | Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " Treatment-emergent adverse events (TEAEs) reported in younger versus older patients, respectively, were: induction, 86." | 7.11 | Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. ( Daly, EJ; Drevets, WC; Hough, D; Jamieson, C; Lane, R; Lim, P; Manji, H; Ochs-Ross, R; Sanacora, G; Singh, JB; Steffens, DC; Wajs, E; Zhang, Y, 2022) |
| " Demographics, adverse events, and patient-reported dissociation were also analyzed." | 7.11 | At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. ( Akiki, TJ; Arden, K; Gazzaley, A; Hull, TD; Klotz, M; Madan, A; Malgaroli, M; Paleos, C; Swain, J; Vando, L, 2022) |
| "Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain." | 7.01 | Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine. ( Chao, Z; Lan, X; Li, H; Ning, Y; Wang, C; Zhou, Y, 2021) |
| "SC ketamine was safe and well tolerated, and most adverse events were mild and transient." | 7.01 | Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities. ( Cunha, UGV; Duarte, DB; Hara, C; Rocha, FL, 2023) |
| "Depression is a well-known serious mental illness, and the onset of treatment using traditional antidepressants is frequently delayed by several weeks." | 7.01 | Ketamine and its metabolites: Potential as novel treatments for depression. ( Hashimoto, K; Yao, Y; Zhang, K, 2023) |
| " Secondary outcomes included postoperative visual analog scale (VAS) scores for pain and adverse effects associated with ketamine." | 7.01 | Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies. ( Gu, HW; Guo, J; Hashimoto, K; Qiu, D; Wang, XM; Yang, JJ; Zhang, GF, 2023) |
| "Norketamine concentration was not associated with antidepressant response." | 6.94 | Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. ( Adeojo, L; Farmer, CA; George, J; Gilbert, JR; Gould, TD; Kadriu, B; Lovett, J; Moaddel, R; Nugent, AC; Park, LT; Yuan, P; Zarate, CA, 2020) |
| " Finally, continuing to monitor research subjects and patients long-term for the emergence of adverse effects on cognition or other organ systems is critical." | 6.82 | Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. ( Kritzer, MD; Masand, PS; Pae, CU, 2022) |
| "Ketamine is a fast-acting anesthetic with hypnotic properties." | 6.82 | Ketamine for resistant depression: a scoping review. ( Andrés, VC; Angel, RO; Angela, A; David, C; Eduardo, TQ; Estefania, C; Juan, G; Juan, P; Mateo, L; Melanie, LZ; Natalia, RS; Valentina, PF, 2022) |
| "Depression is a common psychiatric symptom in numerous neurological disorders." | 6.82 | (R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression. ( Hashimoto, K; Wang, X; Yang, J, 2022) |
| "Depression is disabling and highly prevalent." | 6.82 | International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. ( Abdallah, CG; Ballard, ED; Baumeister, A; Blier, P; Charney, DS; Chen, MH; Deakin, W; Fava, M; Feder, A; Gallagher, B; Grunebaum, MF; Hock, R; Kissel, N; Lundberg, J; Mann, JJ; Mathew, SJ; McLoughlin, DM; McMillan, R; Murrough, JW; Muthukumaraswamy, S; Papakostas, G; Phillips, JL; Price, RB; Rohac, R; Shiroma, P; Šóš, P; Su, TP; Sumner, R; Tiger, M; Wallace, ML; Wilkinson, ST; Woody, ML; Zarate, CA, 2022) |
| "The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas." | 6.82 | BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression. ( Carboni, E; Carta, AR, 2022) |
| "Ketamine is a novel rapid-acting antidepressant with neuroplastic potential." | 6.82 | The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine. ( Cubała, WJ; Wilkowska, A, 2022) |
| "Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with demonstrated antidepressant effects in the adult population, however, the efficacy and safety of ketamine for the treatment of pediatric depression remains poorly understood." | 6.82 | Ketamine use in pediatric depression: A systematic review. ( Cao, B; Ceban, F; Chisamore, N; Danayan, K; Ho, RC; McIntyre, RS; Meshkat, S; Rhee, TG; Rosenblat, JD; Vincenzo, JDD, 2022) |
| "Psychotic depression is a subtype of major depressive disorder characterized by mood congruent hallucinations and/or delusions." | 6.72 | Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. ( Cao, B; Cha, DS; Di Vincenzo, JD; Gill, H; Ho, RC; Le, TT; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Ketamine has rapid antidepressant effects, which are hypothesised to occur via increases in glutamate, with sequelae including increased neuroplasticity, neurogenesis and synaptogenesis." | 6.72 | Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review. ( Himmerich, H; Juruena, MF; Kan, C; Keeler, JL; Treasure, J, 2021) |
| "Ketamine has demonstrated efficacy as a rapid-onset intervention for the treatment of depression." | 6.72 | The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. ( El-Halabi, S; Gill, B; Gill, H; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD, 2021) |
| "One third among them will suffer from treatment resistant depression (TRD) which does not respond to two accepted treatment protocols." | 6.72 | [ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT]. ( Marom, A; Rosca, P, 2021) |
| "Nasal esketamine spray produces the adverse effects of dizziness, vertigo, and blurred vision severe enough to cause discontinuation in 4% of patients; it also can produce transient elevation of blood pressure (SOR: A, meta-analyses)." | 6.72 | Is ketamine effective and safe for treatment-resistant depression? ( Jenkinson, M; Kelsberg, G; Linn, S; Neher, JO; Safranek, S; Zorn, A, 2021) |
| "Ketamine is a racemic mixture comprised of two enantiomers (R)-ketamine and (S)-ketamine and acts as an NMDA receptor antagonist." | 6.66 | Ketamine for depression clinical issues. ( Iqbal, SZ; Mathew, SJ, 2020) |
| "Ketamine is an anaesthetic medication that acts as an antagonist of the NMDA receptor and has antidepressant potential." | 6.61 | Efficacy of Ketamine in bipolar depression: focus on anhedonia. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, Ł; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczk, A, 2019) |
| "Ketamine was studied versus placebo, versus other comparators and as an anesthetic adjuvant before electroconvulsive therapy." | 6.61 | Ketamine and depression: a narrative review. ( Corriger, A; Pickering, G, 2019) |
| "Depression is a worldwide illness with a significant impact on both family and society." | 6.61 | Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect. ( Cui, W; Hong, W; Li, MD; Liu, Z; Ning, Y; Wang, J, 2019) |
| " In case reports, case series, standard operating practice in ketamine facilities, and randomized controlled trials, oral ketamine has been administered through weight-based dosing and as fixed doses, and the dosing strategy has been one-size-fits-all or individualized through a dose discovery process." | 6.61 | Oral Ketamine for Depression, 2: Practical Considerations. ( Andrade, C, 2019) |
| "Ketamine is an N-methyl d-aspartate (NMDA) receptor antagonist used for induction and maintenance of general anaesthesia but paradoxically its euphoric effects lead to its classification under drugs of abuse." | 6.52 | Ketamine and suicidal ideation in depression: Jumping the gun? ( Dawe, GS; Fam, J; Rajkumar, R; Yeo, EY, 2015) |
| "To date, 163 patients, primarily with treatment-resistant depression, have participated in case studies, open-label investigations, or controlled trials." | 6.48 | Ketamine for depression: where do we go from here? ( Aan Het Rot, M; Charney, DS; Mathew, SJ; Zarate, CA, 2012) |
| "Intravenous racemic ketamine is a promising treatment for treatment-resistant depression." | 5.94 | Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis ( Endo, K; Kodama, W; Terao, I; Tsuge, T, 2024) |
| "Esketamine and ketamine have been shown to decrease inflammation in numerous ways principally through reducing pro-inflammatory cytokines (e." | 5.91 | The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation? ( Cook, J; Halaris, A, 2023) |
| "Ketamine has emerged recently as a rapidly acting antidepressant with high efficacy in TRD." | 5.91 | Ketamine supresses REM sleep and markedly increases EEG gamma oscillations in the Wistar Kyoto rat model of treatment-resistant depression. ( de Lannoy, I; Duxon, M; Giggins, L; Kantor, S; Lanigan, M; Lione, L; Magomedova, L; Upton, N, 2023) |
| " While ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits a rapid antidepressant action in the central never system (CNS), the potential addiction and psychotomimetic adverse effects of ketamine limit its chronic use in clinical practice." | 5.91 | The synergistic mechanism of action of Dajianzhong decoction in conjunction with ketamine in the treatment of depression. ( Cai, J; Fogaça, MV; Li, C; Liu, H; Yuan, H; Zhang, J; Zhang, YW, 2023) |
| "Major depressive disorder is frequently characterized by disinhibition of rapid eye movement (REM) sleep and disruption of non-REM (NREM) sleep." | 5.91 | (S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats. ( Bagdy, G; Koncz, S; Papp, N; Pothorszki, D, 2023) |
| "(S)-ketamine has been approved as a rapid-acting antidepressant drug (RAAD)." | 5.72 | The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice. ( Pałucha-Poniewiera, A; Rafało-Ulińska, A, 2022) |
| "Ketamine was also efficacious in decreasing the level of inflammation with an evident reduction in microglial activation and pro-inflammatory cytokines in the studied regions, following CUMS exposure." | 5.72 | Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression. ( Akinluyi, ET; Anyanwu, CC; Edem, EE; Enye, LA; Fafure, AA; Ishola, AO; Nebo, KE, 2022) |
| "Ketamine treatment decreases depressive symptoms within hours, but the mechanisms mediating these rapid antidepressant effects are unclear." | 5.72 | Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice. ( Kessler, JA; McGuire, TL; Peng, CY; Rawat, R; Tunc-Ozcan, E, 2022) |
| "Depression is a serious physical and mental disease, with major depressive disorder (MDD) being a hard-to-treat, life-threatening form of the condition." | 5.72 | Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic. ( Gu, T; Jiang, G; Liu, Q; Liu, S; Wang, Y; Yin, A; Zhang, L, 2022) |
| "Ketamine was generally well tolerated, and we observed improvements in functional impairment, anhedonia, and psychiatric symptoms, with no increases in manic symptoms." | 5.72 | Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study. ( Kang, MJY; Vazquez, GH, 2022) |
| " We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD)." | 5.69 | Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. ( Bandeira, ID; Beanes, G; Caliman-Fontes, AT; Cardoso, TA; Carvalho, LP; Carvalho, MS; Correia-Melo, FS; Echegaray, M; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Machado, P; Magnavita, G; Mello, RP; Paixão, CS; Quarantini, LC; Sampaio, AS; Silva, SS; Vieira, F, 2023) |
| "Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression." | 5.69 | Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. ( Achtyes, E; Ahearn, E; Frye, M; Goes, FS; Greden, J; Lapidos, A; Lopez-Vives, D; Parikh, SV; Senic, I; Sera, CE; Vande Voort, JL; Vest, E, 2023) |
| "To evaluate the effects of ketamine treatment on depression and suicidal ideation in treatment resistant depression (TRD) and to determine whether they are influenced by other psychiatric and personality comorbidities." | 5.69 | Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. ( Ahmed, GK; Ali, MA; Elfadl, GMA; Elserogy, YM; Ghada Abdelsalam, K, 2023) |
| "The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation." | 5.69 | A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. ( Bai, YM; Chen, LF; Chen, MH; Li, CT; Li, WC; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD)." | 5.69 | Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression. ( Al-Sharif, NB; Espinoza, RT; Joshi, SH; Khalil, J; McClintock, SM; Narr, KL; Taraku, B; Zavaliangos-Petropulu, A, 2023) |
| "Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD)." | 5.69 | Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. ( Amarneh, D; Averill, LA; Iqbal, S; Lijffijt, M; Mathew, SJ; Murphy, N; O'Brien, B; Swann, A; Tamman, AJF, 2023) |
| "Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear." | 5.69 | Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "To examine whether psychological well-being, sleep, and suicidality improved with treatment with intravenous (IV) ketamine for late-life treatment-resistant depression (TRD)." | 5.69 | Change in patient-centered outcomes of psychological well-being, sleep, and suicidality following treatment with intravenous ketamine for late-life treatment-resistant depression. ( Brown, PJ; Butters, MA; Farber, NB; Flint, AJ; Gebara, MA; Karp, JF; Lavretsky, H; Lenze, EJ; Mulsant, BH; Oughli, HA; Reynolds, CF; Roose, SP; Vanderschelden, B, 2023) |
| " However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown." | 5.69 | Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8." | 5.69 | Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. ( Bitter, I; Buyze, J; Cebulla, K; Frey, R; Fu, DJ; Godinov, Y; Ito, T; Kambarov, Y; Llorca, PM; Messer, T; Mulhern-Haughey, S; Oliveira-Maia, AJ; Reif, A; Rive, B; von Holt, C; Young, AH, 2023) |
| " This trial will provide efficacy, safety and health economic data on serial ketamine infusions and thus help inform clinical practice on the potential role of this treatment in the management of depression." | 5.69 | Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]). ( Igoe, A; Jelovac, A; Loughran, O; McCaffrey, C; McDonagh, K; McDonogh, S; McLoughlin, DM; Mohamed, E; O'Neill, C; Shackleton, E; Shanahan, E; Terao, M; Whooley, E, 2023) |
| "Ketamine has been demonstrated to be a rapid-onset and long-lasting antidepressant, but its underlying molecular mechanisms remain unclear." | 5.62 | miR-98-5p plays a critical role in depression and antidepressant effect of ketamine. ( Chen, G; Huang, C; Liu, C; Wang, D; Wang, Y; Wu, Z; Xu, J; Yang, C; Yang, L; Zhou, L; Zhu, B, 2021) |
| "Ketamine has been shown to provide rapid and significant efficacy in treating patients with TRD." | 5.62 | Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. ( Di Vincenzo, JD; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, R; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Patients with major depressive disorder (MDD) exhibit impaired control of cognitive and emotional systems, including deficient response selection and inhibition." | 5.62 | Ketamine's modulation of cerebro-cerebellar circuitry during response inhibition in major depression. ( Congdon, E; Espinoza, R; Hellemann, G; Joshi, S; Kubicki, A; Leaver, A; Loureiro, JRA; Narr, KL; Sahib, AK; Vasavada, M; Wade, B; Woods, RP, 2021) |
| "Ketamine use has become of increasing concern because it has spread in many parts of the world during the past few years." | 5.62 | Gender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users. ( Hsu, CY; Wang, PW; Wu, HC; Yang, YY; Yen, CF, 2021) |
| "Esketamine has recently emerged as a new treatment for TRD due to its rapid antidepressant effects." | 5.62 | Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression. ( Asellus, P; Degerlund Maldi, K; Myléus, A; Norström, F, 2021) |
| "Ketamine is a highly effective antidepressant for patients with treatment-resistant major depressive disorder (MDD)." | 5.62 | Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression. ( Congdon, E; Espinoza, RT; Hellemann, G; Kubicki, A; Leaver, AM; Loureiro, J; Narr, KL; Sahib, A; Vasavada, MM; Wade, B, 2021) |
| "Ketamine has demonstrated rapid and robust efficacy in adults with TRD." | 5.62 | Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Esketamine nasal spray is a novel, fast-acting agent that provides an additional treatment option for patients with TRD who have previously failed several therapies." | 5.62 | Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. ( Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH, 2021) |
| "Chronic neuropathic pain can modulate DNA methylation in target genes related to neuroplasticity and mood regulation, which was induced by DNA methyltransferases (DNMTs)." | 5.62 | Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: Reversal by ketamine. ( He, X; Ji, MH; Liu, R; Shen, JC; Wang, RZ; Wu, XM; Yin, XY; Zhou, F, 2021) |
| "Ketamine was associated with transient treatment-emergent hypertension." | 5.62 | Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. ( Cao, B; Cha, DS; Di Vincenzo, JD; Flint, AJ; Greenberg, D; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| " Prospective studies are needed to determine which dosing strategy would be the most beneficial for hospice patients." | 5.62 | Single Subcutaneous Ketamine Dose Followed by Oral Ketamine for Depression Symptoms in Hospice Patients: A Case Series. ( Grant, PC; Hansen, E; Kerr, CW; Latuga, NM; Levy, K; Luczkiewicz, DL, 2021) |
| "About 16% of the world's population has major depressive disorder." | 5.56 | Low-Dose Ketamine Improves LPS-Induced Depression-like Behavior in Rats by Activating Cholinergic Anti-inflammatory Pathways. ( Chang, D; Du, X; Gao, L; Lian, H; Liu, X; Zhang, X; Zhao, J, 2020) |
| "Co-existing chronic pain and depression pose a serious socio-economic burden and result in disability affecting millions of individuals, which urges the development of treatment strategies targeting this comorbidity." | 5.56 | Ketamine induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway. ( Ayazgök, B; Becker, LJ; Humo, M; Rantamäki, T; Waltisperger, E; Yalcin, I, 2020) |
| "Ketamine has rapid-acting antidepressant properties but also potentially concerning transient dissociative side effects (SEs)." | 5.56 | Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, L; Zarate, CA, 2020) |
| "Pretreatment neurocognitive function may predict the treatment response to low-dose ketamine infusion in patients with treatment-resistant depression (TRD)." | 5.51 | Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2022) |
| "Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major depressive disorder (MDD) and clinically significant suicidal ideation examined changes in factor analysis-derived symptom clusters from standard measures of depression (Hamilton Depression Rating Scale, HDRS; Beck Depression Inventory, BDI) and mood disturbance (Profile of Mood States, POMS), and their relationship to severity of suicidal ideation (Beck Scale for Suicidal Ideation; SSI)." | 5.51 | Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. ( Burke, AK; Grunebaum, MF; Hochschild, A; Keilp, JG; Madden, SP; Mann, JJ, 2022) |
| "The objective of this analysis was to determine if there are sex differences with esketamine for treatment-resistant depression (TRD)." | 5.51 | Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. ( Canuso, CM; Cooper, K; Daly, EJ; Freeman, MP; Jones, RR; Kornstein, SG; Nicholson, S, 2022) |
| " Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI)." | 5.51 | mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. ( Abdallah, CG; Ahn, KH; Averill, CL; Averill, LA; D'Souza, DC; Duman, RS; Fouda, S; Gueorguieva, R; Krystal, JH; Ranganathan, M; Sanacora, G; Sherif, M; Southwick, SM, 2022) |
| "Using data from a randomized, double-blind (DB), placebo-controlled trial of esketamine (ESK) in patients with treatment-resistant depression (TRD), we conducted exploratory analyses." | 5.51 | Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression. ( Kobayashi, H; Ohnishi, T; Wakamatsu, A, 2022) |
| "This study examined magnetoencephalographic (MEG) correlates of suicidal ideation (SI) and suicide attempt history in patients with treatment-resistant major depression (TRD) at baseline and following subanesthetic-dose ketamine infusion." | 5.51 | Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression. ( Ballard, ED; Burton, CR; Gerner, JL; Gilbert, JR; Nugent, AC; Zarate, CA, 2022) |
| "Derive and confirm factor structure of the Montgomery-Åsberg Depression Rating Scale (MADRS) in patients with treatment-resistant depression (TRD) and evaluate how the factors evident at baseline change over 4 weeks of esketamine treatment." | 5.51 | Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. ( Borentain, S; Cabrera, P; Carmody, T; Daly, EJ; DiBernardo, A; Gogate, J; Jamieson, C; Popova, V; Trivedi, M; Wajs, E; Williamson, D, 2022) |
| "This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD)." | 5.51 | Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies. ( Bai, YM; Chen, MH; Cheng, CM; Li, CT; Lin, WC; Su, TP; Tsai, SJ, 2022) |
| "Major depression is one of the most frequent psychiatric conditions." | 5.51 | The immunomodulatory effect of ketamine in depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Lisowska, KA; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Depression affects over 121 million people annually worldwide." | 5.51 | Magnesium and ketamine in the treatment of depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Patients with major depressive disorder (MDD) often have structural and functional deficits in the ventromedial prefrontal cortex (vmPFC), but the underlying molecular pathways are incompletely understood." | 5.51 | VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. ( Jiang, C; Labonté, B; Lin, WJ; Nestler, EJ; Russo, SJ; Salton, SR; Tamminga, CA; Turecki, G, 2019) |
| "Ketamine acts as a rapid clinical antidepressant at 25 min after injection with effects sustained for 7 days." | 5.51 | Differences between ketamine's short-term and long-term effects on brain circuitry in depression. ( Becker, R; Cosa-Linan, A; Gass, N; Reinwald, J; Sack, M; Sartorius, A; Vollmayr, B; Weber-Fahr, W, 2019) |
| "Ketamine is a rapid antidepressant." | 5.51 | Effect of ketamine combined with DHA on lipopolysaccharide-induced depression-like behavior in rats. ( Chang, D; Du, X; Gao, L; Lian, H; Wen, Y; Yuan, R; Zhang, X; Zhao, J, 2019) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Depression is present in a large proportion of patients suffering from chronic pain, and yet the underlying mechanisms remain to be elucidated." | 5.48 | Ketamine differentially restores diverse alterations of neuroligins in brain regions in a rat model of neuropathic pain-induced depression. ( Ji, MH; Li, HH; Li, KY; Pan, W; Yang, JJ; Zhang, GF; Zhou, ZQ, 2018) |
| "Patients with advanced cancer often suffer from both severe pain and severe symptoms of depression." | 5.48 | Case Report: Ketamine for Pain and Depression in Advanced Cancer. ( Atayee, RS; Bruner, HC; Sexton, J, 2018) |
| "Ketamine has been extensively studied for its antidepressant potential, with promising results in both preclinical and clinical studies." | 5.46 | Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats. ( Babinska, Z; Ruda-Kucerova, J, 2017) |
| " The higher ketamine use frequency and dosage were associated with more severe depressive symptoms." | 5.43 | Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. ( Deng, X; Ding, Y; Fan, N; He, H; Ke, X; Ning, Y; Rosenheck, R; Sun, B; Tang, W; Wang, D; Xu, K; Zhou, C, 2016) |
| "Whether the antidepressant effects of low-dose ketamine infusion and the therapeutic impact of Val66Met brain-derived neurotrophic factor (BDNF) polymorphism vary across different depression symptom domains, namely affective, cognitive, and somatic, remains unclear." | 5.41 | Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD)." | 5.41 | Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. ( Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A, 2021) |
| "A total of 78 patients with medication-resistant depression were allocated to receive two ketamine infusions (n = 30; days 1 and 4), a single ketamine infusion (n = 24; only day 1), or normal saline placebo infusion (n = 24; only day 1)." | 5.41 | Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Although results are still preliminary, ketamine and classical hallucinogens have shown promise in recent years as novel, fast-acting antidepressants, especially for the treatment of unipolar treatment-resistant depression (TRD)." | 5.41 | The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials. ( Baker, G; Dos Santos, RG; Dursun, SM; Hallak, JEC; Rossi, GN, 2023) |
| "Studies have demonstrated the beneficial therapeutic effects of sarcosine, benzoate, and ketamine (including esketamine and arketamine) on depression." | 5.41 | Ketamine, benzoate, and sarcosine for treating depression. ( Cheng, YJ; Lane, HY; Lin, CH, 2023) |
| "Ketamine, functioning as a channel blocker of the excitatory glutamate-gated N-methyl-d-aspartate (NMDA) receptors, displays compelling fast-acting and sustained antidepressant effects for treatment-resistant depression." | 5.41 | NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. ( Lv, S; Yao, K; Zhang, Y; Zhu, S, 2023) |
| "Ketamine has a fast onset of action that may offer a paradigm change for depression management at the end of life." | 5.41 | Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review. ( Barbosa, MG; Garcia, GT; Jackowski, AP; Sarin, LM, 2023) |
| "Triggered by the ground-breaking finding that ketamine exerts robust and rapid-acting antidepressant effects in patients with treatment-resistant depression, glutamatergic systems have attracted attention as targets for the development of novel antidepressants." | 5.41 | mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development. ( Chaki, S; Watanabe, M, 2023) |
| "Ketamine and esketamine, the S-enantiomer of the racemic mixture, have recently generated considerable interest as potential therapeutic agents for Treatment-Resistant Depression (TRD), a complex disorder that includes various psychopathological dimensions and distinct clinical profiles (e." | 5.41 | Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties? ( d'Andrea, G; Lorenzo, GD; Mancusi, G; Martinotti, G; McIntyre, RS; Pettorruso, M, 2023) |
| "Electronic databases were searched to capture randomised control trials measuring the anxiolytic effects of ketamine in contexts including mood disorders, anxiety disorders and chronic pain." | 5.41 | A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects. ( Alexander, L; Hartland, H; Jelen, LA; Mahdavi, K; Strawbridge, R; Young, AH, 2023) |
| "Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an anesthetic, has shown significant promise as a medication with rapid antidepressant properties in treatment-resistant depression." | 5.41 | The antidepressant actions of ketamine and its enantiomers. ( Henter, ID; Johnston, JN; Zarate, CA, 2023) |
| "The following review will explore ketamine's antidepressant and antisuicidal properties in adults, review of what is known about ketamine's safety in children, and summarize the limited information we have on ketamine's role in treating depression and suicidal ideation in adolescents with depression." | 5.41 | Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions. ( Hosanagar, A; Ryan, K, 2023) |
| "Ketamine recently approved for therapy of treatment-resistant depression shows a complex and not fully understood mechanism of action." | 5.41 | Antidepressant mechanisms of ketamine's action: NF-κB in the spotlight. ( Dobielska, M; Jóźwiak-Bębenista, M; Kowalczyk, E; Seweryn Karbownik, M; Sokołowska, P; Wiktorowska-Owczarek, A, 2023) |
| "This study aims to investigate the effect of the pretreatment of S-ketamine on postoperative depression (POD) for breast cancer patients with mild/moderate depression." | 5.41 | Effect of Pretreatment of S-Ketamine On Postoperative Depression for Breast Cancer Patients. ( Li, P; Li, Q; Liu, C; Liu, P; Peng, S; Shi, X; Yan, H; Zhang, Y, 2021) |
| "Dissociative symptoms are common, possibly severe, side effects associated with the use of ketamine and esketamine in depression." | 5.41 | Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. ( Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Magnavita, GM; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza-Marques, B; Telles, M; Vieira, F, 2021) |
| "Post hoc data support efficacy of esketamine plus an oral antidepressant in patients with TRD, regardless of comorbid anxiety." | 5.41 | The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. ( Borentain, S; Daly, EJ; Fedgchin, M; Ionescu, DF; Salvadore, G; Singh, JB; Starr, HL; Thase, ME; Trivedi, MH; Turkoz, I, 2021) |
| "Ketamine is a potent noncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor." | 5.38 | Effects of ketamine in treatment-refractory obsessive-compulsive disorder. ( Bhagwagar, Z; Billingslea, E; Bloch, MH; Krystal, JH; Landeros-Weisenberger, A; Leckman, JF; Panza, KE; Pittenger, C; Sanacora, G; Wasylink, S, 2012) |
| "Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression." | 5.34 | Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. ( Araújo-de-Freitas, L; Bandeira, ID; Caliman-Fontes, AT; Cavalcanti, DE; Correia-Melo, FS; Del-Porto, JA; Echegaray, MVF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Loo, C; Magnavita, G; Mello, RP; Nakahira, C; Quarantini, LC; Sampaio, AS; Sarin, LM; Silva, SS; Tuena, MA; Turecki, G; Vieira, F, 2020) |
| "Clinically, patients showed significantly reduced SI and depression after ketamine administration." | 5.34 | Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression. ( Ballard, ED; Galiano, CS; Gilbert, JR; Nugent, AC; Zarate, CA, 2020) |
| "BACKGROUND This study investigated the effects of various doses of S-ketamine on depression and pain management of cervical carcinoma patients with mild/moderate depression." | 5.34 | Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression After Laparoscopic Total Hysterectomy. ( Liu, P; Peng, S; Wang, J; Wang, Y; Xu, F; Xu, X, 2020) |
| "The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine." | 5.34 | A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. ( Albott, CS; Erbes, C; Lim, KO; Shiroma, PR; Thuras, P; Tye, S; Wels, J, 2020) |
| "While the psychiatric benefits of ketamine have been verified through clinical trials, there is limited information about ketamine augmentation in patients with treatment-resistant bipolar depression (TRBPD)." | 5.34 | Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study. ( Chen, C; Ji, F; Jia, F; Jiang, D; Lin, X; Tian, H; Wang, L; Zhou, C; Zhu, J; Zhuo, C, 2020) |
| "Ketamine's effects on different dimensions of depressive symptomatology, including typical/melancholic and atypical depression, remain largely unknown." | 5.34 | The effects of ketamine on typical and atypical depressive symptoms. ( Ballard, ED; Henter, ID; Hopkins, MA; Kadriu, B; Lener, MS; Luckenbaugh, DA; Park, LT; Pennybaker, SJ; Zarate, CA, 2020) |
| "Pretreatment with fluvoxamine, MK-801, ketamine and the combination of fluvoxamine with either of the NMDA antagonists antagonised shock-induced depression." | 5.31 | Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice. ( Bapna, JS; Chandra, D; Chaturvedi, HK, 2001) |
| "The ketamine group was superior to the conventional group which was superior to the no-treatment group in reducing negative affect experienced during stressful situations." | 5.26 | Ketamine-facilitated induced anxiety therapy and its effect upon clients' reactions to stressful situations. ( Becker, AT; Corssen, G; Sappington, AA; Tavakoli, M, 1979) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 5.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| " Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine." | 5.24 | Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. ( Ameli, R; Ballard, ED; Brutsche, NE; Lally, N; Luckenbaugh, DA; Niciu, MJ; Park, L; Richards, EM; Walls, T; Wills, K; Zarate, CA, 2017) |
| "This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer." | 5.24 | Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. ( Fan, W; Li, G; Liu, Y; Sun, Y; Yang, H; Zhang, J; Zheng, Y, 2017) |
| " Compared with the control group, ketamine provided significant reduction of postoperative depression scale scores, by a standardized mean difference (SMD) of -0." | 5.22 | The effect of intravenous ketamine on depressive symptoms after surgery: A systematic review. ( Ai, P; An, D; Cui, V; Shi, H; Sun, Y; Wang, J; Wei, C; Wu, A, 2022) |
| "Ketamine is an NMDAR antagonist and is proven effective in depression for the rapid and sustained antidepressant response, while rapastinel is an NMDAR positive allosteric modulator, producing antidepressant effects like ketamine with no severe side effects." | 5.22 | Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants. ( Chen, NH; Hu, D; Jiang, H; Liu, LJ; Wang, YT; Wang, ZZ; Zhang, NN; Zhang, Y, 2022) |
| " Ketamine, a racemic mixture of the two enantiomers, (R)-ketamine and (S)-ketamine, is an N-methyl-d-aspartate receptor (NMDAR) antagonist and has been shown to have rapid-acting antidepressant properties in patients with treatment-resistant depression (TRD)." | 5.22 | Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers. ( Antqueviezc, B; Colombo, R; Dalpiaz, G; Ferraz Goularte, J; Paul Géa, L; Ribeiro Rosa, A; Scotton, E; Vasconcelos, MF, 2022) |
| "Ketamine is a rapid-acting antidepressant with proven efficacy as an add-on agent in unipolar and bipolar treatment-resistant depression." | 5.22 | Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review. ( Cubała, WJ; Jakuszkowiak-Wojten, K; Wiglusz, MS; Wilkowska, A, 2022) |
| " Ketamine, a N-methyl-d-aspartate glutamate receptor antagonist, and its enantiomer esketamine rapidly reduce depressive symptoms in depressed patients with current suicidal ideation." | 5.22 | Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how? ( Courtet, P; Lengvenyte, A; Olié, E; Strumila, R, 2022) |
| "We conducted a PRISMA-guided review for relevant randomized controlled trials of racemic or esketamine for unipolar or bipolar major depression from database inception through 2021." | 5.22 | Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. ( Bahji, A; Vazquez, GH; Zarate, CA, 2022) |
| " Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019." | 5.22 | Long-term safety of ketamine and esketamine in treatment of depression. ( Krystal, JH; Murphy, E; Nikayin, S; Wilkinson, ST, 2022) |
| "Ketamine is an established intervention for treatment-resistant depression (TRD)." | 5.22 | A review of potential neuropathological changes associated with ketamine. ( Ho, R; Lui, LMW; McIntyre, RS; Nazal, H; Nogo, D; Rosenblat, JD; Song, Y; Teopiz, KM, 2022) |
| "While ketamine has been used clinically over the past decades, it has only been recently shown to be a promising therapy for treatment-resistant depression (TRD)." | 5.22 | The abuse liability of ketamine: A scoping review of preclinical and clinical studies. ( Cordero, IP; Di Vincenzo, JD; Ho, R; Jaberi, S; Jawad, MY; Le, TT; Lui, LMW; McIntyre, RS; Phan, L; Rosenblat, JD; Swainson, J, 2022) |
| "Ketamine, an anesthetic available since 1970, and esketamine, its newer S-enantiomer, provide a novel approach for the treatment of depression and other psychiatric disorders." | 5.22 | Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review. ( Alami, A; Alexander, GC; Mattison, DR; Moore, TJ, 2022) |
| "Ketamine is a promising therapeutic option in treatment-resistant depression (TRD)." | 5.22 | Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. ( Alnefeesi, Y; Cao, B; Ceban, F; Chen-Li, D; Di Vincenzo, JD; Gill, H; Ho, RCM; Jawad, MY; Krane, E; Lee, Y; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM, 2022) |
| "S-ketamine is approved for treatment-resistant patients with depression and adult patients with suicide behavior." | 5.22 | Neurobiological, behavioral, and cognitive effects of ketamine in adolescents: A review of human and pre-clinical research. ( Acevedo, J; Siegel, JA, 2022) |
| "Ketamine has demonstrated rapid and significant antidepressant effects in patients with treatment resistant depression (TRD)." | 5.22 | The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review. ( Ceban, F; Di Vincenzo, JD; Ho, C; Lee, Y; Levinta, A; Lui, LMW; Mansur, RB; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM, 2022) |
| "Despite a burgeoning body of literature demonstrating that inflammation is linked to TRD, there is still a lack of comprehensive research on the relationship between proinflammatory biomarkers and ketamine's antidepressant effect on TRD patients." | 5.22 | Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review. ( Gu, J; Sukhram, SD; Yilmaz, G, 2022) |
| "This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment-psilocybin and esketamine." | 5.22 | Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. ( Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U, 2022) |
| "Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression." | 5.22 | Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. ( Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Spijker, J; Veraart, JK, 2022) |
| "Published research studies on the antidepressant activity of ketamine in the last twenty years have significantly changed the way people think about potential new antidepressants and the biological basis of depression." | 5.22 | Ketamine - a long way from anesthetic to a prototype antidepressant: Review of potential mechanisms of action. ( Pochwat, B, 2022) |
| "Esketamine is a promising drug which can induce antidepressant effects in Major Depression Disorder (MDD)." | 5.22 | Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials. ( Chen, G; Li, X; Wang, J; Wang, T; Xu, X; Xu, Z; Yang, S; Zhou, X, 2022) |
| " diclofenac monotherapy in reducing symptoms of mild to moderate depression among patients with chronic pain." | 5.22 | Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. ( Afarideh, M; Agah, E; Akhondzadeh, S; Arbabi, M; Ghajar, A; Jafarinia, M; Noorbala, AA; Saravi, MA; Tafakhori, A, 2016) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 5.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| " Data were examined from 58 patients with major depressive disorder or bipolar disorder enrolled in double-blind, placebo-controlled, crossover studies who received a single infusion of ketamine (0." | 5.20 | Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales. ( Ameli, R; Brutsche, NE; Luckenbaugh, DA; Zarate, CA, 2015) |
| " We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression." | 5.20 | Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. ( Brallier, JW; Charney, DS; Collins, KA; DeWilde, KE; Goodman, WK; Iacoviello, BM; Iosifescu, DV; Kautz, M; Kim, J; Lapidus, KA; Lener, M; Murrough, JW; Perez, AM; Price, RB; Rodriguez, GJ; Soleimani, L; Stern, JB, 2015) |
| "In this double-blind, randomized, crossover, placebo-controlled study, 15 subjects with DSM-IV bipolar I or II depression maintained on therapeutic levels of lithium or valproate received a single intravenous infusion of either ketamine hydrochloride (." | 5.16 | Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. ( Brutsche, NE; Cravchik, A; Diazgranados, N; Franco-Chaves, J; Ibrahim, L; Liberty, V; Luckenbaugh, DA; Marquardt, CA; Selter, J; Zarate, CA, 2012) |
| "The N-methyl-D-aspartate antagonist ketamine has rapid antidepressant effects in patients with treatment-resistant major depression (TRD); these effects have been reported to last for 1 week in some patients." | 5.16 | Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. ( Brutsche, N; Diazgranados, N; Franco-Chaves, J; Henter, ID; Ibrahim, L; Kronstein, P; Luckenbaugh, DA; Manji, HK; Moaddel, R; Wainer, I; Zarate, CA, 2012) |
| "Subjects with major depressive disorder or bipolar disorder referred for ECT treatment of a major depressive episode were randomized to receive thiopental alone or thiopental plus ketamine (0." | 5.16 | Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. ( Abdallah, CG; Fasula, M; Kelmendi, B; Ostroff, R; Sanacora, G, 2012) |
| "Baseline neurocognitive and depression scores were similar in the placebo, ketamine, and nonsurgical control groups." | 5.14 | Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery. ( Byrne, AJ; Gandhi, SD; Hudetz, AG; Hudetz, JA; Iqbal, Z; Pagel, PS; Patterson, KM; Warltier, DC, 2009) |
| "The results suggested that it is possible to improve symptoms of depression earlier by using ketamine anesthesia." | 5.14 | Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. ( Higuchi, T; Nagafusa, Y; Nakai, T; Nishikawa, T; Okamoto, N; Sakamoto, K, 2010) |
| "Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion." | 5.14 | Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. ( Ameli, R; Brutsche, NE; DiazGranados, N; Henter, ID; Ibrahim, LA; Luckenbaugh, DA; Machado-Vieira, R; Zarate, CA, 2010) |
| "To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with unipolar major depressive disorder." | 5.12 | Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. ( Barnes, A; Cipriani, A; Cowen, PJ; Dean, RL; Hawton, K; Hollingsworth, S; Hurducas, C; Marquardt, T; McShane, R; Smith, R; Spyridi, S; Turner, EH, 2021) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 5.12 | Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. ( Barnes, A; Cipriani, A; Cowen, PJ; Dean, RL; Geddes, J; Hawton, K; Hurducas, C; Malhi, GS; Marquardt, T; McShane, R; Smith, R; Spyridi, S, 2021) |
| "The aim of this paper is to review current studies on the use of ketamine in the treatment of drug-resistant depression, compare results of various administration methods - intravenous, intranasal or oral, as well as compare its effectiveness with that of other antidepressants." | 5.12 | Ketamine as a Novel Drug for Depression Treatment. ( Bogudzińska, B; Kaczmarek, B; Kowalski, K; Piotrowski, P, 2021) |
| "Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression." | 5.12 | Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. ( Bahji, A; Vazquez, GH; Zarate, CA, 2021) |
| "The discovery of the rapid antidepressant effects of the dissociative anaesthetic ketamine, an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is arguably the most important breakthrough in depression research in the last 50 years." | 5.12 | Ketamine: A tale of two enantiomers. ( Jelen, LA; Stone, JM; Young, AH, 2021) |
| "The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported." | 5.12 | The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. ( Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J, 2021) |
| "Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects within hours of administration." | 5.12 | Ketamine for depression. ( Jelen, LA; Stone, JM, 2021) |
| "The approval of intranasal esketamine for treatment-resistant depression marks the next step in our understanding of and ability to treat treatment-resistant depression." | 5.12 | Intranasal esketamine: From origins to future implications in treatment-resistant depression. ( Brula, AQ; Sanders, B, 2021) |
| " Ketamine has emerged as a promising new treatment for treatment resistant depression (TRD)." | 5.12 | The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. ( Cao, B; Di Vincenzo, JD; Gill, H; Ho, R; Lin, K; Lipsitz, O; Lui, LMW; McIntyre, RS; Ng, J; Rodrigues, NB; Rosenblat, JD; Siegel, A; Teopiz, KM, 2021) |
| "Ketamine treatment is capable of significant and rapid symptom improvement in adults with treatment-resistant depression (TRD)." | 5.12 | Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. ( Cao, B; Cha, DS; Gill, H; Ho, R; Lee, Y; Lipsitz, O; Lui, LMW; McIntyre, RS; McMullen, EP; Rodrigues, NB; Rosenblat, JD; Teopiz, KM; Vinberg, M, 2021) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 5.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "In recent years, ketamine and esketamine treatment have demonstrated rapid antidepressant effects in adults with treatment-resistant depression (TRD)." | 5.12 | Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. ( Cao, B; Cha, DS; Gill, H; Ho, RC; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Ng, J; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics nationwide that provide this service." | 5.12 | Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. ( Achtyes, E; Bobo, WV; Coryell, W; Drake, K; Frye, MA; Goddard, A; Goes, F; Greden, JF; Kaplin, A; Lopez, D; Maixner, D; Parikh, SV; Rico, J; Riva-Posse, P; Singh, B; Tarnal, V; Vande Voort, JL; Watson, B, 2021) |
| " Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an intranasal formulation for treatment-resistant depression (TRD) and for rapid reduction of depressive symptomatology, including suicidal ideation in MDD patients at imminent risk for suicide." | 5.05 | An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. ( De Berardis, D; Di Giannantonio, M; Fornaro, M; Fraticelli, S; Kim, YK; Martinotti, G; Orsolini, L; Perna, G; Pompili, M; Serafini, G; Tomasetti, C; Valchera, A; Vellante, F; Volpe, U, 2020) |
| "Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes." | 5.05 | Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions. ( Duman, RS; Hare, BD, 2020) |
| "Ketamine has been shown to be efficacious for the treatment of depression, specifically among individuals who do not respond to first-line treatments." | 5.05 | Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement. ( George, TP; Lowe, DJE; Müller, DJ, 2020) |
| "N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP), dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia, both in animals and humans." | 5.05 | Brain NMDA Receptors in Schizophrenia and Depression. ( Adell, A, 2020) |
| "Given that ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist that exerts rapid antidepressant effects in patients with treatment-resistant depression, also has undesirable adverse effects, agents that can be used as alternatives to ketamine have been actively pursued." | 5.05 | mGlu2/3 receptor as a novel target for rapid acting antidepressants. ( Chaki, S, 2020) |
| "Ketamine is regaining popularity in the field of anesthesia and beyond." | 5.05 | Ketamine: a versatile tool for anesthesia and analgesia. ( Barrett, W; Buxhoeveden, M; Dhillon, S, 2020) |
| " Studies of oral ketamine for depression, from case series to randomized clinical trials, were eligible." | 5.05 | An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. ( Frye, MA; Joseph, B; Kung, S; Nuñez, NA; Pahwa, M; Prokop, LJ; Schak, KM; Seshadri, A; Singh, B; Vande Voort, JL, 2020) |
| "Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades." | 5.01 | Rodent ketamine depression-related research: Finding patterns in a literature of variability. ( Fitzgerald, PJ; Hale, PJ; Polis, AJ; Watson, BO, 2019) |
| "Ketamine is an anaesthetic and analgesic agent that demonstrates the antidepressive effect in major depression." | 5.01 | Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. ( Cubała, WJ; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| "Although the robust antidepressant effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown." | 5.01 | Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. ( Hashimoto, K; Luo, A; Yang, C; Yang, J, 2019) |
| " The primary outcome measures were the suicide items from clinician-administered (the Montgomery-Åsberg Depression Rating Scale [MADRS] or the Hamilton Depression Rating Scale [HAM-D]) and self-report scales (the Quick Inventory of Depressive Symptomatology-Self Report [QIDS-SR] or the Beck Depression Inventory [BDI]), obtained for up to 1 week after ketamine administration." | 4.98 | The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. ( Ballard, ED; Bloch, MH; Feder, A; Mathew, SJ; Murrough, JW; Sanacora, G; Sos, P; Wang, G; Wilkinson, ST; Zarate, CA, 2018) |
| "We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression." | 4.95 | Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. ( Curran, V; McShane, R; Morgan, C; Nutt, D; Schlag, A; Singh, I, 2017) |
| " The recent discovery that a single intravenous infusion of ketamine at a subanesthetic dose had robust, rapid and sustained antidepressant effects in individuals with treatment-resistant depression inspired tremendous interest in investigating the molecular mechanisms mediating ketamine's clinical efficacy as well as increased efforts to identify new targets for antidepressant action." | 4.95 | Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. ( Aleksandrova, LR; Phillips, AG; Wang, YT, 2017) |
| "After nearly half a century on the market, ketamine still occupies a unique corner in the medical armamentarium of anesthesiologists or clinicians treating pain." | 4.93 | Ketamine use in current clinical practice. ( Gao, M; Liu, H; Rejaei, D, 2016) |
| "Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal ideation." | 4.93 | Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. ( Mallick, F; McCullumsmith, CB, 2016) |
| "Consistent with clinical research on ketamine as a rapid and effective treatment for depression, ketamine has shown early preliminary evidence of a reduction in depressive symptoms, as well as reducing SI, with minimal short-term side effects." | 4.91 | Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. ( Reinstatler, L; Youssef, NA, 2015) |
| " ketamine; deep brain stimulation) that are reported to be effective in treatment-resistant depression and (iv) a parallel to a known clinical risk factor." | 4.91 | Treatment-resistant depression: are animal models of depression fit for purpose? ( Belzung, C; Willner, P, 2015) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 4.91 | Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. ( Amit, BH; Brett, D; Caddy, C; Cipriani, A; Diamond, PR; Hamadi, L; Hawton, K; Jochim, J; McCloud, TL; McShane, R; Rendell, JM; Shuttleworth, C, 2015) |
| "The electronic database Pubmed, Web of Science and sciencedirect were searched using the keywords: ketamine, N-methyl-d-aspartate receptor antagonist, rapid-acting antidepressant, depression, treatment-resistant depression, bipolar depression, suicidal ideation, electroconvulsive therapy, mechanism of action." | 4.90 | A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. ( Clarke, G; Cryan, JF; Dinan, TG; Naughton, M; O'Leary, OF, 2014) |
| "The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and potent antidepressant effects in treatment-resistant major depressive disorder and bipolar depression." | 4.90 | Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. ( Charney, DS; Henter, ID; Luckenbaugh, DA; Niciu, MJ; Zarate, CA, 2014) |
| " In recent years several open and five controlled trials have demonstrated the antidepressant efficacy of ketamine for major depression." | 4.90 | [Ketamine as antidepressant: the current study situation]. ( Bauer, M; Pilhatsch, M; Ritter, PS, 2014) |
| "Narrative review of the literature on the efficacy and safety of subanaesthetic doses of ketamine for the treatment of depression." | 4.89 | Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. ( Glue, P; Katalinic, N; Lai, R; Loo, CK; Mitchell, PB; Somogyi, A, 2013) |
| "The antidepressant effects of ketamine in patients with anxious depression (AD) remain unclear." | 4.31 | Functional connectivity differences in the amygdala are related to the antidepressant efficacy of ketamine in patients with anxious depression. ( Chen, X; Hu, Y; Luo, X; Ning, Y; Wang, M; Yuan, S; Zhang, B; Zhou, Y, 2023) |
| "The NMDA antagonist ketamine demonstrated a fast antidepressant activity in treatment-resistant depression." | 4.31 | Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons. ( Belloch, FB; Cortés-Erice, M; Díaz-Perdigon, T; Herzog, E; Puerta, E; Tordera, RM; Zhang, XM, 2023) |
| "Ketamine is known for its antinociceptive effect and is also used for treatment-resistant depression." | 4.31 | Intranasal (2R, 6R)-hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice. ( Aleem, M; Goswami, N; Manda, K, 2023) |
| "Most research describing ketamine as a treatment for depression has relied on intravenous dosing." | 4.31 | Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis. ( Cheveldae, I; Halpape, K; Peters, EM; Wanson, A, 2023) |
| "Ketamine is an anesthetic drug that has recently been approved for the treatment of treatment-resistant depression." | 4.31 | The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice. ( Acevedo, J; Johnson, EM; Mugarura, NE; Siegel, JA; Welter, AL, 2023) |
| "Ketamine can produce rapid-acting antidepressant effects in treatment-resistant patients with depression." | 4.31 | A role of GABA ( Diao, YG; Duan, GF; Hashimoto, K; Ren, ZY; Shen, JC; Tang, XH; Wang, XM; Yang, JJ; Zang, YY; Zhang, GF; Zhou, ZQ, 2023) |
| "Hippocampal functional connectivity (FC) alterations, which may happen following ketamine treatment, play a key role in major depression remission." | 4.31 | Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression. ( Hu, Z; Lan, X; Li, W; Liu, H; Ning, Y; Wang, C; Ye, Y; You, Z; Zhang, F; Zhou, Y, 2023) |
| "Ketamine may work as an anti-inflammatory agent, and it increases the levels of vascular endothelial growth factor (VEGF) in patients with treatment-resistant depression." | 4.31 | Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression. ( Bai, YM; Chen, MH; Hong, CJ; Kao, CF; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC, 2023) |
| " The sucrose consumption test, forced swim test, open field test, elevated plus maze, and Morris water maze were respectively used to assess anhedonia, behavioral despair, general locomotor activity, anxiety-like behavior and spatial reference memory." | 4.31 | Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress. ( Kingir, E; Sevinc, C; Unal, G, 2023) |
| "Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety." | 4.31 | Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. ( Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A, 2023) |
| "Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder." | 4.31 | Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. ( Gan, Y; Hu, Z; Lan, X; Li, N; Li, W; Liu, H; Ning, Y; Wang, C; Wu, Z; Ye, Y; Zhang, F; Zhou, Y, 2023) |
| " In this article, we report the case of a Canadian patient who was actively requesting Medical Assistance in Dying for severe and prolonged treatment-resistant depression until she experienced remarkable benefits from a course of intravenous ketamine infusions." | 4.31 | Ketamine for depression: a potential role in requests for Medical Aid in Dying? ( Garel, N; Greenway, KT; Looper, K; Naghi, K; Nazon, M; Rej, S; Willis, E, 2023) |
| "This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression." | 4.31 | A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression. ( Lan, XF; Ning, YP; Wang, CY; Zheng, W; Zhou, YL, 2023) |
| "Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality." | 4.31 | Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth. ( Arekapudi, A; Chau, E; Chisamore, N; Danayan, K; Di Vincenzo, JD; Doyle, Z; Fancy, F; Kratiuk, K; Mansur, R; McIntyre, RS; Meshkat, S; Phan, L; Rodrigues, NB; Rosenblat, JD; Tabassum, A, 2023) |
| "Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions." | 4.31 | The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. ( Heifets, BD; Hietamies, TM; Klise, AJ; Levine, SP; McInnes, LA; Qian, JJ; Williams, LM; Worley, MJ, 2023) |
| "Ketamine and its enantiomers are widely researched and increasingly used to treat mental disorders, especially treatment-resistant depression." | 4.31 | Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. ( Breeksema, JJ; Kamphuis, J; Kuin, B; Niemeijer, A; Schoevers, R; van den Brink, W; Veraart, J; Vermetten, E, 2023) |
| " We have previously used the chronic mild stress (CMS) model of depression in male rats to show that CMS induces morphological, functional, and molecular changes in the hippocampus of vulnerable animals, the majority of which were recovered using acute subanesthetic ketamine in just 24 h." | 4.31 | Functional and Molecular Changes in the Prefrontal Cortex of the Chronic Mild Stress Rat Model of Depression and Modulation by Acute Ketamine. ( Barbon, A; Bertoli, M; Bonanno, G; Bonifacino, T; La Via, L; Milanese, M; Mingardi, J; Misztak, P; Musazzi, L; Ndoj, E; Popoli, M; Russo, I; Torazza, C, 2023) |
| " Ketamine, known as an anesthetic, is a new treatment option that can be effective in patients with treatment-resistant depression." | 4.31 | [Consider (es)ketamine for treatment-resistant depression]. ( Kramers, CK; Ruhé, HG; Stuiver, S; van Verseveld, M; van Waarde, JA; Vos, CF, 2023) |
| "We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs)." | 4.31 | Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. ( Dinh-Williams, LL; Garel, N; Greenway, KT; Jutras-Aswad, D; Rej, S; Richard-Devantoy, S; Thibault-Levesque, J; Turecki, G, 2023) |
| "Ketamine has been recently approved to treat resistant depression; however preclinical studies showed sex differences in its efficacy." | 4.31 | Aromatase inhibition and ketamine in rats: sex-differences in antidepressant-like efficacy. ( García-Fuster, MJ; Jornet-Plaza, J; Ledesma-Corvi, S, 2023) |
| "This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD)." | 4.31 | Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? ( Anand, A; Jha, MK; Mathew, SJ, 2023) |
| "Whether a single low-dose ketamine infusion may have rapid antidepressant and antisuicidal effects in patients with treatment-resistant double depression remains unclear." | 4.12 | Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2022) |
| " This report describes a recent approach adopted at Janssen of integrating patient-experience data into the NDA for esketamine (SPRAVATO®) nasal spray with a newly initiated oral antidepressant (esketamine + AD) for treatment-resistant depression." | 4.12 | U.S. Food and Drug Administration's Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant ( Jamieson, C; Katz, EG; Levitan, B; Martynowicz, J; McNulty, P; Treichler, P, 2022) |
| "(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression." | 4.12 | Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. ( Cao, Q; Chen, J; Hashimoto, K; He, L; Luo, S; Qi, Q; Yang, C; Yao, W; Zhang, JC, 2022) |
| " We report the case of a 57-year-old woman diagnosed with treatment-resistant depression (TRD) and comorbid FMD treated with weekly intranasal administrations of esketamine over a six-month follow-up period." | 4.12 | Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. ( Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G, 2022) |
| " In this study, we compared the effects of single administration of the new mGlu2/3 receptor antagonist TP0178894 and the selective serotonin reuptake inhibitor (SSRI) escitalopram in the chronic social defeat stress (CSDS) model of depression, a model which has been shown to be resistant to treatment with a single dose of SSRI." | 4.12 | Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram. ( Dong, C; Fujita, A; Fujita, Y; Hashimoto, K; Hino, N; Iijima, M; Tian, Z, 2022) |
| "In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of esketamine nasal spray (ESK) in treatment-resistant depression (TRD)-short-term study (TRANSFORM-2) and maintenance study (SUSTAIN-1)-were analyzed to evaluate the relationship between dissociation and antidepressant effects of ESK." | 4.12 | Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. ( Chen, G; Chen, L; Daly, EJ; Drevets, WC; Fedgchin, M; Furey, ML; Lane, R; Li, X; Lim, P; Popova, V; Singh, JB; Zhang, Y, 2022) |
| "Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated." | 4.12 | A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. ( DeBattista, C; Gargeya, RS; Heifets, BD; McInnes, LA; Qian, JJ, 2022) |
| "Ketamine enhances the resilience against stress-induced depressive-like behavior, but its prophylactic efficacy in anxiety-related behaviors remains to be elucidated." | 4.12 | Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment. ( Alves, EC; Camargo, A; Dalmagro, AP; Fraga, DB; Kouba, BR; Rodrigues, ALS; Torrá, ACNC; Valverde, AP, 2022) |
| "Ketamine is efficacious in treating treatment-resistant depression in medical settings and the drug was approved for such use by the US Federal Drug Administration in 2019." | 4.12 | Ketamine use in relation to depressive symptoms among high school seniors. ( Han, BH; Kumar, S; Palamar, JJ; Yang, KH, 2022) |
| "Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression." | 4.12 | Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. ( Haroutounian, S; Lenze, EJ; Palanca, BJA; Subramanian, S, 2022) |
| "Veterans receiving ketamine treatment ( across both IN-(S)-ketamine and IV-(R,S)-ketamine) showed significant reductions in both the Patient Health Questionnaire-9 (PHQ-9), a self-report scale measuring depression symptoms (rm ANOVA F(14,42) = 12." | 4.12 | Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series. ( Artin, H; Baker, DG; Bentley, S; Bismark, A; De Peralta, S; Lee, EE; Liu, F; Martis, B; Mehaffey, E; Mishra, J; Printz, D; Ramanathan, D; Sojourner, K, 2022) |
| "Esketamine was licensed for use in treatment resistant depression by the European Medicines Agency in December 2019." | 4.12 | Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees. ( Curran, HV; Freeman, TP; Grabski, M; van Laar, M; Waldron, J, 2022) |
| "Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression." | 4.12 | Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. ( Brennan, S; Chokka, P; Katzman, MA; Khullar, A; Klassen, LJ; Swainson, J; Tanguay, RL, 2022) |
| "Ketamine has rapid and robust antidepressant effects in adults with treatment-resistant depression (TRD), while its effects on functional outcomes have not been sufficiently evaluated." | 4.12 | The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Zheng, W; Zhou, Y, 2022) |
| "Intranasal esketamine has been recently approved for the treatment of resistant depression." | 4.12 | Intranasal esketamine for depression: Not so special K. ( Rosenman, S, 2022) |
| "Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD)." | 4.12 | Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series. ( Budd, GP; Do, A; Fridfinnson, J; Lam, RW; Rafizadeh, R; Siu, JTP; Tham, JCW, 2022) |
| "One hundred thirty-five Chinese individuals with anxious depression (n = 92) and nonanxious depression (n = 43) received six intravenous infusions of ketamine (0." | 4.12 | Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. ( Gu, LM; Ning, YP; Tan, JQ; Wang, CY; Yang, XH; Zheng, W; Zhou, YL, 2022) |
| " The authors set out to investigate the neurotoxicity of S-ketamine, which possesses anesthetic and antidepressant effects and may cause attention deficit hyperactivity disorder (ADHD)- and depression-like behaviors in offspring mice." | 4.12 | S-ketamine administration in pregnant mice induces ADHD- and depression-like behaviors in offspring mice. ( Bai, Y; Bi, XY; Cao, L; Liu, NN; Xin, Y; Xing, BH; Zhang, DX; Zhang, LM; Zhang, W; Zheng, WC, 2022) |
| "Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019." | 4.12 | Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022) |
| "A short course of repeated ketamine infusions did not impair neurocognitive function in patients with treatment-resistant depression." | 4.12 | Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions. ( Batten, LA; Blier, P; Burhunduli, P; Norris, S; Ortiz, A; Owoeye, O; Phillips, JL; Talbot, J; Van Geel, A; Vasudev, D, 2022) |
| " These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression." | 4.12 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. ( Ballard, ED; Bloomfield-Clagett, B; Fava, M; Greenstein, DK; Grunebaum, MF; Mathew, SJ; Murrough, JW; Phillips, JL; Sanacora, G; Wilkinson, ST; Zarate, CA, 2022) |
| "Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses." | 4.12 | Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression. ( Bottemanne, H; Claret, A; Fossati, P; Morlaas, O; Schmidt, L; Sharot, T, 2022) |
| "(R,S)-ketamine is known to elicit persistent prophylactic effects in rodent models of depression." | 4.12 | A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice. ( Chang, L; Fujita, Y; Hashimoto, K; Ma, L; Qu, Y; Shan, J; Wan, X; Wang, L; Wang, X, 2022) |
| "Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics." | 4.12 | Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. ( Ahuja, S; Brendle, M; Moore, C; Robison, R; Smart, L; Thielking, P, 2022) |
| "Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits." | 4.12 | Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. ( Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G, 2022) |
| "Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form." | 4.02 | Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. ( Garakani, A, 2021) |
| "Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine's antidepressant actions in rodent models at sub-therapeutic doses." | 4.02 | Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression. ( Butters, K; Frye, MA; McGee, SL; Morath, BA; Price, JB; Tye, SJ; Van De Wakker, SK; Yates, CG; Yates, NJ, 2021) |
| "Τhe Food and Drug Administration (FDA) approval of the use of S-ketamine in the form of nasal spray for the treatment of treatment-resistant depression, launched a new category of therapeutic agents in psychiatry." | 4.02 | [Ketamine infusion therapy in treatment-resistant depression]. ( Christodoulakis, ΤΕ, 2021) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 4.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| " Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics." | 4.02 | Perspectives of Ketamine Use in COVID-19 Patients. ( Weinbroum, AA, 2021) |
| "This study suggests the possible clinical utility of resting-state functional magnetic resonance imaging for predicting the antidepressant effects of ketamine in treatment-resistant depression patients and implicated resting-state functional connectivity alterations to determine the trait-like pathophysiology underlying treatment response heterogeneity in treatment-resistant depression." | 4.02 | Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression. ( Abe, T; Hiraki, T; Horikawa, N; Ishibashi, M; Nakamura, T; Tomita, M; Uchimura, N; Uematsu, K, 2021) |
| "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response." | 4.02 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Adults with treatment-resistant depression (TRD) receiving intravenous (IV) ketamine had depressive symptoms measured with the 16-Item Quick Inventory Depressive Symptoms Self-Report (QIDS-SR-16) and MARRRS at baseline and as a repeated measure across an acute course of four infusions." | 4.02 | Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "(R,S)-ketamine causes rapid-acting and sustained antidepressant effects in treatment-resistant patients with depression although the precise molecular mechanisms underlying its antidepressant action remain unclear." | 4.02 | Intranasal administration of transforming growth factor-β1 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: A role of TrkB signaling. ( Chang, L; Hashimoto, K; Wei, Y, 2021) |
| "These findings not only suggest that ketamine represents a viable candidate for the treatment of poststroke depression but also that ketamine's lasting antidepressant effects might be achieved through modulation of NMDAR/CaMKII-induced synaptic plasticity in key brain regions." | 4.02 | Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model. ( Abdoulaye, IA; Cao, XJ; Chibaatar, E; Guo, YJ; Le, K; Wu, SS; Yu, DF, 2021) |
| " Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine." | 4.02 | Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? ( Cha, DS; Gill, H; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD)." | 4.02 | Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. ( Abrishami, A; Arekapudi, AK; Chau, EH; Di Vincenzo, JD; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Szpejda, W; Wong, L, 2021) |
| " The treatments with ketamine, guanosine, and ketamine plus guanosine were effective to counteract corticosterone-induced anxiety-like phenotype, but not disturbances in the hippocampal NLRP3 pathway." | 4.02 | Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway. ( Camargo, A; Dalmagro, AP; Fraga, DB; Kaster, MP; Rodrigues, ALS; Rosa, JM; Zeni, ALB, 2021) |
| "Ketamine and related compounds are emerging as rapidly acting therapies for treatment-resistant depression." | 4.02 | Ketamine treatment for depression: A model of care. ( Alonzo, A; Bayes, A; Dong, V; Kabourakis, M; Loo, C; Martin, D, 2021) |
| "We included 104 patients with KD (76 males and 28 females) who received inpatient treatment for ketamine withdrawal and assessed them by using Beck Depression Inventory (BDI), Beck Anxiety Inventory, and a visual analog scale (VAS; 0-100 mm) for ketamine craving on day 2 to 3 of admission." | 3.96 | Association of Craving and Depressive Symptoms in Ketamine-Dependent Patients Undergoing Withdrawal Treatment. ( Chang, HM; Chen, CH; Chen, CK; Chen, LY; Huang, MC; Xu, K, 2020) |
| "Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects." | 3.96 | Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, LT; Zarate, CA, 2020) |
| "In rodent models of depression, (R)-ketamine has greater potency and longer-lasting antidepressant effects than (S)-ketamine; however, the precise molecular mechanisms underlying the antidepressant actions of (R)-ketamine remain unknown." | 3.96 | Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. ( Chang, L; Fujita, Y; Hashimoto, K; Hatano, M; Ishima, T; Pu, Y; Qu, Y; Sakamoto, A; Shirayama, Y; Suzuki, T; Tan, Y; Tanaka, KF; Wang, S; Wang, X; Yang, C; Zhang, K, 2020) |
| " Here we aimed to compare the effects of (R)-norketamine ((R)-NK), (S)-NK, (2R,6R)-HNK, and (2S,6S)-HNK in a mouse model of depression induced by chronic corticosterone (CORT) injection." | 3.96 | (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. ( Ago, Y; Chen, L; Hashimoto, H; Hashimoto, K; Higuchi, M; Kasai, A; Naito, M; Nakagawa, S; Nakazawa, T; Seiriki, K; Tanabe, W; Tsukada, S; Yamaguchi, T; Yokoyama, R, 2020) |
| "The present study evaluated the effects of ketamine in rats with the comorbidity of CPSP and depression." | 3.96 | Ketamine relieves depression-like behaviors induced by chronic postsurgical pain in rats through anti-inflammatory, anti-oxidant effects and regulating BDNF expression. ( Liu, Y; Ma, P; Ma, T; Song, Y; Yang, Y; Zhang, H; Zhang, X; Zhao, W; Zhao, Y, 2020) |
| "To investigate the effects of adjunct ketamine treatment on chronic treatment-resistant schizophrenia patients with treatment-resistant depressive symptoms (CTRS-TRD patients), including alterations in brain function." | 3.96 | Adjunct ketamine treatment of depression in treatment-resistant schizophrenia patients is unsatisfactory in pilot and secondary follow-up studies. ( Bian, H; Chen, C; Lin, X; Liu, S; Tian, H; Zhuo, C, 2020) |
| " Ketamine can quickly relieve depression, and its subcutaneous administration appears to be as effective as and probably safer than its standard intravenous administration." | 3.96 | Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: A case report. ( Barbosa, MG; Delfino, RS; Jackowski, AP; Sarin, LM, 2020) |
| "The ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) has recently been suggested as an ideal antidepressant for treating animal models of depression." | 3.96 | Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions. ( Chou, D, 2020) |
| "We used a rat prenatal stress (PS) model of depression to explore the functional role of mGluR5 in ketamine's rapidly induced antidepressant activity." | 3.96 | mGluR5 mediates ketamine antidepressant response in susceptible rats exposed to prenatal stress. ( Cao, Y; Che, F; He, W; Sun, H; Wang, Y; Yao, Z; Zhang, H, 2020) |
| " Ketamine produces a rapid-onset and sustained antidepressant response, but there is no evidence whether ketamine treatment is effective for GWI depression." | 3.96 | Molecular mechanisms for the antidepressant-like effects of a low-dose ketamine treatment in a DFP-based rat model for Gulf War Illness. ( Deshpande, LS; Hawkins, E; Jahr, FM; Kronfol, MM; McClay, JL; Ribeiro, ACR; Younis, RM; Zhu, J, 2020) |
| " Considering that ketamine has significant knock-on effects, this study investigated the effects of a single coadministration with subthreshold doses of ketamine plus guanosine in a corticosterone (CORT)-induced animal model of depression and the role of anti-inflammatory and antioxidant pathways." | 3.96 | Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-κB/IDO-1 signaling. ( B Zeni, AL; Camargo, A; Dalmagro, AP; M Rosa, J; P Kaster, M; S Rodrigues, AL; Tasca, CI, 2020) |
| "The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently characterized." | 3.96 | The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. ( Abrishami, A; Arekapudi, AK; Brietzke, E; Carvalho, IP; Chau, EH; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Senyk, O; Siegel, A; Subramaniapillai, M; Szpejda, W, 2020) |
| "Subanesthetic ketamine is found to induce fast-acting and pronounced antidepressant effects, even in treatment resistant depression (TRD)." | 3.96 | Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. ( Congdon, E; Espinoza, R; Joshi, SH; Kubicki, A; Loureiro, JR; Narr, KL; Sahib, AK; Vasavada, MM; Wade, B; Woods, RP, 2020) |
| "Ketamine has been clinically proven to ameliorate depression, including treatment-resistant depression." | 3.96 | Immobility-reducing Effects of Ketamine during the Forced Swim Test on 5-HT1A Receptor Activity in the Medial Prefrontal Cortex in an Intractable Depression Model. ( Kitamura, Y; Sendo, T; Takahashi, K; Ushio, S, 2020) |
| "In CFA-treated mice that exhibited pain behavior and depression-like behavior, ketamine reversed depression-like behavior." | 3.96 | Subanesthetic Dose of Ketamine Improved CFA-induced Inflammatory Pain and Depression-like Behaviors Via Caveolin-1 in Mice. ( Han, R; Han, S; Li, J; Peng, Y; Sun, W; Wang, J; Zhao, Q; Zhou, Y, 2020) |
| "In this longitudinal study, 114 ketamine users completed clinical and cognitive assessments at both baseline and 12-week follow-up with the following instruments: Severity of Dependence Scale, Beck Depression Inventory (BDI), Anxiety Subscale of the Hospital Anxiety Depression Scale (HADSA), and a cognitive battery." | 3.91 | Recovery of cognitive functioning following abstinence from ketamine. ( Lane, HY; Lau, CG; Lin, SK; Tang, WK; Ungvari, GS, 2019) |
| " There is a rising promise in a N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, which may be used in the treatment of resistant depression." | 3.91 | Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. ( Cubała, WJ; Małyszko, A; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| "In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults." | 3.91 | Esketamine for treatment resistant depression: a trick of smoke and mirrors? ( Barbui, C; Gastaldon, C; Ostuzzi, G; Papola, D, 2019) |
| "A recent review proposed four criteria for an animal model of treatment-resistant depression (TRD): a phenotypic resemblance to a risk factor for depression; enhanced response to stress; nonresponse to antidepressant drugs and response to treatments effective in TRD, such as deep brain stimulation (DBS) of the prefrontal cortex or ketamine." | 3.91 | Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. ( Gruca, P; Lason, M; Litwa, E; Niemczyk, M; Papp, M; Tota-Glowczyk, K; Willner, P, 2019) |
| "Ketamine has been shown to induce a rapid antidepressant effect on patients with depression." | 3.91 | Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats. ( Pałucha-Poniewiera, A; Pilc, A; Podkowa, K, 2019) |
| "Ketamine has rapid antidepressant effects, but no study to date has investigated changes in resting-state brain activity following ketamine administration in inflammation-induced depression." | 3.91 | Acute ketamine administration attenuates lipopolysaccharide-induced depressive-like behavior by reversing abnormal regional homogeneity in the nucleus accumbens. ( Ji, M; Li, B; Li, S; Mao, M; Qiu, L; Xia, J; Yang, J; Zhang, L, 2019) |
| "A growing body of literature has demonstrated the potential for ketamine in the treatment of major depression." | 3.91 | Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission. ( Fariborzi, M; Higley, MJ; Lur, G, 2019) |
| "The purpose of this study was to explore the possible interaction between ketamine and cannabinoid system in the modulation of depression-related responses using the forced swimming test (FST), tail suspension test (TST) and open-field test (OFT) in mice." | 3.91 | Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system. ( Alijanpour, S; Ebrahimi-Ghiri, M; Khakpai, F; Zarrindast, MR, 2019) |
| "Major depression is a stress-linked disease with significant morbidity and the anesthetic drug ketamine is of growing interest in the treatment of depression, since in responsive individuals a single dose has rapid (within hours) antidepressant effects that can be sustained for over a week in some instances." | 3.91 | Stress-sensitive antidepressant-like effects of ketamine in the mouse forced swim test. ( Fitzgerald, PJ; Watson, BO; Yen, JY, 2019) |
| "The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine produces rapid and sustained antidepressant effects in treatment-resistant patients with depression although intranasal use of (R,S)-ketamine in ketamine abusers is popular." | 3.91 | Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. ( Chang, L; Dong, C; Fujita, Y; Hashimoto, K; Pu, Y; Qu, Y; Ren, Q; Wang, SM; Xiong, Z; Zhang, K, 2019) |
| "Ketamine produces a rapid-onset antidepressant effect in patients with treatment-resistant depression (TRD), although it concurrently causes undesirable psychotomimetic side effects." | 3.91 | TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats. ( Hara, H; Kimura, H; Kunugi, A; Murakami, K; Suzuki, A; Tajima, Y, 2019) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| "Recent studies have shown that ketamine, an open channel blocker of the N-methyl-d-aspartate receptor (NMDAR), is effective for patients with treatment-resistant depression." | 3.91 | Potential link between antidepressant-like effects of ketamine and promotion of adult neurogenesis in the ventral hippocampus of mice. ( Jinno, S; Yamada, J, 2019) |
| "Our findings suggest that skeletal muscular glycine contributes to the antidepressant effects of ketamine in inflammation." | 3.91 | Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression. ( Hua, D; Hua, F; Huang, N; Jiang, R; Li, S; Luo, A; Wang, Y; Wu, Y; Yang, C; Yang, L; Yu, F; Zhan, G; Zhu, B, 2019) |
| "This study investigated the risk factors of ketamine associated-lower urinary tract symptoms (LUTS), such as duration of use, dosage of ketamine, co-occurring substance use of other psychoactive drugs, comorbidities, and depression." | 3.88 | Risk Factors of Lower Urinary Tract Syndrome among Ketamine Users. ( Chen, IC; Chen, WC; Hu, TC; Lee, MH; Lin, HY, 2018) |
| "(R)-Ketamine exhibits rapid and sustained antidepressant effects in animal models of depression." | 3.88 | Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine. ( Hashimoto, K; Shirayama, Y, 2018) |
| "The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication." | 3.88 | Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions. ( Dunlop, BW; Edwards, JA; Galendez, GC; Garlow, SJ; Job, GP; McDonald, WM; Reiff, CM; Riva-Posse, P; Saah, TC, 2018) |
| "Ketamine, an N-methyl-D-aspartate receptor antagonist, exerts robust antidepressant effects in patients with treatment-resistant depression." | 3.88 | AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine. ( Chaki, S; Dong, C; Han, M; Hashimoto, K; Kobayashi, S; Ma, M; Manabe, T; Nakao, K; Nakazawa, K; Qu, Y; Ren, Q; Shirayama, Y; Toki, H; Yamaguchi, JI; Yang, C; Zhang, JC, 2018) |
| "Rapid anti-suicidal and antidepressant effects of ketamine have repeatedly been confirmed in unipolar and bipolar depression." | 3.88 | Rapid antidepressant effect of S-ketamine in schizophrenia. ( Bartova, L; Dold, M; Kasper, S; Milenkovic, I; Papageorgiou, K; Weidenauer, A; Willeit, M; Winkler, D, 2018) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 3.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "Previous studies have suggested that rapid reductions in depression-like behaviors are observed in response to sub-anesthetic-doses of ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist." | 3.88 | Essential roles of neuropeptide VGF regulated TrkB/mTOR/BICC1 signaling and phosphorylation of AMPA receptor subunit GluA1 in the rapid antidepressant-like actions of ketamine in mice. ( Chen, Y; Li, S; Liu, X; Lv, D; Shen, M; Wang, C; Wang, Z; Zhang, Y, 2018) |
| "The efficacy of ketamine to alleviate depressive symptoms has promoted a wealth of research exploring alternate therapeutic targets for depression." | 3.88 | Interactive effects of ghrelin and ketamine on forced swim performance: Implications for novel antidepressant strategies. ( Abizaid, A; Dwyer, Z; Hayley, S; Landrigan, J; Shawaf, F, 2018) |
| "Chronic ketamine use leads to cognitive and affective deficits including depression." | 3.85 | Depression in chronic ketamine users: Sex differences and neural bases. ( Chen, CM; Duann, JR; Hung, CC; Lee, TS; Li, CR; Lin, CP; Zhang, S, 2017) |
| "Effects of a single bilateral infusion of R-enantiomer of ketamine in rat brain regions of learned helplessness model of depression were examined." | 3.85 | Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. ( Hashimoto, K; Shirayama, Y, 2017) |
| "The acute antidepressant effects of ketamine provide hope for the development of a fast acting approach to treat depression but the consequences of chronic treatment with ketamine are still unclear." | 3.85 | Lack of effect of chronic ketamine administration on depression-like behavior and frontal cortex autophagy in female and male ICR mice. ( Agam, G; Anderson, GW; Einat, H; Kara, NZ; Zitron, N, 2017) |
| "Clinical studies on the role of the glutamatergic system in the pathogenesis of depression found that ketamine induces an antidepressant response, but the molecular mechanisms remain unclear." | 3.85 | Sub-anesthetic doses of ketamine exert antidepressant-like effects and upregulate the expression of glutamate transporters in the hippocampus of rats. ( Hao, X; Luo, J; Wang, Z; Ye, G; Zhu, X, 2017) |
| "Ketamine has emerged as a novel strategy to treat refractory depression, producing rapid remission, but elicits some side effects that limit its use." | 3.83 | Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway. ( Colla, AR; Cunha, MP; Lieberknecht, V; Oliveira, Á; Pazini, FL; Rodrigues, AL; Rosa, JM, 2016) |
| "The use of ketamine in research and treatment of depressive disorders is controversial." | 3.83 | Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications. ( Harris, KM; Ho, RC; Zhang, MW, 2016) |
| "The aim of the present study was to investigate the effects of ketamine, imipramine, and ketamine plus imipramine on chronic depression-like behaviors of Wistar Kyoto (WKY) rats and underlying mechanism." | 3.83 | [Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats]. ( Jin, XJ; Li, QQ; Peng, LC; Ye, K, 2016) |
| " We examined the effects of isolation stress (IS) and the fast-acting antidepressant ketamine on anhedonia and depression-like behavior, spine density, and synaptic proteins in male and female rats." | 3.83 | Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats. ( Kabbaj, M; Sarkar, A, 2016) |
| "Altogether, these data suggest that the joint administration of ketamine and LY341495 might be a noteworthy alternative to the use of solely ketamine in the therapy of depression." | 3.83 | Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. ( Brański, P; Pałucha-Poniewiera, A; Pilc, A; Pochwat, B; Podkowa, K, 2016) |
| "One of the most striking discoveries in the treatment of major depression was the finding that infusion of a single sub-anesthetic dose of ketamine induces rapid and sustained antidepressant effects in treatment-resistant depressed patients." | 3.83 | Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice. ( Mauch, J; Pandit, R; Pitychoutis, PM; Sens, J; Thelen, C, 2016) |
| "Ketamine is emerging as a new hope against depression, but ketamine-associated psychotomimetic effects limit its clinical use." | 3.83 | Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice. ( Chan, MH; Chen, HH; Chen, YC; Lee, MY; Lin, JC, 2016) |
| "The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression." | 3.83 | Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. ( Chen, QX; Han, M; Hashimoto, K; Ma, M; Ren, Q; Yang, B; Yang, C; Yao, W; Zhang, JC, 2016) |
| "The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive antidepressants since this drug causes rapid-onset and sustained antidepressant effects in treatment resistant patients with depression." | 3.83 | Ketamine's antidepressant action: beyond NMDA receptor inhibition. ( Hashimoto, K, 2016) |
| " Fifty stressed rats were randomly divided into 5 groups (n = 10 per group): depression group (with no application, group D), ECS group (applied with ECS after intraperitoneal injection of isotonic sodium chloride solution, 8 mL/kg, group E), ketamine + ECS group (applied with ECS after intraperitoneal injection of ketamine, 10 mg/kg, group KE), propofol + ECS group (applied with ECS after intraperitoneal injection of propofol, 80 mg/kg, group PE), and ketamine + propofol + ECS group (applied with ECS after intraperitoneal injection of ketamine, 10 mg/kg, and propofol, 80 mg/kg, group KPE)." | 3.81 | Effects of low-dose ketamine combined with propofol on phosphorylation of AMPA receptor GluR1 subunit and GABAA receptor in hippocampus of stressed rats receiving electroconvulsive shock. ( Ao, L; Chen, J; Hao, XC; Li, P; Liu, L; Luo, J; Lv, F; Min, S; Peng, LH, 2015) |
| "We investigated whether the nitric oxide (NO) precursor, L-arginine, can prevent the antidepressant-like action of the fast-acting antidepressant, ketamine, in a genetic rat model of depression, and/or induce changes in the glutamate (Glu)/N-methyl-D-aspartate receptor (NMDAR)/NO/cyclic guanosine monophosphate (cGMP) signalling pathway." | 3.81 | Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression. ( Joca, S; Liebenberg, N; Wegener, G, 2015) |
| "Studies have suggested that ketamine, a nonselective NMDA receptor antagonist, could be a new drug in the treatment of major depression, but the way ketamine presents such effects remains to be elucidated." | 3.81 | Ketamine treatment partly reverses alterations in brain derived- neurotrophic factor, oxidative stress and energy metabolism parameters induced by an animal model of depression. ( Abelaira, HM; Carlessi, AS; da Luz, JR; dos Santos, MA; Jeremias, GC; Matias, BI; Morais, MO; Nacif, MP; Quevedo, J; Réus, GZ; Scaini, G; Steckert, AV; Streck, EL; Tomaz, DB, 2015) |
| "The benefits of creatine supplementation have been reported in a broad range of central nervous systems diseases, including depression." | 3.81 | Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A₁ and A2A receptor activation. ( Cunha, MP; Kaster, MP; Oliveira, Á; Pazini, FL; Ramos-Hryb, AB; Rodrigues, AL; Rosa, JM, 2015) |
| "Ketamine, N-methyl-d-aspartate (NMDA) receptor antagonist and anti-inflammatory agent, has rapid therapeutic effects in a subset of patients with more intractable forms of depression." | 3.81 | Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. ( Foley, BM; Frye, MA; McGillivray, JA; Sutor, SL; Tye, SJ; Walker, AJ, 2015) |
| "CUMS induced depression-like behaviours and up-regulated the hippocampal levels of IL-1β, IL-6, TNF-α, IDO, and the KYN/TRP ratio, which were attenuated by a sub-anaesthetic dose of ketamine." | 3.81 | The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus. ( Gao, ZQ; Shen, XF; Wang, N; Yang, C; Yang, JJ; Yu, HY; Zhang, GF, 2015) |
| "Increasing evidence underscores the strong, rapid, and sustained antidepressant properties of ketamine with a good tolerability profile in patients with depression; however, the underlying mechanisms are not fully elucidated." | 3.80 | Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine. ( Liu, XY; Qiu, LL; Sun, HL; Wang, N; Wang, XM; Yang, C; Yang, JJ; Zhang, GF, 2014) |
| "Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, and group II metabotropic glutamate (mGlu2/3) receptor antagonists produce antidepressant effects in animal models of depression, which last for at least 24h, through the transient increase in glutamate release, leading to activation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptor." | 3.80 | Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. ( Chaki, S; Koike, H, 2014) |
| "We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression." | 3.80 | Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. ( Belujon, P; Grace, AA, 2014) |
| "Ketamine is used preclinically and clinically to study schizophrenia and depression." | 3.80 | Enhancing ketamine translational pharmacology via receptor occupancy normalization. ( Liu, J; Osgood, SM; Shaffer, CL; Smith, DL; Trapa, PE, 2014) |
| "In this study, we tested whether AMPA alone has an antidepressant effect and if the combination of AMPA and ketamine provides added benefit in Wistar-Kyoto rats, a putative animal model of depression." | 3.79 | Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. ( Akinfiresoye, L; Tizabi, Y, 2013) |
| "Ketamine (20 mg/kg) reversed the chronic unpredictable stress-induced depression-like behaviors in the FST." | 3.79 | Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. ( Alcantara, LF; Bolaños-Guzmán, CA; Hadad, R; Iñiguez, SD; Kroeck, KG; Parise, EM; Sial, OK; Warren, BL; Wright, KN, 2013) |
| "The authors examined whether the spared nerve injury model of neuropathic pain induces depressive behavior in rats, using sucrose preference test and forced swim test, and tested whether a subanesthetic dose of ketamine treats spared nerve injury-induced depression." | 3.77 | A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. ( Blanck, TJ; Eberle, SE; Goffer, Y; Shamir, DB; Tukey, DS; Wang, J; Xu, D; Ziff, EB; Zou, AH, 2011) |
| "Clinical findings suggest that ketamine may be used for the treatment of major depression." | 3.75 | Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. ( Assis, LC; Comim, CM; Jeremias, IC; Quevedo, J; Rezin, GT; Streck, EL; Valvassori, SS; Zugno, AI, 2009) |
| "Ketamine is an open channel blocker of ionotropic glutamatergic N-Methyl-D-Aspartate (NMDA) receptors." | 3.54 | Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. ( Kavalali, ET; Krystal, JH; Monteggia, LM, 2024) |
| "For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach." | 3.30 | Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series. ( Desbeaumes Jodoin, V; Elkrief, L; Garel, N; Lespérance, P; Longpré-Poirier, C; Miron, JP; Payette, O; Richard, M, 2023) |
| "The optimal dosage and method of esketamine for postpartum depressive symptoms (PDS) are unclear." | 3.30 | Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: A randomized, double-blind, controlled clinical study. ( Bai, ZH; Chen, L; Duan, KM; Gao, K; Li, QW; Mao, XY; Ping, AQ; Wang, SY; Xu, SY; Yang, SQ; Yang, ST; Zhou, YY, 2023) |
| "Forty-eight patients with treatment-resistant depression and strong suicidal ideation (TRD-SI) were randomly assigned to a single infusion of 0." | 3.30 | Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " In the esketamine group, the total dosage of esketamine will be 0." | 3.11 | Effect of esketamine on perioperative depressive symptoms in major surgery patients (PASSION II): study protocol for a randomised controlled trial. ( Fu, Y; Han, R; Ma, B; Sun, W; Wang, A; Wang, G; Wang, J; Zhou, Y, 2022) |
| " Demographics, adverse events, and patient-reported dissociation were also analyzed." | 3.11 | At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. ( Akiki, TJ; Arden, K; Gazzaley, A; Hull, TD; Klotz, M; Madan, A; Malgaroli, M; Paleos, C; Swain, J; Vando, L, 2022) |
| "Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain." | 3.01 | Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine. ( Chao, Z; Lan, X; Li, H; Ning, Y; Wang, C; Zhou, Y, 2021) |
| "SC ketamine was safe and well tolerated, and most adverse events were mild and transient." | 3.01 | Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities. ( Cunha, UGV; Duarte, DB; Hara, C; Rocha, FL, 2023) |
| "Ketamine has shown antidepressant effects in patients with major depressive disorder (MDD) resistant to first-line treatments and approved for use in this patient population." | 3.01 | Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders. ( Aguilar-Valles, A; Arsenault, E; Lewis, V; Matta-Camacho, E; Myers, M; Rodrigue, B; Silva, WCC; Taghavi-Abkuh, FF; Zhang, M, 2023) |
| "Major depressive disorder is a prevalent and heterogeneous disorder with treatment resistance in at least 50% of individuals." | 3.01 | Imaging synaptic density in depression. ( Abdallah, C; Esterlis, I; Holmes, SE, 2023) |
| "Depression is a well-known serious mental illness, and the onset of treatment using traditional antidepressants is frequently delayed by several weeks." | 3.01 | Ketamine and its metabolites: Potential as novel treatments for depression. ( Hashimoto, K; Yao, Y; Zhang, K, 2023) |
| "Ketamine is a NMDA receptor antagonist that has a rapid acting antidepressant effect with high efficacy in treatment-resistant patients." | 3.01 | Biomarkers of ketamine's antidepressant effect: An umbrella review. ( Cao, B; Ceban, F; Di Vincenzo, JD; Ho, RC; Jawad, MY; McIntyre, RS; Meshkat, S; Rhee, TG; Rosenblat, JD; Teopiz, KM, 2023) |
| " Secondary outcomes included postoperative visual analog scale (VAS) scores for pain and adverse effects associated with ketamine." | 3.01 | Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies. ( Gu, HW; Guo, J; Hashimoto, K; Qiu, D; Wang, XM; Yang, JJ; Zhang, GF, 2023) |
| "Despite this, there are few effective treatments for BD depression, with only a handful of atypical anti-psychotics and inconsistent evidence for traditional mood stabilizing agents." | 3.01 | New Pharmacologic Approaches to the Treatment of Bipolar Depression. ( Chakrabarty, T; DuBois, A; Keramatian, K; Saraf, G; Yatham, LN, 2023) |
| "Depression is a profound mental disorder that dampens the mood and undermines volition, which exhibited an increased incidence over the years." | 3.01 | A synopsis of multitarget therapeutic effects of anesthetics on depression. ( Wu, G; Xu, H, 2023) |
| "Patients with major depressive disorder who do not respond to ≥2 different pharmacological treatments within the current depressive episode are considered to have treatment resistant depression (TRD)." | 3.01 | Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr ( Blackowicz, M; Cooper, K; Drevets, WC; Fedgchin, M; Floden, L; Hudgens, S; Jamieson, C; Lane, R; Popova, V; Singh, J, 2021) |
| "Ketamine infusions were well tolerated overall, without serious adverse events." | 3.01 | A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. ( Bevilacqua, L; Brallier, J; Charney, DS; Collins, AB; Collins, KA; Corniquel, M; Costi, S; Feder, A; Glasgow, AM; Govindarajulu, U; Horn, SR; Jha, MK; Kautz, M; Murrough, JW; Pietrzak, RH; Rutter, SB, 2021) |
| "Ketamine is an N-methyl-D-aspartate receptor antagonist with rapid antidepressant effects." | 3.01 | Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. ( Bagiella, E; Bevilacqua, L; Brallier, J; Charney, A; Charney, DS; Glasgow, A; Jha, MK; Kirkwood, K; Murrough, JW; Pierce, CR; Richards, SM, 2021) |
| "Norketamine concentration was not associated with antidepressant response." | 2.94 | Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. ( Adeojo, L; Farmer, CA; George, J; Gilbert, JR; Gould, TD; Kadriu, B; Lovett, J; Moaddel, R; Nugent, AC; Park, LT; Yuan, P; Zarate, CA, 2020) |
| "Ketamine is a general anaesthetic with anti-depressant effects at subanaesthetic doses." | 2.87 | Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. ( Avidan, MS; Ben Abdallah, A; El-Gabalawy, R; Jacobsohn, E; Lenze, E; Mashour, GA; Maybrier, HR; Pryor, KO; Veselis, RA; Vlisides, PE, 2018) |
| "A breakthrough in the treatment of depression was the discovery that the anesthetic (R,S)-ketamine (ketamine), when administered at sub-anesthetic doses, elicits rapid (sometimes within hours) antidepressant effects in humans that are otherwise resistant to monoaminergic-acting therapies." | 2.82 | Mechanisms of ketamine and its metabolites as antidepressants. ( Gould, TD; Hess, EM; Michaelides, M; Riggs, LM, 2022) |
| "Current first-line treatments for major depressive disorder (MDD), i." | 2.82 | Rapid treatments for depression: Endocannabinoid system as a therapeutic target. ( Ahmadalipour, A; Fakhari, A; Khajehnasiri, N; Pakkhesal, S; Sharafi, A, 2022) |
| " Finally, continuing to monitor research subjects and patients long-term for the emergence of adverse effects on cognition or other organ systems is critical." | 2.82 | Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. ( Kritzer, MD; Masand, PS; Pae, CU, 2022) |
| "Ketamine is a fast-acting anesthetic with hypnotic properties." | 2.82 | Ketamine for resistant depression: a scoping review. ( Andrés, VC; Angel, RO; Angela, A; David, C; Eduardo, TQ; Estefania, C; Juan, G; Juan, P; Mateo, L; Melanie, LZ; Natalia, RS; Valentina, PF, 2022) |
| "Depression is a common psychiatric symptom in numerous neurological disorders." | 2.82 | (R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression. ( Hashimoto, K; Wang, X; Yang, J, 2022) |
| "Pharmacotherapy of depression is characterized by the delayed onset of action, chronic treatment requirements, and insufficient effectiveness." | 2.82 | New investigational agents for the treatment of major depressive disorder. ( Krupa, AJ; Pochwat, B; Siwek, M; Szewczyk, B, 2022) |
| "Depression is disabling and highly prevalent." | 2.82 | International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. ( Abdallah, CG; Ballard, ED; Baumeister, A; Blier, P; Charney, DS; Chen, MH; Deakin, W; Fava, M; Feder, A; Gallagher, B; Grunebaum, MF; Hock, R; Kissel, N; Lundberg, J; Mann, JJ; Mathew, SJ; McLoughlin, DM; McMillan, R; Murrough, JW; Muthukumaraswamy, S; Papakostas, G; Phillips, JL; Price, RB; Rohac, R; Shiroma, P; Šóš, P; Su, TP; Sumner, R; Tiger, M; Wallace, ML; Wilkinson, ST; Woody, ML; Zarate, CA, 2022) |
| "The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas." | 2.82 | BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression. ( Carboni, E; Carta, AR, 2022) |
| "Ketamine is a novel rapid-acting antidepressant with neuroplastic potential." | 2.82 | The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine. ( Cubała, WJ; Wilkowska, A, 2022) |
| "Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with demonstrated antidepressant effects in the adult population, however, the efficacy and safety of ketamine for the treatment of pediatric depression remains poorly understood." | 2.82 | Ketamine use in pediatric depression: A systematic review. ( Cao, B; Ceban, F; Chisamore, N; Danayan, K; Ho, RC; McIntyre, RS; Meshkat, S; Rhee, TG; Rosenblat, JD; Vincenzo, JDD, 2022) |
| "Ketamine infusion was associated with significant and rapid reduction in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion (mean difference in Impact of Event Scale-Revised score, 12." | 2.79 | Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. ( Aan Het Rot, M; Charney, DS; Feder, A; Iosifescu, D; Kirkwood, K; Lapidus, KA; Morgan, JE; Murrough, JW; Parides, MK; Perez, AM; Saxena, S; Wan, LB, 2014) |
| "Psychotic depression is a subtype of major depressive disorder characterized by mood congruent hallucinations and/or delusions." | 2.72 | Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. ( Cao, B; Cha, DS; Di Vincenzo, JD; Gill, H; Ho, RC; Le, TT; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Ketamine has rapid antidepressant effects, which are hypothesised to occur via increases in glutamate, with sequelae including increased neuroplasticity, neurogenesis and synaptogenesis." | 2.72 | Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review. ( Himmerich, H; Juruena, MF; Kan, C; Keeler, JL; Treasure, J, 2021) |
| "Ketamine is an antagonist of the N-Methyl-D-aspartate receptor (NMDAR) and its main mechanism of action via NMDAR inhibition expressed in GABAergic (gamma-Aminobutyric acid, GABA) interneurons may be relayed to its antidepressant effects." | 2.72 | [Pharmacology of ketamine and esketamine as rapid-acting antidepressants]. ( Dalla, C; Kokras, N; Megalokonomou, A; Pavlidi, P; Sofron, A, 2021) |
| " This rapid release of BDNF differs from typical monoaminergic agents that require chronic administration to produce a slow induction of BDNF expression, consistent with the time lag for the therapeutic action of these agents." | 2.72 | Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants. ( Deyama, S; Duman, RS; Fogaça, MV, 2021) |
| "Depression is a highly debilitating psychiatric disorder and a worldwide health issue." | 2.72 | Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery. ( Musazzi, L, 2021) |
| "Ketamine has demonstrated efficacy as a rapid-onset intervention for the treatment of depression." | 2.72 | The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. ( El-Halabi, S; Gill, B; Gill, H; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD, 2021) |
| "Major depression is a frequent and disabling disorder." | 2.72 | [A review of the antidepressant properties of ketamine]. ( Blier, P; Desfossés, CY, 2021) |
| "One third among them will suffer from treatment resistant depression (TRD) which does not respond to two accepted treatment protocols." | 2.72 | [ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT]. ( Marom, A; Rosca, P, 2021) |
| "Nasal esketamine spray produces the adverse effects of dizziness, vertigo, and blurred vision severe enough to cause discontinuation in 4% of patients; it also can produce transient elevation of blood pressure (SOR: A, meta-analyses)." | 2.72 | Is ketamine effective and safe for treatment-resistant depression? ( Jenkinson, M; Kelsberg, G; Linn, S; Neher, JO; Safranek, S; Zorn, A, 2021) |
| "Ketamine is a racemic mixture comprising equal parts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine)." | 2.66 | Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. ( Hashimoto, K, 2020) |
| "Ketamine is an anaesthetic medication that acts as an antagonist of the NMDA receptor and has antidepressant potential." | 2.61 | Efficacy of Ketamine in bipolar depression: focus on anhedonia. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, Ł; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczk, A, 2019) |
| "Depression is a worldwide illness with a significant impact on both family and society." | 2.61 | Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect. ( Cui, W; Hong, W; Li, MD; Liu, Z; Ning, Y; Wang, J, 2019) |
| "Ketamine alone was not more efficacious in treating depressive symptoms than other anesthetic drugs at early study, post-ECT and end of study time points." | 2.61 | Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials. ( Cai, DB; He, SH; Hu, YD; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, G; Xiang, YT; Yang, XH; Zheng, W; Zhu, XM, 2019) |
| "Among patients with Parkinson's disease (PD), depression is prevalent and disabling, impacting both health outcomes and quality of life." | 2.58 | NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. ( Bashmi, L; Danovitch, I; IsHak, WW; Jimenez, J; Olcott, W; Vanle, B, 2018) |
| "Depression is one of the major causes of disability worldwide." | 2.58 | Ketamine and magnesium common pathway of antidepressant action. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Słupski, J, 2018) |
| "As ketamine has serious self-limiting drawbacks that restrict its widespread use for this purpose, a safer alternative is needed." | 2.55 | What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. ( Bhimani, PM; Cavaretta, MJ; Kaabe, JH; Krysiak, JT; Nanchanatt, DL; Nguyen, TN; Pough, KA; Prince, TA; Raffa, RB; Ramsey, NS; Savsani, KH; Scandlen, L; Strasburger, SE, 2017) |
| "Major depression is a chronic and debilitating illness that effects approximately 1 in 5 people, but currently available treatments are limited by low rates of efficacy, therapeutic time lag, and undesirable side effects." | 2.53 | Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. ( Duman, RS; Gerhard, DM; Wohleb, ES, 2016) |
| "Ketamine has been generally well tolerated across patient groups, with transient mild-to-moderate adverse effects during infusion." | 2.52 | Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. ( Abdallah, CG; Averill, LA; Krystal, JH, 2015) |
| "Depression is a major psychiatric disorder affecting more than 120 million people worldwide every year." | 2.52 | The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity? ( Celikel, T; Freudenberg, F; Reif, A, 2015) |
| "Depression affects nearly 15% of the population." | 2.49 | New paradigms for treatment-resistant depression. ( Duman, RS; Liu, G; Murck, H; Quiroz, J; Sartori, S; Zarate, C, 2013) |
| "Depression is drug-resistant, if the severity of the symptoms has not decreased to half of the starting situation, despite appropriately conducted treatment with two antidepressants belonging to two different pharmacological categories." | 2.49 | [Treatment of drug-resistant depression]. ( Taiminen, T, 2013) |
| " However, previous reports have been essentially based on ketamine dosing modes that differ from the clinical route of administration (slow intravenous infusion)." | 2.44 | Temporal dynamics of BDNF signaling recruitment in the rat prefrontal cortex and hippocampus following a single infusion of a translational dose of ketamine. ( Caffino, L; Chiamulera, C; Fumagalli, F; Mottarlini, F; Piva, A; Rizzi, B, 2024) |
| "Ketamine is a well-characterized NMDA receptor (NMDAR) antagonist, although the relevance of this pharmacology to its rapid (within hours of administration) antidepressant actions, which depend on mechanisms convergent with strengthening of excitatory synapses, is unclear." | 1.91 | NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine. ( Brown, KA; Georgiou, P; Gould, TD; Thompson, SM; Yuan, P; Zanos, P; Zarate, CA, 2023) |
| "Treatment with ketamine or R,R-HNK failed to influence the levels of perineuronal nets (PNNs) surrounding parvalbumin-positive interneurons." | 1.91 | Ketamine and its metabolite 2R,6R-hydroxynorketamine promote ocular dominance plasticity and release tropomyosin-related kinase B from inhibitory control without reducing perineuronal nets enwrapping parvalbumin interneurons. ( Cannarozzo, C; Casarotto, P; Castrén, E; Rubiolo, A, 2023) |
| "Guanosine has been reported to elicit antidepressant-like responses in rodents, but if these actions are associated with its ability to afford neuroprotection against glutamate-induced toxicity still needs to be fully understood." | 1.91 | NMDA receptor-mediated modulation on glutamine synthetase and glial glutamate transporter GLT-1 is involved in the antidepressant-like and neuroprotective effects of guanosine. ( Altê, GA; Camargo, A; Dalmagro, AP; Rodrigues, ALS; Tasca, CI; Zeni, ALB, 2023) |
| " Chronic administration of antidepressant drugs reverses the decreased sucrose intake and other behavioral changes in these subjects." | 1.91 | Models of Affective Illness: Chronic Mild Stress in the Rat. ( Papp, M; Willner, P, 2023) |
| "Esketamine and ketamine have been shown to decrease inflammation in numerous ways principally through reducing pro-inflammatory cytokines (e." | 1.91 | The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation? ( Cook, J; Halaris, A, 2023) |
| "Rapid onset and the ability to impact treatment-resistant depression, raises the question of the best first-line medicines for patients." | 1.91 | Clinical pharmacological innovation in the treatment of depression. ( Golani, LK; Smith, JL; Witkin, JM, 2023) |
| "Depression is a multifactorial and heterogeneous disease with several neurobiological mechanisms underlying its pathophysiology, including dysfunctional glutamatergic neurotransmission, which makes the exploration of the glutamate pathway an interesting strategy for developing novel rapid-acting antidepressant treatments." | 1.91 | Pharmacological evidence for glutamatergic pathway involvement in the antidepressant-like effects of 2-phenyl-3-(phenylselanyl)benzofuran in male Swiss mice. ( Alves, D; Blödorn, GB; Bortolatto, CF; Brüning, CA; Krüger, LD; Neto, JSS; Rech, TDST; Strelow, DN, 2023) |
| "Ketamine has been increasingly used as a rapid-onset antidepressant in specific clinical settings." | 1.91 | Retigabine promotes ketamine's antidepressant effect in the forced swim test in male and female C57BL/6J mice. ( Cao, JL; Li, H; Qin, Y; Zhang, H; Zhang, W; Zhang, Y, 2023) |
| "Major depressive disorder is frequently characterized by disinhibition of rapid eye movement (REM) sleep and disruption of non-REM (NREM) sleep." | 1.91 | (S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats. ( Bagdy, G; Koncz, S; Papp, N; Pothorszki, D, 2023) |
| "Ketamine is an anaesthetic known to have short but rapid-acting anti-depressant effects; however, the neurobehavioural effects of its prolonged use and its role on the oxytocin system in the gut-brain axis are largely undetermined." | 1.91 | Prolonged ketamine therapy differentially rescues psychobehavioural deficits via modulation of nitro-oxidative stress and oxytocin receptors in the gut-brain-axis of chronically-stressed mice. ( Akinluyi, ET; Edem, EE; Fafure, AA; Ikuelogbon, DA; Isaac, GT; Kunlere, OE; Nebo, KE; Oguntala, OA, 2023) |
| "Ketamine was also efficacious in decreasing the level of inflammation with an evident reduction in microglial activation and pro-inflammatory cytokines in the studied regions, following CUMS exposure." | 1.72 | Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression. ( Akinluyi, ET; Anyanwu, CC; Edem, EE; Enye, LA; Fafure, AA; Ishola, AO; Nebo, KE, 2022) |
| "Ketamine is a rapidly-acting antidepressant treatment with robust response rates." | 1.72 | Anterior default mode network and posterior insular connectivity is predictive of depressive symptom reduction following serial ketamine infusion. ( Congdon, E; Espinoza, RT; Hellemann, G; Joshi, SH; Kubicki, A; Loureiro, J; Narr, KL; Sahib, A; Wade, BSC; Woods, RP, 2022) |
| "Depression is a serious physical and mental disease, with major depressive disorder (MDD) being a hard-to-treat, life-threatening form of the condition." | 1.72 | Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic. ( Gu, T; Jiang, G; Liu, Q; Liu, S; Wang, Y; Yin, A; Zhang, L, 2022) |
| "Depression is common at the end of life, and there is longstanding concern that it may affect terminally ill patients' decisions to request physician-assisted death (PAD)." | 1.72 | Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis. ( Berens, N; Kim, SY, 2022) |
| "Ketamine was generally well tolerated, and we observed improvements in functional impairment, anhedonia, and psychiatric symptoms, with no increases in manic symptoms." | 1.72 | Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study. ( Kang, MJY; Vazquez, GH, 2022) |
| "Depression is a common mental disorder that occurs all over the world with treatment resistance commonly seen in clinical practice." | 1.72 | Dietary Patterns of Treatment-Resistant Depression Patients. ( Cubała, WJ; Gruchała-Niedoszytko, M; Małgorzewicz, S; Mechlińska, A; Włodarczyk, A, 2022) |
| "Ketamine has been shown to provide rapid and significant efficacy in treating patients with TRD." | 1.62 | Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. ( Di Vincenzo, JD; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, R; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Patients with major depressive disorder (MDD) exhibit impaired control of cognitive and emotional systems, including deficient response selection and inhibition." | 1.62 | Ketamine's modulation of cerebro-cerebellar circuitry during response inhibition in major depression. ( Congdon, E; Espinoza, R; Hellemann, G; Joshi, S; Kubicki, A; Leaver, A; Loureiro, JRA; Narr, KL; Sahib, AK; Vasavada, M; Wade, B; Woods, RP, 2021) |
| "Ketamine use has become of increasing concern because it has spread in many parts of the world during the past few years." | 1.62 | Gender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users. ( Hsu, CY; Wang, PW; Wu, HC; Yang, YY; Yen, CF, 2021) |
| "Ketamine is a highly effective antidepressant for patients with treatment-resistant major depressive disorder (MDD)." | 1.62 | Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression. ( Congdon, E; Espinoza, RT; Hellemann, G; Kubicki, A; Leaver, AM; Loureiro, J; Narr, KL; Sahib, A; Vasavada, MM; Wade, B, 2021) |
| "Ketamine has demonstrated rapid and robust efficacy in adults with TRD." | 1.62 | Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Esketamine nasal spray is a novel, fast-acting agent that provides an additional treatment option for patients with TRD who have previously failed several therapies." | 1.62 | Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. ( Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH, 2021) |
| "Chronic neuropathic pain can modulate DNA methylation in target genes related to neuroplasticity and mood regulation, which was induced by DNA methyltransferases (DNMTs)." | 1.62 | Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: Reversal by ketamine. ( He, X; Ji, MH; Liu, R; Shen, JC; Wang, RZ; Wu, XM; Yin, XY; Zhou, F, 2021) |
| "The most common features of Parkinson's disease (PD) are motor impairments, but many patients also present depression and memory impairment." | 1.62 | Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease. ( Andreatini, R; Da Cunha, C; Hocayen, PAS; Kanazawa, LKS; Miyoshi, E; Takahashi, RN; Vecchia, DD; Vital, MABF; Wendler, E, 2021) |
| "Ketamine was associated with transient treatment-emergent hypertension." | 1.62 | Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. ( Cao, B; Cha, DS; Di Vincenzo, JD; Flint, AJ; Greenberg, D; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "(S)-ketamine was recently approved by the United States' FDA for treatment-resistant depression." | 1.62 | Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. ( Boehm, MA; Bonaventura, J; Carlton, M; Fredriksson, I; Gomez, JL; Lam, S; Michaelides, M; Morris, PJ; Sánchez-Soto, M; Shaham, Y; Sibley, DR; Solís, O; Thomas, CJ; Zarate, CA, 2021) |
| "Post-traumatic stress disorder (PTSD) is a chronic and disabling condition arising after exposure to a severe traumatic event, which affects approximately eight percent of the population." | 1.56 | Ketamine reverses the impaired fear memory extinction and accompanied depressive-like behaviors in adolescent mice. ( Chen, WY; Lu, K; Lv, BJ; Wang, Y; Wang, YH; Wei, MD, 2020) |
| "Slow response to the standard treatment for depression increases suffering and risk of suicide." | 1.56 | Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. ( Chandra, J; Klein, ME; Malinow, R; Sheriff, S, 2020) |
| "About 16% of the world's population has major depressive disorder." | 1.56 | Low-Dose Ketamine Improves LPS-Induced Depression-like Behavior in Rats by Activating Cholinergic Anti-inflammatory Pathways. ( Chang, D; Du, X; Gao, L; Lian, H; Liu, X; Zhang, X; Zhao, J, 2020) |
| "Ketamine has been recently identified as a potential novel antidepressant." | 1.56 | Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant. ( de Abreu, GR; Fukushima, AR; Manes, M; Moreira, N; Ricci, EL; Spinosa, HS; Waziry, PAF; Zaccarelli-Magalhães, J, 2020) |
| "Traditional monoaminergic treatments of depression frequently exhibit suboptimal tolerability and effectiveness." | 1.56 | Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction. ( Hannan, AJ; Li, S; Renoir, T; Wilson, C, 2020) |
| "Co-existing chronic pain and depression pose a serious socio-economic burden and result in disability affecting millions of individuals, which urges the development of treatment strategies targeting this comorbidity." | 1.56 | Ketamine induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway. ( Ayazgök, B; Becker, LJ; Humo, M; Rantamäki, T; Waltisperger, E; Yalcin, I, 2020) |
| "Ketamine has also been shown to induce psychotomimetic/dissociative side effects, aberrant gamma oscillations, and effects similar to sleep deprivation, which may potentially limit its clinical use." | 1.56 | Rapastinel, an NMDAR positive modulator, produces distinct behavioral, sleep, and EEG profiles compared with ketamine. ( Banerjee, P; Donello, JE; Duman, RS; Hare, B, 2020) |
| "Ketamine has rapid-acting antidepressant properties but also potentially concerning transient dissociative side effects (SEs)." | 1.56 | Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, L; Zarate, CA, 2020) |
| "Major depression is one of the most frequent psychiatric conditions." | 1.51 | The immunomodulatory effect of ketamine in depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Lisowska, KA; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Depression affects over 121 million people annually worldwide." | 1.51 | Magnesium and ketamine in the treatment of depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Patients with major depressive disorder (MDD) often have structural and functional deficits in the ventromedial prefrontal cortex (vmPFC), but the underlying molecular pathways are incompletely understood." | 1.51 | VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. ( Jiang, C; Labonté, B; Lin, WJ; Nestler, EJ; Russo, SJ; Salton, SR; Tamminga, CA; Turecki, G, 2019) |
| " While (R)-ketamine has lower potency than (R,S)-ketamine to inhibit NMDA receptors in vitro, the extent to which (R)-ketamine shares the NMDA receptor-mediated adverse effects of (R,S)-ketamine in vivo has not been fully characterised." | 1.51 | (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. ( Georgiou, P; Gould, TD; Highland, JN; Liu, X; Lovett, J; Moaddel, R; Morris, PJ; Stewart, BW; Thomas, CJ; Thompson, SM; Troppoli, TA; Zanos, P, 2019) |
| "Depression is a chronic and debilitating illness that interferes severely with many human behaviors, and is the leading cause of disability in the world." | 1.51 | Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine. ( Adell, A; Campa, L; Castro, E; Frago, C; Jiménez-Sánchez, L; López-Gil, X, 2019) |
| "Ketamine is a non-competitive NMDA receptor antagonist used as a major anesthetic agent, especially in children." | 1.51 | Oral ketamine alleviates behavioral despair without cognitive impairment in Wistar rats. ( Canbeyli, R; Ecevitoglu, A; Unal, G, 2019) |
| "Ketamine acts as a rapid clinical antidepressant at 25 min after injection with effects sustained for 7 days." | 1.51 | Differences between ketamine's short-term and long-term effects on brain circuitry in depression. ( Becker, R; Cosa-Linan, A; Gass, N; Reinwald, J; Sack, M; Sartorius, A; Vollmayr, B; Weber-Fahr, W, 2019) |
| "Ketamine has become increasingly popular in adolescent drug abusers worldwide." | 1.51 | The effects of sub-anesthetic ketamine plus ethanol on behaviors and apoptosis in the prefrontal cortex and hippocampus of adolescent rats. ( Fan, SJ; Jiang, H; Li, Q; Liu, DX; Pan, F; Wu, HR; Zhang, Q, 2019) |
| "An effective rapid-onset treatment for major depressive disorder could save lives." | 1.48 | The rapid-onset antidepressant effect of ketamine: More surprises? ( Pergolizzi, JV; Raffa, RB; Taylor, R, 2018) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Ketamine is an N-methyl-D-aspartate receptor antagonist, which on administration produces fast-acting antidepressant responses in patients with major depressive disorder." | 1.48 | Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine. ( Adaikkan, C; Barrera, I; David, O; Rosenblum, K; Taha, E, 2018) |
| "Depression is present in a large proportion of patients suffering from chronic pain, and yet the underlying mechanisms remain to be elucidated." | 1.48 | Ketamine differentially restores diverse alterations of neuroligins in brain regions in a rat model of neuropathic pain-induced depression. ( Ji, MH; Li, HH; Li, KY; Pan, W; Yang, JJ; Zhang, GF; Zhou, ZQ, 2018) |
| "This will promote the research and treatment of pruritus and depression." | 1.48 | The behavioral study on the interactive aggravation between pruritus and depression. ( Bai, Y; Feng, YP; Li, H; Wang, XD; Yang, G, 2018) |
| "Agmatine is a neuromodulator that has been proposed as a therapeutic strategy for the treatment of major depressive disorder (MDD)." | 1.48 | Single administration of agmatine reverses the depressive-like behavior induced by corticosterone in mice: Comparison with ketamine and fluoxetine. ( Bettio, LB; Fraga, DB; Freitas, AE; Gonçalves, FM; Heinrich, IA; Leal, RB; Lopes, MW; Moretti, M; Neis, VB; Olescowicz, G; Rodrigues, ALS; Rosa, PB, 2018) |
| "Patients with advanced cancer often suffer from both severe pain and severe symptoms of depression." | 1.48 | Case Report: Ketamine for Pain and Depression in Advanced Cancer. ( Atayee, RS; Bruner, HC; Sexton, J, 2018) |
| "Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence." | 1.46 | Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. ( Abagyan, R; Atayee, R; Cohen, IV; Makunts, T, 2017) |
| "Major depression is one of the most common affective disorders caused by schizophrenia." | 1.46 | Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration. ( Briones-Aranda, A; Espinosa-Raya, J; Picazo, O; Suárez-Santiago, JE, 2017) |
| "Ketamine has been extensively studied for its antidepressant potential, with promising results in both preclinical and clinical studies." | 1.46 | Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats. ( Babinska, Z; Ruda-Kucerova, J, 2017) |
| " The higher ketamine use frequency and dosage were associated with more severe depressive symptoms." | 1.43 | Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. ( Deng, X; Ding, Y; Fan, N; He, H; Ke, X; Ning, Y; Rosenheck, R; Sun, B; Tang, W; Wang, D; Xu, K; Zhou, C, 2016) |
| "N,N-dimethylglycine (DMG) is a derivative of the amino acid glycine and is used as a dietary supplement." | 1.43 | N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice. ( Chan, MH; Chen, HH; Chen, YC; Lee, MY; Lin, JC, 2016) |
| "Dextromethorphan (DM) is an antitussive with rapid acting antidepressant potential based on pharmacodynamic similarities to ketamine." | 1.42 | Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. ( Matsumoto, RR; Nguyen, L, 2015) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Several non-pharmacological treatments of depression upregulate adenosine concentration and/or adenosine A1 receptors (A1R) in the brain." | 1.42 | Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a. ( Biber, K; Clement, HW; de Bartolomeis, A; Iasevoli, F; Idzko, M; Jacobson, KA; Normann, C; Schwarz, MK; Serchov, T; Tosh, DK; van Calker, D, 2015) |
| "Ketamine (Ketalar®) is a non-competitive glutamatergic antagonist classically used to induce sedation." | 1.42 | Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine. ( Hylton, A; Pittman, J, 2015) |
| " On the other hand, chronic administration of ketamine significantly elicited an increase in immobility score as well as reversed the reduction induced by fluoxetine." | 1.40 | Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test. ( Adeyemi, OI; Akanmu, MA; Owolabi, RA, 2014) |
| " The depression model of mice was developed by continuously oral administration of low dosage of corticosterone (CORT)." | 1.40 | [Inhibition of HCN1 channels by ketamine accounts for its antidepressant actions]. ( Chen, FF; Chen, XD; Li, J; Zhou, C, 2014) |
| "Ketamine users are often poly-substance users." | 1.39 | Cognitive impairments in poly-drug ketamine users. ( Chan, F; Lau, CG; Liang, HJ; Tang, A; Tang, WK; Ungvari, GS, 2013) |
| "Ketamine is a potent noncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor." | 1.38 | Effects of ketamine in treatment-refractory obsessive-compulsive disorder. ( Bhagwagar, Z; Billingslea, E; Bloch, MH; Krystal, JH; Landeros-Weisenberger, A; Leckman, JF; Panza, KE; Pittenger, C; Sanacora, G; Wasylink, S, 2012) |
| "Pretreatment with fluvoxamine, MK-801, ketamine and the combination of fluvoxamine with either of the NMDA antagonists antagonised shock-induced depression." | 1.31 | Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice. ( Bapna, JS; Chandra, D; Chaturvedi, HK, 2001) |
| "The ketamine group was superior to the conventional group which was superior to the no-treatment group in reducing negative affect experienced during stressful situations." | 1.26 | Ketamine-facilitated induced anxiety therapy and its effect upon clients' reactions to stressful situations. ( Becker, AT; Corssen, G; Sappington, AA; Tavakoli, M, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.37) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (1.73) | 29.6817 |
| 2010's | 333 (41.21) | 24.3611 |
| 2020's | 458 (56.68) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, C | 3 |
| Wang, Y | 9 |
| Wu, Z | 5 |
| Xu, J | 3 |
| Zhou, L | 3 |
| Wang, D | 2 |
| Yang, L | 6 |
| Zhu, B | 4 |
| Chen, G | 6 |
| Liu, C | 4 |
| Yang, C | 20 |
| Estrada-Reyes, R | 1 |
| Quero-Chávez, DB | 1 |
| Trueta, C | 1 |
| Miranda, A | 1 |
| Valdés-Tovar, M | 1 |
| Alarcón-Elizalde, S | 1 |
| Oikawa-Sala, J | 1 |
| Argueta, J | 1 |
| Constantino-Jonapa, LA | 1 |
| Muñoz-Estrada, J | 1 |
| Dubocovich, ML | 1 |
| Benítez-King, G | 1 |
| Di Vincenzo, JD | 12 |
| Lipsitz, O | 14 |
| Rodrigues, NB | 18 |
| Lee, Y | 15 |
| Gill, H | 13 |
| Kratiuk, K | 10 |
| Subramaniapillai, M | 10 |
| Mansur, R | 3 |
| McIntyre, RS | 31 |
| Rosenblat, JD | 25 |
| Dean, RL | 2 |
| Hurducas, C | 2 |
| Hawton, K | 4 |
| Spyridi, S | 2 |
| Cowen, PJ | 2 |
| Hollingsworth, S | 1 |
| Marquardt, T | 2 |
| Barnes, A | 2 |
| Smith, R | 2 |
| McShane, R | 6 |
| Turner, EH | 2 |
| Cipriani, A | 4 |
| White, PF | 1 |
| Ouyang, X | 1 |
| Wang, Z | 6 |
| Luo, M | 1 |
| Wang, M | 4 |
| Liu, X | 4 |
| Chen, J | 7 |
| Feng, J | 1 |
| Jia, J | 1 |
| Wang, X | 7 |
| Zhou, Y | 12 |
| Wang, C | 8 |
| Lan, X | 5 |
| Li, H | 6 |
| Chao, Z | 2 |
| Ning, Y | 11 |
| Chen, MH | 13 |
| Lin, WC | 12 |
| Li, CT | 12 |
| Tsai, SJ | 11 |
| Wu, HJ | 10 |
| Bai, YM | 12 |
| Hong, CJ | 5 |
| Tu, PC | 11 |
| Su, TP | 13 |
| Cano, M | 1 |
| Cardoner, N | 1 |
| Loureiro, JRA | 1 |
| Sahib, AK | 2 |
| Vasavada, M | 1 |
| Leaver, A | 1 |
| Kubicki, A | 5 |
| Wade, B | 4 |
| Joshi, S | 1 |
| Hellemann, G | 5 |
| Congdon, E | 6 |
| Woods, RP | 4 |
| Espinoza, R | 3 |
| Narr, KL | 7 |
| Wang, PW | 1 |
| Yen, CF | 1 |
| Wu, HC | 1 |
| Hsu, CY | 1 |
| Yang, YY | 1 |
| Mao, WC | 5 |
| Katz, EG | 1 |
| McNulty, P | 1 |
| Levitan, B | 1 |
| Treichler, P | 1 |
| Martynowicz, J | 1 |
| Jamieson, C | 5 |
| Malhi, GS | 1 |
| Geddes, J | 1 |
| Sun, W | 4 |
| Zhang, G | 2 |
| Wang, A | 2 |
| Lin, S | 1 |
| Chan, MTV | 1 |
| Peng, Y | 3 |
| Wang, G | 6 |
| Han, R | 4 |
| Rafało-Ulińska, A | 2 |
| Pałucha-Poniewiera, A | 6 |
| Della Vecchia, S | 1 |
| Marchese, M | 1 |
| Santorelli, FM | 1 |
| Sicca, F | 1 |
| Takahashi, N | 1 |
| Yamada, A | 1 |
| Shiraishi, A | 1 |
| Shimizu, H | 1 |
| Goto, R | 1 |
| Tominaga, Y | 1 |
| López-Díaz, Á | 1 |
| Rendón de Lope, L | 1 |
| de la Vega Sánchez, D | 1 |
| Kvam, TM | 1 |
| Stewart, LH | 1 |
| Blomkvist, AW | 1 |
| Andreassen, OA | 1 |
| Keilp, JG | 2 |
| Madden, SP | 2 |
| Marver, JE | 1 |
| Frawley, A | 1 |
| Burke, AK | 2 |
| Herzallah, MM | 1 |
| Gluck, M | 1 |
| Mann, JJ | 3 |
| Grunebaum, MF | 4 |
| Vestring, S | 1 |
| Domschke, K | 1 |
| Normann, C | 2 |
| Ochs-Ross, R | 1 |
| Wajs, E | 2 |
| Daly, EJ | 9 |
| Zhang, Y | 13 |
| Lane, R | 4 |
| Lim, P | 2 |
| Drevets, WC | 6 |
| Steffens, DC | 1 |
| Sanacora, G | 14 |
| Hough, D | 2 |
| Manji, H | 1 |
| Singh, JB | 6 |
| Garakani, A | 1 |
| Liu, H | 7 |
| Wu, X | 1 |
| Fang, Y | 1 |
| Edem, EE | 2 |
| Anyanwu, CC | 1 |
| Nebo, KE | 2 |
| Akinluyi, ET | 2 |
| Fafure, AA | 2 |
| Ishola, AO | 1 |
| Enye, LA | 1 |
| Le, TT | 2 |
| Teopiz, KM | 14 |
| Cha, DS | 8 |
| Lui, LMW | 12 |
| Ho, RC | 10 |
| Cao, B | 10 |
| Lin, K | 5 |
| Nasri, F | 5 |
| Mansur, RB | 11 |
| Yao, W | 4 |
| Cao, Q | 1 |
| Luo, S | 1 |
| He, L | 2 |
| Qi, Q | 1 |
| Hashimoto, K | 41 |
| Zhang, JC | 5 |
| Price, JB | 1 |
| Yates, CG | 1 |
| Morath, BA | 1 |
| Van De Wakker, SK | 1 |
| Yates, NJ | 1 |
| Butters, K | 1 |
| Frye, MA | 10 |
| McGee, SL | 1 |
| Tye, SJ | 4 |
| Moccia, L | 1 |
| Lanzotti, P | 1 |
| Pepe, M | 1 |
| Palumbo, L | 1 |
| Janiri, D | 1 |
| Camardese, G | 1 |
| Bentivoglio, AR | 1 |
| Di Nicola, M | 4 |
| Calabresi, P | 1 |
| Sani, G | 3 |
| Keeler, JL | 1 |
| Treasure, J | 1 |
| Juruena, MF | 1 |
| Kan, C | 1 |
| Himmerich, H | 1 |
| Lijffijt, M | 2 |
| Murphy, N | 2 |
| Iqbal, S | 2 |
| Green, CE | 1 |
| Iqbal, T | 1 |
| Chang, LC | 2 |
| Haile, CN | 1 |
| Hirsch, LC | 1 |
| Ramakrishnan, N | 1 |
| Fall, DA | 1 |
| Swann, AC | 1 |
| Al Jurdi, RK | 1 |
| Mathew, SJ | 15 |
| Degerlund Maldi, K | 1 |
| Asellus, P | 1 |
| Myléus, A | 1 |
| Norström, F | 1 |
| Caliman-Fontes, AT | 5 |
| Leal, GC | 7 |
| Correia-Melo, FS | 8 |
| Paixão, CS | 2 |
| Carvalho, MS | 2 |
| Jesus-Nunes, AP | 7 |
| Vieira, F | 7 |
| Magnavita, G | 4 |
| Bandeira, ID | 6 |
| Mello, RP | 8 |
| Beanes, G | 2 |
| Silva, SS | 4 |
| Echegaray, M | 1 |
| Carvalho, LP | 2 |
| Machado, P | 1 |
| Sampaio, AS | 4 |
| Cardoso, TA | 1 |
| Kapczinski, F | 3 |
| Lacerda, ALT | 7 |
| Quarantini, LC | 8 |
| Kaczmarek, B | 1 |
| Kowalski, K | 1 |
| Bogudzińska, B | 1 |
| Piotrowski, P | 1 |
| Hochschild, A | 1 |
| Hess, EM | 1 |
| Riggs, LM | 3 |
| Michaelides, M | 2 |
| Gould, TD | 11 |
| Dong, C | 5 |
| Tian, Z | 2 |
| Fujita, Y | 7 |
| Fujita, A | 1 |
| Hino, N | 1 |
| Iijima, M | 5 |
| Zhang, K | 9 |
| Yang, Y | 7 |
| Yuan, X | 1 |
| Zhang, W | 4 |
| Han, X | 2 |
| Lei, C | 1 |
| Tao, Z | 1 |
| Li, Y | 4 |
| Wang, J | 12 |
| Sun, Y | 2 |
| Ai, P | 1 |
| Cui, V | 1 |
| Shi, H | 1 |
| An, D | 1 |
| Wu, A | 1 |
| Wei, C | 1 |
| Jones, RR | 1 |
| Freeman, MP | 2 |
| Kornstein, SG | 1 |
| Cooper, K | 3 |
| Canuso, CM | 2 |
| Nicholson, S | 1 |
| Singh, B | 7 |
| Port, JD | 3 |
| Pazdernik, V | 1 |
| Coombes, BJ | 2 |
| Vande Voort, JL | 9 |
| Özgen, MH | 1 |
| van den Brink, W | 3 |
| Goldberg, JF | 1 |
| Pavlidi, P | 1 |
| Megalokonomou, A | 1 |
| Sofron, A | 1 |
| Kokras, N | 2 |
| Dalla, C | 2 |
| Christodoulakis, ΤΕ | 1 |
| Karakatsoulis, GN | 1 |
| Tsapakis, EM | 1 |
| Fountoulakis, KN | 1 |
| Camargo, A | 11 |
| Dalmagro, AP | 8 |
| Delanogare, E | 1 |
| Fraga, DB | 6 |
| Wolin, IAV | 2 |
| Zeni, ALB | 6 |
| Brocardo, PS | 3 |
| Rodrigues, ALS | 13 |
| Taillefer de Laportalière, T | 2 |
| Yrondi, A | 2 |
| Jullien, A | 2 |
| Cestac, P | 2 |
| Montastruc, F | 2 |
| Chen, L | 4 |
| Li, X | 2 |
| Furey, ML | 2 |
| Fedgchin, M | 4 |
| Popova, V | 6 |
| McInnes, LA | 2 |
| Qian, JJ | 2 |
| Gargeya, RS | 1 |
| DeBattista, C | 2 |
| Heifets, BD | 6 |
| Torrá, ACNC | 1 |
| Valverde, AP | 1 |
| Kouba, BR | 1 |
| Alves, EC | 1 |
| Horowitz, M | 1 |
| Moncrieff, J | 1 |
| Vanicek, T | 1 |
| Unterholzner, J | 1 |
| Lanzenberger, R | 2 |
| Naderi-Heiden, A | 1 |
| Kasper, S | 5 |
| Praschak-Rieder, N | 1 |
| Ma, L | 2 |
| Zhang, J | 6 |
| Qu, Y | 7 |
| Shan, J | 3 |
| Wan, X | 2 |
| Ishima, T | 3 |
| Kobayashi, K | 1 |
| Wang, L | 3 |
| Wang, YT | 3 |
| Zhang, NN | 2 |
| Liu, LJ | 1 |
| Jiang, H | 3 |
| Hu, D | 1 |
| Wang, ZZ | 2 |
| Chen, NH | 2 |
| Palamar, JJ | 1 |
| Kumar, S | 1 |
| Yang, KH | 1 |
| Han, BH | 1 |
| Zhu, X | 4 |
| Zhang, F | 5 |
| You, Y | 1 |
| Wang, H | 1 |
| Yuan, S | 3 |
| Wu, B | 1 |
| Zhu, R | 1 |
| Liu, D | 2 |
| Yan, F | 1 |
| Subramanian, S | 2 |
| Haroutounian, S | 1 |
| Palanca, BJA | 2 |
| Lenze, EJ | 4 |
| Averill, LA | 3 |
| Averill, CL | 1 |
| Gueorguieva, R | 1 |
| Fouda, S | 1 |
| Sherif, M | 1 |
| Ahn, KH | 1 |
| Ranganathan, M | 1 |
| D'Souza, DC | 1 |
| Southwick, SM | 1 |
| Duman, RS | 16 |
| Krystal, JH | 12 |
| Abdallah, CG | 7 |
| Abbar, M | 1 |
| Demattei, C | 1 |
| El-Hage, W | 1 |
| Llorca, PM | 2 |
| Samalin, L | 1 |
| Demaricourt, P | 1 |
| Gaillard, R | 2 |
| Courtet, P | 2 |
| Vaiva, G | 1 |
| Gorwood, P | 1 |
| Fabbro, P | 1 |
| Jollant, F | 1 |
| Highland, JN | 4 |
| Morris, PJ | 5 |
| Konrath, KM | 1 |
| Hagen, NR | 1 |
| Zanos, P | 7 |
| Powels, CF | 1 |
| Moaddel, R | 7 |
| Thomas, CJ | 5 |
| Wang, AQ | 1 |
| Bentley, S | 1 |
| Artin, H | 1 |
| Mehaffey, E | 1 |
| Liu, F | 2 |
| Sojourner, K | 1 |
| Bismark, A | 1 |
| Printz, D | 1 |
| Lee, EE | 1 |
| Martis, B | 1 |
| De Peralta, S | 1 |
| Baker, DG | 1 |
| Mishra, J | 1 |
| Ramanathan, D | 1 |
| Grabski, M | 1 |
| Waldron, J | 1 |
| Freeman, TP | 2 |
| van Laar, M | 1 |
| Curran, HV | 3 |
| Swainson, J | 4 |
| Klassen, LJ | 1 |
| Brennan, S | 1 |
| Chokka, P | 1 |
| Katzman, MA | 1 |
| Tanguay, RL | 1 |
| Khullar, A | 1 |
| Evers, A | 1 |
| Klein, M | 1 |
| Aloysi, A | 1 |
| Murrough, J | 2 |
| Jha, MK | 6 |
| Zheng, W | 6 |
| Echegaray, MVF | 4 |
| Marback, RF | 3 |
| Guerreiro-Costa, LNF | 3 |
| Souza-Marques, B | 5 |
| Santos-Lima, C | 3 |
| Souza, LS | 1 |
| Scotton, E | 2 |
| Antqueviezc, B | 1 |
| Vasconcelos, MF | 1 |
| Dalpiaz, G | 1 |
| Paul Géa, L | 1 |
| Ferraz Goularte, J | 1 |
| Colombo, R | 2 |
| Ribeiro Rosa, A | 1 |
| Kung, S | 2 |
| Wilkowska, A | 7 |
| Wiglusz, MS | 7 |
| Jakuszkowiak-Wojten, K | 5 |
| Cubała, WJ | 14 |
| Lengvenyte, A | 1 |
| Strumila, R | 1 |
| Olié, E | 1 |
| Bahji, A | 4 |
| Zarate, CA | 43 |
| Vazquez, GH | 6 |
| Tamman, A | 1 |
| Anand, A | 3 |
| Becker, B | 1 |
| Ju, L | 1 |
| Yang, J | 6 |
| Zhu, T | 1 |
| Liu, P | 3 |
| Kojic, M | 1 |
| Saelens, J | 1 |
| Kadriu, B | 13 |
| Kraus, C | 9 |
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 6 |
| Xie, J | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 4 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 3 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 4 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 7 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 3 |
| Leng, S | 1 |
| Hu, Z | 3 |
| Tang, J | 2 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 5 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 3 |
| Ma, X | 2 |
| Chen, X | 3 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Sharafi, A | 1 |
| Pakkhesal, S | 1 |
| Fakhari, A | 1 |
| Khajehnasiri, N | 1 |
| Ahmadalipour, A | 1 |
| Andrade, C | 6 |
| Wang, T | 2 |
| Weng, H | 1 |
| Zhou, H | 1 |
| Yang, Z | 1 |
| Xi, B | 1 |
| Moraga-Amaro, R | 1 |
| Guerrin, CGJ | 1 |
| Reali Nazario, L | 1 |
| Lima Giacobbo, B | 1 |
| J O Dierckx, RA | 1 |
| Stehberg, J | 1 |
| de Vries, EFJ | 1 |
| Doorduin, J | 1 |
| Nikayin, S | 2 |
| Murphy, E | 1 |
| Wilkinson, ST | 7 |
| Floden, L | 2 |
| Hudgens, S | 2 |
| Singh, J | 3 |
| Ma, B | 1 |
| Fu, Y | 1 |
| Terao, I | 2 |
| Honyashiki, M | 1 |
| Inoue, T | 1 |
| Kritzer, MD | 1 |
| Pae, CU | 1 |
| Masand, PS | 1 |
| Rosenman, S | 1 |
| Rocha, FL | 1 |
| Cunha, UGV | 1 |
| Duarte, DB | 1 |
| Hara, C | 1 |
| Nogo, D | 1 |
| Nazal, H | 1 |
| Song, Y | 2 |
| Ho, R | 7 |
| Rhee, TG | 5 |
| Cunningham, ME | 1 |
| de Fontnouvelle, CA | 1 |
| Ostroff, RB | 1 |
| Rawat, R | 1 |
| Tunc-Ozcan, E | 1 |
| McGuire, TL | 1 |
| Peng, CY | 1 |
| Kessler, JA | 1 |
| Deyama, S | 7 |
| Kondo, M | 1 |
| Shimada, S | 1 |
| Kaneda, K | 4 |
| Wade, BSC | 2 |
| Loureiro, J | 3 |
| Sahib, A | 3 |
| Joshi, SH | 4 |
| Espinoza, RT | 4 |
| Ohnishi, T | 1 |
| Wakamatsu, A | 1 |
| Kobayashi, H | 1 |
| Jiang, G | 1 |
| Liu, Q | 1 |
| Gu, T | 1 |
| Liu, S | 2 |
| Yin, A | 1 |
| Zhang, L | 3 |
| Cordero, IP | 1 |
| Jawad, MY | 5 |
| Jaberi, S | 1 |
| Phan, L | 4 |
| Eduardo, TQ | 1 |
| Angela, A | 1 |
| Mateo, L | 1 |
| Melanie, LZ | 1 |
| Valentina, PF | 1 |
| David, C | 1 |
| Estefania, C | 1 |
| Natalia, RS | 1 |
| Andrés, VC | 1 |
| Angel, RO | 1 |
| Juan, G | 1 |
| Juan, P | 1 |
| Ledesma-Corvi, S | 2 |
| Hernández-Hernández, E | 1 |
| García-Fuster, MJ | 2 |
| Zhang, Z | 1 |
| Liu, L | 5 |
| Shi, W | 1 |
| Li, S | 8 |
| Cai, X | 2 |
| Zhou, Q | 1 |
| Moore, TJ | 1 |
| Alami, A | 1 |
| Alexander, GC | 1 |
| Mattison, DR | 1 |
| Arlt, C | 1 |
| Lewis, V | 1 |
| Rodrigue, B | 1 |
| Arsenault, E | 1 |
| Zhang, M | 1 |
| Taghavi-Abkuh, FF | 1 |
| Silva, WCC | 1 |
| Myers, M | 1 |
| Matta-Camacho, E | 2 |
| Aguilar-Valles, A | 2 |
| Alnefeesi, Y | 1 |
| Chen-Li, D | 2 |
| Krane, E | 1 |
| Ceban, F | 6 |
| Meshkat, S | 8 |
| Ho, RCM | 1 |
| Tham, JCW | 1 |
| Do, A | 2 |
| Fridfinnson, J | 1 |
| Rafizadeh, R | 1 |
| Siu, JTP | 1 |
| Budd, GP | 1 |
| Lam, RW | 2 |
| Gilbert, JR | 5 |
| Gerner, JL | 1 |
| Burton, CR | 1 |
| Nugent, AC | 5 |
| Ballard, ED | 10 |
| MahmoudianDehkordi, S | 1 |
| Voort, JLV | 2 |
| Kaddurah-Daouk, R | 1 |
| Borentain, S | 3 |
| Gogate, J | 1 |
| Williamson, D | 1 |
| Carmody, T | 1 |
| Trivedi, M | 1 |
| Cabrera, P | 1 |
| DiBernardo, A | 2 |
| Holmes, SE | 2 |
| Abdallah, C | 1 |
| Esterlis, I | 4 |
| Yang, XH | 2 |
| Gu, LM | 1 |
| Tan, JQ | 1 |
| Zhou, YL | 2 |
| Wang, CY | 2 |
| Ning, YP | 3 |
| Hull, TD | 1 |
| Malgaroli, M | 1 |
| Gazzaley, A | 1 |
| Akiki, TJ | 1 |
| Madan, A | 1 |
| Vando, L | 1 |
| Arden, K | 1 |
| Swain, J | 1 |
| Klotz, M | 1 |
| Paleos, C | 1 |
| Zhang, LM | 1 |
| Liu, NN | 1 |
| Cao, L | 1 |
| Xin, Y | 2 |
| Zhang, DX | 1 |
| Bai, Y | 2 |
| Zheng, WC | 1 |
| Bi, XY | 1 |
| Xing, BH | 1 |
| Rossi, GN | 1 |
| Hallak, JEC | 1 |
| Baker, G | 1 |
| Dursun, SM | 1 |
| Dos Santos, RG | 1 |
| Cook, J | 2 |
| Halaris, A | 2 |
| Scott, F | 1 |
| Hampsey, E | 1 |
| Gnanapragasam, S | 1 |
| Carter, B | 1 |
| Marwood, L | 1 |
| Taylor, RW | 1 |
| Emre, C | 1 |
| Korotkova, L | 1 |
| Martín-Dombrowski, J | 1 |
| Cleare, AJ | 1 |
| Young, AH | 6 |
| Strawbridge, R | 2 |
| de Arruda, CM | 1 |
| Doneda, DL | 1 |
| de Oliveira, VV | 1 |
| da Silva, RAL | 1 |
| de Matos, YAV | 1 |
| Fernandes, IL | 1 |
| Rohden, CAH | 1 |
| Viola, GG | 1 |
| Rios-Santos, F | 1 |
| de Lima, E | 1 |
| da Silva Buss, Z | 1 |
| Vandresen-Filho, S | 1 |
| Berens, N | 1 |
| Kim, SY | 1 |
| Phillips, JL | 5 |
| Van Geel, A | 1 |
| Burhunduli, P | 1 |
| Vasudev, D | 1 |
| Batten, LA | 1 |
| Norris, S | 1 |
| Talbot, J | 1 |
| Ortiz, A | 1 |
| Owoeye, O | 1 |
| Blier, P | 5 |
| Pilc, A | 5 |
| Machaczka, A | 2 |
| Kawalec, P | 1 |
| Smith, JL | 2 |
| Witkin, JM | 3 |
| Cheng, CM | 1 |
| Acevedo, J | 3 |
| Siegel, JA | 3 |
| Pochwat, B | 3 |
| Krupa, AJ | 1 |
| Siwek, M | 1 |
| Szewczyk, B | 3 |
| Bloomfield-Clagett, B | 1 |
| Greenstein, DK | 1 |
| Murrough, JW | 11 |
| Fava, M | 3 |
| Shinohara, R | 2 |
| Levinta, A | 1 |
| Ho, C | 1 |
| Kang, MJY | 1 |
| Price, RB | 5 |
| Kissel, N | 1 |
| Baumeister, A | 1 |
| Rohac, R | 1 |
| Woody, ML | 1 |
| Deakin, W | 1 |
| Feder, A | 4 |
| Charney, DS | 11 |
| Gallagher, B | 1 |
| McLoughlin, DM | 3 |
| Muthukumaraswamy, S | 1 |
| McMillan, R | 2 |
| Sumner, R | 1 |
| Papakostas, G | 1 |
| Hock, R | 1 |
| Shiroma, P | 1 |
| Šóš, P | 2 |
| Tiger, M | 2 |
| Lundberg, J | 2 |
| Wallace, ML | 3 |
| Monahan, K | 1 |
| Weyandt, L | 1 |
| Shepard, E | 1 |
| Oliver, PA | 1 |
| Snyder, AD | 1 |
| Feinn, R | 1 |
| Malov, S | 1 |
| McDiarmid, G | 1 |
| Arias, AJ | 1 |
| Carboni, E | 1 |
| Carta, AR | 1 |
| Mechlińska, A | 1 |
| Włodarczyk, A | 6 |
| Gruchała-Niedoszytko, M | 1 |
| Małgorzewicz, S | 1 |
| Williamson, DJ | 1 |
| Gogate, JP | 1 |
| Kern Sliwa, JK | 1 |
| Manera, LS | 1 |
| Preskorn, SH | 1 |
| Winokur, A | 1 |
| Starr, HL | 2 |
| Sukhram, SD | 1 |
| Yilmaz, G | 1 |
| Gu, J | 1 |
| Brendle, M | 2 |
| Robison, R | 2 |
| Malone, DC | 1 |
| Ferrarelli, LK | 1 |
| Martinotti, G | 8 |
| Vita, A | 4 |
| Fagiolini, A | 2 |
| Maina, G | 2 |
| Bertolino, A | 2 |
| Dell'Osso, B | 3 |
| Siracusano, A | 1 |
| Clerici, M | 4 |
| Bellomo, A | 2 |
| d'Andrea, G | 6 |
| Chiaie, RD | 1 |
| Conca, A | 1 |
| Barlati, S | 3 |
| Di Lorenzo, G | 4 |
| De Fazio, P | 2 |
| De Filippis, S | 3 |
| Nicolò, G | 2 |
| Rosso, G | 2 |
| Valchera, A | 3 |
| Nucifora, D | 2 |
| Di Mauro, S | 2 |
| Bassetti, R | 3 |
| Martiadis, V | 2 |
| Olivola, M | 1 |
| Belletti, S | 1 |
| Andriola, I | 4 |
| Pettorruso, M | 6 |
| di Giannantonio, M | 3 |
| Bottemanne, H | 1 |
| Morlaas, O | 1 |
| Claret, A | 1 |
| Sharot, T | 1 |
| Fossati, P | 2 |
| Schmidt, L | 1 |
| Hua, H | 1 |
| Xu, X | 5 |
| Chang, L | 9 |
| Luo, X | 1 |
| Hu, Y | 1 |
| Zhang, B | 3 |
| Ahuja, S | 1 |
| Smart, L | 1 |
| Moore, C | 1 |
| Thielking, P | 1 |
| Belloch, FB | 1 |
| Cortés-Erice, M | 1 |
| Herzog, E | 1 |
| Zhang, XM | 1 |
| Díaz-Perdigon, T | 1 |
| Puerta, E | 1 |
| Tordera, RM | 1 |
| Psiuk, D | 1 |
| Nowak, EM | 1 |
| Dycha, N | 1 |
| Łopuszańska, U | 1 |
| Kurzepa, J | 1 |
| Samardakiewicz, M | 1 |
| Smith-Apeldoorn, SY | 3 |
| Veraart, JK | 1 |
| Spijker, J | 1 |
| Kamphuis, J | 3 |
| Schoevers, RA | 4 |
| Tao, Y | 1 |
| Xu, H | 3 |
| Huang, X | 1 |
| Kato, T | 3 |
| Badulescu, S | 1 |
| Tabassum, A | 3 |
| Mckenzie, A | 1 |
| Yao, Y | 1 |
| Goswami, N | 1 |
| Aleem, M | 1 |
| Manda, K | 1 |
| Zhao, XH | 3 |
| An, N | 3 |
| Xia, MH | 3 |
| Liu, WP | 3 |
| Wang, QQ | 3 |
| Bao, JZ | 3 |
| Cheng, YJ | 3 |
| Lin, CH | 3 |
| Lane, HY | 5 |
| Chaki, S | 16 |
| Watanabe, M | 4 |
| Chen, BK | 3 |
| Denny, CA | 7 |
| Schatzberg, AF | 10 |
| Peters, EM | 2 |
| Halpape, K | 2 |
| Cheveldae, I | 2 |
| Wanson, A | 2 |
| Lapidos, A | 2 |
| Lopez-Vives, D | 2 |
| Sera, CE | 2 |
| Ahearn, E | 2 |
| Vest, E | 2 |
| Senic, I | 2 |
| Frye, M | 2 |
| Goes, FS | 2 |
| Achtyes, E | 3 |
| Greden, J | 2 |
| Parikh, SV | 4 |
| Mugarura, NE | 2 |
| Welter, AL | 2 |
| Johnson, EM | 2 |
| Ru, Q | 2 |
| Lu, Y | 2 |
| Saifullah, AB | 2 |
| Blanco, FA | 2 |
| Yao, C | 2 |
| Cata, JP | 2 |
| Li, DP | 2 |
| Tolias, KF | 2 |
| Li, L | 2 |
| Oughli, HA | 2 |
| Gebara, MA | 2 |
| Ciarleglio, A | 1 |
| Lavretsky, H | 3 |
| Brown, PJ | 2 |
| Flint, AJ | 3 |
| Farber, NB | 4 |
| Karp, JF | 2 |
| Mulsant, BH | 2 |
| Reynolds, CF | 2 |
| Roose, SP | 3 |
| Butters, MA | 2 |
| Lv, S | 1 |
| Yao, K | 1 |
| Zhu, S | 1 |
| Tang, XH | 3 |
| Diao, YG | 1 |
| Ren, ZY | 1 |
| Zang, YY | 1 |
| Zhang, GF | 8 |
| Wang, XM | 5 |
| Duan, GF | 2 |
| Shen, JC | 3 |
| Zhou, ZQ | 7 |
| Yang, JJ | 12 |
| Barbosa, MG | 2 |
| Garcia, GT | 1 |
| Sarin, LM | 6 |
| Jackowski, AP | 2 |
| Vazquez, G | 1 |
| Gutierrez, G | 1 |
| Rosenblat, J | 1 |
| Schaffer, A | 1 |
| Karthikeyan, G | 1 |
| Ravindran, N | 1 |
| Giacobbe, P | 1 |
| Hawken, E | 1 |
| Milev, R | 2 |
| Brown, KA | 1 |
| Georgiou, P | 5 |
| Yuan, P | 3 |
| Thompson, SM | 3 |
| Ahmed, GK | 1 |
| Elserogy, YM | 1 |
| Elfadl, GMA | 1 |
| Ghada Abdelsalam, K | 1 |
| Ali, MA | 1 |
| Marcatili, M | 1 |
| Cavallotto, C | 1 |
| Chiappini, S | 3 |
| Zanardi, R | 2 |
| Sensi, SL | 2 |
| Li, W | 2 |
| Ye, Y | 2 |
| You, Z | 1 |
| Johnston, JN | 5 |
| Allen, J | 2 |
| Henter, ID | 11 |
| Guo, J | 2 |
| Qiu, D | 1 |
| Gu, HW | 1 |
| Riva-Posse, P | 3 |
| Pazdernik, VM | 1 |
| Casa, PL | 1 |
| de Abreu, FP | 1 |
| de Avila E Silva, S | 1 |
| Wilges, RLB | 1 |
| Rossetto, MV | 1 |
| Géa, LP | 1 |
| Rosa, AR | 1 |
| Cannarozzo, C | 1 |
| Rubiolo, A | 1 |
| Casarotto, P | 1 |
| Castrén, E | 2 |
| Greenwald, MS | 1 |
| Mkrtchian, A | 2 |
| Clark, NG | 1 |
| Park, LT | 6 |
| Gold, P | 1 |
| Kao, CF | 1 |
| Lineham, A | 1 |
| Avila-Quintero, VJ | 1 |
| Bloch, MH | 3 |
| Dwyer, J | 1 |
| Kingir, E | 1 |
| Sevinc, C | 1 |
| Unal, G | 3 |
| Onisiforou, A | 1 |
| Lorenzo, GD | 1 |
| Mancusi, G | 1 |
| Altê, GA | 1 |
| Tasca, CI | 2 |
| Danayan, K | 3 |
| Chisamore, N | 3 |
| Vincenzo, JDD | 2 |
| Doyle, Z | 2 |
| Fancy, F | 2 |
| Chau, E | 2 |
| Arekapudi, A | 2 |
| Papp, M | 4 |
| Willner, P | 5 |
| Chen, LF | 2 |
| Jeng, JS | 1 |
| Li, WC | 2 |
| Laurin, A | 1 |
| Capelle, N | 1 |
| Bukowski, N | 1 |
| Le Page, A | 1 |
| Gendre, I | 1 |
| Sauvaget, A | 1 |
| Bulteau, S | 1 |
| Kim, JW | 1 |
| Suzuki, K | 2 |
| Kavalali, ET | 5 |
| Monteggia, LM | 7 |
| Golani, LK | 1 |
| Hartland, H | 1 |
| Mahdavi, K | 1 |
| Jelen, LA | 3 |
| Alexander, L | 1 |
| Yeung, A | 1 |
| Sapirstein, G | 1 |
| Crain, LD | 1 |
| Cramer, MA | 1 |
| Forcen, FE | 1 |
| Ge, J | 1 |
| Tan, R | 1 |
| Gao, Q | 1 |
| Li, R | 1 |
| Xu, P | 1 |
| Song, H | 1 |
| Wang, S | 4 |
| Wan, Y | 1 |
| Salari, M | 1 |
| Eftekhar-Vaghefi, SH | 1 |
| Asadi-Shekaari, M | 1 |
| Esmaeilpour, K | 1 |
| Solhjou, S | 1 |
| Amiri, M | 1 |
| Ahmadi-Zeidabadi, M | 1 |
| Zavaliangos-Petropulu, A | 1 |
| McClintock, SM | 1 |
| Khalil, J | 1 |
| Taraku, B | 1 |
| Al-Sharif, NB | 1 |
| Arjmand, S | 1 |
| Vadstrup Pedersen, M | 1 |
| Silva, NR | 1 |
| Landau, AM | 1 |
| Joca, S | 2 |
| Wegener, G | 6 |
| Payette, O | 1 |
| Lespérance, P | 1 |
| Desbeaumes Jodoin, V | 1 |
| Longpré-Poirier, C | 1 |
| Elkrief, L | 1 |
| Richard, M | 1 |
| Garel, N | 3 |
| Miron, JP | 1 |
| Tamman, AJF | 1 |
| Amarneh, D | 1 |
| Swann, A | 1 |
| O'Brien, B | 1 |
| Kantor, S | 1 |
| Lanigan, M | 1 |
| Giggins, L | 1 |
| Lione, L | 1 |
| Magomedova, L | 1 |
| de Lannoy, I | 1 |
| Upton, N | 1 |
| Duxon, M | 1 |
| Sensi, S | 1 |
| Kamal, S | 1 |
| Radhakrishnan, R | 1 |
| Howland, RH | 2 |
| Gan, Y | 1 |
| Li, N | 4 |
| Nazon, M | 1 |
| Naghi, K | 1 |
| Willis, E | 1 |
| Looper, K | 1 |
| Rej, S | 2 |
| Greenway, KT | 2 |
| Lan, XF | 1 |
| Rech, TDST | 1 |
| Strelow, DN | 1 |
| Krüger, LD | 1 |
| Neto, JSS | 1 |
| Blödorn, GB | 1 |
| Alves, D | 1 |
| Brüning, CA | 1 |
| Bortolatto, CF | 1 |
| Kopelman, J | 1 |
| Keller, TA | 1 |
| Panny, B | 1 |
| Griffo, A | 1 |
| Degutis, M | 1 |
| Spotts, C | 1 |
| Cruz, N | 1 |
| Bell, E | 1 |
| Do-Nguyen, K | 1 |
| Floriano, I | 1 |
| Silvinato, A | 1 |
| Bernardo, WM | 1 |
| Hietamies, TM | 1 |
| Klise, AJ | 1 |
| Worley, MJ | 1 |
| Williams, LM | 1 |
| Levine, SP | 1 |
| Breeksema, JJ | 1 |
| Niemeijer, A | 1 |
| Kuin, B | 1 |
| Veraart, J | 1 |
| Vermetten, E | 1 |
| Schoevers, R | 1 |
| Freedman, R | 2 |
| Keramatian, K | 1 |
| Chakrabarty, T | 1 |
| DuBois, A | 1 |
| Saraf, G | 1 |
| Yatham, LN | 1 |
| Adzic, M | 1 |
| Lukic, I | 1 |
| Mitic, M | 1 |
| Glavonic, E | 1 |
| Dragicevic, N | 1 |
| Ivkovic, S | 1 |
| Harris, E | 2 |
| van Amsterdam, J | 1 |
| Bartsch, CJ | 1 |
| Aaflaq, S | 1 |
| Jacobs, JT | 1 |
| Smith, M | 1 |
| Summa, F | 1 |
| Skinner, S | 1 |
| Qasem, E | 1 |
| Thompson, R | 1 |
| Nordman, JC | 1 |
| Qin, Y | 1 |
| Cao, JL | 1 |
| White, SW | 2 |
| Squires, GD | 1 |
| Smith, SJ | 1 |
| Wright, GM | 1 |
| Sufka, KJ | 2 |
| Rimoldi, JM | 1 |
| Gadepalli, RS | 1 |
| Lins-Silva, DH | 1 |
| Dorea-Bandeira, I | 1 |
| Faria-Guimarães, D | 1 |
| Carneiro, B | 1 |
| Miranda-Scippa, Â | 1 |
| Ryan, K | 1 |
| Hosanagar, A | 1 |
| Vanderschelden, B | 1 |
| Yang, SQ | 1 |
| Zhou, YY | 1 |
| Yang, ST | 1 |
| Mao, XY | 1 |
| Bai, ZH | 1 |
| Ping, AQ | 1 |
| Xu, SY | 1 |
| Li, QW | 1 |
| Gao, K | 1 |
| Wang, SY | 1 |
| Duan, KM | 1 |
| Mingardi, J | 2 |
| Ndoj, E | 1 |
| Bonifacino, T | 1 |
| Misztak, P | 2 |
| Bertoli, M | 1 |
| La Via, L | 1 |
| Torazza, C | 1 |
| Russo, I | 1 |
| Milanese, M | 1 |
| Bonanno, G | 1 |
| Popoli, M | 1 |
| Barbon, A | 1 |
| Musazzi, L | 3 |
| Li, C | 2 |
| Yuan, H | 1 |
| Cai, J | 1 |
| Fogaça, MV | 5 |
| Zhang, YW | 1 |
| Stefanelli, G | 1 |
| Carullo, R | 1 |
| Fritz, BA | 1 |
| Tellor Pennington, BR | 1 |
| Schweiger, JA | 1 |
| Willie, JT | 1 |
| Akan, M | 1 |
| Skorodumov, I | 1 |
| Meinhardt, MW | 1 |
| Canbeyli, R | 2 |
| Liu, YL | 1 |
| Burrows, M | 1 |
| Kotoula, V | 2 |
| Dipasquale, O | 1 |
| Stringaris, A | 2 |
| Mehta, MA | 2 |
| van Verseveld, M | 2 |
| Stuiver, S | 2 |
| Vos, CF | 1 |
| Ruhé, HG | 1 |
| van Waarde, JA | 2 |
| Kramers, CK | 1 |
| Dinh-Williams, LL | 1 |
| Thibault-Levesque, J | 1 |
| Jutras-Aswad, D | 1 |
| Turecki, G | 9 |
| Richard-Devantoy, S | 2 |
| Shkolnikov, I | 1 |
| Sanchez-Lafuente, CL | 1 |
| Reive, BS | 1 |
| Scheil, K | 1 |
| Liang, S | 1 |
| Christie, BR | 1 |
| Kalynchuk, LE | 1 |
| Caruncho, HJ | 1 |
| Lee, MT | 1 |
| Ho, YC | 1 |
| Koning, MV | 1 |
| De Wit, NCJ | 1 |
| Shafiee, A | 1 |
| Soltani Abhari, F | 1 |
| Jafarabady, K | 1 |
| Bakhtiyari, M | 1 |
| Koncz, S | 1 |
| Papp, N | 1 |
| Pothorszki, D | 1 |
| Bagdy, G | 1 |
| de Leon, VC | 1 |
| Kumar, A | 2 |
| Nagele, P | 1 |
| Palanca, BJ | 1 |
| Gott, B | 1 |
| Janski, A | 1 |
| Zorumski, CF | 1 |
| Conway, CR | 1 |
| Romani, S | 1 |
| Jacquet, B | 1 |
| Cohen, D | 1 |
| Curiale, V | 1 |
| Laurent, I | 1 |
| Louchart De La Chapelle, S | 1 |
| Wu, G | 1 |
| Holsinger, T | 1 |
| Riordan, P | 1 |
| Souza, SA | 1 |
| Josino, TR | 1 |
| Bisol, LW | 1 |
| Silberbauer, LR | 1 |
| Spies, M | 1 |
| Hu, B | 1 |
| Movahed, P | 1 |
| Nordenskjöld, A | 1 |
| Kellner, CH | 2 |
| Oguntala, OA | 1 |
| Ikuelogbon, DA | 1 |
| Isaac, GT | 1 |
| Kunlere, OE | 1 |
| Jerath, AU | 1 |
| Oldak, SE | 1 |
| Parrish, MS | 1 |
| Zaydlin, M | 1 |
| Martin, S | 1 |
| Brown, K | 1 |
| Cara, V | 1 |
| Coffey, BJ | 1 |
| Reif, A | 2 |
| Bitter, I | 1 |
| Buyze, J | 1 |
| Cebulla, K | 1 |
| Frey, R | 1 |
| Fu, DJ | 1 |
| Ito, T | 1 |
| Kambarov, Y | 1 |
| Oliveira-Maia, AJ | 1 |
| Messer, T | 1 |
| Mulhern-Haughey, S | 1 |
| Rive, B | 1 |
| von Holt, C | 1 |
| Godinov, Y | 1 |
| Derosa, S | 1 |
| Mazzini, G | 1 |
| Müller, HK | 2 |
| Ma, S | 2 |
| Chen, M | 1 |
| Jiang, Y | 1 |
| Xiang, X | 1 |
| Cui, Y | 3 |
| Zhu, Y | 1 |
| Ma, H | 1 |
| Duan, S | 1 |
| Lingle, CJ | 1 |
| Hu, H | 3 |
| Caffino, L | 1 |
| Mottarlini, F | 1 |
| Piva, A | 1 |
| Rizzi, B | 1 |
| Fumagalli, F | 1 |
| Chiamulera, C | 1 |
| Schwartz, OS | 1 |
| Amminger, P | 1 |
| Baune, BT | 1 |
| Bedi, G | 1 |
| Berk, M | 2 |
| Cotton, SM | 1 |
| Daglas-Georgiou, R | 1 |
| Glozier, N | 1 |
| Harrison, B | 1 |
| Hermens, DF | 1 |
| Jennings, E | 1 |
| Lagopoulos, J | 1 |
| Loo, C | 7 |
| Mallawaarachchi, S | 1 |
| Martin, D | 3 |
| Phelan, B | 1 |
| Read, N | 1 |
| Rodgers, A | 2 |
| Schmaal, L | 1 |
| Somogyi, AA | 2 |
| Thurston, L | 1 |
| Weller, A | 1 |
| Davey, CG | 2 |
| Jornet-Plaza, J | 1 |
| Yu, T | 2 |
| Feng, W | 1 |
| Xu, Y | 1 |
| Chruścicka-Smaga, B | 1 |
| Kwaśny, A | 1 |
| Niciu, MJ | 5 |
| Meisner, RC | 1 |
| Carr, BR | 1 |
| Farooqui, AA | 1 |
| Feifel, D | 2 |
| Kaplin, A | 2 |
| Kendrick, EJ | 1 |
| Kim, PM | 1 |
| Schneck, CD | 1 |
| Tsuge, T | 1 |
| Endo, K | 1 |
| Kodama, W | 1 |
| Brandão, AAC | 1 |
| Deus, DLS | 1 |
| Duarte-Filho, LAMS | 1 |
| Menezes, PMN | 1 |
| Massaranduba, ABR | 1 |
| Silva, FS | 1 |
| Ribeiro, LAA | 1 |
| Sokołowska, P | 1 |
| Seweryn Karbownik, M | 1 |
| Jóźwiak-Bębenista, M | 1 |
| Dobielska, M | 1 |
| Kowalczyk, E | 1 |
| Wiktorowska-Owczarek, A | 1 |
| Jelovac, A | 1 |
| McCaffrey, C | 1 |
| Terao, M | 1 |
| Shanahan, E | 1 |
| Mohamed, E | 1 |
| Whooley, E | 1 |
| McDonagh, K | 1 |
| McDonogh, S | 1 |
| Igoe, A | 1 |
| Loughran, O | 1 |
| Shackleton, E | 1 |
| O'Neill, C | 1 |
| McCall, WV | 1 |
| Kaye, AP | 1 |
| Jefferson, S | 1 |
| Girgenti, MJ | 2 |
| Parel, ST | 1 |
| Bennett, SN | 1 |
| Cheng, CJ | 1 |
| Timmermans, OC | 1 |
| Fiori, LM | 1 |
| Peña, CJ | 1 |
| Polis, AJ | 1 |
| Fitzgerald, PJ | 3 |
| Hale, PJ | 1 |
| Watson, BO | 3 |
| Wang, W | 2 |
| Zhou, T | 1 |
| Jia, R | 1 |
| Dong, Y | 2 |
| Sheng, L | 1 |
| Wu, H | 2 |
| Xue, W | 2 |
| Tang, WK | 3 |
| Lau, CG | 3 |
| Ungvari, GS | 4 |
| Lin, SK | 1 |
| Szałach, ŁP | 3 |
| Lisowska, KA | 1 |
| Słupski, J | 6 |
| Górska, N | 6 |
| Szarmach, J | 6 |
| Gałuszko-Węgielnik, M | 6 |
| Krysta, K | 1 |
| Małyszko, A | 1 |
| Szałach, Ł | 1 |
| Włodarczk, A | 1 |
| Veraart, JKE | 2 |
| Pal, H | 1 |
| Jauhar, S | 1 |
| Morrison, P | 1 |
| Roman, M | 1 |
| Irwin, MR | 2 |
| Mastrodonato, A | 2 |
| Cohensedgh, O | 1 |
| LaGamma, CT | 2 |
| McGowan, JC | 2 |
| Hunsberger, HC | 1 |
| Baldwin, DS | 1 |
| McAllister-Williams, RH | 1 |
| Stone, JM | 4 |
| Taylor, D | 1 |
| Winstock, AR | 1 |
| Moretti, M | 4 |
| Werle, I | 2 |
| da Rosa, PB | 1 |
| Neis, VB | 4 |
| Platt, N | 2 |
| Souza, SVS | 1 |
| Chen, LY | 1 |
| Chen, CK | 1 |
| Chen, CH | 1 |
| Chang, HM | 1 |
| Huang, MC | 1 |
| Xu, K | 2 |
| Corriger, A | 1 |
| Pickering, G | 2 |
| Luo, A | 3 |
| Wei, MD | 1 |
| Wang, YH | 1 |
| Lu, K | 1 |
| Lv, BJ | 1 |
| Chen, WY | 1 |
| Ghosal, S | 1 |
| Duman, CH | 1 |
| Liu, RJ | 3 |
| Wu, M | 1 |
| Terwilliger, R | 1 |
| Wohleb, E | 1 |
| Teichman, EM | 1 |
| Hare, B | 3 |
| Rincón-Cortés, M | 1 |
| Grace, AA | 2 |
| Cavalcanti, DE | 2 |
| Araújo-de-Freitas, L | 3 |
| Tuena, MA | 3 |
| Nakahira, C | 3 |
| Del-Porto, JA | 2 |
| Acevedo-Diaz, EE | 2 |
| Cavanaugh, GW | 2 |
| Greenstein, D | 3 |
| Wu, C | 1 |
| He, Y | 1 |
| Wu, S | 1 |
| Xie, Z | 1 |
| Shen, J | 1 |
| Gastaldon, C | 1 |
| Papola, D | 1 |
| Ostuzzi, G | 1 |
| Barbui, C | 1 |
| Morris, LS | 1 |
| Costi, S | 2 |
| Tan, A | 1 |
| Stern, ER | 1 |
| Christensen, A | 1 |
| Pruskowski, J | 1 |
| Galiano, CS | 1 |
| Klein, ME | 1 |
| Chandra, J | 1 |
| Sheriff, S | 1 |
| Malinow, R | 1 |
| Li, P | 3 |
| Yan, H | 1 |
| Shi, X | 1 |
| Peng, S | 2 |
| Ji, MH | 3 |
| Mao, MJ | 1 |
| Qiu, LL | 2 |
| Maher, DP | 1 |
| Cohen, SP | 1 |
| Evans, JW | 1 |
| De Berardis, D | 1 |
| Tomasetti, C | 2 |
| Pompili, M | 2 |
| Serafini, G | 2 |
| Vellante, F | 2 |
| Fornaro, M | 2 |
| Perna, G | 2 |
| Volpe, U | 1 |
| Fraticelli, S | 1 |
| Kim, YK | 2 |
| Orsolini, L | 2 |
| Zhao, J | 2 |
| Chang, D | 2 |
| Lian, H | 2 |
| Du, X | 2 |
| Gao, L | 2 |
| Zaccarelli-Magalhães, J | 1 |
| Fukushima, AR | 1 |
| Moreira, N | 1 |
| Manes, M | 1 |
| de Abreu, GR | 1 |
| Ricci, EL | 1 |
| Waziry, PAF | 1 |
| Spinosa, HS | 1 |
| Wei, Y | 3 |
| Liu, W | 2 |
| Zhan, Y | 2 |
| Zhang, C | 1 |
| Wilson, C | 1 |
| Hannan, AJ | 1 |
| Renoir, T | 1 |
| Sakamoto, A | 1 |
| Suzuki, T | 1 |
| Pu, Y | 5 |
| Tan, Y | 2 |
| Shirayama, Y | 5 |
| Hatano, M | 1 |
| Tanaka, KF | 1 |
| Liu, GL | 1 |
| Cui, YF | 1 |
| Lu, C | 1 |
| Zhao, P | 2 |
| Hare, BD | 1 |
| Mathews, M | 2 |
| Naudet, F | 1 |
| Cristea, IA | 1 |
| Yokoyama, R | 1 |
| Higuchi, M | 1 |
| Tanabe, W | 1 |
| Tsukada, S | 1 |
| Naito, M | 1 |
| Yamaguchi, T | 1 |
| Kasai, A | 1 |
| Seiriki, K | 1 |
| Nakazawa, T | 1 |
| Nakagawa, S | 1 |
| Hashimoto, H | 1 |
| Ago, Y | 1 |
| Humo, M | 1 |
| Ayazgök, B | 1 |
| Becker, LJ | 1 |
| Waltisperger, E | 1 |
| Rantamäki, T | 3 |
| Yalcin, I | 1 |
| Zhao, W | 1 |
| Ma, T | 1 |
| Ma, P | 1 |
| Zhao, Y | 1 |
| Hibicke, M | 1 |
| Landry, AN | 1 |
| Kramer, HM | 1 |
| Talman, ZK | 1 |
| Nichols, CD | 1 |
| Zhuo, C | 2 |
| Lin, X | 2 |
| Tian, H | 2 |
| Bian, H | 1 |
| Delfino, RS | 1 |
| Chou, D | 1 |
| Farmer, CA | 2 |
| George, J | 1 |
| Adeojo, L | 1 |
| Lovett, J | 3 |
| Lowe, DJE | 1 |
| Müller, DJ | 1 |
| George, TP | 1 |
| Muthukumaraswamy, SD | 1 |
| Deng, ZD | 1 |
| Lisanby, SH | 1 |
| Banerjee, P | 1 |
| Donello, JE | 1 |
| Citrome, L | 1 |
| Jaworska, N | 2 |
| Kamler, E | 1 |
| Bhat, V | 1 |
| Blier, J | 1 |
| Foster, JA | 1 |
| Hassel, S | 1 |
| Ho, K | 1 |
| McMurray, L | 1 |
| Moazamigoudarzi, Z | 1 |
| Placenza, FM | 1 |
| Rotzinger, S | 1 |
| Kennedy, SH | 1 |
| Xu, N | 2 |
| Jia, M | 1 |
| Liu, R | 3 |
| Aikawa, K | 1 |
| Yoshida, T | 1 |
| Ohmura, Y | 1 |
| Lyttle, K | 1 |
| Yoshioka, M | 1 |
| Morimoto, Y | 1 |
| Aleksandrova, LR | 2 |
| Phillips, AG | 2 |
| He, W | 1 |
| Yao, Z | 1 |
| Che, F | 1 |
| Cao, Y | 1 |
| Sun, H | 1 |
| Xu, F | 1 |
| Adell, A | 2 |
| Shiroma, PR | 2 |
| Thuras, P | 2 |
| Wels, J | 2 |
| Albott, CS | 2 |
| Erbes, C | 1 |
| Tye, S | 1 |
| Lim, KO | 2 |
| Ribeiro, ACR | 1 |
| Zhu, J | 2 |
| Kronfol, MM | 1 |
| Jahr, FM | 1 |
| Younis, RM | 1 |
| Hawkins, E | 1 |
| McClay, JL | 1 |
| Deshpande, LS | 1 |
| Kolar, D | 1 |
| Gupta, A | 1 |
| Dhar, R | 1 |
| Patadia, P | 1 |
| Funaro, M | 1 |
| Bhattacharya, G | 1 |
| Farheen, SA | 1 |
| Tampi, RR | 1 |
| Hu, Q | 1 |
| Wang, F | 1 |
| Li, J | 4 |
| Cui, J | 1 |
| Shen, H | 1 |
| Iqbal, SZ | 1 |
| Luscher, B | 1 |
| Feng, M | 1 |
| Jefferson, SJ | 1 |
| Ji, F | 1 |
| Jia, F | 1 |
| Jiang, D | 1 |
| Zhou, C | 3 |
| Ross, EL | 1 |
| Soeteman, DI | 1 |
| M Rosa, J | 1 |
| B Zeni, AL | 1 |
| P Kaster, M | 1 |
| S Rodrigues, AL | 1 |
| Majeed, A | 1 |
| Senyk, O | 1 |
| Carvalho, IP | 1 |
| Siegel, A | 2 |
| Brietzke, E | 1 |
| Arekapudi, AK | 2 |
| Abrishami, A | 2 |
| Chau, EH | 2 |
| Szpejda, W | 2 |
| Luckenbaugh, DA | 10 |
| Pennybaker, SJ | 1 |
| Hopkins, MA | 1 |
| Lener, MS | 2 |
| Bartlett, MJ | 1 |
| Flores, AJ | 1 |
| Ye, T | 1 |
| Smidt, SI | 1 |
| Dollish, HK | 1 |
| Stancati, JA | 1 |
| Farrell, DC | 1 |
| Parent, KL | 1 |
| Doyle, KP | 1 |
| Besselsen, DG | 1 |
| Heien, ML | 1 |
| Cowen, SL | 1 |
| Steece-Collier, K | 1 |
| Sherman, SJ | 1 |
| Falk, T | 1 |
| Loureiro, JR | 1 |
| Vasavada, MM | 3 |
| Del Sant, L | 1 |
| de Jesus Mari, J | 1 |
| Yao, J | 1 |
| Song, T | 1 |
| Guo, N | 1 |
| Barrett, W | 1 |
| Buxhoeveden, M | 1 |
| Dhillon, S | 1 |
| Takahashi, K | 1 |
| Kitamura, Y | 1 |
| Ushio, S | 1 |
| Sendo, T | 1 |
| Rosa, PB | 3 |
| Dalsenter, YO | 1 |
| Kaufmann, FN | 1 |
| Rosado, AF | 1 |
| Besen, MH | 1 |
| Park, L | 3 |
| de Souza, MM | 1 |
| Leaver, AM | 1 |
| Lamanna, J | 1 |
| Isotti, F | 1 |
| Ferro, M | 1 |
| Racchetti, G | 1 |
| Anchora, L | 1 |
| Rucco, D | 1 |
| Malgaroli, A | 1 |
| Nuñez, NA | 1 |
| Joseph, B | 1 |
| Pahwa, M | 1 |
| Seshadri, A | 1 |
| Prokop, LJ | 1 |
| Schak, KM | 1 |
| Ramos-Quiroga, JA | 1 |
| Souery, D | 1 |
| Papakostas, GI | 2 |
| Yamamoto, M | 1 |
| Medeiros, GC | 1 |
| Reinert, J | 1 |
| Parmentier, BL | 1 |
| Gill, B | 1 |
| El-Halabi, S | 1 |
| Wu, XM | 1 |
| He, X | 1 |
| Wang, RZ | 1 |
| Yin, XY | 2 |
| Zhou, F | 1 |
| Słupska, A | 1 |
| Blackowicz, M | 1 |
| Savalia, NK | 1 |
| Shao, LX | 1 |
| Kwan, AC | 1 |
| Vecchia, DD | 2 |
| Kanazawa, LKS | 2 |
| Wendler, E | 2 |
| Hocayen, PAS | 1 |
| Vital, MABF | 2 |
| Takahashi, RN | 1 |
| Da Cunha, C | 1 |
| Miyoshi, E | 2 |
| Andreatini, R | 2 |
| Xiong, J | 1 |
| Carvalho, I | 1 |
| Narsi, F | 1 |
| Rutter, SB | 1 |
| Collins, AB | 1 |
| Govindarajulu, U | 1 |
| Horn, SR | 1 |
| Kautz, M | 2 |
| Corniquel, M | 1 |
| Collins, KA | 3 |
| Bevilacqua, L | 2 |
| Glasgow, AM | 1 |
| Brallier, J | 2 |
| Pietrzak, RH | 2 |
| Podkowa, K | 3 |
| Xu, Z | 1 |
| Zhou, X | 2 |
| Lucchese, AC | 3 |
| Magalhães, EJM | 1 |
| Del Sant, LC | 1 |
| B Puertas, C | 1 |
| Fava, VA | 1 |
| Delfino, R | 1 |
| Surjan, J | 1 |
| Steiglich, MS | 1 |
| Barbosa, M | 1 |
| Abdo, G | 1 |
| Cohrs, FM | 1 |
| Liberatori, A | 1 |
| Del Porto, JA | 1 |
| Lacerda, AL | 1 |
| B Andreoli, S | 1 |
| Greenberg, D | 1 |
| Desfossés, CY | 1 |
| Weinbroum, AA | 1 |
| Kounelis-Wuillaume, SK | 1 |
| Gheidi, A | 1 |
| Morrow, JD | 1 |
| Spencer-Segal, JL | 1 |
| Charney, A | 1 |
| Pierce, CR | 1 |
| Richards, SM | 1 |
| Glasgow, A | 1 |
| Kirkwood, K | 2 |
| Bagiella, E | 1 |
| Desai, U | 1 |
| Kirson, NY | 1 |
| Guglielmo, A | 1 |
| Le, HH | 1 |
| Spittle, T | 1 |
| Tseng-Tham, J | 1 |
| Shawi, M | 1 |
| Sheehan, JJ | 1 |
| Cepeda, MS | 1 |
| Manji, HK | 3 |
| Nakamura, T | 1 |
| Tomita, M | 1 |
| Horikawa, N | 1 |
| Ishibashi, M | 1 |
| Uematsu, K | 1 |
| Hiraki, T | 1 |
| Abe, T | 1 |
| Uchimura, N | 1 |
| Fields, J | 1 |
| Sanders, B | 1 |
| Brula, AQ | 1 |
| Clark, SM | 1 |
| Pereira, EFR | 1 |
| Reddy, BR | 1 |
| Babu, NS | 1 |
| Das, T | 1 |
| Bhattacharya, D | 1 |
| Murthy, CLN | 1 |
| Idris, MM | 1 |
| Chakravarty, S | 1 |
| Ng, J | 2 |
| Kruse, JL | 1 |
| Olmstead, R | 1 |
| Breen, EC | 1 |
| Brooks, JO | 1 |
| Parikh, T | 1 |
| Walkup, JT | 1 |
| Stocker, K | 2 |
| Hasler, G | 2 |
| Hartmann, M | 2 |
| Latuga, NM | 1 |
| Luczkiewicz, DL | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Hansen, E | 1 |
| Kerr, CW | 1 |
| Arns, M | 1 |
| van Dijk, H | 1 |
| Bonaventura, J | 1 |
| Lam, S | 1 |
| Carlton, M | 1 |
| Boehm, MA | 1 |
| Gomez, JL | 1 |
| Solís, O | 1 |
| Sánchez-Soto, M | 1 |
| Fredriksson, I | 1 |
| Sibley, DR | 1 |
| Shaham, Y | 1 |
| Olescowicz, G | 3 |
| Azevedo Padilha, D | 1 |
| Mina, F | 2 |
| Budni, J | 2 |
| Joseph, TT | 1 |
| Bu, W | 1 |
| Lin, W | 1 |
| Zoubak, L | 1 |
| Yeliseev, A | 1 |
| Eckenhoff, RG | 1 |
| Brannigan, G | 1 |
| McMullen, EP | 1 |
| Vinberg, M | 1 |
| Geske, JR | 1 |
| Lanza, IR | 1 |
| Morgan, RJ | 1 |
| Padilha, DA | 1 |
| Ekstrand, J | 1 |
| Kohtala, S | 1 |
| Abdoulaye, IA | 1 |
| Wu, SS | 1 |
| Chibaatar, E | 1 |
| Yu, DF | 1 |
| Le, K | 1 |
| Cao, XJ | 1 |
| Guo, YJ | 1 |
| Magnavita, GM | 1 |
| Telles, M | 2 |
| Bentzley, BS | 2 |
| Williams, N | 1 |
| Veldman, ER | 1 |
| Mamula, D | 1 |
| Ekman, CJ | 1 |
| Svenningsson, P | 2 |
| Botanas, CJ | 2 |
| Perez Custodio, RJ | 1 |
| Kim, HJ | 2 |
| de la Pena, JB | 1 |
| Sayson, LV | 2 |
| Ortiz, DM | 1 |
| Kim, M | 2 |
| Lee, HJ | 2 |
| Acharya, S | 2 |
| Kim, KM | 2 |
| Lee, CJ | 1 |
| Ryu, JH | 1 |
| Lee, YS | 2 |
| Cheong, JH | 2 |
| Fagerholm, ED | 1 |
| Leech, R | 1 |
| Williams, S | 1 |
| Moran, RJ | 1 |
| Siteneski, A | 1 |
| Mackes, N | 1 |
| Mazibuko, N | 1 |
| Hawkins, PCT | 1 |
| Furey, M | 1 |
| Cubala, WJ | 1 |
| Swiecicki, L | 1 |
| Newman-Tancredi, A | 1 |
| Shekotikhina, M | 1 |
| Mendonça-Filho, E | 1 |
| França, RJAF | 1 |
| Cardoso, TL | 1 |
| Marback, R | 1 |
| Teles, M | 1 |
| Echegaray, MV | 1 |
| Rabanea, T | 1 |
| Abreu, N | 1 |
| Sartim, AG | 1 |
| Marques, J | 1 |
| Silveira, KM | 1 |
| Gobira, PH | 1 |
| Guimarães, FS | 1 |
| Joca, SR | 1 |
| Marom, A | 1 |
| Rosca, P | 1 |
| Bakker, IM | 1 |
| Visser, BAE | 1 |
| Touw, DJ | 1 |
| Jiang, R | 3 |
| Yan, E | 1 |
| Hillhouse, TM | 2 |
| Anderson, PM | 1 |
| Koppenhaver, PO | 1 |
| Kegen, TN | 1 |
| Manicka, SG | 1 |
| Lane, JT | 1 |
| Pottanat, E | 1 |
| Van Fossen, M | 1 |
| Rice, R | 2 |
| Porter, JH | 2 |
| Galloway, MP | 2 |
| Wong, L | 1 |
| Turkoz, I | 1 |
| Salvadore, G | 2 |
| Ionescu, DF | 4 |
| Trivedi, MH | 2 |
| Thase, ME | 1 |
| Zorn, A | 1 |
| Linn, S | 1 |
| Jenkinson, M | 1 |
| Neher, JO | 1 |
| Safranek, S | 1 |
| Kelsberg, G | 1 |
| Mason, GF | 1 |
| Rosa, JM | 3 |
| Kaster, MP | 3 |
| Bayes, A | 2 |
| Dong, V | 2 |
| Alonzo, A | 2 |
| Kabourakis, M | 1 |
| Lopez, D | 1 |
| Rico, J | 1 |
| Coryell, W | 1 |
| Goddard, A | 1 |
| Goes, F | 1 |
| Greden, JF | 1 |
| Maixner, D | 1 |
| Watson, B | 1 |
| Drake, K | 1 |
| Tarnal, V | 1 |
| Bobo, WV | 1 |
| Rozet, I | 1 |
| Iosifescu, DV | 3 |
| Ryan, CJ | 1 |
| Singh, I | 1 |
| Morgan, C | 1 |
| Curran, V | 1 |
| Nutt, D | 1 |
| Schlag, A | 1 |
| DellaGioia, N | 1 |
| Matuskey, D | 1 |
| Nabulsi, N | 1 |
| Pittenger, C | 2 |
| Parsey, RV | 1 |
| Carson, RE | 1 |
| DeLorenzo, C | 2 |
| Glue, P | 3 |
| Medlicott, NJ | 1 |
| Harland, S | 1 |
| Neehoff, S | 1 |
| Anderson-Fahey, B | 1 |
| Le Nedelec, M | 1 |
| Gray, A | 1 |
| McNaughton, N | 1 |
| Lin, FB | 1 |
| Hou, DR | 1 |
| Tang, QP | 1 |
| Cohen, IV | 1 |
| Makunts, T | 1 |
| Atayee, R | 1 |
| Abagyan, R | 1 |
| Wills, K | 1 |
| Lally, N | 1 |
| Richards, EM | 3 |
| Walls, T | 1 |
| Ameli, R | 4 |
| Brutsche, NE | 6 |
| Schiavone, S | 1 |
| Tucci, P | 1 |
| Mhillaj, E | 1 |
| Bove, M | 1 |
| Trabace, L | 1 |
| Morgese, MG | 1 |
| Fernandes, A | 1 |
| Li, YW | 1 |
| Xie, ZM | 2 |
| Pan, W | 3 |
| Harraz, MM | 2 |
| Snyder, SH | 2 |
| Golzari, SEJ | 1 |
| Mahmoodpoor, A | 1 |
| Rasmussen, KG | 1 |
| Suárez-Santiago, JE | 1 |
| Briones-Aranda, A | 1 |
| Espinosa-Raya, J | 1 |
| Picazo, O | 1 |
| Chen, IC | 1 |
| Lee, MH | 1 |
| Chen, WC | 1 |
| Hu, TC | 1 |
| Lin, HY | 1 |
| Anderson, IM | 1 |
| McDaniel, W | 1 |
| Vyas, B | 1 |
| Laguerta, N | 2 |
| Li, CR | 1 |
| Zhang, S | 1 |
| Hung, CC | 1 |
| Chen, CM | 1 |
| Duann, JR | 1 |
| Lin, CP | 1 |
| Lee, TS | 1 |
| McGirr, A | 1 |
| LeDue, J | 1 |
| Chan, AW | 1 |
| Xie, Y | 1 |
| Murphy, TH | 1 |
| Huang, BS | 1 |
| Liston, C | 1 |
| Sharma, P | 1 |
| Ren, Q | 6 |
| Ma, M | 6 |
| Weckmann, K | 1 |
| Deery, MJ | 1 |
| Howard, JA | 1 |
| Feret, R | 1 |
| Asara, JM | 1 |
| Dethloff, F | 1 |
| Filiou, MD | 1 |
| Iannace, J | 1 |
| Labermaier, C | 1 |
| Maccarrone, G | 1 |
| Webhofer, C | 1 |
| Teplytska, L | 1 |
| Lilley, K | 1 |
| Müller, MB | 1 |
| Turck, CW | 1 |
| Jiang, C | 2 |
| Lin, WJ | 2 |
| Sadahiro, M | 1 |
| Labonté, B | 2 |
| Menard, C | 1 |
| Pfau, ML | 1 |
| Tamminga, CA | 3 |
| Nestler, EJ | 3 |
| Russo, SJ | 2 |
| Salton, SR | 2 |
| Yao, N | 1 |
| Skiteva, O | 1 |
| Chergui, K | 1 |
| Wei, IH | 1 |
| Chen, KT | 1 |
| Tsai, MH | 1 |
| Wu, CH | 1 |
| Huang, CC | 1 |
| Pham, TH | 2 |
| Defaix, C | 1 |
| Deng, SX | 1 |
| Fabresse, N | 1 |
| Alvarez, JC | 1 |
| Landry, DW | 1 |
| Brachman, RA | 3 |
| Gardier, AM | 2 |
| Ide, S | 1 |
| Ikekubo, Y | 1 |
| Mishina, M | 1 |
| Ikeda, K | 1 |
| Dossat, AM | 1 |
| Wright, KN | 2 |
| Strong, CE | 1 |
| Kabbaj, M | 2 |
| Raffa, RB | 2 |
| Pergolizzi, JV | 1 |
| Taylor, R | 1 |
| Yan, W | 1 |
| Liu, JF | 1 |
| Han, Y | 2 |
| Luo, YX | 1 |
| Xue, YX | 1 |
| Zhu, WL | 1 |
| Chen, WH | 1 |
| Guo, HL | 1 |
| Ma, YN | 1 |
| Yuan, K | 2 |
| Wang, JS | 1 |
| Shi, J | 1 |
| Lu, L | 2 |
| Li, XY | 2 |
| Fukumoto, K | 3 |
| DeVylder, J | 1 |
| Ruda-Kucerova, J | 2 |
| Babinska, Z | 2 |
| Luptak, M | 1 |
| Getachew, B | 1 |
| Tizabi, Y | 3 |
| de Almeida Soares Hocayen, P | 1 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Adaikkan, C | 1 |
| Taha, E | 1 |
| Barrera, I | 1 |
| David, O | 1 |
| Rosenblum, K | 1 |
| Sang, K | 1 |
| Ni, Z | 1 |
| Hultman, R | 1 |
| Ulrich, K | 1 |
| Sachs, BD | 1 |
| Blount, C | 1 |
| Carlson, DE | 1 |
| Ndubuizu, N | 1 |
| Bagot, RC | 1 |
| Parise, EM | 2 |
| Vu, MT | 1 |
| Gallagher, NM | 1 |
| Silva, AJ | 1 |
| Deisseroth, K | 1 |
| Mague, SD | 1 |
| Caron, MG | 1 |
| Carin, L | 1 |
| Dzirasa, K | 1 |
| Reiff, CM | 1 |
| Edwards, JA | 1 |
| Job, GP | 1 |
| Galendez, GC | 1 |
| Garlow, SJ | 1 |
| Saah, TC | 1 |
| Dunlop, BW | 1 |
| McDonald, WM | 1 |
| Nemeroff, CB | 1 |
| Martinez, R | 1 |
| Pavlova, IP | 1 |
| Robison, AJ | 1 |
| Fallon, MT | 2 |
| Wilcock, A | 1 |
| Kelly, CA | 1 |
| Paul, J | 1 |
| Lewsley, LA | 1 |
| Norrie, J | 1 |
| Laird, BJA | 1 |
| Brown, AS | 1 |
| Cannon, TD | 1 |
| Druss, BG | 1 |
| Earls, FJ | 1 |
| Escobar, J | 1 |
| Hurd, YL | 1 |
| Lewis, DA | 1 |
| López-Jaramillo, C | 1 |
| Luby, J | 1 |
| Mayberg, HS | 1 |
| Moffitt, TE | 1 |
| Oquendo, M | 1 |
| Perlis, RH | 1 |
| Pine, DS | 1 |
| Rush, AJ | 1 |
| Tohen, M | 1 |
| Vieta, E | 1 |
| Wisner, KL | 1 |
| Li, HH | 1 |
| Li, KY | 1 |
| Eldufani, J | 1 |
| Nekoui, A | 1 |
| Blaise, G | 1 |
| Shouan, A | 1 |
| Grover, S | 1 |
| Wray, NH | 1 |
| Schappi, JM | 1 |
| Singh, H | 1 |
| Senese, NB | 1 |
| Rasenick, MM | 1 |
| Vanle, B | 1 |
| Olcott, W | 1 |
| Jimenez, J | 1 |
| Bashmi, L | 1 |
| Danovitch, I | 1 |
| IsHak, WW | 1 |
| Haji, N | 1 |
| De Gregorio, D | 1 |
| Eslamizade, MJ | 1 |
| Popic, J | 1 |
| Sharma, V | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 1 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Lacaille, JC | 1 |
| Gobbi, G | 1 |
| Sonenberg, N | 1 |
| Kobayashi, S | 1 |
| Nakao, K | 1 |
| Han, M | 3 |
| Toki, H | 2 |
| Yamaguchi, JI | 2 |
| Nakazawa, K | 2 |
| Manabe, T | 1 |
| Harvey, BH | 1 |
| Ren, L | 2 |
| Hao, X | 3 |
| Min, S | 3 |
| Deng, J | 1 |
| Chen, Q | 1 |
| Chen, H | 1 |
| Bartova, L | 1 |
| Papageorgiou, K | 1 |
| Milenkovic, I | 1 |
| Dold, M | 1 |
| Weidenauer, A | 1 |
| Willeit, M | 1 |
| Winkler, D | 1 |
| Cover, KK | 1 |
| Kerkhoff, WG | 1 |
| Mathur, BN | 1 |
| Wang, XD | 1 |
| Yang, G | 1 |
| Feng, YP | 1 |
| Bettio, LB | 1 |
| Gonçalves, FM | 1 |
| Freitas, AE | 1 |
| Heinrich, IA | 1 |
| Lopes, MW | 1 |
| Leal, RB | 1 |
| Cui, W | 1 |
| Hong, W | 1 |
| Liu, Z | 1 |
| Li, MD | 1 |
| Fang, J | 1 |
| Zhen, L | 1 |
| Goodwill, HL | 1 |
| Manzano-Nieves, G | 1 |
| Gallo, M | 1 |
| Lee, HI | 1 |
| Oyerinde, E | 1 |
| Serre, T | 1 |
| Bath, KG | 1 |
| Gruca, P | 2 |
| Lason, M | 1 |
| Tota-Glowczyk, K | 1 |
| Litwa, E | 1 |
| Niemczyk, M | 1 |
| Li, M | 1 |
| Luo, J | 4 |
| Ferreira, CBN | 1 |
| Vale, LAS | 1 |
| Argolo, FC | 1 |
| Cardoso, T | 1 |
| Souza, CDS | 1 |
| Fontes, ATC | 1 |
| Ferreira, MB | 1 |
| Lima, CS | 1 |
| Abreu, JN | 1 |
| Machado, PRL | 1 |
| Flynn, M | 1 |
| Judge, H | 1 |
| Hoeppner, BB | 1 |
| Cusin, C | 1 |
| Shen, M | 1 |
| Lv, D | 1 |
| Chen, Y | 1 |
| Weigmann, K | 1 |
| Mashour, GA | 1 |
| Ben Abdallah, A | 1 |
| Pryor, KO | 1 |
| El-Gabalawy, R | 1 |
| Vlisides, PE | 1 |
| Jacobsohn, E | 1 |
| Lenze, E | 1 |
| Maybrier, HR | 1 |
| Veselis, RA | 1 |
| Avidan, MS | 1 |
| Sexton, J | 1 |
| Atayee, RS | 1 |
| Bruner, HC | 1 |
| Harkin, A | 2 |
| Hirota, K | 1 |
| Lambert, DG | 1 |
| Li, JM | 1 |
| Liu, LL | 1 |
| Su, WJ | 1 |
| Wang, B | 1 |
| Zhang, T | 1 |
| Jiang, CL | 1 |
| Xiong, Z | 3 |
| Huang, N | 2 |
| Hua, D | 2 |
| Zhan, G | 2 |
| Bi, J | 1 |
| Bartoli, F | 1 |
| Crocamo, C | 1 |
| Carrà, G | 1 |
| Yang, X | 1 |
| Gao, H | 1 |
| Tang, QK | 1 |
| Yin, LY | 1 |
| Hao, JR | 1 |
| Geng, DQ | 1 |
| Gao, C | 1 |
| Lee, V | 1 |
| Archer, S | 1 |
| Chrenek, C | 1 |
| Gálvez Ortiz, V | 1 |
| Mitchell, PB | 2 |
| Li, A | 1 |
| Huggins, C | 1 |
| Loo, CK | 2 |
| Williams, NR | 3 |
| Blasey, C | 2 |
| Sudheimer, K | 2 |
| Rodriguez, CI | 2 |
| Gärtner, M | 1 |
| Aust, S | 1 |
| Bajbouj, M | 1 |
| Fan, Y | 1 |
| Wingenfeld, K | 1 |
| Otte, C | 1 |
| Heuser-Collier, I | 1 |
| Böker, H | 1 |
| Hättenschwiler, J | 1 |
| Seifritz, E | 1 |
| Grimm, S | 1 |
| Scheidegger, M | 1 |
| Hu, S | 1 |
| Vindas, MA | 1 |
| Helland-Riise, SH | 1 |
| Nilsson, GE | 1 |
| Øverli, Ø | 1 |
| Li, XH | 1 |
| Zhu, XM | 1 |
| Cai, DB | 1 |
| Ng, CH | 1 |
| Hu, YD | 1 |
| He, SH | 1 |
| Xiang, YT | 1 |
| Ji, M | 1 |
| Mao, M | 1 |
| Qiu, L | 1 |
| Li, B | 1 |
| Xia, J | 1 |
| Montemitro, C | 1 |
| Fiengo, ALC | 1 |
| Santone, C | 1 |
| Carano, A | 1 |
| Giannantonio, MD | 1 |
| Nicola, MD | 1 |
| Ventriglio, A | 1 |
| Berardis, DD | 1 |
| Lur, G | 1 |
| Fariborzi, M | 1 |
| Higley, MJ | 1 |
| Stewart, BW | 2 |
| Jenne, CE | 1 |
| Custodio, RJP | 1 |
| Abiero, A | 1 |
| Yoo, SY | 1 |
| Lee, KW | 1 |
| Ryu, HW | 1 |
| Ruan, J | 1 |
| Shan, X | 1 |
| Xia, B | 2 |
| Fu, Q | 1 |
| Troppoli, TA | 1 |
| Krzystyniak, A | 1 |
| Baczynska, E | 1 |
| Magnowska, M | 1 |
| Antoniuk, S | 1 |
| Roszkowska, M | 1 |
| Zareba-Koziol, M | 1 |
| Das, N | 1 |
| Basu, S | 1 |
| Pikula, M | 1 |
| Wlodarczyk, J | 1 |
| Khakpai, F | 1 |
| Ebrahimi-Ghiri, M | 1 |
| Alijanpour, S | 1 |
| Zarrindast, MR | 1 |
| Jaksch, W | 1 |
| Likar, R | 1 |
| Aigner, M | 1 |
| Yen, JY | 1 |
| Wang, SM | 1 |
| Yoon, G | 1 |
| Petrakis, IL | 1 |
| Goldman, N | 1 |
| Frankenthaler, M | 1 |
| Klepacz, L | 1 |
| Zhao, Q | 1 |
| Han, S | 1 |
| Suzuki, A | 1 |
| Murakami, K | 1 |
| Tajima, Y | 1 |
| Hara, H | 1 |
| Kunugi, A | 1 |
| Kimura, H | 1 |
| López-Gil, X | 1 |
| Jiménez-Sánchez, L | 1 |
| Campa, L | 1 |
| Castro, E | 1 |
| Frago, C | 1 |
| Ecevitoglu, A | 1 |
| Gass, N | 1 |
| Becker, R | 1 |
| Reinwald, J | 1 |
| Cosa-Linan, A | 1 |
| Sack, M | 1 |
| Weber-Fahr, W | 1 |
| Vollmayr, B | 1 |
| Sartorius, A | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| Yamada, J | 1 |
| Jinno, S | 1 |
| Yu, F | 1 |
| Wu, Y | 1 |
| Hua, F | 1 |
| Reardon, S | 3 |
| Wu, HR | 1 |
| Fan, SJ | 1 |
| Liu, DX | 1 |
| Zhang, Q | 1 |
| Pan, F | 1 |
| Hanania, T | 1 |
| Manfredi, P | 1 |
| Inturrisi, C | 1 |
| Vitolo, OV | 1 |
| Yuan, R | 1 |
| Wen, Y | 1 |
| Wasserman, D | 1 |
| Acevedo-Diaz, E | 1 |
| Gigliucci, V | 1 |
| O'Dowd, G | 1 |
| Casey, S | 1 |
| Egan, D | 1 |
| Gibney, S | 1 |
| Liang, HJ | 2 |
| Tang, A | 2 |
| Walker, AK | 1 |
| Budac, DP | 1 |
| Bisulco, S | 1 |
| Lee, AW | 1 |
| Smith, RA | 1 |
| Beenders, B | 1 |
| Kelley, KW | 1 |
| Dantzer, R | 1 |
| Katalinic, N | 1 |
| Lai, R | 1 |
| Somogyi, A | 1 |
| O'Connor, RM | 1 |
| Grenham, S | 1 |
| Dinan, TG | 2 |
| Cryan, JF | 2 |
| Akinfiresoye, L | 2 |
| Alcantara, LF | 1 |
| Warren, BL | 1 |
| Hadad, R | 1 |
| Sial, OK | 1 |
| Kroeck, KG | 1 |
| Iñiguez, SD | 1 |
| Bolaños-Guzmán, CA | 1 |
| Jenyon, T | 1 |
| Sole, G | 1 |
| Miller, AH | 1 |
| Zarate, C | 2 |
| Liu, G | 2 |
| Sartori, S | 1 |
| Quiroz, J | 1 |
| Murck, H | 1 |
| Chan, F | 1 |
| Perrine, SA | 1 |
| Ghoddoussi, F | 1 |
| Michaels, MS | 1 |
| Sheikh, IS | 1 |
| McKelvey, G | 1 |
| Taiminen, T | 1 |
| Naughton, M | 1 |
| Clarke, G | 1 |
| O'Leary, OF | 1 |
| Owolabi, RA | 1 |
| Akanmu, MA | 1 |
| Adeyemi, OI | 1 |
| Potter, WZ | 1 |
| Brady, LS | 1 |
| Wang, N | 2 |
| Liu, XY | 1 |
| Sun, HL | 2 |
| Parides, MK | 1 |
| Perez, AM | 2 |
| Morgan, JE | 1 |
| Saxena, S | 1 |
| Aan Het Rot, M | 3 |
| Lapidus, KA | 2 |
| Wan, LB | 1 |
| Iosifescu, D | 1 |
| Peng, LH | 1 |
| Lv, F | 1 |
| Ao, L | 1 |
| Hao, XC | 1 |
| Bernstein, HG | 1 |
| Keilhoff, G | 1 |
| Steiner, J | 1 |
| Laube, G | 1 |
| Bogerts, B | 1 |
| Aligeti, S | 1 |
| Quinones, M | 1 |
| Salazar, R | 1 |
| Koike, H | 3 |
| Best, SR | 1 |
| Griffin, B | 1 |
| Belujon, P | 2 |
| Pereira, B | 1 |
| Morel, V | 1 |
| Tiberghien, F | 1 |
| Martin, E | 1 |
| Marcaillou, F | 1 |
| Picard, P | 1 |
| Delage, N | 1 |
| de Montgazon, G | 1 |
| Sorel, M | 1 |
| Roux, D | 1 |
| Dubray, C | 1 |
| Johns, B | 1 |
| Shaffer, CL | 1 |
| Osgood, SM | 1 |
| Smith, DL | 1 |
| Liu, J | 1 |
| Trapa, PE | 1 |
| Kilic, FS | 1 |
| Ismailoglu, S | 1 |
| Kaygisiz, B | 1 |
| Oner, S | 1 |
| Ritter, PS | 1 |
| Bauer, M | 1 |
| Pilhatsch, M | 1 |
| Miller, OH | 1 |
| Wang, CC | 1 |
| Hargroder, EA | 1 |
| Delpire, E | 1 |
| Hall, BJ | 1 |
| Permoda-Osip, A | 1 |
| Kisielewski, J | 1 |
| Bartkowska-Sniatkowska, A | 1 |
| Rybakowski, JK | 1 |
| Réus, GZ | 3 |
| Nacif, MP | 2 |
| Abelaira, HM | 2 |
| Tomaz, DB | 2 |
| dos Santos, MA | 2 |
| Carlessi, AS | 2 |
| da Luz, JR | 2 |
| Gonçalves, RC | 1 |
| Vuolo, F | 1 |
| Dal-Pizzol, F | 1 |
| Carvalho, AF | 1 |
| Quevedo, J | 4 |
| Liebenberg, N | 1 |
| Huynh, TN | 1 |
| Klann, E | 1 |
| Chiu, CT | 1 |
| Scheuing, L | 1 |
| Liao, HM | 1 |
| Linares, GR | 1 |
| Lin, D | 1 |
| Chuang, DM | 1 |
| Chen, FF | 1 |
| Chen, XD | 1 |
| Matias, BI | 1 |
| Steckert, AV | 1 |
| Jeremias, GC | 1 |
| Scaini, G | 1 |
| Morais, MO | 1 |
| Streck, EL | 2 |
| Cunha, MP | 2 |
| Pazini, FL | 2 |
| Ramos-Hryb, AB | 1 |
| Oliveira, Á | 2 |
| Rodrigues, AL | 5 |
| Reinstatler, L | 1 |
| Youssef, NA | 1 |
| Freudenberg, F | 1 |
| Celikel, T | 1 |
| Nguyen, L | 1 |
| Matsumoto, RR | 1 |
| Młyniec, K | 1 |
| Gaweł, M | 1 |
| Nowak, G | 3 |
| Wei, K | 1 |
| Xie, F | 1 |
| Jin, J | 1 |
| Rajkumar, R | 1 |
| Fam, J | 1 |
| Yeo, EY | 1 |
| Dawe, GS | 1 |
| Perusini, JN | 1 |
| Lim, SC | 1 |
| Faye, C | 1 |
| Mendez-David, I | 1 |
| David, DJ | 1 |
| Hen, R | 1 |
| Melo, A | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 1 |
| Pêgo, JM | 1 |
| Wróbel, A | 1 |
| Serefko, A | 1 |
| Wlaź, P | 1 |
| Poleszak, E | 2 |
| Walker, AJ | 1 |
| Foley, BM | 1 |
| Sutor, SL | 1 |
| McGillivray, JA | 1 |
| Yu, HY | 1 |
| Shen, XF | 1 |
| Gao, ZQ | 2 |
| Serchov, T | 1 |
| Clement, HW | 1 |
| Schwarz, MK | 1 |
| Iasevoli, F | 1 |
| Tosh, DK | 1 |
| Idzko, M | 1 |
| Jacobson, KA | 1 |
| de Bartolomeis, A | 1 |
| Biber, K | 1 |
| van Calker, D | 1 |
| Soleimani, L | 1 |
| DeWilde, KE | 1 |
| Iacoviello, BM | 1 |
| Lener, M | 1 |
| Kim, J | 1 |
| Stern, JB | 1 |
| Brallier, JW | 1 |
| Rodriguez, GJ | 1 |
| Goodman, WK | 1 |
| Belzung, C | 1 |
| Pittman, J | 1 |
| Hylton, A | 1 |
| Kirby, T | 1 |
| Caddy, C | 2 |
| Amit, BH | 2 |
| McCloud, TL | 2 |
| Rendell, JM | 2 |
| Furukawa, TA | 1 |
| Jochim, J | 1 |
| Diamond, PR | 1 |
| Shuttleworth, C | 1 |
| Brett, D | 1 |
| Hamadi, L | 1 |
| Jing, L | 1 |
| Duan, TT | 1 |
| Tian, M | 1 |
| Yuan, Q | 1 |
| Tan, JW | 1 |
| Zhu, YY | 1 |
| Ding, ZY | 1 |
| Cao, J | 1 |
| Yang, YX | 1 |
| Mao, RR | 1 |
| Richter-Levin, G | 1 |
| Zhou, QX | 1 |
| Xu, L | 1 |
| Bolton, JM | 1 |
| Gunnell, D | 1 |
| Carreno, FR | 1 |
| Donegan, JJ | 2 |
| Boley, AM | 1 |
| Shah, A | 1 |
| DeGuzman, M | 1 |
| Frazer, A | 1 |
| Lodge, DJ | 2 |
| Colla, AR | 1 |
| Lieberknecht, V | 1 |
| Moreira, SF | 1 |
| Nunes, EA | 1 |
| Kuo, J | 1 |
| de Macedo, IC | 1 |
| Muchale, A | 1 |
| de Oliveira, C | 1 |
| Scarabelot, VL | 1 |
| Marques Filho, PR | 1 |
| Medeiros, LF | 1 |
| Caumo, W | 1 |
| Torres, IL | 1 |
| Holleran, KM | 1 |
| Wilson, HH | 1 |
| Fetterly, TL | 1 |
| Bluett, RJ | 1 |
| Centanni, SW | 1 |
| Gilfarb, RA | 1 |
| Rocco, LE | 1 |
| Patel, S | 1 |
| Winder, DG | 1 |
| Romeo, B | 1 |
| Choucha, W | 1 |
| Rotge, JY | 1 |
| Zhang, MW | 2 |
| Harris, KM | 2 |
| Tyagi, R | 1 |
| Cortés, P | 1 |
| Fan, N | 1 |
| Rosenheck, R | 1 |
| Ke, X | 1 |
| Ding, Y | 1 |
| Sun, B | 1 |
| Deng, X | 1 |
| Tang, W | 1 |
| He, H | 1 |
| Tao, W | 1 |
| Wu, R | 1 |
| Cai, B | 1 |
| Doronc, R | 1 |
| Arunogiri, S | 1 |
| Keks, NA | 1 |
| Hope, J | 1 |
| Gerhard, DM | 1 |
| Wohleb, ES | 1 |
| Sampath, H | 1 |
| Sharma, I | 1 |
| Dutta, S | 1 |
| Ye, K | 1 |
| Li, QQ | 1 |
| Jin, XJ | 1 |
| Peng, LC | 1 |
| Sarkar, A | 1 |
| Gao, M | 1 |
| Rejaei, D | 1 |
| Choi, M | 1 |
| Lee, SH | 1 |
| Chang, HL | 1 |
| Son, H | 1 |
| Mallick, F | 1 |
| McCullumsmith, CB | 1 |
| du Jardin, KG | 1 |
| Elfving, B | 1 |
| Dale, E | 1 |
| Sanchez, C | 1 |
| Brański, P | 1 |
| Lin, JC | 2 |
| Chan, MH | 2 |
| Lee, MY | 2 |
| Chen, YC | 2 |
| Chen, HH | 2 |
| Jafarinia, M | 1 |
| Afarideh, M | 1 |
| Tafakhori, A | 1 |
| Arbabi, M | 1 |
| Ghajar, A | 1 |
| Noorbala, AA | 1 |
| Saravi, MA | 1 |
| Agah, E | 1 |
| Akhondzadeh, S | 1 |
| Thelen, C | 1 |
| Sens, J | 1 |
| Mauch, J | 1 |
| Pandit, R | 1 |
| Pitychoutis, PM | 1 |
| do Vale, EM | 1 |
| Xavier, CC | 1 |
| Nogueira, BG | 1 |
| Campos, BC | 1 |
| de Aquino, PE | 1 |
| da Costa, RO | 1 |
| Leal, LK | 1 |
| de Vasconcelos, SM | 1 |
| Neves, KR | 1 |
| de Barros Viana, GS | 1 |
| Ribeiro, CM | 1 |
| Ardalan, M | 2 |
| Polsinelli, B | 1 |
| Madsen, TM | 1 |
| Nyengaard, JR | 2 |
| Yang, B | 1 |
| Chen, QX | 1 |
| Han, JF | 1 |
| Sun, KJ | 1 |
| Landrigan, J | 1 |
| Shawaf, F | 1 |
| Dwyer, Z | 1 |
| Abizaid, A | 1 |
| Hayley, S | 1 |
| Pešić, V | 1 |
| Petrović, J | 1 |
| M Jukić, M | 1 |
| Yamaki, VN | 1 |
| Wei, Z | 1 |
| Kara, NZ | 1 |
| Agam, G | 1 |
| Anderson, GW | 1 |
| Zitron, N | 1 |
| Einat, H | 1 |
| Grieco, SF | 1 |
| Velmeshev, D | 1 |
| Magistri, M | 1 |
| Eldar-Finkelman, H | 1 |
| Faghihi, MA | 1 |
| Jope, RS | 2 |
| Beurel, E | 2 |
| Burger, J | 1 |
| Capobianco, M | 1 |
| Lovern, R | 1 |
| Boche, B | 1 |
| Ross, E | 1 |
| Darracq, MA | 1 |
| McLay, R | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Rafati, AH | 1 |
| Li, DJ | 1 |
| Wang, FC | 1 |
| Chu, CS | 1 |
| Chen, TY | 1 |
| Tang, CH | 1 |
| Yang, WC | 1 |
| Chow, PC | 1 |
| Wu, CK | 1 |
| Tseng, PT | 1 |
| Lin, PY | 1 |
| Lepow, L | 1 |
| Fan, W | 1 |
| Yang, H | 1 |
| Li, G | 1 |
| Ye, G | 1 |
| Strasburger, SE | 1 |
| Bhimani, PM | 1 |
| Kaabe, JH | 1 |
| Krysiak, JT | 1 |
| Nanchanatt, DL | 1 |
| Nguyen, TN | 1 |
| Pough, KA | 1 |
| Prince, TA | 1 |
| Ramsey, NS | 1 |
| Savsani, KH | 1 |
| Scandlen, L | 1 |
| Cavaretta, MJ | 1 |
| Hashihayata, T | 1 |
| Frere, M | 1 |
| Tepper, J | 1 |
| Apeldoorn, SY | 1 |
| de Boer, MK | 1 |
| Hong, YX | 1 |
| Husain, SF | 1 |
| Reich, DL | 1 |
| Engin, E | 1 |
| Treit, D | 1 |
| Dickson, CT | 1 |
| Hudetz, JA | 1 |
| Iqbal, Z | 1 |
| Gandhi, SD | 1 |
| Patterson, KM | 1 |
| Byrne, AJ | 1 |
| Hudetz, AG | 1 |
| Pagel, PS | 1 |
| Warltier, DC | 1 |
| Nock, MK | 1 |
| Assis, LC | 1 |
| Rezin, GT | 1 |
| Comim, CM | 1 |
| Valvassori, SS | 1 |
| Jeremias, IC | 1 |
| Zugno, AI | 1 |
| Okamoto, N | 1 |
| Nakai, T | 1 |
| Sakamoto, K | 1 |
| Nagafusa, Y | 1 |
| Higuchi, T | 1 |
| Nishikawa, T | 1 |
| Paslakis, G | 1 |
| Gilles, M | 1 |
| Meyer-Lindenberg, A | 1 |
| Deuschle, M | 1 |
| Thangathurai, D | 2 |
| Roby, J | 1 |
| Roffey, P | 1 |
| Wu, J | 1 |
| Jiang, X | 1 |
| Qu, Q | 1 |
| Ou, C | 1 |
| Zhou, S | 1 |
| DiazGranados, N | 3 |
| Ibrahim, LA | 1 |
| Machado-Vieira, R | 1 |
| Lee, B | 1 |
| Banasr, M | 1 |
| Dwyer, JM | 1 |
| Iwata, M | 1 |
| Aghajanian, G | 2 |
| Messer, M | 1 |
| Haller, IV | 1 |
| Larson, P | 1 |
| Pattison-Crisostomo, J | 1 |
| Gessert, CE | 1 |
| Glazer, WM | 1 |
| Stringari, RB | 1 |
| Ribeiro, KF | 1 |
| Ferraro, AK | 1 |
| Vitto, MF | 1 |
| Cesconetto, P | 1 |
| Souza, CT | 1 |
| Mogos, M | 1 |
| Song, L | 1 |
| Autry, AE | 1 |
| Adachi, M | 1 |
| Nosyreva, E | 1 |
| Na, ES | 1 |
| Los, MF | 1 |
| Cheng, PF | 1 |
| Lu, W | 1 |
| Romero-Sandoval, EA | 1 |
| Lindholm, JS | 1 |
| Autio, H | 1 |
| Vesa, L | 1 |
| Antila, H | 1 |
| Lindemann, L | 1 |
| Hoener, MC | 1 |
| Skolnick, P | 1 |
| Malkesman, O | 1 |
| Austin, DR | 1 |
| Tragon, T | 1 |
| Rompala, G | 1 |
| Hamidi, AB | 1 |
| Cui, Z | 1 |
| Young, WS | 1 |
| Duric, V | 1 |
| Goffer, Y | 1 |
| Xu, D | 1 |
| Tukey, DS | 1 |
| Shamir, DB | 1 |
| Eberle, SE | 1 |
| Zou, AH | 1 |
| Blanck, TJ | 1 |
| Ziff, EB | 1 |
| Ibrahim, L | 2 |
| Franco-Chaves, J | 2 |
| Cravchik, A | 1 |
| Selter, J | 1 |
| Marquardt, CA | 1 |
| Liberty, V | 1 |
| Brutsche, N | 1 |
| Kronstein, P | 1 |
| Wainer, I | 1 |
| Vanzella, C | 1 |
| Bianchetti, P | 1 |
| Sbaraini, S | 1 |
| Vanzin, SI | 1 |
| Melecchi, MI | 1 |
| Caramão, EB | 1 |
| Siqueira, IR | 1 |
| Bhatti, BH | 1 |
| Manaye, KF | 1 |
| Das, JR | 1 |
| Wasylink, S | 1 |
| Landeros-Weisenberger, A | 1 |
| Panza, KE | 1 |
| Billingslea, E | 1 |
| Leckman, JF | 1 |
| Bhagwagar, Z | 1 |
| Machado, DG | 1 |
| Santos, AR | 2 |
| Morgan, CJ | 1 |
| Pepper, F | 1 |
| Howes, OD | 1 |
| Smith, MA | 1 |
| Pathak, S | 1 |
| Fasula, M | 1 |
| Kelmendi, B | 1 |
| Ostroff, R | 1 |
| Shi, JY | 1 |
| Gideons, E | 1 |
| Segmiller, F | 1 |
| Frisse, D | 1 |
| Eser, D | 1 |
| Möller, HJ | 1 |
| Rüther, T | 1 |
| Schüle, C | 1 |
| Burgdorf, J | 1 |
| Zhang, XL | 1 |
| Nicholson, KL | 1 |
| Balster, RL | 1 |
| Leander, JD | 1 |
| Stanton, PK | 1 |
| Gross, AL | 1 |
| Kroes, RA | 1 |
| Moskal, JR | 1 |
| Krupitsky, E | 1 |
| Burakov, A | 1 |
| Romanova, T | 1 |
| Dunaevsky, I | 1 |
| Strassman, R | 1 |
| Grinenko, A | 1 |
| Rosa, AO | 1 |
| Lin, J | 1 |
| Calixto, JB | 1 |
| Hayase, T | 1 |
| Yamamoto, Y | 1 |
| Yamamoto, K | 1 |
| McDaniel, WW | 1 |
| Sahota, AK | 1 |
| Vyas, BV | 1 |
| Hategan, L | 1 |
| Oswald, J | 1 |
| Check, E | 1 |
| Pavarin, RM | 1 |
| Popik, P | 1 |
| Kos, T | 1 |
| Sowa-Kućma, M | 1 |
| Chaturvedi, HK | 1 |
| Bapna, JS | 1 |
| Chandra, D | 1 |
| Mitchell, AC | 1 |
| Sappington, AA | 1 |
| Corssen, G | 1 |
| Becker, AT | 1 |
| Tavakoli, M | 1 |
| Winters, WD | 1 |
| Brewer, CL | 1 |
| Davidson, JR | 1 |
| Hereward, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| N-methyl-D-aspartate Receptor (NMDAR)-Based Pharmacotherapy With D-cycloserine for Treatment-resistant Major Depressive Disorder[NCT00408031] | Phase 2 | 26 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients[NCT00491686] | Phase 2 | 34 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing A[NCT01457677] | Phase 2 | 357 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)[NCT00680433] | Phase 4 | 83 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder[NCT04019704] | Phase 3 | 327 participants (Actual) | Interventional | 2019-06-20 | Completed | ||
| N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder[NCT00977353] | Phase 2 | 40 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression[NCT02417064] | Phase 3 | 346 participants (Actual) | Interventional | 2015-08-10 | Completed | ||
| An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression[NCT00986479] | Phase 2 | 22 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)[NCT01304147] | 20 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Single Center, Randomized, Placebo-Controlled Trial to Establish Maximum Tolerated Dose, Optimal Titration Schedule, Safety, Tolerability, and Pharmacokinetics of Org 26576 in Patients Diagnosed With Major Depressive Disorder (Protocol No. P174001)[NCT00610649] | Phase 2 | 54 participants (Actual) | Interventional | 2007-09-20 | Completed | ||
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideati[NCT03039192] | Phase 3 | 226 participants (Actual) | Interventional | 2017-06-09 | Completed | ||
| A Multicentre, Double-blind, Randomised, Placebo - Controlled Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Inhaled Esketamine in Subject With Treatment-resistant Bipolar Depression[NCT03965871] | Phase 2 | 88 participants (Actual) | Interventional | 2019-03-28 | Completed | ||
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideati[NCT03097133] | Phase 3 | 230 participants (Actual) | Interventional | 2017-06-15 | Completed | ||
| A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders[NCT00344682] | Phase 4 | 31 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder[NCT04210804] | Phase 2 | 80 participants (Actual) | Interventional | 2014-04-01 | Completed | ||
| A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants[NCT00781742] | Phase 2 | 152 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression[NCT02418585] | Phase 3 | 236 participants (Actual) | Interventional | 2015-08-07 | Completed | ||
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009)[NCT01797575] | Phase 2 | 38 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia[NCT01881763] | Phase 4 | 31 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Effect of Low-dose Ketamine on Postoperative Depressive Symptom in Patients Undergoing Intracranial Tumor Resection (PASSION)[NCT03086148] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-07-05 | Completed | ||
| A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression[NCT02918318] | Phase 2 | 202 participants (Actual) | Interventional | 2016-12-12 | Completed | ||
| Ketamine vs. Midazolam: Testing Rapid Relief of Suicide Risk in Depression[NCT01700829] | Phase 4 | 82 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression[NCT02497287] | Phase 3 | 802 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Central Versus Peripheral GABA and Glutamate Biomarkers for Treatment Response During Two Infusions of Intravenous Ketamine for Treatment-Resistant Depression[NCT03573349] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2019-01-03 | Enrolling by invitation | ||
| A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression[NCT02493868] | Phase 3 | 719 participants (Actual) | Interventional | 2015-10-01 | Completed | ||
| Evaluation of the Effects of Ketamine in the Acute Phase of Suicidal Ideation: a Multicenter Randomized Double-blind Trial[NCT02299440] | Phase 3 | 156 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Effect of Esketamine on Perioperative Depressive Symptoms in Patients Undergoing Major Surgery[NCT04425473] | Phase 2/Phase 3 | 564 participants (Anticipated) | Interventional | 2021-02-19 | Recruiting | ||
| Effect of Intravenous Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth in Women With Prenatal Depression: 2-year Follow-up of a Randomized Controlled Trial[NCT05698394] | Phase 4 | 364 participants (Actual) | Interventional | 2020-06-19 | Active, not recruiting | ||
| Long-term Observation of Participants With Mood Disorders[NCT04877977] | 1,000 participants (Anticipated) | Observational | 2021-08-17 | Recruiting | |||
| (2R,6R)-Hydroxynorketamine a Novel Therapeutic Analgesic for the Treatment of Neuropathic Pain: A Randomized Double Blind Cross-Over Trial.[NCT05864053] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Investigations on the Efficacy of Ketamine in Depression in Comparison to Electroconvulsive Therapy[NCT03674671] | Phase 3 | 240 participants (Anticipated) | Interventional | 2018-10-29 | Suspended (stopped due to insufficient funding) | ||
| Intravenous Sub-anesthetic Ketamine Treatment in Treatment-Resistant Depression[NCT02360280] | Phase 2 | 62 participants (Actual) | Interventional | 2015-04-01 | Completed | ||
| Impact of Night-time Dexmedetomidine-esketamine Infusion on Sleep Quality of Patients With Mechanical Ventilation in ICU: a Randomized Controlled Trial[NCT05718024] | Phase 4 | 174 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study[NCT06003218] | 88 participants (Anticipated) | Interventional | 2023-10-16 | Recruiting | |||
| Effects of Low-dose Dexmedetomidine-esketamine Combined Nasal Administration at Night on Perioperative Sleep Quality in Breast Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial[NCT05732064] | Phase 4 | 180 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | ||
| Translational Biomarkers of Fast Acting Therapies in Major Depression[NCT02165449] | Phase 1 | 60 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD[NCT06036511] | Phase 1/Phase 2 | 14 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Randomized Controlled Trial of Repeated-Dose Intravenous Ketamine for PTSD[NCT02397889] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2015-05-18 | Completed | ||
| Pharmacologic Attenuation of Ketamine Using Nitroprusside[NCT03102736] | Phase 2 | 40 participants (Actual) | Interventional | 2017-02-14 | Completed | ||
| The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.[NCT03156504] | Phase 4 | 75 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Ketamine Infusion for Social Anxiety Disorder[NCT02083926] | Early Phase 1 | 18 participants (Actual) | Interventional | 2015-01-02 | Completed | ||
| Effect of S-ketamine on Depressed Patients Undergoing Electroconvulsive Therapy-a Randomized, Double-blind, Controlled Clinical Study[NCT04399070] | 150 participants (Anticipated) | Interventional | 2020-08-01 | Not yet recruiting | |||
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| A Randomized, Parallel-group，Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety of Ethosuximide in Chinese Patients With Treatment-Resistant Depression.[NCT03887624] | Early Phase 1 | 16 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to Participates could not stand the side effects) | ||
| Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder: A Randomized, Group Sequential, Adaptive Design, Controlled Clinical Trial[NCT05181527] | Phase 4 | 60 participants (Actual) | Interventional | 2022-02-10 | Completed | ||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics[NCT04780152] | Phase 2/Phase 3 | 172 participants (Anticipated) | Interventional | 2021-10-31 | Recruiting | ||
| Effects of Low-dose S-ketamine on the Incidence of Postpartum Depression in Women With Prenatal Depression: a Randomized, Double-blind, Placebo-controlled Trial[NCT04414943] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Patient-controlled Analgesia After Scoliosis Correction Surgery: a Randomized, Double-blind, Placebo-controlled Trial[NCT04791059] | Phase 4 | 200 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| Effect of Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia on Long-term Outcomes Following Scoliosis Correction Surgery: 2-year Follow-up of a Randomized Controlled Trial[NCT05718544] | Phase 4 | 199 participants (Actual) | Interventional | 2023-01-30 | Active, not recruiting | ||
| Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)[NCT01920555] | Phase 2 | 99 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial[NCT01690988] | Phase 3 | 746 participants (Actual) | Interventional | 2014-02-01 | Completed | ||
| Modulating Probabilities: Prediction, Assessment, and Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS[NCT04870255] | 45 participants (Anticipated) | Interventional | 2021-07-20 | Recruiting | |||
| Brain Activation Patterns Under Emotional and Neurochemic Stimulation With Ketamine: A Multimodal Neuroimaging Study[NCT03609190] | Early Phase 1 | 10 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition[NCT03693105] | 100 participants (Anticipated) | Interventional | 2021-11-07 | Enrolling by invitation | |||
| [NCT02099630] | 40 participants (Actual) | Observational [Patient Registry] | 2014-03-31 | Completed | |||
| Rapid Acting Transcranial Magnetic Stimulation for Suicide Ideation in Depression[NCT05100004] | 100 participants (Anticipated) | Interventional | 2021-11-07 | Recruiting | |||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: Blind Test, Randomized, Placebo-controlled Trial[NCT03336541] | Phase 4 | 64 participants (Actual) | Interventional | 2017-11-23 | Completed | ||
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| The Effects of a Single Dose on Reward and Emotional Processing in Healthy Volunteers[NCT04130087] | 54 participants (Anticipated) | Interventional | 2019-09-18 | Recruiting | |||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease[NCT02783430] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms[NCT02422303] | 12 participants (Actual) | Interventional | 2015-12-31 | Terminated | |||
| Memantine for Refractory OCD Patients: a Pragmatic Double Blind, Randomized, Parallel Group, Placebo Controlled, Monocentric Trial[NCT05015595] | Phase 3 | 20 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder[NCT00749203] | Phase 2 | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain Patients[NCT04322968] | Phase 3 | 41 participants (Actual) | Interventional | 2018-01-09 | Completed | ||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| Assessing a Combined Ketamine and Online Cognitive Behavioural Therapy Intervention for Treatment Resistant Post-Traumatic Stress Disorder[NCT04771767] | Phase 2 | 16 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans[NCT03088384] | 30 participants (Actual) | Observational | 2016-11-28 | Completed | |||
| Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial[NCT02305394] | Phase 4 | 132 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| Antagonists NMDA in Relay to Ketamine in Neuropathic Pain[NCT01602185] | Phase 2 | 7 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders[NCT02579928] | Phase 4 | 17 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Investigating Rapid Anti-Suicidal Ideation Effects of Intravenous (IV) Ketamine in Hospitalized Patients[NCT01507181] | Phase 4 | 24 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| ED Treatment of Suicidal Patients With Ketamine Infusion[NCT03502551] | Phase 2 | 0 participants (Actual) | Interventional | 2019-04-01 | Withdrawn (stopped due to Trial never received funding.) | ||
| The Prevention of Post Operative Cognitive Dysfunction by Ketamine: a Prospective Multicenter Randomized Blinded Placebo-controlled Trial in Elderly Patients Undergoing Elective Orthopaedic Surgery[NCT02892916] | Phase 3 | 307 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression[NCT00040261] | Phase 3 | 112 participants | Interventional | 2002-06-30 | Completed | ||
| Effects of Low-dose S-Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression: A Randomized, Double-blind, Placebo-controlled Trial[NCT03927378] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression[NCT00419003] | Phase 4 | 26 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| The Role of Ketamine in Preventing Cognitive Dysfunctions in Postoperative Period of Cardiac Surgery[NCT02782429] | Phase 4 | 50 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.[NCT02049411] | Phase 2 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention[NCT00548964] | Phase 1 | 36 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Prospective Randomized Double Blinded Control Trial Using Ketamine or Propofol Anesthesia for Electroconvulsive Therapy: Improving Treatment-Resistant Depression[NCT01935115] | Phase 4 | 27 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy[NCT02579642] | Phase 4 | 48 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Clinical Trial of the Use of Ketamine in Treatment Resistant Depression[NCT02610712] | Phase 4 | 20 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| A Double-blind Pilot Trial of the Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.[NCT02593643] | Early Phase 1 | 9 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia[NCT02397356] | Phase 4 | 0 participants (Actual) | Interventional | 2018-08-31 | Withdrawn (stopped due to Lack of study personnel) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary objective of the study was to evaluate the efficacy of AXS-05 as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms from baseline to Week 6. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points. (NCT04019704)
Timeframe: 6 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| AXS-05 | 15.91 |
| Placebo | 12.04 |
"CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients (a decrease in score indicates improvement). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -2.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -2.0 |
| Oral AD Plus Intranasal Placebo | -1.0 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02417064)
Timeframe: Baseline up to end of Double-blind induction phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 20.9 |
| Intranasal Esketamine 84 mg Plus Oral AD | 19.1 |
| Oral AD Plus Intranasal Placebo | 14.9 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). (NCT02417064)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 0.224 |
| Intranasal Esketamine 84 mg Plus Oral AD | 0.243 |
| Oral AD Plus Intranasal Placebo | 0.181 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state. (NCT02417064)
Timeframe: Baseline up to end of Double-blind Induction phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -19.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -19.4 |
| Oral AD Plus Intranasal Placebo | -14.6 |
"GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants responded to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -7.4 |
| Intranasal Esketamine 84 mg Plus Oral AD | -7.7 |
| Oral AD Plus Intranasal Placebo | -6.0 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -19.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -18.8 |
| Oral AD Plus Intranasal Placebo | -14.8 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using Last Observation Carried Forward (LOCF) method and last post baseline observation during double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -18.3 |
| Intranasal Esketamine 84 mg Plus Oral AD | -17.4 |
| Oral AD Plus Intranasal Placebo | -14.3 |
PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -11.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -11.7 |
| Oral AD Plus Intranasal Placebo | -9.1 |
"PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -10.9 |
| Intranasal Esketamine 84 mg Plus Oral AD | -10.9 |
| Oral AD Plus Intranasal Placebo | -8.9 |
The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired), where higher score indicates greater impairment. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -11.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -11.1 |
| Oral AD Plus Intranasal Placebo | -8.4 |
"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired) where higher score indicates greater impairment. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -10.7 |
| Intranasal Esketamine 84 mg Plus Oral AD | -10.2 |
| Oral AD Plus Intranasal Placebo | -8.1 |
Participants who had a MADRS total score of less than or equal to (<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: At Day 28 of Double-blind Induction Phase
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 36 |
| Intranasal Esketamine 84 mg Plus Oral AD | 38.8 |
| Oral AD Plus Intranasal Placebo | 30.6 |
"Participants who had a MADRS total score of less than or equal to (<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: At Day 28 (Double-blind Endpoint)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 34.8 |
| Intranasal Esketamine 84 mg Plus Oral AD | 35.4 |
| Oral AD Plus Intranasal Placebo | 29.2 |
A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: At Day 28 of Double-blind Induction phase
| Intervention | Percentage of Participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 54.1 |
| Intranasal Esketamine 84 mg Plus Oral AD | 53.1 |
| Oral AD Plus Intranasal Placebo | 38.9 |
"A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: At Day 28 (Double-blind Endpoint)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 53.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | 47.8 |
| Oral AD Plus Intranasal Placebo | 37.2 |
A participant was defined as having a clinical response if there was at least 50% improvement (decrease) from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, however score must show at least 25% improvement. Participants who did not meet these criteria or discontinued during the study before Day 28 were considered as non-responders and were assigned the value of 0 (that is no). MADRS is clinician-rated scale that consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), for total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: Day 2 up to Day 28 and Day 8 up to Day 28
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Day 2 up to Day 28 | Day 8 up to Day 28 | |
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 10.4 | 13.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | 8.8 | 11.4 |
| Oral AD Plus Intranasal Placebo | 1.8 | 3.5 |
Beck Depression Inventory (BDI) is a 21-question instrument for measuring the severity of depression. Each question has a set of at least four possible answer choices, ranging in intensity. A value of 0 to 3 is assigned for each answer and the total score is computed. Higher total scores indicate more severe depressive symptoms. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 21.081 | 22.217 | 21.535 | 21.126 | 22.444 | 22.923 | 23.494 | 24.447 |
| Placebo | 22.886 | 23.122 | 23.586 | 23.686 | 22.936 | 24.586 | 23.786 | 24.070 |
Brief Psychiatric Rating Scale (BPRS) Positive is a 4-item scale which measures positive symptoms of schizophrenia (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content). Each item is rated from 1 to 7 with higher score indicating greater severity. The total score is the sum of the 4 items, resulting in a range of scores from 4-28. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 9.433 | 8.751 | 8.660 | 8.751 | 9.114 | 9.118 | 9.118 | 9.356 |
| Placebo | 8.946 | 8.996 | 8.996 | 8.666 | 9.296 | 9.296 | 9.446 | 9.338 |
"The Brief Psychiatric Rating Scale (BPRS) is a 18-item scale which measures symptoms and behaviors that are characteristic of schizophrenia. Each item is rated from 1 to 7 with higher score indicating greater severity. The total score is the sum of the 18 items, resulting in a range of scores from 18-126.~18 is considered to be the best outcome, 126 the worst." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 32.191 | 30.237 | 30.555 | 30.737 | 33.418 | 32.882 | 34.168 | 35.739 |
| Placebo | 32.896 | 33.496 | 33.696 | 31.772 | 33.596 | 34.496 | 33.046 | 34.428 |
Clinician- Administered Dissociative States Scale (CADSS) is a clinician-administered measure of perceptual, behavioral, and attentional alterations occurring during dissociative experiences. This scale involves a 23 questions and each is rated from 0 (not at all) to 4 (extremely). The total score is sum of the 23 items and range from 0 to 92 - best is 0 and worst is 92. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 4.104 | 3.324 | 2.831 | 1.240 | 1.013 | 1.360 | 1.456 | 1.313 |
| Placebo | 1.997 | 2.297 | 2.047 | 1.497 | 1.147 | 1.397 | 1.447 | 1.212 |
Hamilton Anxiety Rating Scale (HAM-A) is used as a rating measure of anxiety severity. The scale consists of 14 items. Each item is rated on a scale of 0 to 4. The HAM-A total score is the sum of the 14 items and the score ranges from 0 to 56. 0 is considered the best outcome, 56 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 16.211 | 16.666 | 16.817 | 17.055 | 18.817 |
| Placebo | 17.160 | 17.675 | 18.125 | 18.525 | 19.631 |
Hamilton Depression Rating Scale-17 item (HDRS) is a scale that assesses depressive symptoms. HDRS consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher scores indicate more severe depression. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 15.930 | 14.975 | 15.475 | 16.112 | 16.748 | 16.732 | 17.732 | 18.160 |
| Placebo | 17.389 | 17.739 | 18.039 | 17.339 | 17.639 | 19.289 | 19.039 | 19.438 |
Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 26.881 | 25.381 | 25.835 | 26.517 | 27.654 | 29.161 | 30.732 | 31.447 |
| Placebo | 28.618 | 29.718 | 29.818 | 29.418 | 29.118 | 31.368 | 30.368 | 31.222 |
Scale for Suicide Ideation (SSI) is a 19-item scale designed to quantify the intensity of current conscious suicide ideation. Each item is rated on a scale of 0 to 2 (with higher scores indicating greater suicidal ideation). The individual item scores are added together to form a total score, ranging between 0 and 38. 0 is considered the best outcome, 38 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 0.955 | 1.137 | 1.137 | 0.864 | 1.364 | 1.236 | 1.379 | 1.379 |
| Placebo | 0.939 | 1.039 | 0.989 | 0.939 | 1.539 | 1.189 | 1.226 | 1.507 |
Response defined as a >= 50% reduction from baseline in MADRS total score. MADRS is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 5 | 6 | 4 | 4 | 3 | 1 | 1 | 1 |
| Placebo | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
Remission defined as a Montgomery-Asberg Depression Rating Scale (MADRS) total score <10. MADRS is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 |
| Placebo | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The Visual Analog Scale (VAS) Anxious is a 0 to 100-mm self-administered scale where patients rate their mood between extreme sad (0-mm) and extreme happy (100-mm), with a median normal point." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 43.898 | 44.216 | 42.853 | 44.580 | 44.989 | 44.718 | 42.623 | 50.147 |
| Placebo | 41.929 | 44.079 | 44.729 | 46.029 | 47.229 | 50.479 | 48.279 | 56.595 |
"The Visual Analog Scale (VAS) Depressed is a 0 to 100-mm self-administered scale where patients rate their mood between extreme sad (0-mm) and extreme happy (100-mm), with a median normal point." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
| Intervention | Scores on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 55.614 | 58.614 | 60.750 | 55.614 | 62.160 | 65.753 | 66.896 | 68.467 |
| Placebo | 60.562 | 57.662 | 59.062 | 61.212 | 64.762 | 63.262 | 63.312 | 65.576 |
Young Mania Rating Scale (YMRS) consists of 11 items, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe) or from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. 0 is considered to be the best outcome, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 4.294 | 3.748 | 3.475 | 3.748 | 3.748 | 3.699 | 4.270 | 4.366 |
| Placebo | 3.626 | 3.526 | 3.526 | 3.526 | 3.326 | 3.676 | 3.476 | 4.339 |
"Number of patients meeting response criteria of >=50% decrease in MADRS score from baseline , ie, difference in depressive symptoms using MADRS instrument, 24 hours following drug administration~10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points." (NCT01304147)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Ketamine | 8 |
| Placebo | 1 |
This is a self-report measure for systematically assessing 48 possible adverse events. It documents their severity, relationship to study drug, and the action taken. (NCT01304147)
Timeframe: 2 weeks
| Intervention | events (Number) |
|---|---|
| Ketamine | 79 |
| Placebo | 57 |
The MADRS is a 10-item scale designed to assess the severity of depression. The questionnaire includes questions on the following symptoms: Apparent sadness, Reported sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimistic thoughts, and Suicidal thoughts. Each of the 10 symptoms are rated on a scale of 1 to 6, with 1=absent to 6=severe. The MADRS score can range from 0 (symptoms absent) to 60 (severe depression), with a higher score indicating more severe depression. (NCT00610649)
Timeframe: Baseline and end of treatment (Up to Day 16)
| Intervention | score on a scale (Mean) |
|---|---|
| Part 1: Block A MK-8777 | -10.00 |
| Part 1: Block A Placebo | -24.50 |
| Part 1: Block B MK-8777 | -13.50 |
| Part 1: Block B Placebo | -7.00 |
| Part 1: Block C MK-8777 | -10.25 |
| Part 1: Block C Placebo | -9.50 |
| Part 1: Block D MK-8777 | -19.00 |
| Part 1: Block D Placebo | -2.00 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Discontinuation refers to discontinuation of study drug (MK-8777 or Placebo). (NCT00610649)
Timeframe: Up to the last dose of study drug (Up to 16 days)
| Intervention | participants (Number) |
|---|---|
| Part 1: Block A MK-8777 | 1 |
| Part 1: Block A Placebo | 0 |
| Part 1: Block B MK-8777 | 0 |
| Part 1: Block B Placebo | 0 |
| Part 1: Block C MK-8777 | 0 |
| Part 1: Block C Placebo | 0 |
| Part 1: Block D MK-8777 | 0 |
| Part 1: Block D Placebo | 0 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. A moderate intensity AE is defined as an AE that causes no significant interference with functioning. (NCT00610649)
Timeframe: Up to 7 days following the last dose of study drug (Up to 23 days)
| Intervention | participants (Number) |
|---|---|
| Part 1: Block A MK-8777 | 2 |
| Part 1: Block A Placebo | 0 |
| Part 1: Block B MK-8777 | 1 |
| Part 1: Block B Placebo | 2 |
| Part 1: Block C MK-8777 | 4 |
| Part 1: Block C Placebo | 0 |
| Part 1: Block D MK-8777 | 3 |
| Part 1: Block D Placebo | 2 |
An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. (NCT00610649)
Timeframe: Up to 30 days following the last dose of study drug (Up to 46 days)
| Intervention | participants (Number) |
|---|---|
| Part 1: Block A MK-8777 | 0 |
| Part 1: Block A Placebo | 0 |
| Part 1: Block B MK-8777 | 0 |
| Part 1: Block B Placebo | 0 |
| Part 1: Block C MK-8777 | 0 |
| Part 1: Block C Placebo | 0 |
| Part 1: Block D MK-8777 | 0 |
| Part 1: Block D Placebo | 0 |
The MADRS is a 10-item scale designed to assess the severity of depression. The questionnaire includes questions on the following symptoms: Apparent sadness, Reported sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimistic thoughts, and Suicidal thoughts. Each of the 10 symptoms are rated on a scale of 1 to 6, with 1=absent to 6=severe. The MADRS score can range from 0 (symptoms absent) to 60 (severe depression), with a higher score indicating more severe depression. (NCT00610649)
Timeframe: Baseline and end of treatment (Up to Day 28)
| Intervention | score on a scale (Mean) |
|---|---|
| Part 2: MK-8777 200 mg | -15.40 |
| Part 2: MK-8777 800 mg | -13.70 |
| Part 2: Placebo | -13.30 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00610649)
Timeframe: Up to 7 days following the last dose of study drug (Up to 35 days)
| Intervention | participants (Number) |
|---|---|
| Part 2: MK-8777 200 mg | 10 |
| Part 2: MK-8777 800 mg | 9 |
| Part 2: Placebo | 9 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Discontinuation refers to discontinuation of study drug (MK-8777 or Placebo). (NCT00610649)
Timeframe: Up to the last dose of study drug (Up to 28 days)
| Intervention | participants (Number) |
|---|---|
| Part 2: MK-8777 200 mg | 0 |
| Part 2: MK-8777 800 mg | 0 |
| Part 2: Placebo | 1 |
CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition and a reduction in score indicates improvement (that is, lower severity of suicidality). (NCT03039192)
Timeframe: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
| Intervention | units on a scale (Median) |
|---|---|
| Placebo Plus SOC Antidepressant Treatment | -1.0 |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -1.0 |
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo Plus SOC Antidepressant Treatment | -12.8 |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -16.4 |
Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to >= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Plus SOC Antidepressant Treatment | 2 |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 1 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Plus SOC Antidepressant Treatment | 83 |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 100 |
BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness. (NCT03039192)
Timeframe: Baseline, Days 8 and 25
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change at Day 8 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -5.3 | -6.9 |
| Placebo Plus SOC Antidepressant Treatment | -4.4 | -6.6 |
The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 |
| Placebo Plus SOC Antidepressant Treatment | 0.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 |
CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -1.0 | -1.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 | -3.0 |
| Placebo Plus SOC Antidepressant Treatment | 0.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.5 | -3.0 | -3.0 |
EQ-5D-5L measures health outcome. It consists of EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-VAS score from 0 (worst health) to 100 (best health), positive change in score indicates improvement. (NCT03039192)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 13.5 | 17.9 | 21.4 |
| Placebo Plus SOC Antidepressant Treatment | 7.8 | 16.3 | 20.0 |
"EQ-5D-5L measures health outcome. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a health status index (HSI). Health Status Index ranges from 0.148 - 0.949, anchored at 0 (dead) and 1 (full health). Positive change in score indicates improvement." (NCT03039192)
Timeframe: Baseline and Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 0.156 | 0.206 | 0.227 |
| Placebo Plus SOC Antidepressant Treatment | 0.096 | 0.169 | 0.189 |
"EQ-5D-5L measures health outcome. It consists of EQ-5D-5L system and EQ-VAS. EQ-5D-5L system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, and Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a health status index (HSI). Health Status Index ranges from 0.148 - 0.949, anchored at 0 (dead) and 1 (full health), a lower score indicates worse health. Sum score=(sum of the scores from the 5 dimensions minus 5)*5. Sum score ranges from 0-100. Higher score indicates a more severe problem. Negative change in score indicates improvement." (NCT03039192)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -11.2 | -15.2 | -16.8 |
| Placebo Plus SOC Antidepressant Treatment | -6.1 | -12.3 | -13.4 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition and a negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25: predose | Change at Day 25 (4 hours postdose) | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -13.5 | -16.4 | -19.1 | -19.7 | -21.8 | -22.3 | -23.9 | -24.0 | -24.8 | -29.5 |
| Placebo Plus SOC Antidepressant Treatment | -10.9 | -12.9 | -14.5 | -17.4 | -19.0 | -20.4 | -21.4 | -21.6 | -23.0 | -25.8 |
"The QLDS is a disease specific patient-reported outcome designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of at the moment, contains 34-items with true/not true response options and takes approximately 5-10 minutes to complete. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement." (NCT03039192)
Timeframe: Baseline and Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -3.1 | -5.6 | -6.8 |
| Placebo Plus SOC Antidepressant Treatment | -2.5 | -4.4 | -5.6 |
SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time). SIBAT Module 5 (My Risk) Question 3 (Patient-reported FoST) total score ranges from 0 to 4; a higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline, Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 0.0 | -1.0 | -1.0 | -1.0 | -1.5 | -2.0 | -2.0 | -2.0 | -2.0 |
| Placebo Plus SOC Antidepressant Treatment | 0.0 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 |
SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking (FoST) that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -3.0 |
| Placebo Plus SOC Antidepressant Treatment | -1.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
Participants who had a MADRS total score of <=12 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition and a negative change in score indicates improvement. (NCT03039192)
Timeframe: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25 (predose and 4 hours postdose)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (4 Hours postdose) | Day 2 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 (Predose) | Day 25 (4 hours postdose) | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 12 | 21 | 28 | 30 | 33 | 38 | 42 | 41 | 46 | 60 |
| Placebo Plus SOC Antidepressant Treatment | 9 | 10 | 13 | 23 | 26 | 29 | 30 | 25 | 38 | 42 |
CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition. Negative change in score indicates improvement. A participant was considered to achieve resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal). (NCT03039192)
Timeframe: Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 37 | 42 | 49 | 53 | 60 | 68 | 68 | 70 | 71 |
| Placebo Plus SOC Antidepressant Treatment | 25 | 39 | 45 | 48 | 46 | 52 | 55 | 62 | 57 |
Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed. (NCT03039192)
Timeframe: At Day 25
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epistaxis: Mild | Epistaxis: Moderate | Epistaxis: Severe | Nasal Crusts: Mild | Nasal Crusts: Moderate | Nasal Crusts: Severe | Nasal Discharge: Mild | Nasal Discharge: Moderate | Nasal Discharge: Severe | Nasal Erythema: Mild | Nasal Erythema: Moderate | Nasal Erythema: Severe | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 3 | 0 | 0 |
| Placebo Plus SOC Antidepressant Treatment | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of > 0) was reported." (NCT03039192)
Timeframe: Days 1, 4, 8, 11, 15, 18, 22 and 25
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 95 | 84 | 81 | 77 | 69 | 70 | 70 | 72 |
| Placebo Plus SOC Antidepressant Treatment | 34 | 23 | 29 | 19 | 17 | 19 | 16 | 14 |
Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to [<=] 50 beats per minute [bpm] , abnormally high refers greater than or equal to [>=] 100 bpm), pulse rate (PR) interval (abnormally high refers to >= 210 milliseconds [msec]), QRS interval (abnormally Low refers to <= 50, abnormally high refers to >= 120 msec) and QT interval (abnormally low refers to <= 200, abnormally high >= 500 msec) were reported. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Heart Rate <= 50 bpm | Heart Rate >= 100 bpm | PR Duration >= 210 msec | QRS Duration <= 50 msec | QRS Duration >= 120 msec | QT Duration <= 200 msec | QT Duration >= 500 msec | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 2 | 5 | 5 | 0 | 0 | 0 | 0 |
| Placebo Plus SOC Antidepressant Treatment | 8 | 4 | 3 | 0 | 0 | 0 | 0 |
Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin(low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine(High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0*1012/L,high=6.4*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5*109/L,high=15.5*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100*109/L,high=600*109/L]; Potassium(low=3.0mmol/L,high=5.8 mmol/L]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH). (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT>3*ULN | ALT: Abnormal High | Albumin: Abnormal High | Albumin: Abnormal Low | Alkaline phosphatase (ALP): Abnormal High | AST: AST>3*ULN | AST: Abnormal High | Bicarbonate: Abnormal High | Bicarbonate: Abnormal Low | Bilirubin: Abnormal High | Calcium: Abnormal High | Calcium: Abnormal Low | Chloride: Abnormal High | Chloride: Abnormal Low | Creatine Kinase (CK): Abnormal High | Creatinine: Abnormal High | GGT: Abnormal High | Glucose: Abnormal High | Glucose: Abnormal Low | ALT>3*ULN or AST>3*ULN and BILI>2*ULN | Lactate Dehydrogenase(LD): Abnormal High | Phosphate: Abnormal High | Phosphate: Abnormal Low | Potassium: Abnormal High | Potassium: Abnormal Low | Protein: Abnormal Low | Sodium: Abnormal High | Sodium: Abnormal Low | Urate: Abnormal High | Urate: Abnormal Low | Basophils: Abnormal High | Eosinophils: Abnormal High | Erythrocytes: Abnormal High | Erythrocytes: Abnormal Low | Hematocrit: Abnormal High | Hematocrit: Abnormal Low | Hemoglobin(Hb): Abnormal High | Hemoglobin: Abnormal Low | Leukocytes: Abnormal High | Leukocytes: Abnormal Low | Lymphocytes: Abnormal High | Lymphocytes: Abnormal Low | Monocytes: Abnormal High | Neutrophils: Abnormal High | Neutrophils: Abnormal Low | Platelets: Abnormal High | Platelets: Abnormal Low | Urine pH: Abnormal High | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Placebo Plus SOC Antidepressant Treatment | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm [abnormally low = a decrease from baseline of >= 15 to a value <= 50; abnormally high = an increase from baseline of >=15 to a value >=100] , systolic blood pressure [SBP] in mmHg [abnormally low = a decrease from baseline of >= 20 to a value <= 90; abnormally high = an increase from baseline of >= 20 to a value >= 180], and diastolic blood pressure [DBP] in mmHg [abnormally low= a decrease from baseline of >=15 to a value <= 50; abnormally high = an increase from baseline of >= 15 to a value >= 105) were reported. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Pulse rate (bpm): Decrease of >=15 to <=50 | Pulse rate (bpm): Increase of >=15 to >=100 | SBP (mmHg): Decrease of >=20 to <=90 | SBP (mmHg): Increase of >=20 to >=180 | DBP (mmHg): Decrease of >=15 to <=50 | DBP (mmHg): Increase of >=15 to >=105 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 3 | 13 | 0 | 2 | 0 | 11 |
| Placebo Plus SOC Antidepressant Treatment | 2 | 6 | 4 | 0 | 4 | 1 |
MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Score <=2: Yes | Score <=3: Yes | Score <=4: Yes | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 3 | 13 | 43 |
| Placebo Plus SOC Antidepressant Treatment | 0 | 1 | 20 |
The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = [(item 1 + item 2 + item 3) - 3]/18*100, (ii) Convenience = [(item 4 + item 5 + item 6) - 3]/18*100 and (iii) Global satisfaction = [(item 7 + item 8 + item 9) - 3]/14*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction. (NCT03039192)
Timeframe: Days 15 and 25
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Effectiveness: Day 15 | Effectiveness: Day 25 | Convenience: Day 15 | Convenience: Day 25 | Global Satisfaction: Day 15 | Global Satisfaction: Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 63.5 | 65.8 | 70.5 | 71.3 | 64.5 | 68.5 |
| Placebo Plus SOC Antidepressant Treatment | 51.7 | 57.6 | 70.9 | 74.0 | 52.2 | 55.7 |
Clinical global impression-severity of suicidality-revised (CGI-SS-R) scale is revised version of the clinical global impression severity scale (CGI-S),a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
| Intervention | units on a scale (Median) |
|---|---|
| Placebo + Standard of Care (SOC) | -1.0 |
| Esketamine 84 mg + SOC | -1.0 |
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo + Standard of Care (SOC) | -12.4 |
| Esketamine 84 mg + SOC | -15.7 |
Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to >= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Standard of Care (SOC) | 2 |
| Esketamine 84 mg + SOC | 3 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Standard of Care (SOC) | 87 |
| Esketamine 84 mg + SOC | 104 |
BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness. (NCT03097133)
Timeframe: Baseline, Days 8 and 25
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change at Day 8 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -6.1 | -8.0 |
| Placebo + Standard of Care (SOC) | -6.3 | -7.0 |
CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. A higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -1.0 | -1.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 | -3.0 |
| Placebo + Standard of Care (SOC) | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 |
The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 |
| Placebo + Standard of Care (SOC) | 0.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). Positive change in score indicates improvement." (NCT03097133)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg + SOC | 0.160 | 0.202 | 0.235 |
| Placebo + Standard of Care (SOC) | 0.129 | 0.194 | 0.194 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (no problem, slight, moderate, severe and extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst imaginable health)-100 (best imaginable health). Sum score ranges from 0 -100. Sum score=(sum of the scores from the 5 dimensions minus 5)*5. Higher score indicates worse health state. Negative change in score indicates improvement." (NCT03097133)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -11.8 | -15.0 | -18.8 |
| Placebo + Standard of Care (SOC) | -9.0 | -15.1 | -15.3 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Positive change in score indicates improvement. (NCT03097133)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg + SOC | 13.4 | 21.4 | 27.0 |
| Placebo + Standard of Care (SOC) | 9.7 | 17.6 | 18.6 |
MADRS is a clinician-rated scale designed to be used in participants with MDD to measure depression severity and detect changes due to antidepressant treatment. MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The instrument consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25: Predose | Change at Day 25: 4 hours postdose | |
| Esketamine 84 mg + SOC | -12.2 | -16.0 | -17.7 | -20.1 | -21.3 | -23.4 | -23.1 | -24.5 | -26.2 | -28.7 |
| Placebo + Standard of Care (SOC) | -8.2 | -12.4 | -15.7 | -17.4 | -19.5 | -20.0 | -21.4 | -22.0 | -22.5 | -26.4 |
"The QLDS is a disease-specific patient-reported outcome designed to assess health-related quality of life in patients with MDD, it captures the impact of depression and its treatment from the participant's perspective. The instrument has a recall period of at the moment and contains 34 items with true/not true response options. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement." (NCT03097133)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -3.5 | -5.1 | -6.3 |
| Placebo + Standard of Care (SOC) | -2.5 | -5.2 | -5.5 |
SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time). (NCT03097133)
Timeframe: Baseline, Days 1 (4h postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -1.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
| Placebo + Standard of Care (SOC) | -1.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline, Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 |
| Placebo + Standard of Care (SOC) | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. A participant was considered to have achieved resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal). Participants who did not met such criterion or discontinued prior to the time point for any reason were not considered to have resolution of suicidality. (NCT03097133)
Timeframe: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 1: 4 hours postdose | Day 2 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 | |
| Esketamine 84 mg + SOC | 38 | 36 | 52 | 53 | 62 | 65 | 62 | 68 | 69 |
| Placebo + Standard of Care (SOC) | 20 | 35 | 51 | 54 | 58 | 58 | 59 | 65 | 66 |
Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed. (NCT03097133)
Timeframe: At Day 25
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epistaxis: Mild | Epistaxis: Moderate | Epistaxis: Severe | Nasal Crusts: Mild | Nasal Crusts: Moderate | Nasal Crusts: Severe | Nasal Discharge: Mild | Nasal Discharge: Moderate | Nasal Discharge: Severe | Nasal Erythema: Mild | Nasal Erythema: Moderate | Nasal Erythema: Severe | |
| Esketamine 84 mg + SOC | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Placebo + Standard of Care (SOC) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of > 0) was reported." (NCT03097133)
Timeframe: Days 1, 4, 8, 11, 15, 18, 22 and 25
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 | |
| Esketamine 84 mg + SOC | 106 | 86 | 75 | 68 | 68 | 53 | 58 | 56 |
| Placebo + Standard of Care (SOC) | 28 | 21 | 16 | 8 | 11 | 8 | 7 | 4 |
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Days 1 (4 hours [h] postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: 4 hours post dose | Day 2 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25: Predose | Day 25: 4 hours postdose | |
| Esketamine 84 mg + SOC | 12 | 25 | 26 | 28 | 32 | 36 | 29 | 42 | 49 | 54 |
| Placebo + Standard of Care (SOC) | 4 | 12 | 20 | 23 | 26 | 29 | 32 | 37 | 31 | 42 |
Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to [<=] 50 beats per minute [bpm] , abnormally high refers greater than or equal to [>=] 100 bpm), pulse rate (PR) interval (abnormally high refers to >= 210 milliseconds [msec]), QRS interval (abnormally Low refers to <= 50, abnormally high refers to >= 120 msec) and QT interval (abnormally low refers to <= 200, abnormally high >= 500 msec) were reported. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Heart Rate <= 50 bpm | Heart Rate >= 100 bpm | PR Duration >= 210 msec | QRS Duration <= 50 msec | QRS Duration >= 120 msec | QT Duration <= 200 msec | QT Duration >= 500 msec | |
| Esketamine 84 mg + SOC | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Placebo + Standard of Care (SOC) | 9 | 3 | 2 | 0 | 1 | 0 | 0 |
Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin (low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine (High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0*1012/L,high=6.4*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5*109/L,high=15.5*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100*109/L,high=600*109/L]; Potassium(low=3.0mmol/L,high=5.8 mmol/L]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH). (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT: ALT>3*ULN | ALT: Abnormal High | Albumin: Abnormal High | Albumin: Abnormal Low | Alkaline phosphatase (ALP): Abnormal High | AST: AST>3*ULN | AST: Abnormal High | Bicarbonate: Abnormal High | Bicarbonate: Abnormal Low | Bilirubin: Abnormal High | Calcium: Abnormal High | Calcium: Abnormal Low | Chloride: Abnormal High | Chloride: Abnormal Low | Creatine Kinase (CK): Abnormal High | Creatinine: Abnormal High | GGT: Abnormal High | Glucose: Abnormal High | Glucose: Abnormal Low | ALT>3*ULN or AST>3*ULN and BILI>2*ULN | Lactate Dehydrogenase (LD): Abnormal High | Phosphate: Abnormal High | Phosphate: Abnormal Low | Potassium: Abnormal High | Potassium: Abnormal Low | Protein: Abnormal Low | Sodium: Abnormal High | Sodium: Abnormal Low | Urate: Abnormal High | Urate: Abnormal Low | Basophils: Abnormal High | Eosinophils: Abnormal High | Erythrocytes: Abnormal High | Erythrocytes: Abnormal Low | Hematocrit: Abnormal High | Hematocrit: Abnormal Low | Hemoglobin (Hb): Abnormal High | Hemoglobin: Abnormal Low | Leukocytes: Abnormal High | Leukocytes: Abnormal Low | Lymphocytes: Abnormal High | Lymphocytes: Abnormal Low | Monocytes: Abnormal High | Neutrophils: Abnormal High | Neutrophils: Abnormal Low | Platelets: Abnormal High | Platelets: Abnormal Low | Urine pH: Abnormal High | |
| Esketamine 84 mg + SOC | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Placebo + Standard of Care (SOC) | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm [abnormally low = a decrease from baseline of >= 15 to a value <= 50; abnormally high = an increase from baseline of >=15 to a value >=100] , systolic blood pressure [SBP] in mmHg [abnormally low = a decrease from baseline of >= 20 to a value <= 90; abnormally high = an increase from baseline of >= 20 to a value >= 180], and diastolic blood pressure [DBP] in mmHg [abnormally low= a decrease from baseline of >=15 to a value <= 50; abnormally high = an increase from baseline of >= 15 to a value >= 105) were reported. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Pulse rate (bpm): Decrease of >=15 to <=50 | Pulse rate (bpm): Increase of >=15 to >=100 | SBP: Decrease of >=20 to <=90 | SBP (mmHg): Increase of >=20 to >=180 | DBP (mmHg): Decrease of >=15 to <=50 | DBP (mmHg): Increase of >=15 to >=105 | |
| Esketamine 84 mg + SOC | 1 | 12 | 2 | 3 | 4 | 6 |
| Placebo + Standard of Care (SOC) | 2 | 11 | 5 | 2 | 4 | 3 |
MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Score <=2: Yes | Score <=3: Yes | Score <=4: Yes | |
| Esketamine 84 mg + SOC | 4 | 21 | 65 |
| Placebo + Standard of Care (SOC) | 0 | 3 | 20 |
The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = [(item 1 + item 2 + item 3) - 3]/18*100, (ii) Convenience = [(item 4 + item 5 + item 6) - 3]/18*100 and (iii) Global satisfaction = [(item 7 + item 8 + item 9) - 3]/14*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction. (NCT03097133)
Timeframe: Days 15 and 25
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Effectiveness: Day 15 | Effectiveness: Day 25 | Convenience: Day 15 | Convenience: Day 25 | Global Satisfaction: Day 15 | Global Satisfaction: Day 25 | |
| Esketamine 84 mg + SOC | 63.5 | 68.8 | 71.3 | 77.0 | 63.6 | 71.5 |
| Placebo + Standard of Care (SOC) | 55.3 | 54.8 | 77.2 | 76.9 | 59.7 | 56.8 |
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Scores > 30 indicate severe anxiety. (NCT00344682)
Timeframe: baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -4.13 |
| Memantine | -5.53 |
The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 & 8. (NCT00344682)
Timeframe: baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -3.69 |
| Memantine | -6.47 |
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures. (NCT00344682)
Timeframe: baseline and week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -10.75 |
| Memantine | -7.13 |
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure. (NCT00344682)
Timeframe: Baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -7.25 |
| Memantine | -7.13 |
"CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -2.0 |
| Intranasal Placebo Plus Oral AD | -2.0 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 29.1 |
| Intranasal Placebo Plus Oral AD | 20.9 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -23.2 |
| Intranasal Placebo Plus Oral AD | -17.1 |
"European Quality of Life Group-5 Dimension-5-Level (EQ-5D-5L) is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health)." (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 0.288 |
| Intranasal Placebo Plus Oral AD | 0.231 |
"GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -7.9 |
| Intranasal Placebo Plus Oral AD | -6.8 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -21.4 |
| Intranasal Placebo Plus Oral AD | -17.0 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -19.6 |
| Intranasal Placebo Plus Oral AD | -16.3 |
PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day. Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -13.0 |
| Intranasal Placebo Plus Oral AD | -10.2 |
"PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day). Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -12.2 |
| Intranasal Placebo Plus Oral AD | -10.1 |
The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -13.6 |
| Intranasal Placebo Plus Oral AD | -9.4 |
"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -12.5 |
| Intranasal Placebo Plus Oral AD | -9.3 |
"Remission was defined as participants who had a MADRS total score of less than or equal to (=<) 12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: At Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 48.2 |
| Intranasal Placebo Plus Oral AD | 30.3 |
Remission defined as SDS total score <= 6 and individual item scores each <= 2. SDS is a participant reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items were summed to create a total score of 0-30 where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: At Day 28 (End of Double-blind Induction Phase)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 39.5 |
| Intranasal Placebo Plus Oral AD | 20.9 |
Response defined as SDS total score <= 12 and individual item scores each <= 4. SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: At Day 28 [end of Double-blind Induction Phase]
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 57.0 |
| Intranasal Placebo Plus Oral AD | 39.5 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The percentage of participants with greater than or equal to (>=) 50 % reduction from baseline in MADRS total score was reported. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: At Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 63.4 |
| Intranasal Placebo Plus Oral AD | 49.5 |
A participant was defined as having a clinical response if there is at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Participants who did not meet such criterion or discontinue during the study before Day 28 for any reason were considered as non-responders. (NCT02418585)
Timeframe: Day 2 up to Day 28 and Day 8 up to Day 28
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Onset of Clinical response on Day 2 | Onset of Clinical response on Day 8 | |
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 7.9 | 10.5 |
| Intranasal Placebo Plus Oral AD | 4.6 | 6.4 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. This 30% MADRS reduction was analyzed in addition to initial outcome measures of 50% MADRS reduction due to the smaller than expected study sample size. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 0 to week 8 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 2 |
| N-Acetyl Cysteine (NAC) | 6 |
| Placebo | 7 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. This 30% MADRS reduction was analyzed in addition to initial outcome measures of 50% MADRS reduction due to the smaller than expected study sample size. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 9 to week 16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 4 |
| Aspirin | 3 |
| N-Acetyl Cysteine (NAC) | 3 |
| Placebo | 4 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 0 to week 8 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 2 |
| N-Acetyl Cysteine (NAC) | 5 |
| Placebo | 6 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 9 to week 16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 1 |
| N-Acetyl Cysteine (NAC) | 3 |
| Placebo | 4 |
C-reactive protein (CRP) levels are blood test markers of inflammation. Higher CRP corresponds with higher levels of inflammation. CRP is measured in milligrams per liter. (NCT01797575)
Timeframe: baseline, week 8, week 16
| Intervention | milligrams per liter (Mean) | ||
|---|---|---|---|
| CRP at Baseline | CRP at Week 8 | CRP at Week 16 | |
| Aspirin | 6.85 | 6.82 | 10.76 |
| Aspirin and NAC | 5.1 | 17.02 | 9.39 |
| N-acetyl-cysteine | 17.65 | 41.09 | 17.69 |
| Sugar Pill | 17.30 | 7.4 | 13.10 |
Interleukin 6 (IL-6) is an interleukin that acts as a pro-inflammatory cytokine and an anti-inflammatory myokine. IL-6 is measured in picograms (pg) per milliliter (mL). Elevated interleukin-6 indicates potential immune system dysregulation and increased inflammation. (NCT01797575)
Timeframe: baseline, week 8, week 16
| Intervention | picograms per milliliter (Mean) | ||
|---|---|---|---|
| IL-6 at Baseline | IL-6 at Week 8 | IL-6 at Week 16 | |
| Aspirin | 1.27 | .78 | .90 |
| Aspirin and NAC | .85 | 1.76 | 1.72 |
| N-acetyl-cysteine | 3.22 | 3.53 | 2.6 |
| Sugar Pill | 2.3 | 1.87 | 1.71 |
The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)
| Intervention | HRSD units (Mean) |
|---|---|
| Ketamine | 7.82 |
| Methohexital | 8.60 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time. (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB induction pahse)
| Intervention | Units on a scale (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | -1.0 |
| Esketamine 56 mg | -1.0 |
| Esketamine 84 mg | -1.0 |
| Placebo | -1.0 |
GAD-7 was a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB induction phase)
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -8.2 |
| Esketamine 56 mg | -7.8 |
| Esketamine 84 mg | -8.1 |
| Placebo | -7.7 |
SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02918318)
Timeframe: Baseline (Day 1) to Day 28 (DB induction phase)
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -8.6 |
| Esketamine 56 mg | -7.9 |
| Esketamine 84 mg | -9.5 |
| Placebo | -7.0 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB phase) induction
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -15.2 |
| Esketamine 56 mg | -14.5 |
| Esketamine 84 mg | -15.1 |
| Placebo | -15.3 |
Time to relapse in participants with remission at the end of the double-blind phase was defined as the time between induction phase and the first documentation of a relapse event during the posttreatment phase. Relapse was defined as any of the following: 1) MADRS total score >= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse; 2) Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score <=12. (NCT02918318)
Timeframe: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
| Intervention | Days (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | 34.0 |
| Esketamine 56 mg | 52.0 |
| Esketamine 84 mg | 37.0 |
| Placebo | 30.0 |
Time to relapse in participants with response (>=50% reduction from baseline in MADRS total score) but who are not in remission was reported. Relapse is defined as any of the following: 1) MADRS total score >= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse. 2)Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score <=12. (NCT02918318)
Timeframe: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
| Intervention | Days (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | 32.0 |
| Esketamine 56 mg | 26.0 |
| Esketamine 84 mg | 79.5 |
| Placebo | 91.0 |
A participant was defined as having a clinical response if there was at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that was maintained to Day 28 in DB induction phase. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, provided the score is at least 25% improvement. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Day 2 up to Day 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Onset of clinical response: Yes | Onset of clinical response: No | |
| Esketamine 28 Milligrams (mg) | 2.4 | 97.6 |
| Esketamine 56 mg | 2.6 | 97.4 |
| Esketamine 84 mg | 7.3 | 92.7 |
| Placebo | 6.3 | 93.7 |
A participant was considered in remission at a given time point if the MADRS total score <=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 2, 8, 15, 22 and 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine 28 Milligrams (mg) | 9.8 | 2.4 | 7.5 | 10.3 | 23.1 |
| Esketamine 56 mg | 0 | 0 | 2.8 | 5.6 | 11.8 |
| Esketamine 84 mg | 7.5 | 4.9 | 10.0 | 7.7 | 23.1 |
| Placebo | 3.8 | 1.3 | 3.9 | 14.9 | 20.8 |
A participant is defined as responder (yes=1 and no=0) at a given time point if the percent improvement from baseline in MADRS is greater than or equal to (>=) 50 percent (%). MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 2, 8, 15, 22 and 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine 28 Milligrams (mg) | 22.0 | 2.4 | 17.5 | 23.1 | 33.3 |
| Esketamine 56 mg | 13.2 | 2.6 | 8.3 | 13.9 | 35.3 |
| Esketamine 84 mg | 10.0 | 9.8 | 15.0 | 20.5 | 43.6 |
| Placebo | 9.0 | 3.8 | 18.2 | 29.7 | 37.5 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Baseline (Prior to first Dose of OL induction phase on Day 1) up to endpoint of OL induction phase (last post baseline assessment value during OL induction phase [OL: up to Day 28])
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Esketamine: Flexible Dose | 16.1 | -14.5 |
A participant was considered in remission at a given time point if the MADRS total score <=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 8, 15, 22 and 28 (OL induction phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine: Flexible Dose | 14.6 | 23.4 | 31.9 | 42.6 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. (NCT02918318)
Timeframe: Baseline (Prior to first dose of OL induction phase on Day 1), endpoint of OL induction phase (last post baseline assessment value during the OL induction phase [OL: up to Day 28])
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal, not at all ill:Baseline | Normal, not at all ill:Endpoint | Borderline mentally ill:Baseline | Borderline mentally ill:Endpoint | Mildly ill:Baseline | Mildly ill:Endpoint | Moderately ill:Baseline | Moderately ill:Endpoint | Markedly ill:Baseline | Markedly ill:Endpoint | Severely ill:Baseline | Severely ill:Endpoint | Among the most extremely ill patients:Baseline | Among the most extremely ill patients:Endpoint | |
| Esketamine: Flexible Dose | 0 | 14.6 | 0 | 16.7 | 4.2 | 43.8 | 75.0 | 20.8 | 14.6 | 4.2 | 4.2 | 0 | 2.1 | 0 |
SDS is a participant-reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. FAS (responders): All randomized participants who received at least 1 dose of intranasal study medication during DB induction phase and who were responders at the end of DB induction phase and entered posttreatment phase (NCT02918318)
Timeframe: Baseline (DB induction phase), Weeks 2, 4, 6, 8, 12, 16, 20 and 24 (posttreatment phase)
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
| Esketamine 28 Milligrams (mg) | -14.6 | -12.9 | -17.7 | -12.0 | -20.5 | -21.5 | -22.0 | -21.5 |
| Esketamine 56 mg | -8.1 | -8.3 | -11.0 | -13.3 | -13.0 | -17.5 | -18.0 | -16.0 |
| Esketamine 84 mg | -13.1 | -13.6 | -14.6 | -15.3 | -18.3 | -12.5 | -28.0 | -28.0 |
| Placebo | -11.2 | -9.8 | -12.0 | -11.4 | -14.8 | -15.8 | -14.0 | -14.8 |
Change in suicidal ideation in depressed patients with moderate to severe suicidal thoughts from the pre-infusion baseline to 24 hours after the infusion with ketamine or midazolam, a sedative not known to reduce suicidal ideation, measured with Beck Scale for Suicidal Ideation - clinician rated version. This scale has 19 items scaled 0 (least severe) to 2 (most severe) and a potential score ranging from 0 to 38, with higher score indicating greater severity. (NCT01700829)
Timeframe: Day 1 (24 hours) post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Midazolam | -3.66 |
| Ketamine | -8.62 |
The average Z-scores reported below are the average of the Z-scores for all tests administered. The Z-scores for each test were based on published normative data and normative data available in our laboratory. The population mean for a Z-score is zero, with a SD of 1, thus scores below zero would indicate performance below the population norm; a score close to zero indicates performance close to the population norm (or a normalizing of performance). (NCT01700829)
Timeframe: Baseline and Day 1
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Pre-infusion overall neuropsych performance | Day1 post-infusion overall neuropsych performance | |
| Ketamine | -0.306 | -0.01 |
| Midazolam | -0.252 | -0.146 |
"On the mornings of an infusion day and on post-treatment day1, participants used salivettes (Sarstedt AG & Co.) to provide saliva samples upon awakening (Cort1) and 30 minutes later (Cort2) to measure cortisol awakening response (CAR) = (Cort2 - Cort1).~Differences between the midazolam and ketamine groups were tested using an analysis of covariance (ANCOVA) model of the change in CAR from baseline to day1, with treatment group and baseline measurement of the outcome variable as predictors.~Range from 0.1 to 12.5 ng/ml and lower means less stress response, higher means greater stress response." (NCT01700829)
Timeframe: Cort2 - Cort1 = (Day 1 30-mins post-awakening cortisol) - (Day 1 awakening cortisol)
| Intervention | log(ng/mL) (Mean) | |||
|---|---|---|---|---|
| Baseline awakening | Baseline 30 mins post-awakening | Day1 awakening | Day1 30 minutes post-awakening | |
| Ketamine | 0.47 | 0.88 | 0.74 | 1.06 |
| Midazolam | 0.94 | 1.29 | 0.77 | 1.19 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. The DET is a measure of psychomotor function and uses a well-validated simple reaction time. In this outcome measure, speed of performance of participants (calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported. Total score ranges from 2 to 3.3 log 10 milliseconds (msec). Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of Optimization/Maintenance [OP/MA] Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.0028 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. GMLT measures executive function; maze/sequencing test, scored for total number of errors. Total score ranges from 0 to 999 number of errors. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number of Errors (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 6.9 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. IDN test is a measure of visual attention (choice reaction time) and scored for speed of response (mean of the log10 transformed reaction times for correct responses). Total score ranges from 2 to 3.3 log 10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.0083 |
The ONB is a measure of working memory and scored for speed of correct response (mean of the log10-transformed reaction times for correct responses). Total score ranges from 2 to 3.54 log10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0177 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. OCL test is a measure of visual episodic memory and visual recall test scored using arcsine transformation of the percentage of correct responses (CR). The range for OCL is 0 to 100 percent (%) accuracy; presented as an arcsin transformation, the range is 0 to 1.57. Higher score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Arcsine ([sqrt] of proportion of [CR]) (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0502 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number correct (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.8 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number of words recalled (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.3 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Number of words (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.5 |
Hopkins Verbal Learning Test (HVLT) measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number correct (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 2.8 |
"SDS was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, (3) family life/home responsibilities using a 0 to 10 rating scale. Score for the first three items are summed to create a total score of 0 to 30, higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -9.3 |
"SDS was a participant-reported outcome measure and was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0 to 10 rating scale. The score for the first three items are summed to create a total score of 0 to 30 where a higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -1.6 |
"The CGI-S measures the severity of the participant's illness that include knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Median) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0 |
"CGI-S measures severity of participant's illness that include knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on a scale range from 0 - 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Median) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -2.0 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health)." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.190 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health)." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.009 |
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 17.0 |
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 1.6 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -15.3 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.7 |
"GAD-7 is brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.2 |
"GAD-7 is brief, validated 7-item self-reported assessment of overall anxiety. Participant's responded to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of GAD-7 is categorized as: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method, last post baseline observation during the phase was carried forward as Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -5.9 |
"MADRS measure depression severity, detects changes due to AD treatment. It evaluates 10 items: apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.3 |
"MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using last observation carried forward (LOCF) method, last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -16.4 |
"PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Unit on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -8.9 |
"PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.2 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition." (NCT02497287)
Timeframe: Predose, up to 1.5 hours postdose (up to end of OP/MA phase [Week 52])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 86.1 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition." (NCT02497287)
Timeframe: Predose, up to 1.5 hours postdose (up to end of IND phase [Week 4])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 92.0 |
An adverse event is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an event that was new in onset or increased in severity following treatment initiation. (NCT02497287)
Timeframe: Up to End of Follow up Phase (Week 56)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 90.1 |
"Percentage of participants with cystitis, urinary tract infections, renal and urinary tract symptoms, renal and urinary disorders were evaluated. Cystitis and urinary tract infections are selected MedDRA preferred terms, renal and urinary tract symptoms refers to any preferred term (PT) in the group of selected PTs; and renal and urinary disorders refers to a MedDRA System Organ Class (SOC)." (NCT02497287)
Timeframe: Up to End of Follow up Phase (Week 56)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Cystitis | Urinary tract infections | Renal and urinary disorders | Renal and urinary tract symptoms | |
| Intranasal Esketamine + Oral Antidepressant | 0.6 | 8.1 | 10.5 | 17.0 |
"Remission is defined as MADRS total score less than or equal to (<=) 12. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Days 8, 15, 22 and Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 7.3 | 15.6 | 27.2 | 47.2 |
"Remission is defined as PHQ-9 total score <= 4. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Day 15 and Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Day 15 | Endpoint | |
| Intranasal Esketamine + Oral Antidepressant | 12.7 | 26.9 |
"Response is defined as greater than or equal to (>=) 50 % reduction from baseline in the MADRS total score. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Days 8, 15, 22 and Endpoint (last post-baseline assessment during 4 weeks of IND phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 11.6 | 25.0 | 42.8 | 78.4 |
"Response is defined as >= 50 % reduction from baseline (IND phase) in PHQ-9 total score. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Day 15 and Endpoint (last post-baseline assessment value during 4 Week IND phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Day 15 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 37.2 | 62.0 |
Percentage of participants with treatment-emergent acute hypertension (Systolic Blood Pressure >=180 millimeters of mercury [mm Hg] or Diastolic Blood Pressure >= 110 mm Hg) during IND and OP/MA Phases were evaluated. (NCT02497287)
Timeframe: Up to End of OP/MA phase (Week 52)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Systolic BP >=180 | Diastolic BP >=110 | Acute hypertension | |
| Intranasal Esketamine + Oral Antidepressant | 2.2 | 2.4 | 4.1 |
CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The change from baseline in CGI-S score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 0.0 |
| Oral AD+ Intranasal Placebo | 1.0 |
CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The change from baseline in CGI-S score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 0.0 |
| Oral AD+ Intranasal Placebo | 1.0 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -10.4 |
| Oral AD+ Intranasal Placebo | -16.1 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -1.3 |
| Oral AD+ Intranasal Placebo | -13.8 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health)." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -0.067 |
| Oral AD+ Intranasal Placebo | -0.096 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health)." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -0.023 |
| Oral AD+ Intranasal Placebo | -0.073 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 7.5 |
| Oral AD+ Intranasal Placebo | 10.9 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 3.0 |
| Oral AD+ Intranasal Placebo | 8.4 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). Item responses are summed to yield a total score (range of 0 to 21), with higher scores indicating more anxiety. The change from baseline in GAD-7 total score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 2.2 |
| Oral AD+ Intranasal Placebo | 4.0 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). Item responses are summed to yield a total score (range of 0 to 21), with higher scores indicating more anxiety. The change from baseline in GAD-7 total score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 1.4 |
| Oral AD+ Intranasal Placebo | 2.6 |
MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal - severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. The change from baseline in MADRS total score (last observation carried forward [LOCF] data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 7.5 |
| Oral AD+ Intranasal Placebo | 12.5 |
MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal - severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. The change from baseline in MADRS total score (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 4.4 |
| Oral AD+ Intranasal Placebo | 11.4 |
PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). The change from baseline in PHQ-9 total score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 3.3 |
| Oral AD+ Intranasal Placebo | 5.9 |
PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). The change from baseline in PHQ-9 total score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 1.7 |
| Oral AD+ Intranasal Placebo | 4.7 |
The SDS is a participant-reported outcome measure and is a 5-item questionnaire used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1: work/school 2: social life 3: family life/home responsibilities using a 0-10 rating scale. It also has one item on days lost from school or work and one item on days when underproductive. The score for the first 3 items are summed to create a total score of 0-30 where a higher score indicates greater impairment. The recall period is 7 days. Scores <= 4 for each item and <= 12 for the total score are considered response. Scores <= 2 for each item and <= 6 for the total score are considered remission. The change from baseline in SDS total Score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 4.7 |
| Oral AD+ Intranasal Placebo | 7.2 |
The SDS is a participant-reported outcome measure and is a 5-item questionnaire used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1: work/school 2: social life 3: family life/home responsibilities using a 0-10 rating scale. It also has one item on days lost from school or work and one item on days when underproductive. The score for the first 3 items are summed to create a total score of 0-30 where a higher score indicates greater impairment. The recall period is 7 days. Scores <= 4 for each item and <= 12 for the total score are considered response. Scores <= 2 for each item and <= 6 for the total score are considered remission. The change from baseline in SDS total Score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 2.2 |
| Oral AD+ Intranasal Placebo | 6.8 |
Relapse is defined as any of following: Montgomery-asberg depression rating scale (MADRS) total score greater than or equal to (>=) 22 for 2 consecutive assessments separated by 5-15 days and/or hospitalization for worsening depression or any other clinically relevant event to be suggestive of a relapse of depressive illness such as suicide attempt/completed suicide/hospitalization for suicide prevention; If hospitalized, start date of hospitalization will be date of relapse, if not hospitalized date of event will be used. MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal-severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. Stable remission: MADRS total score less than or equal to (<=) 12 for at least 3 of last 4 weeks of OP phase, with 1 excursion total score greater than (>) 12 or one missing assessment at OP week 13 or 14. (NCT02493868)
Timeframe: Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)
| Intervention | Days (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | NA |
| Oral AD+ Intranasal Placebo | 273.0 |
Relapse is defined as any of following: MADRS total score >= 22 for 2 consecutive assessments separated by 5-15 days and/or hospitalization for worsening depression or any other clinically relevant event to be suggestive of a relapse of depressive illness such as suicide attempt/completed suicide/hospitalization for suicide prevention; If hospitalized, start date of hospitalization will be date of relapse, if not hospitalized date of event will be used. MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal-severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. Stable response is defined as >= 50 percent (%) reduction in MADRS total score from baseline (Day 1 of induction phase, prior to first intranasal dose) in each of the last 2 weeks of the OP phase, but without meeting criteria for stable remission. (NCT02493868)
Timeframe: Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)
| Intervention | Days (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 635.0 |
| Oral AD+ Intranasal Placebo | 88.0 |
Comparing the number of subjects that achieve response between groups as defined above. (NCT02360280)
Timeframe: 13 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Six Ketamine Infusions | 19 |
| Single Ketamine Infusion Preceded by 5 Midazolam Infusions | 20 |
Average difference in the Montgomery-Asberg Depression Rating Scale (MADRS) score change between groups. The MADRS has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). (NCT02360280)
Timeframe: 13 days
| Intervention | units on a scale (Mean) |
|---|---|
| Six Ketamine Infusions | 21.0 |
| Single Ketamine Infusion Preceded by 5 Midazolam Infusions | 17.2 |
Comparing the number of subjects that achieve remission between groups as defined above (NCT02360280)
Timeframe: 13 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Six Ketamine Infusions | 12 |
| Single Ketamine Infusion Preceded by 5 Midazolam Infusions | 11 |
The length of time from post-infusion response until relapse (defined as >50% of MADRS baseline score) assessed for up to 6 months. (NCT02360280)
Timeframe: 6 months
| Intervention | weeks (Median) |
|---|---|
| Six Ketamine Infusions | 6.00 |
| Single Ketamine Infusion Preceded by 5 Midazolam Infusions | 2.00 |
full range score from 0-80, with higher scores indicating greater PTSD symptoms (NCT02397889)
Timeframe: 2 weeks after the first infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 22.5 |
| Active Control Midazolam Group | 33.2 |
full range score from 0-60, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 2 weeks after the first drug infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 14.7 |
| Active Control Midazolam Group | 21.9 |
full range score from 0-60, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 24 hours after the first drug infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 16.5 |
| Active Control Midazolam Group | 17.1 |
All side effects listed in Adverse Event section. (NCT02397889)
Timeframe: up to 21 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Ketamine Group | 15 |
| Active Control Midazolam Group | 15 |
full range score from 0-27, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 2 weeks after the first drug infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 6.6 |
| Active Control Midazolam Group | 6.7 |
full range score from 0-88, with higher scores indicating greater PTSD symptoms (NCT02397889)
Timeframe: 24 hours after the first drug infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Experimental Ketamine Group | 19.7 |
| Active Control Midazolam Group | 24.8 |
BPRS used to assess acute behavioral changes during the infusions. Four key BPRS items for the positive (+) symptoms of psychosis will be used: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content. Three items representing the negative (-) symptoms of psychosis will also be used: blunted affect, emotional withdrawal, and motor retardation. Each item scored 1-7. Full scale from 7 - 49, with higher score indicating more symptoms. (NCT03102736)
Timeframe: +240 minutes (after start of Placebo/Nitroprusside infusion)
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo and Ketamine | 7.5 |
| Nitroprusside and Ketamine | 7.2 |
This is used to measure dissociative effects during the infusions. The scale includes 23 clinician administered items scored from 0 (not at all) to 4 (extremely). The CADSS measures impairment in body perception, environmental perception, time perception, memory impairment, and feelings of unreality. Full scale from 0-92, with lower score indicating better health outcomes. (NCT03102736)
Timeframe: 240 minutes after start of infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo and Ketamine | 11.5 |
| Nitroprusside and Ketamine | 8.4 |
This is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 (normal) and 60 (severe depression). (NCT03102736)
Timeframe: 24 hours after start of infusion
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo and Ketamine | 13.4 |
| Nitroprusside and Ketamine | 14.2 |
Total number of subjects with ≤ 9 MADRS score 24 hours post Ketamine infusion #3. The Montgomery Åsberg Depression Scale (MÅDRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression. (NCT03156504)
Timeframe: 24 hours post infusion #3
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 39 |
Total number of subjects to have a reduction of suicidality, as defined by a 50% reduction on the Beck Scale for Suicidal Ideation (BSS) 24 hours post Ketamine infusion #3. The Beck Scale for Suicidal Ideation consists of 19 items which can be used to evaluate a patient's suicidal intentions. Each of the 19 items is rated on a 0-3 point scale (range 0-38, with higher scores indicating greater suicidal ideations or risk), and includes specific items that assess wish to live, wish to die, desire to make an active suicide attempt, passive suicidal desire, duration of suicidal ideations, frequency of suicidal ideations, and subjective level of control over suicidal actions. (NCT03156504)
Timeframe: 24 hours post infusion #3
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 42 |
Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 66.1 |
| Saline Infusion on Day 0 or Day 28 | 86.1 |
"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 12.1 |
| Saline Infusion on Day 0 or Day 28 | 19.6 |
"The CGI-I is a clinician rated single-item scale: Compared to the patient's condition at admission, how much has the patient changed?, rated on a 7-point response scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse. In this case, admission referred to the CGI-S screening assessments performed between Day -28 an -7, one conducted during the screening visit, and a second rating conducted by a remote, independent rater." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 3.8888889 | 3.0625000 | 2.9333333 |
| Ketamine 0.2mg | 4.0500000 | 3.3684211 | 2.8421053 |
| Ketamine 0.5mg | 4.1363636 | 2.6363636 | 2.5714286 |
| Ketamine 1.0mg | 4.0000000 | 3.0500000 | 2.5500000 |
| Midazolam 0.045mg | 4.1578947 | 3.6111111 | 3.1666667 |
"The CGI-S is a clinician rated single-item scale: How depressed is the patient at this time?, rated on a 7-point response scale: 1 = Normal, not at all depressed, 2 = Borderline depressed, 3 = Mildly depressed, 4 = Moderately depressed. 5 = Markedly depressed, 6 = severely depressed, 7 = Among the most severely depressed patients. When rating patients, clinicians were asked to consider the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 5.0000000 | 3.5625000 | 3.4000000 |
| Ketamine 0.2mg | 5.2000000 | 4.2631579 | 3.7368421 |
| Ketamine 0.5mg | 4.8636364 | 3.2727273 | 3.1428571 |
| Ketamine 1.0mg | 5.2000000 | 3.5000000 | 3.3000000 |
| Midazolam 0.045mg | 5.000000 | 4.555556 | 4.1666667 |
"The CPAS is a 16-item self-report scale to assess the level to which participants experience persistent distress due to feeling that they have not returned to their normal or premorbid state. Items (e.g., I look forward to things) are rated on a 5-point scale (0=not at all, 1=very much less than normal, 2=much less than normal, 3=slightly less than normal, 4=same as best or normal self). The possible scale range is 0 to 64, with higher scores indicating greater recovery from depression. Patients were asked to rate their experience of the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 19.3333333 | 35.2500000 | 38.8666667 |
| Ketamine 0.2mg | 20.5000000 | 27.0526316 | 28.3888889 |
| Ketamine 0.5mg | 20.6363636 | 40.8696964 | 39.7619048 |
| Ketamine 1.0mg | 21.2500000 | 33.0000000 | 37.4500000 |
| Midazolam 0.045mg | 21.2631579 | 24.4444444 | 33.3750000 |
"The CADSS is a 23-item self-report scale for the assessment of dissociative states. It is a reliable, valid self-report instrument. The severity of each dissociative symptom ranges from 0 (not present) to 4 (extreme). The total score is calculated by summing across items, with a total possible range of 0-92. The CADSS was administered right before infusion, and 40, 80 minute and 120 minutes after the start of infusion. The timeframe is at this moment." (NCT01920555)
Timeframe: Day 0/baseline at 0, 40, 80, and 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Minute 0 | Minute 40 | Minute 80 | Minute 120 | |
| Ketamine 0.1mg | 0.1111111 | 3.0000000 | 0.4444444 | 0.0555556 |
| Ketamine 0.2mg | 0.1000000 | 4.0500000 | 0.1000000 | 0 |
| Ketamine 0.5mg | 0 | 14.2727273 | 0.7727273 | 0.1363636 |
| Ketamine 1.0mg | 0.1000000 | 24.6842105 | 1.8000000 | 0.6500000 |
| Midazolam 0.045mg | 0.4210526 | 2.6842105 | 1.1578947 | 0.5789474 |
The HAMD6 is a 6-item clinician-rated scale, where clinicians rate the presence of depression symptoms (i.e., depressed mood, guilt, work and interests, psychomotor retardation, psychic anxiety, somatic symptoms) on a 5-point scale, where 0 = not present, and 1-4 represent increasingly severe symptoms. One item (i.e., somatic symptoms) is rated on only a 3-point scale, ranging from 0-2. The possible scale range is 0-22, where higher values represent more severe depression. This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week. In this study, the HAMD6 was used to assess symptoms occurring in the past 24 hours. (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1, & 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 12.5555556 | 7.5000000 | 6.8000000 |
| Ketamine 0.2mg | 12.7500000 | 9.2631579 | 8.4736842 |
| Ketamine 0.5mg | 12.5909091 | 5.8636364 | 5.9047619 |
| Ketamine 1.0mg | 12.6315789 | 6.9000000 | 7.2000000 |
| Midazolam 0.045mg | 13.0526316 | 10.6666667 | 9.0555556 |
"The MADRS is a 10-item clinician-rated scale measuring depression severity. Symptoms are rated on a 7-point scale, where 0 = not present, and 1-6 represent increasing severity. Values 2, 4, and 6 have specific anchoring text (e.g., 2=Difficulties in starting activities. 4=Difficulties in starting simple routine activities which are carried out with effort, 6=Complete lassitude. Unable to do anything without help.) Values 1, 3, and 5 do not have specific text. The possible scale range is 0-60, where higher values represent higher severity. In this study, the MADRS was used to rate symptoms occurring in the past 3 days." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0 and 3.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Day 0 | Day 3 | |
| Ketamine 0.1mg | 33.8333333 | 19.6666667 |
| Ketamine 0.2mg | 34.4500000 | 22.6315789 |
| Ketamine 0.5mg | 31.5909091 | 14.7619048 |
| Ketamine 1.0mg | 32.6500000 | 17.1000000 |
| Midazolam 0.045mg | 33.6315789 | 24.8333333 |
The Columbia Suicide Severity Rating Scale (C-SSRS): The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed in the National Institute of Mental Health Treatment of Adolescent Suicide Attempters Study to assess severity and track suicidal events through any treatment. It is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the level and type of suicidality present. The C-SSRS can also be used during treatment to monitor for clinical worsening or improvement. It contains 5 rating scale questions (yes/no) for suicidal ideation increasing severity and 5 rating scale questions (yes/no) for suicidal behavior of increasing severity. The time frame is for both lifetime and the past six months for the Baseline/Screening scale and since the last visit for the Since Last Visit scale. (NCT01920555)
Timeframe: Screening Visit and Days 0, 1, 3, 5, 7, 14 and 30 combined
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Screening: # with suicidal ideation/behavior | Follow-Up: # with suicidal ideation/behavior | |
| Ketamine 0.1mg | 17 | 15 |
| Ketamine 0.2mg | 15 | 9 |
| Ketamine 0.5mg | 17 | 10 |
| Ketamine 1.0mg | 14 | 6 |
| Midazolam 0.045mg | 17 | 13 |
"CBC~Chemistry (Total bilirubin, AST, ALT, GGT, ALK Phosphatase, Creatinine, BUN/Urea, Glucose, Uric Acid)~Testing was performed by study site laboratories and used institutional normal lab value ranges." (NCT01920555)
Timeframe: Day 3 and Early Termination Visit (approximately 3 weeks following intervention)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Chemistry ALT(SGPT) | Chemistry AST(SGOT) | Chemistry Total Bilirubin | Chemistry Remaining Tests | CBC | |
| Ketamine 0.1mg | 0 | 0 | 0 | 0 | 0 |
| Ketamine 0.2mg | 1 | 1 | 1 | 0 | 0 |
| Ketamine 0.5mg | 0 | 0 | 0 | 0 | 0 |
| Ketamine 1.0mg | 0 | 0 | 0 | 0 | 0 |
| Midazolam 0.045mg | 0 | 0 | 0 | 0 | 0 |
"The SHAPS is a 14-item self-report scale to measure hedonic tone. Items (e.g., I would enjoy reading a book, magazine, or newspaper.) are rated on a 4-point scale (1=strongly disagree, 2=disagree, 3=agree, 4=strongly agree). Either of the 'disagree' responses scores 1 point, and either of the 'agree' responses scores 0 points, for a total scale range of 0-14. Higher scores indicate greater inability to experience pleasure. Patients were asked to rate their experience of the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 7.2222222 | 3.9375000 | 3.5333333 |
| Ketamine 0.2mg | 7.5500000 | 5.7368421 | 6.3888889 |
| Ketamine 0.5mg | 6.5909091 | 2.22727273 | 3.0000000 |
| Ketamine 1.0mg | 7.3500000 | 4.3000000 | 3.6500000 |
| Midazolam 0.045mg | 6.4736842 | 5.0000000 | 4.2500000 |
"The SDQ is a 44-item self-report scale, which aims to measure depression more comprehensively by including the assessment of symptoms in the anxiety-depression spectrum, including symptoms of irritability, anger attacks, and anxiety. Items are rated on an 6-point Likert scale, where participants are asked to rate if a specific symptom (e.g. How has your mood been over the past 24 hours?) is normal for him or her (score = 2), what is better than normal (score = 1), and what is worse than normal (scores = 3-6). The total scale score is calculated by averaging across the items, resulting in a possible range from 1 to 6. Higher scores indicate greater depression severity. When rating, patients were asked to consider their symptoms during the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 3.5164141 | 2.5752843 | 2.5106061 |
| Ketamine 0.2mg | 3.4636364 | 2.9096195 | 2.7828283 |
| Ketamine 0.5mg | 3.5392562 | 2.3109504 | 2.5573593 |
| Ketamine 1.0mg | 3.4113636 | 2.6113636 | 2.5909091 |
| Midazolam 0.045mg | 3.4264507 | 2.9200573 | 2.8751353 |
Assessed via Confusion Assessment Method or Confusion Assessment Method for Intensive Care Unit (NCT01690988)
Timeframe: Postoperative days 1-3
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine (0.5 mg/kg) | 45 |
| Normal Saline (Placebo) | 40 |
| Ketamine (1 mg/kg) | 62 |
Assessed via Confusion Assessment Method or Confusion Assessment Method for Intensive care Unit (NCT01690988)
Timeframe: Postoperative days 1-3
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine (0.5 mg/kg) | 27 |
| Normal Saline (Placebo) | 18 |
| Ketamine (1 mg/kg) | 34 |
"Assessed from patients' medical charts. All morphine equivalent drugs consumed by patients perioperatively~Opioid Drugs included:~* Postoperatively while still in hospital, the list of pain medication used included Morphine, Hydromorphone, Meperidine, Nalbuphine, Oxycodone,Oxymorphone, Tramadol, bupivacaine, (Codeine, Fentanyl, Naloxone) Total Opiates (Morphine Equivalent) in milligrams The median(IQR) opioid consumption was compared across the three study groups Placebo vs. Lo-K (0.5 mg/kg) vs. Hi-K (1 mg/kg)" (NCT01690988)
Timeframe: Postoperative days 0-3
| Intervention | mg (Median) |
|---|---|
| Ketamine (0.5 mg/kg) | 88.9 |
| Normal Saline (Placebo) | 94.7 |
| Ketamine (1 mg/kg) | 78.7 |
"According to Confusion Assessment Method or Confusion Assessment Method for Intensive Care Unit criteria the number of patients that had any positive CAM on any day for all patients. The main effect evaluated will be to determine whether ketamine decreases delirium, table 3 of the protocol provides a useful guide for the potential findings of the current study with their implications.~To further clarify, delirium will be assessed on the day of surgery, when possible and on the subsequent three days POD 1-3, as long as as patients remain in the hospital and are assessable (i.e., not sedated to a RASS <-3). The assessments on POD 1-3 will be done twice daily, once in the morning and once in the afternoon. The primary outcome of the study includes only the delirium incidence on POD 1-3.~The primary comparison will be between the combined ketamine groups and the placebo group." (NCT01690988)
Timeframe: Delirium incidence on postoperative days 1-3, calculated by any positive CAM on any day for all patients
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine (0.5 mg/kg and 1 mg/kg) | 85 |
| Normal Saline (Placebo) | 43 |
"Assessed from patient-reported postoperative nausea and vomiting section of Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) Patients where asked whether they currently have nausea/vomiting AM & PM the response choices: None, Mild, Moderate, Severe Incidence of nauseavomiting accounted for any positive reporting(Mild, moderate, or sever) Daily incidence accounted for any positive incidence AM/PM in each POD Any POD nausea/vomiting reports the incidence across day 1-3~The incidence of nausea and or vomiting was compared across the three study groups Placebo vs. Lo-K (0.5 mg/kg) vs. Hi-K (1 mg/kg) for POD 1-3 and overall." (NCT01690988)
Timeframe: Postoperative days 1-3
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine (0.5 mg/kg) | 72 |
| Normal Saline (Placebo) | 73 |
| Ketamine (1 mg/kg) | 64 |
Assessed by observer-based Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) with subsequent administration of patient-reported Visual Analog Scale The behavioral pain scale has three domains and ranges from 3 to 15. The visual analog scale is a continuous scale from 0 to 100 mm. Daily Maximum Pain accounted for pain level in the AM or PM for both the VAS and the BPS/BPS-NI a higher value means a worse outcome. (NCT01690988)
Timeframe: Postoperative days 1-3, two assessment daily (morning and afternoon), with at least six hours between assessments
| Intervention | participants (Median) | |||||
|---|---|---|---|---|---|---|
| VAS day 1 | VAS day 2 | VAS day 3 | BPS/BPS-NI day 1 | BPS/BPS-NI 2 | BPS/BPS-NI 3 | |
| Ketamine (0.5 mg/kg ) | 70 | 56 | 46 | 4 | 4 | 3 |
| Ketamine (1 mg/kg) | 68 | 57.5 | 47 | 4 | 3 | 3 |
| Normal Saline (Placebo) | 63.5 | 59 | 52.5 | 4 | 3 | 3 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
Clinician-administered structured interview measuring PTSD symptoms. frequency score - scale 0 = none of the time to 4 = most or all of the time intensity score - scale 0 = none to 4 = extreme To meet criteria for a symptom, a patient must meet criteria in both frequency and intensity score for each item. Frequency and intensity and then combined to form a single severity score. 30 questions scale, with total score ranging from 0 to 240. (NCT00749203)
Timeframe: 7 days after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 54 |
| Midazolam | 65.69 |
"A 22-item self-report questionnaire measuring PTSD symptoms. Items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score ranging from 0 (not at all) to 88 (extremely)" (NCT00749203)
Timeframe: 7 days after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 25.76 |
| Midazolam | 36.32 |
Clinician-administered questionnaire measuring depressive symptoms. The MADRS-S has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). Mean difference between baseline and 2 weeks. (NCT00749203)
Timeframe: 24 hours after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 12.6 |
| Midazolam | 10.1 |
Self-report questionnaire measuring depressive symptoms. Each item is rated 0 (no depression) to 3 (severe depression). The total score ranges from 0-27. (NCT00749203)
Timeframe: 24 hours after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 12.4 |
| Midazolam | 11.3 |
"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms" (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 28.22 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 33.66666667 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 11.44 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 13.41 |
"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms" (NCT04322968)
Timeframe: 24 hrs post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 36.33333333 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 37 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 10.44444444 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 15.64705882 |
"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity." (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 48.22 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 52.88 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 43.33 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 48.23 |
"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity." (NCT04322968)
Timeframe: 24 hrs post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 37.22222222 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 49.66666667 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 29.88888889 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 38.70588235 |
"Severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week; No scoring algorithm, but worst pain or the arithmetic mean of the four severity items can be used as measures of pain severity (a range of 0-10, with 10 being worse scores); the arithmetic mean of the seven interference items can be used as a measure of pain interference (a range of 0-10, with 10 being worse scores). The total score is reported for severity items and interference items, which range from 0-40 and 0-70, respectively. Higher values represent worse outcome." (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Pain interference Scale | Pain severity Scale | |
| Chronic Pain With PTSD+IV Ketamine Infusion | 38.62 | 20.75 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 25.66 | 14.66 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 9.62 | 12.75 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 28.33 | 22.66 |
"Depressive symptoms (measured by Montgomery-Asberg Depression Rating Scale, revised (MADRS) score) on 1 day after infusion, for the cohort of subjects enrolled in the MDD arm of this trial.~Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal /symptom absent. 7 to 19 - mild depression. 20 to 34 - moderate depression. >34 - severe depression." (NCT02579928)
Timeframe: 1 day after the infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 15.44 |
| Midazolam | 24.13 |
Change in BSI score at 24 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity. (NCT01507181)
Timeframe: baseline and 24 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 10.8 |
| Midazolam | 14.0 |
Change in BSI score at 48 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity. (NCT01507181)
Timeframe: baseline and 48 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 8.8 |
| Midazolam | 15.3 |
The PRISE assesses the presence of treatment side effects in nine organ/function systems (gastrointestinal, nervous system, heart, eyes/ears, skin, genital/urinary, sleep, sexual functioning, and other). Data reported in in Adverse Events section. (NCT01507181)
Timeframe: duration of study
| Intervention | events (Number) |
|---|---|
| Ketamine | 29 |
| Midazolam | 23 |
The MADRS-SI ranges from 0 to 6; a score of 2 corresponds to fleeting, passive SI; a score of 4 indicates that SI is frequent with at least moderate intensity but without specific plans or intention; a score of 6 corresponds to active intention and planning for suicide. (NCT01507181)
Timeframe: 24 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.8 |
| Midazolam | 3.3 |
The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT01507181)
Timeframe: up to 7 days post infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 24 hours | 48 hours | 72 hours | 7 days | |
| Ketamine | 19.0 | 19.3 | 20.9 | 21.7 |
| Midazolam | 26.2 | 28 | 24.1 | 22.2 |
The BPRS measures psychomimetic effects with higher scores indicating more severe symptoms (scale range 7 - 49). (NCT01507181)
Timeframe: baseline, 40 minutes post infusion, and 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 7.7 | 9.9 | 8.1 |
| Midazolam | 7.7 | 7.9 | 7.0 |
The CADSS measures dissociation with higher scores indicating more severe symptoms (scale range 0 - 92). (NCT01507181)
Timeframe: baseline, 40 minutes post infusion and 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 1.1 | 17.1 | 1.2 |
| Midazolam | 4.0 | 3.3 | 1.3 |
An 11-item questionnaire, used to assess manic symptoms based on the patient's subjective report of his or her clinical condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. (NCT01507181)
Timeframe: baseline, 40 minutes post infusion, 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 0.0 | 0.0 | 0.2 |
| Midazolam | 0.1 | 0.3 | 0.2 |
Montgomery-Asberg Depression Rating Scale, each of the ten items can be scored from 0 (absence of symptoms to 6 most severe) and has a total score range of 0-60. A lower score on a MADRS indicates a less severe depression. The primary outcome for the initial phase of the trial was the 24-h MADRS score, which included all 10 MADRS items. (NCT00419003)
Timeframe: 24 Hours
| Intervention | scores on a scale (Mean) |
|---|---|
| Riluzole Group | 24.4 |
| Placebo | 22.0 |
191 reviews available for ketamine and Depression
| Article | Year |
|---|---|
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Kir4.1 Dysfunction in the Pathophysiology of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Astrocytes; Brain-Derived Neurotrophic Fact | 2021 |
[Ketamine and other N-methyl-D-aspartate receptor modulators in treatment of depression].
Topics: Antidepressive Agents; Depression; Humans; Ketamine; Mood Disorders; Receptors, N-Methyl-D-Aspartate | 2022 |
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine | 2021 |
Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review.
Topics: Anorexia Nervosa; Antidepressive Agents; Brain; Comorbidity; Depression; Glutamic Acid; Humans; Keta | 2021 |
Ketamine as a Novel Drug for Depression Treatment.
Topics: Antidepressive Agents; Depression; Humans; Ketamine; Pharmaceutical Preparations; Suicidal Ideation | 2021 |
Mechanisms of ketamine and its metabolites as antidepressants.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Excitatory Amino Acid | 2022 |
The effect of intravenous ketamine on depressive symptoms after surgery: A systematic review.
Topics: Adult; Antidepressive Agents; Depression; Humans; Ketamine; Nausea; Pain, Postoperative | 2022 |
[Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamin | 2021 |
[The role of ketamine in the treatment of treatment-resistant bipolar depression].
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Drug- | 2021 |
Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine; Mechanistic Target of Rapamycin Comple | 2022 |
Connexin 43: insights into candidate pathological mechanisms of depression and its implications in antidepressant therapy.
Topics: Animals; Antidepressive Agents; Astrocytes; Connexin 43; Connexins; Depression; Depressive Disorder, | 2022 |
Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, N-Methyl | 2022 |
Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review.
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine; Lamotrigine; Psychopharmacology | 2022 |
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2022 |
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Male | 2022 |
A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Electroconvulsive Therapy; Feasibility Studies; Humans; Ketamine; | 2022 |
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
Rapid treatments for depression: Endocannabinoid system as a therapeutic target.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Endocannabinoids; Humans; Ketamine | 2022 |
Long-term safety of ketamine and esketamine in treatment of depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resist | 2022 |
Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities.
Topics: Aged; Clinical Deterioration; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; Fem | 2023 |
A review of potential neuropathological changes associated with ketamine.
Topics: Adult; Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Excitat | 2022 |
The abuse liability of ketamine: A scoping review of preclinical and clinical studies.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketami | 2022 |
Ketamine for resistant depression: a scoping review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine | 2022 |
Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review.
Topics: Animals; Depression; Humans; Ketamine; Mammals; N-Methylaspartate; Phencyclidine; Receptors, N-Methy | 2022 |
Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Major; Humans; Ketamine; Mechanis | 2023 |
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Treat | 2022 |
Guanosine as a promising target for fast-acting antidepressant responses.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Glutamic Acid; Guanosin | 2022 |
Imaging synaptic density in depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Neuroimaging; Positron-Emission Tomography | 2023 |
(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression.
Topics: Antidepressive Agents; Dementia; Depression; Humans; Ketamine; Nervous System Diseases; Stroke | 2022 |
The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Treatment-Resistant; Hallucinoge | 2023 |
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression.
Topics: Adult; Aripiprazole; Depression; Depressive Disorder, Major; Humans; Ketamine; Risperidone | 2023 |
Neurobiological, behavioral, and cognitive effects of ketamine in adolescents: A review of human and pre-clinical research.
Topics: Adolescent; Adult; Animals; Anxiety; Behavior, Animal; Cognition; Depression; Female; Humans; Ketami | 2022 |
New investigational agents for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Ketamine; Rece | 2022 |
Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatme | 2022 |
The role of mGlu
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Ketamine; Receptors, Metabotropic Glutamate | 2022 |
The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.
Topics: Administration, Intravenous; Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine; | 2022 |
Diversity inclusion in clinical trials investigating esketamine for depression: A systematic review.
Topics: Adult; Depression; Female; Humans; Ketamine | 2023 |
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Depressive Dis | 2022 |
Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
Topics: Adult; Antidepressive Agents; Biomarkers; Cytokines; Depression; Depressive Disorder, Major; Humans; | 2022 |
Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Gast | 2022 |
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; | 2022 |
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Letter to the editor about "Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis".
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants.
Topics: Antidepressive Agents; Depression; Ketamine; Mechanistic Target of Rapamycin Complex 1; Receptors, N | 2023 |
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.
Topics: Anhedonia; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2023 |
Ketamine and its metabolites: Potential as novel treatments for depression.
Topics: Cognitive Dysfunction; Depression; Dissociative Disorders; Humans; Ketamine; Psychotherapy | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Insulin-Like Growth F | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders.
Topics: Depression; Depression, Postpartum; Female; Hippocampus; Humans; Ketamine; Neuronal Plasticity; Pref | 2023 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Biomarkers of ketamine's antidepressant effect: An umbrella review.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Biomarkers of ketamine's antidepressant effect: An umbrella review.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Biomarkers of ketamine's antidepressant effect: An umbrella review.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Biomarkers of ketamine's antidepressant effect: An umbrella review.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research.
Topics: Animals; Antidepressive Agents; Artificial Intelligence; Depression; Glutamic Acid; Ketamine; Recept | 2023 |
Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review.
Topics: Antidepressive Agents; Depression; Humans; Ketamine; Palliative Care | 2023 |
Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis."
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.
Topics: Antidepressive Agents; Depression; gamma-Aminobutyric Acid; Hallucinogens; Ketamine; Signal Transduc | 2023 |
Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Pain; Pain, Postoperative; | 2023 |
mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, Metabotr | 2023 |
Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, AMPA; Re | 2023 |
Inflammation, stress and depression: An exploration of ketamine's therapeutic profile.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Depression; Inflammation; Ketamine | 2023 |
Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Ketamine; Receptors, Metabot | 2023 |
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder | 2023 |
Bridging rapid and sustained antidepressant effects of ketamine.
Topics: Antidepressive Agents; Depression; Hippocampus; Humans; Ketamine; Signal Transduction | 2023 |
A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Depression; Humans; Ketamine; Mood Disorders | 2023 |
Ketamine - a long way from anesthetic to a prototype antidepressant: Review of potential mechanisms of action.
Topics: Anesthetics; Antidepressive Agents; Depression; Glutamates; Humans; Ketamine; Receptors, N-Methyl-D- | 2022 |
The antidepressant actions of ketamine and its enantiomers.
Topics: Antidepressive Agents; Depression; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine | 2023 |
Role of Psychedelics in Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin | 2023 |
Reporting of harms in clinical trials of esketamine in depression: a systematic review.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depression; Humans; Ketamine | 2023 |
The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2023 |
New Pharmacologic Approaches to the Treatment of Bipolar Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine; Psilocybin; Randomized Contro | 2023 |
Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine.
Topics: Analgesics, Opioid; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; | 2023 |
Ketamine in neuropsychiatric disorders: an update.
Topics: Anhedonia; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Depression; Humans; Ketamine | 2024 |
Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions.
Topics: Adolescent Psychiatry; Animals; Antidepressive Agents; Child; Depression; Humans; Ketamine; Suicidal | 2023 |
Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Recep | 2024 |
A synopsis of multitarget therapeutic effects of anesthetics on depression.
Topics: Anesthetics; Depression; Humans; Isoflurane; Ketamine; Propofol; Receptors, AMPA; Receptors, N-Methy | 2023 |
Ketamine use in pediatric depression: A systematic review.
Topics: Adolescent; Adult; Child; Databases, Factual; Depression; Humans; Ketamine; Mental Disorders; Random | 2022 |
Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Topics: Antidepressive Agents; Depression; Hallucinogens; Ketamine; Psilocybin; Receptors, Metabotropic Glut | 2023 |
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis
Topics: Adult; Antidepressive Agents; Aripiprazole; Depression; Depressive Disorder; Depressive Disorder, Tr | 2024 |
Antidepressant mechanisms of ketamine's action: NF-κB in the spotlight.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Depression; Humans; Ketamine; NF-kappa B; Signal Tr | 2023 |
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.
Topics: Antidepressive Agents; Depression; Ketamine | 2023 |
Rodent ketamine depression-related research: Finding patterns in a literature of variability.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; Huma | 2019 |
Efficacy of Ketamine in bipolar depression: focus on anhedonia.
Topics: Anhedonia; Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine | 2019 |
Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
Topics: Antidepressive Agents; Cardiovascular Diseases; Cardiovascular System; Depression; Depressive Disord | 2019 |
Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far.
Topics: Antidepressive Agents; Cytokines; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate | 2020 |
Ketamine and depression: a narrative review.
Topics: Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Excitatory Amino Acid | 2019 |
Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Anima | 2019 |
Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms.
Topics: Allosteric Regulation; Animals; Antidepressive Agents; Clinical Trials as Topic; Depression; Excitat | 2020 |
Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Dop | 2020 |
Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Ketamine; Vascular Endothelial | 2021 |
Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Hippocampus; Humans; | 2020 |
mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects.
Topics: Animals; Antidepressive Agents; Cyclohexanes; Depression; Excitatory Amino Acid Antagonists; Humans; | 2020 |
Emerging concepts on the use of ketamine for chronic pain.
Topics: Analgesics; Animals; Chronic Pain; Depression; Disease Models, Animal; Excitatory Amino Acid Antagon | 2020 |
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
Topics: Administration, Intranasal; Antidepressive Agents; Clinical Trials as Topic; Databases, Factual; Dep | 2020 |
A historical review of antidepressant effects of ketamine and its enantiomers.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketami | 2020 |
Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression.
Topics: Anesthetics, Dissociative; Animals; Brain; Depression; Gene Expression; Humans; Ketamine; Signal Tra | 2020 |
Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions.
Topics: Antidepressive Agents; Anxiety; Depression; Ketamine; Neural Pathways; Prefrontal Cortex | 2020 |
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Gastrointestin | 2020 |
Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine | 2020 |
The neurophysiology of ketamine: an integrative review.
Topics: Antidepressive Agents; Depression; Humans; Ketamine; Magnetic Resonance Imaging; Neuroimaging; Recep | 2020 |
Brain NMDA Receptors in Schizophrenia and Depression.
Topics: Animals; Brain; Depression; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2020 |
A systematic review of ketamine for the treatment of depression among older adults.
Topics: Aged; Antidepressive Agents; Depression; Humans; Ketamine; Randomized Controlled Trials as Topic; Tr | 2021 |
Ketamine for depression clinical issues.
Topics: Antidepressive Agents; Depression; Humans; Ketamine; Randomized Controlled Trials as Topic; Receptor | 2020 |
mGlu2/3 receptor as a novel target for rapid acting antidepressants.
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine; Molecular Targeted Therapy; Receptors, | 2020 |
Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition.
Topics: Animals; Antidepressive Agents; Depression; GABAergic Neurons; Humans; Ketamine; Metabolome; Neural | 2020 |
The role of eEF2 kinase in the rapid antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Depression; Elongation Factor 2 Kinase; Humans; Ketamine; Neuronal P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Ketamine: a versatile tool for anesthesia and analgesia.
Topics: Analgesia; Analgesics; Anesthesia; Anesthetics, Dissociative; Burns; Depression; Humans; Ketamine; P | 2020 |
Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
Topics: Animals; Antidepressive Agents; Depression; Drug Discovery; Excitatory Amino Acid Antagonists; Human | 2021 |
An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Male | 2020 |
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine | 2021 |
Ketamine: A tale of two enantiomers.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Intern | 2021 |
Effect of Perioperative Ketamine on Postoperative Mood and Depression: A Review of the Literature.
Topics: Affect; Anesthetics, Dissociative; Depression; Humans; Ketamine; Perioperative Care; Postoperative C | 2021 |
The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2021 |
A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics.
Topics: Antidepressive Agents; Dendrites; Depression; Hallucinogens; Humans; Ketamine; Neuronal Plasticity | 2021 |
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2021 |
Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials.
Topics: Depression; Dizziness; Humans; Hypesthesia; Ketamine; Nausea; Paresthesia; Randomized Controlled Tri | 2022 |
[A review of the antidepressant properties of ketamine].
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; History, 20th Century; Histo | 2021 |
Ketamine for depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Recep | 2021 |
Intranasal esketamine: From origins to future implications in treatment-resistant depression.
Topics: Administration, Intranasal; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-R | 2021 |
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.
Topics: Anesthetics; Antidepressive Agents; Depression; Humans; Ketamine; Synaptic Transmission | 2021 |
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant | 2021 |
Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Recep | 2022 |
Rapid-acting antidepressants and the regulation of TrkB neurotrophic signalling-Insights from ketamine, nitrous oxide, seizures and anaesthesia.
Topics: Anesthesia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Depr | 2021 |
Perspectives for therapy of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Ketamine | 2022 |
[ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT].
Topics: Administration, Intranasal; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2021 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressio | 2021 |
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Is ketamine effective and safe for treatment-resistant depression?
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depression; Depressi | 2021 |
Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Ketamine in depression and electroconvulsive therapy.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Electroconvulsive Therapy; Humans; Ke | 2021 |
Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Off-L | 2017 |
[Research progress of depression and the application of esketamine].
Topics: Antidepressive Agents; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate | 2016 |
Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb.
Topics: Animals; Antidepressive Agents; Brain; Depression; Humans; Ketamine; Nitric Oxide; Ras Homolog Enric | 2017 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.
Topics: Antidepressive Agents; Brain; Carbon Radioisotopes; Depression; Depressive Disorder, Major; Excitato | 2018 |
Mechanisms of ketamine action as an antidepressant.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; | 2018 |
Nonanesthetic Effects of Ketamine: A Review Article.
Topics: Chronic Pain; Cognition; Dementia; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2018 |
The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
Topics: Animals; Antidepressive Agents; Biomarkers; Depression; Disease Models, Animal; Drug Development; Gl | 2018 |
NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Depression; Excitatory Amino Acid Antagonists; Humans; | 2018 |
Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.
Topics: Animals; Antidepressive Agents; Biomarkers; Depression; Glutamic Acid; Humans; Inflammation; Ketamin | 2019 |
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.
Topics: Animals; Antidepressive Agents; Brain; Depression; Humans; Ketamine | 2019 |
Ketamine and magnesium common pathway of antidepressant action.
Topics: Analgesics; Animals; Antidepressive Agents; Depression; Humans; Ketamine; Magnesium | 2018 |
Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Habenula; Humans; Ketamine; Recepto | 2019 |
Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials.
Topics: Adult; Anesthetics, Dissociative; Combined Modality Therapy; Depression; Depressive Disorder, Major; | 2019 |
Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System.
Topics: Depression; Depressive Disorder, Major; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Ketamin | 2019 |
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Glutamic Acid; Humans; Ketam | 2019 |
Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence.
Topics: Antidepressive Agents; Depression; Drug Administration Routes; Humans; Ketamine | 2019 |
[Ketamine in the therapy of chronic pain and depression].
Topics: Analgesics; Chronic Pain; Depression; Humans; Ketamine; Neuralgia | 2019 |
Oral Ketamine for Depression, 2: Practical Considerations.
Topics: Administration, Oral; Antidepressive Agents; Depression; Drug Administration Schedule; Humans; Ketam | 2019 |
The Efficacy of Ketamine in the Palliative Care Setting: A Comprehensive Review of the Literature.
Topics: Administration, Intranasal; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antidepress | 2019 |
mGlu2/3 receptor antagonists.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Humans; Ketamine; Receptors, Metabotropic Gluta | 2019 |
The influence of ketamine on drug discovery in depression.
Topics: Animals; Antidepressive Agents; Depression; Drug Discovery; Drug Repositioning; Hallucinogens; Human | 2019 |
Ketamine as a fast acting antidepressant: current knowledge and open questions.
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Depression; Drug Evaluation, Preclinical; | 2013 |
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Treatment Outcome | 2013 |
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Treatment Outcome | 2013 |
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Treatment Outcome | 2013 |
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Treatment Outcome | 2013 |
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
Topics: Animals; Antidepressive Agents; Depression; Glutamic Acid; Humans; Ketamine | 2013 |
New paradigms for treatment-resistant depression.
Topics: Animals; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine; Magnesium; Receptors, N-Me | 2013 |
[Treatment of drug-resistant depression].
Topics: Antidepressive Agents; Depression; Drug Resistance; Drug Therapy, Combination; Electric Stimulation | 2013 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
Topics: Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Glycogen Synthase Kinase 3; Hu | 2014 |
[Ketamine as antidepressant: the current study situation].
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Evidence-Based Medicine; Humans; Keta | 2014 |
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depression; Humans; Ketamine; Receptors, N-Methyl-D | 2015 |
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
Topics: Animals; Antidepressive Agents, Second-Generation; Biomarkers; Depression; Excitatory Amino Acid Ant | 2015 |
Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature.
Topics: Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine; Suicidal Ideation; Suicide; Suicide | 2015 |
The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity?
Topics: Animals; Antidepressive Agents; Central Nervous System; Depression; Humans; Ketamine; Neuronal Plast | 2015 |
Ketamine and suicidal ideation in depression: Jumping the gun?
Topics: Animals; Antidepressive Agents; Brain; Clinical Trials as Topic; Depression; Hallucinogens; Humans; | 2015 |
Treatment-resistant depression: are animal models of depression fit for purpose?
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Disea | 2015 |
Development of New Psychopharmacological Agents for Depression and Anxiety.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Botulinum Toxins; Depression; Excitatory Amino | 2015 |
Ketamine and other glutamate receptor modulators for depression in adults.
Topics: Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine; Rando | 2015 |
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cytidine; Depression; Excitatory Amino Acid Antagoni | 2015 |
Suicide risk assessment and intervention in people with mental illness.
Topics: Antidepressive Agents; Antipsychotic Agents; Anxiety; Cognitive Behavioral Therapy; Crisis Intervent | 2015 |
Should ketamine be used for the clinical treatment of depression?
Topics: Depression; Humans; Ketamine; Randomized Controlled Trials as Topic | 2016 |
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Excitatory Amino Acid Agents | 2016 |
Ketamine use in current clinical practice.
Topics: Depression; Humans; Ketamine; Pain; Pain Management; Suicide Prevention | 2016 |
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.
Topics: Depression; Depressive Disorder; Humans; Ketamine; Mood Disorders; Receptors, N-Methyl-D-Aspartate; | 2016 |
Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine; Serotonin; Signal Transduction | 2016 |
Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.
Topics: Animals; Antidepressive Agents; Brain; Depression; Disease Models, Animal; Humans; Ketamine; Swimmin | 2016 |
On the Eve of Upgrading Antidepressants: (R)-Ketamine and Its Metabolites.
Topics: Animals; Brain; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2016 |
Significant treatment effect of add-on ketamine anesthesia in electroconvulsive therapy in depressive patients: A meta-analysis.
Topics: Databases, Bibliographic; Depression; Electroconvulsive Therapy; Excitatory Amino Acid Antagonists; | 2017 |
What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Electroconvulsive The | 2017 |
What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Electroconvulsive The | 2017 |
What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Electroconvulsive The | 2017 |
What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Electroconvulsive The | 2017 |
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.
Topics: Depression; Excitatory Amino Acid Agents; Humans; Ketamine | 2017 |
Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine; Models, Neurological; Receptors, AMPA; | 2017 |
Signaling pathways underlying the rapid antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Depression; Gene Expression Regulation; Humans; Ketamine; Models, Bi | 2012 |
Investigational NMDA receptor modulators for depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Design; Drugs, Investigatio | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
Ketamine for depression: where do we go from here?
Topics: Animals; Antidepressive Agents; Databases, Factual; Depression; Humans; Ketamine | 2012 |
A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Dendrites; Depression; Gene-Envir | 2012 |
[The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
Topics: Animals; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine; Rec | 2012 |
The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.
Topics: Animals; Antidepressive Agents; Depression; Elongation Factor 2 Kinase; Gene Expression Regulation, | 2013 |
92 trials available for ketamine and Depression
| Article | Year |
|---|---|
Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine.
Topics: Case-Control Studies; Cytokines; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketam | 2021 |
Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Memory, Short-Term; Treatmen | 2022 |
Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2021 |
Ketamine Alleviates Depressive Symptoms in Patients Undergoing Intracranial Tumor Resection: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Anesthetics, Dissociative; Antidepressive Agents; Brain Neoplasms; Depression; Do | 2021 |
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2021 |
Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation.
Topics: Adult; Anesthetics, Intravenous; Cognition; Depression; Female; Humans; Ketamine; Male; Midazolam; N | 2021 |
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depression; Double-Blind Metho | 2022 |
Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intr | 2021 |
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial.
Topics: Bayes Theorem; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Hu | 2022 |
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
Topics: Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ket | 2023 |
Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Suicidal Ideation | 2022 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Comb | 2022 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Comb | 2022 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Comb | 2022 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Comb | 2022 |
mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Mechanistic Target | 2022 |
Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.
Topics: Adolescent; Adult; Aged; Analgesics; Depression; Double-Blind Method; Female; Humans; Ketamine; Male | 2022 |
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Topics: Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blin | 2022 |
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
Topics: Adult; Antidepressive Agents; Depression; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Patie | 2022 |
Effect of esketamine on perioperative depressive symptoms in major surgery patients (PASSION II): study protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; China; Depression; Humans; Ketamine; Middle Aged; Ra | 2022 |
Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine; Magneto | 2022 |
Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; | 2022 |
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.
Topics: Anxiety; COVID-19; Depression; Humans; Ketamine; Pandemics; Prospective Studies; Telemedicine | 2022 |
Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; H | 2023 |
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; H | 2023 |
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; H | 2023 |
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; H | 2023 |
Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition.
Topics: Aged; Cognition; Depression; Humans; Infusions, Intravenous; Ketamine; Pilot Projects | 2023 |
Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Hu | 2023 |
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Depressive | 2023 |
Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Topics: Borderline Personality Disorder; Canada; Depression; Depressive Disorder, Treatment-Resistant; Human | 2023 |
Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression and strong suicidal ideation.
Topics: Antidepressive Agents; Depression; Evoked Potentials, Motor; Humans; Ketamine; Neural Inhibition; Su | 2023 |
A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2023 |
Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusion | 2023 |
Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamine; Retr | 2023 |
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Treatment-Resistant; Electroence | 2023 |
One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Administration, Intravenous; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2023 |
Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression.
Topics: Adult; Animals; Cerebral Cortex; Depression; Diffusion Tensor Imaging; Humans; Ketamine; Neuronal Pl | 2023 |
Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Major; Depressive Disorder, Treat | 2023 |
Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method | 2023 |
Change in patient-centered outcomes of psychological well-being, sleep, and suicidality following treatment with intravenous ketamine for late-life treatment-resistant depression.
Topics: Depression; Humans; Ketamine; Patient-Centered Care; Psychological Well-Being; Sleep; Suicidal Ideat | 2023 |
Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: A randomized, double-blind, controlled clinical study.
Topics: Cesarean Section; Depression; Double-Blind Method; Female; Humans; Ketamine; Postpartum Period; Preg | 2023 |
Protocol for the Ketamine for Postoperative Avoidance of Depressive Symptoms (K-PASS) feasibility study: A randomized clinical trial.
Topics: Antidepressive Agents; Depression; Feasibility Studies; Humans; Ketamine; Pilot Projects; Randomized | 2022 |
Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Matri | 2023 |
Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression.
Topics: Adult; Antidepressive Agents; Brain; Depression; Female; Humans; Ketamine; Magnetic Resonance Imagin | 2023 |
Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2023 |
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Topics: Antidepressive Agents; Delayed-Action Preparations; Depression; Depressive Disorder, Treatment-Resis | 2023 |
The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder.
Topics: Adolescent; Australia; Depression; Depressive Disorder, Major; Humans; Infant; Ketamine; Randomized | 2023 |
Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]).
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Q | 2023 |
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Met | 2020 |
Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2020 |
Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2020 |
Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2020 |
Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2020 |
Effect of Pretreatment of S-Ketamine On Postoperative Depression for Breast Cancer Patients.
Topics: Breast Neoplasms; Depression; Double-Blind Method; Female; Humans; Ketamine; Pain, Postoperative | 2021 |
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.
Topics: Antidepressive Agents; Cross-Over Studies; Depression; Depressive Disorder, Major; Humans; Ketamine | 2020 |
Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Adult; Depression; Humans; Ketamine; Nasal Sprays; Treatment Outcome | 2020 |
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.
Topics: Biomarkers; Canada; Cross-Over Studies; Depression; Depressive Disorder, Major; Electroconvulsive Th | 2020 |
Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression After Laparoscopic Total Hysterectomy.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Carcinoma; Depression; Depressive D | 2020 |
A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Hu | 2020 |
Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketam | 2020 |
The effects of ketamine on typical and atypical depressive symptoms.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Metho | 2020 |
Intraoperative ketamine for reduction in postpartum depressive symptoms after cesarean delivery: A double-blind, randomized clinical trial.
Topics: Cesarean Section; Depression; Double-Blind Method; Female; Humans; Infant, Newborn; Ketamine; Postpa | 2020 |
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Fe | 2021 |
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Fe | 2021 |
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Fe | 2021 |
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Fe | 2021 |
Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depression; Double-Blind Method; Excitatory Amino Acid Antagonists; Fe | 2021 |
Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers.
Topics: Depression; Electroconvulsive Therapy; Female; Humans; Interleukin-8; Ketamine; Male; Psychiatric St | 2021 |
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine | 2021 |
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Topics: Adult; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Ther | 2021 |
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Depression; Depressiv | 2017 |
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.
Topics: Adult; Anesthetics, Dissociative; Anhedonia; Bipolar Disorder; Depression; Depressive Disorder, Majo | 2017 |
Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain: A Randomized Clinical Trial.
Topics: Aged; Analgesics; Antineoplastic Agents; Anxiety; Cancer Pain; Cognition Disorders; Depression; Doub | 2018 |
Effect of low-dose ketamine on PerioperAtive depreSsive Symptoms in patients undergoing Intracranial tumOr resectioN (PASSION): study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; China; Craniotomy; Depression; Double-Blind Method; | 2018 |
Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.
Topics: Anesthetics, Dissociative; Brazil; Depression; Depressive Disorder, Treatment-Resistant; Female; Hum | 2018 |
Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.
Topics: Age Factors; Aged; Anesthetics, Dissociative; Depression; Double-Blind Method; Female; Health Status | 2018 |
Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG.
Topics: Adult; Antidepressive Agents; Depression; Diagnosis, Computer-Assisted; Electroencephalography; Fema | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depression; Female; Functional Neuroimaging; Gyrus Cinguli | 2019 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients.
Topics: Depression; Dextromethorphan; Dose-Response Relationship, Drug; Humans; Ketamine; Memantine; Neuralg | 2014 |
Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.
Topics: Adolescent; Adult; Aged; Analgesics; Depression; Female; Humans; Infusions, Subcutaneous; Ketamine; | 2014 |
Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.
Topics: Adolescent; Adult; Aged; Analgesics; Depression; Female; Humans; Infusions, Subcutaneous; Ketamine; | 2014 |
Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.
Topics: Adolescent; Adult; Aged; Analgesics; Depression; Female; Humans; Infusions, Subcutaneous; Ketamine; | 2014 |
Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.
Topics: Adolescent; Adult; Aged; Analgesics; Depression; Female; Humans; Infusions, Subcutaneous; Ketamine; | 2014 |
Single ketamine infusion and neurocognitive performance in bipolar depression.
Topics: Adult; Aged; Bipolar Disorder; Depression; Female; Humans; Infusions, Intravenous; Ketamine; Male; M | 2015 |
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Topics: Adult; Affect; Anxiety; Anxiety Disorders; Bipolar Disorder; Cross-Over Studies; Depression; Double- | 2015 |
Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Depressive Disorder, Major; Double-Blind Me | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial.
Topics: Administration, Oral; Adult; Antidepressive Agents; Chronic Pain; Depression; Diclofenac; Double-Bli | 2016 |
A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Depression; Dissociative Disorders; Doubl | 2016 |
Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.
Topics: Adult; Antidepressive Agents; Depression; Female; Humans; Ketamine; Male; Midazolam; Middle Aged; Ne | 2017 |
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
Topics: Adult; Aged; Depression; Drug Interactions; Drug Resistance; Excitatory Amino Acid Antagonists; Fema | 2010 |
Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery.
Topics: Aged; Anesthesia, General; Anesthetics, Dissociative; Anti-Inflammatory Agents, Non-Steroidal; C-Rea | 2009 |
Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery.
Topics: Aged; Anesthesia, General; Anesthetics, Dissociative; Anti-Inflammatory Agents, Non-Steroidal; C-Rea | 2009 |
Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery.
Topics: Aged; Anesthesia, General; Anesthetics, Dissociative; Anti-Inflammatory Agents, Non-Steroidal; C-Rea | 2009 |
Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery.
Topics: Aged; Anesthesia, General; Anesthetics, Dissociative; Anti-Inflammatory Agents, Non-Steroidal; C-Rea | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Topics: Cohort Studies; Depression; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infu | 2009 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.
Topics: Anesthetics; Antidepressive Agents; Depression; Electroconvulsive Therapy; Female; Headache; Humans; | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Depression; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; | 2012 |
Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.
Topics: Adolescent; Adult; Aged; Anesthesia; Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disor | 2012 |
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.
Topics: Adolescent; Adult; Anesthetics, Dissociative; Anxiety; Attitude; Depression; Double-Blind Method; Fe | 2002 |
A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double blind randomised controlled trial.
Topics: Aged; Analgesics; Analgesics, Opioid; Anxiety; Depression; Double-Blind Method; Extremities; Female; | 2002 |
525 other studies available for ketamine and Depression
| Article | Year |
|---|---|
miR-98-5p plays a critical role in depression and antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Depression; Hippocampus; Ketamine; Mice; MicroRNAs; Prefrontal Corte | 2021 |
Low Doses of Ketamine and Melatonin in Combination Produce Additive Antidepressant-like Effects in Mice.
Topics: Animals; Antidepressive Agents; Depression; Drug Combinations; Drug Synergism; Ketamine; Male; Melat | 2021 |
Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence.
Topics: Adult; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hum | 2021 |
Ketamine and depression: An old drug in search of a clinical indication.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pharm | 2021 |
Ketamine ameliorates depressive-like behaviors in mice through increasing glucose uptake regulated by the ERK/GLUT3 signaling pathway.
Topics: Animals; Behavior, Animal; Cell Line; Depression; Glucose; Glucose Transporter Type 3; Ketamine; Lac | 2021 |
Biomarkers of response to rapid-acting antidepressants.
Topics: Antidepressive Agents; Biomarkers; Depression; Ketamine | 2021 |
Ketamine's modulation of cerebro-cerebellar circuitry during response inhibition in major depression.
Topics: Cerebellum; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Magnetic Resonance Ima | 2021 |
Gender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users.
Topics: Depression; Depressive Disorder; Humans; Ketamine; Quality of Life; Sex Factors | 2021 |
Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intr | 2022 |
U.S. Food and Drug Administration's Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant
Topics: Antidepressive Agents; Depression; Double-Blind Method; Drug Development; Humans; Ketamine; Nasal Sp | 2022 |
The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blotting, Western; Depression; Ketamine; Male; Mic | 2022 |
Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: Towards registry-based surveillance systems.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Regis | 2022 |
Ketamine for depression - evidence and proposals for practice.
Topics: Depression; Humans; Ketamine; Norway | 2021 |
Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine.
Topics: Adult; Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Elect | 2021 |
A Breakthrough in Understanding the Rapid Antidepressant Effect of Ketamine Based on Structural Analysis.
Topics: Antidepressive Agents; Depression; Ketamine | 2022 |
Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Depressive Disorder, Major; Disease Models, A | 2022 |
Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Extracellular Signal- | 2022 |
Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depres | 2021 |
Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression.
Topics: Adult; Cost-Benefit Analysis; Depression; Electroconvulsive Therapy; Humans; Ketamine; Quality-Adjus | 2021 |
Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disks Large Homolog 4 Protein; Escital | 2022 |
Efficacy and safety of repeated esketamine intravenous infusion in the treatment of treatment-resistant depression: A case series.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamine | 2022 |
Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: A pilot study.
Topics: Depression; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Ketamine; Pilot Projects | 2022 |
[Ketamine self-medication in a patient with autism spectrum disorder and comorbid treatment-resistant depression].
Topics: Autism Spectrum Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Res | 2021 |
Ketamine and Cognitive Function in Depression: Detrimental, Neutral, or Advantageous?
Topics: Cognition; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
[Ketamine infusion therapy in treatment-resistant depression].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intr | 2021 |
Guanosine boosts the fast, but not sustained, antidepressant-like and pro-synaptogenic effects of ketamine by stimulating mTORC1-driven signaling pathway.
Topics: Animals; Antidepressive Agents; Depression; Glycogen Synthase Kinase 3 beta; Guanosine; Hippocampus; | 2022 |
How to deprescribe esketamine in resistant depression? A point of view after first clinical uses.
Topics: Deprescriptions; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.
Topics: Depression; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine; Retrospective Stud | 2022 |
Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment.
Topics: Adaptor Proteins, Signal Transducing; Analgesics; Animals; Antidepressive Agents; Anxiety; Behavior, | 2022 |
Esketamine: uncertain safety and efficacy data in depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder.
Topics: Antidepressive Agents; Borderline Personality Disorder; Depression; Depressive Disorder, Major; Depr | 2022 |
Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine.
Topics: Animals; Antidepressive Agents; Depression; Ketamine; Lipopolysaccharides; Mice; Prefrontal Cortex; | 2022 |
Ketamine use in relation to depressive symptoms among high school seniors.
Topics: Adolescent; Depression; Humans; Ketamine; Prevalence; Schools; Substance-Related Disorders; United S | 2022 |
S-Ketamine Exerts Antidepressant Effects by Regulating Rac1 GTPase Mediated Synaptic Plasticity in the Hippocampus of Stressed Rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; GTP | 2023 |
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.
Topics: Antidepressive Agents; Chronic Pain; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate | 2022 |
Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Female; Ketamine; Male; Mice | 2022 |
Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series.
Topics: Depression; Humans; Ketamine; Retrospective Studies; Stress Disorders, Post-Traumatic; Veterans | 2022 |
Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees.
Topics: Adolescent; Adult; Antidepressive Agents; Cross-Sectional Studies; Depression; Depressive Disorder, | 2022 |
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood | 2022 |
Antidepressant effect of prolonged twice-weekly intranasal esketamine treatments after nonresponse to electroconvulsive therapy in a patient with treatment-resistant depression.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resist | 2022 |
The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamin | 2022 |
Can ketamine be a safe option for treatment-resistant bipolar depression?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Human | 2022 |
Ketamine as a Potential Transdiagnostic Treatment for Anhedonia?
Topics: Anhedonia; Depression; Depressive Disorder, Major; Humans; Ketamine; Reward | 2022 |
BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Depression; D | 2022 |
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
Topics: Antidepressive Agents; Depression; Hallucinogens; Ketamine; Receptors, N-Methyl-D-Aspartate | 2022 |
Insights for the Use of Ketamine From Randomized Controlled Trials That Compared Ketamine With Electroconvulsive Therapy in Severe Depression.
Topics: Aged; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Ketamine; Randomize | 2022 |
Esketamine alleviates postoperative depression-like behavior through anti-inflammatory actions in mouse prefrontal cortex.
Topics: Animals; Anti-Inflammatory Agents; Depression; Humans; Ketamine; Mice; NF-kappa B; Prefrontal Cortex | 2022 |
A single dose of ketamine cannot prevent protracted stress-induced anhedonia and neuroinflammation in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Carrier Proteins; Corticosterone; Depression; Disease Mod | 2022 |
A letter to the editor, associated with the article entitled "Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium" by Vázquez et al. (
Topics: Antidepressive Agents; Antipsychotic Agents; Depression; Depressive Disorder, Major; Drug Therapy, C | 2022 |
Intranasal esketamine for depression: Not so special K.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice.
Topics: Animals; Antidepressive Agents; Depression; Hippocampus; Ketamine; Mice; Neurons | 2022 |
IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Female; Insulin-Like | 2022 |
Anterior default mode network and posterior insular connectivity is predictive of depressive symptom reduction following serial ketamine infusion.
Topics: Antidepressive Agents; Default Mode Network; Depression; Depressive Disorder, Major; Humans; Ketamin | 2022 |
Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic.
Topics: Animals; Antidepressive Agents; Autophagy; Brain-Derived Neurotrophic Factor; Cytokines; Depression; | 2022 |
Exploring pharmacological options for adolescent depression: a preclinical evaluation with a sex perspective.
Topics: Animals; Antidepressive Agents; Cannabidiol; Depression; Female; Ketamine; Male; Rats; Rats, Sprague | 2022 |
Rapid and sustained restoration of astrocytic functions by ketamine in depression model mice.
Topics: Animals; Antidepressive Agents; Astrocytes; Brain-Derived Neurotrophic Factor; Depression; Depressiv | 2022 |
How K helps quickly.
Topics: Animals; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Ketamine; Mice | 2022 |
Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2022 |
Anterior Default Mode Network and Posterior Insular Connectivity is Predictive of Depressive Symptom Reduction Following Serial Ketamine Infusion - CORRIGENDUM.
Topics: Brain; Brain Mapping; Default Mode Network; Depression; Humans; Ketamine; Magnetic Resonance Imaging | 2022 |
Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pilot | 2022 |
Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression.
Topics: Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Major; Depressive Disorder, Treatme | 2022 |
S-ketamine administration in pregnant mice induces ADHD- and depression-like behaviors in offspring mice.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Depression; Female; Humans | 2022 |
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
Topics: Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Dopamine; Humans; Ketamine; N-Methy | 2022 |
Involvement of kynurenine pathway and N-methyl-d-aspartate receptors in the antidepressant-like effect of vilazodone in the tail suspension test in mice.
Topics: Animals; Antidepressive Agents; Depression; Hindlimb Suspension; Ketamine; Kynurenine; Mice; Quinoli | 2022 |
Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis.
Topics: Depression; Ethical Analysis; Female; Humans; Ketamine; Physicians; Psilocybin; Suicide, Assisted | 2022 |
Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
Topics: Cognition; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2022 |
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, AMPA; Re | 2022 |
A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine.
Topics: Anhedonia; Data Analysis; Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Place | 2022 |
[Neural circuit mechanisms of rapid antidepressant actions of ketamine].
Topics: Antidepressive Agents; Depression; Ketamine; Receptors, N-Methyl-D-Aspartate | 2022 |
Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
Topics: Adult; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Depression; Depressive | 2022 |
Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients With Treatment-Resistant Depression, Suicidal Ideation, and Generalized Anxiety Symptoms: A Retrospective Chart Review.
Topics: Anxiety; Depression; Depressive Disorder, Major; Humans; Ketamine; Retrospective Studies; Suicidal I | 2022 |
Dietary Patterns of Treatment-Resistant Depression Patients.
Topics: Depression; Dietary Fats; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Humans; Ketamine; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates.
Topics: Cost-Benefit Analysis; Depression; Humans; Ketamine; Nasal Sprays; Quality-Adjusted Life Years | 2022 |
Stress with ketamine tackles depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hormones; Ketamine; Stress, Psyc | 2022 |
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Bias; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2022 |
A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice.
Topics: Animals; Antagomirs; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Ketamine; | 2022 |
Functional connectivity differences in the amygdala are related to the antidepressant efficacy of ketamine in patients with anxious depression.
Topics: Amygdala; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infus | 2023 |
Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study.
Topics: Adult; Anxiety; Anxiety Disorders; Cohort Studies; Depression; Depressive Disorder, Major; Humans; K | 2022 |
Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Mo | 2023 |
Intranasal (2R, 6R)-hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice.
Topics: Acute Pain; Analgesics; Animals; Antidepressive Agents; Depression; Ketamine; Mice | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Inflammasomes; Inte | 2023 |
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; | 2022 |
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; | 2022 |
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; | 2022 |
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; | 2022 |
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Topics: Administration, Intranasal; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Majo | 2023 |
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Topics: Administration, Intranasal; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Majo | 2023 |
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Topics: Administration, Intranasal; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Majo | 2023 |
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Topics: Administration, Intranasal; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Majo | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Mice; Neuronal Plasticity; T-Lym | 2022 |
TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Mice; Neuronal Plasticity; T-Lym | 2022 |
TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Mice; Neuronal Plasticity; T-Lym | 2022 |
TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Mice; Neuronal Plasticity; T-Lym | 2022 |
A role of GABA
Topics: Animals; Antidepressive Agents; Depression; GABA Antagonists; GABAergic Neurons; gamma-Aminobutyric | 2023 |
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine.
Topics: Animals; Antidepressive Agents; Depression; Ketamine; Male; Mice; N-Methylaspartate; Receptors, N-Me | 2023 |
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Human | 2023 |
Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hippocampus; Humans; Ketamine; Magnet | 2023 |
Ketamine-Associated Change in Anhedonia and mTOR Expression in Treatment-Resistant Depression.
Topics: Anhedonia; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2023 |
Ketamine and its metabolite 2R,6R-hydroxynorketamine promote ocular dominance plasticity and release tropomyosin-related kinase B from inhibitory control without reducing perineuronal nets enwrapping parvalbumin interneurons.
Topics: Animals; Antidepressive Agents; Depression; Dominance, Ocular; Interneurons; Ketamine; Mice; Parvalb | 2023 |
Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression.
Topics: Adiponectin; Antidepressive Agents; Cytokines; Depression; Depressive Disorder, Treatment-Resistant; | 2023 |
Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress.
Topics: Anhedonia; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Habenula; Ketamine; M | 2023 |
NMDA receptor-mediated modulation on glutamine synthetase and glial glutamate transporter GLT-1 is involved in the antidepressant-like and neuroprotective effects of guanosine.
Topics: Amino Acid Transport System X-AG; Animals; Antidepressive Agents; Depression; Excitatory Amino Acid | 2023 |
Ketamine and its metabolites: Potential as novel treatments for depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine | 2023 |
Models of Affective Illness: Chronic Mild Stress in the Rat.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketami | 2023 |
[Ketamine and lorazepam combination as an alternative to electroconvulsive therapy for catatonia in late-life depression: A case report].
Topics: Catatonia; Depression; Electroconvulsive Therapy; Humans; Ketamine; Lorazepam | 2023 |
The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Inflammation; Ketamine | 2023 |
Clinical pharmacological innovation in the treatment of depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Ketamine | 2023 |
Pharmacotherapy and Ketamine Assisted Psychotherapy for Treatment-Resistant Depression: A Patient With Lifelong Self-Doubt and Self-Criticism.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Male; | 2023 |
A Multifunctional Nanocarrier System for Highly Efficient and Targeted Delivery of Ketamine to NMDAR Sites for Improved Treatment of Depression.
Topics: Animals; Depression; Drug Delivery Systems; Hyaluronic Acid; Ketamine; Mice; Nanoparticles; Peptides | 2023 |
Impact of ketamine administration on chronic unpredictable stress-induced rat model of depression during extremely low-frequency electromagnetic field exposure: Behavioral, histological and molecular study.
Topics: Animals; Brain-Derived Neurotrophic Factor; Caspase 3; Depression; Electromagnetic Fields; Ketamine; | 2023 |
Sex and Estrous Cycle Are Not Mediators of S-Ketamine's Rapid-Antidepressant Behavioral Effects in a Genetic Rat Model of Depression.
Topics: Animals; Antidepressive Agents; Depression; Estrous Cycle; Female; Ketamine; Male; Rats | 2023 |
Ketamine supresses REM sleep and markedly increases EEG gamma oscillations in the Wistar Kyoto rat model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Depression; Electroencephalography; Ketamine; Male; Rats; Rats, Inbr | 2023 |
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Comorbidity; Depression; Depressive Disord | 2023 |
Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression.
Topics: Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; | 2023 |
Ketamine for depression: a potential role in requests for Medical Aid in Dying?
Topics: Canada; Depression; Female; Humans; Ketamine; Mood Disorders; Suicide, Assisted | 2023 |
A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2023 |
Pharmacological evidence for glutamatergic pathway involvement in the antidepressant-like effects of 2-phenyl-3-(phenylselanyl)benzofuran in male Swiss mice.
Topics: Animals; Antidepressive Agents; Benzofurans; Depression; Hindlimb Suspension; Ketamine; Male; Mice; | 2023 |
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
Topics: Adolescent; Adult; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intraven | 2023 |
The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis.
Topics: Anxiety; Anxiety Disorders; Depression; Humans; Ketamine; Retrospective Studies | 2023 |
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Patie | 2023 |
Ketamine and ECT in Depression - Risks and Rewards.
Topics: Antidepressive Agents; Depression; Electroconvulsive Therapy; Humans; Ketamine; Reward; Treatment Ou | 2023 |
Ketamine Noninferior to Electroconvulsive Therapy for Depression.
Topics: Anesthetics, Dissociative; Anesthetics, Intravenous; Antidepressive Agents; Depression; Depressive D | 2023 |
Progress in treatment-resistant bipolar depression using repeated ketamine infusions.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
A single dose of ketamine enhances early life stress-induced aggression with no effect on fear memory, anxiety-like behavior, or depression-like behavior in mice.
Topics: Adverse Childhood Experiences; Aggression; Animals; Anxiety; Depression; Fear; Humans; Ketamine; Mic | 2023 |
Retigabine promotes ketamine's antidepressant effect in the forced swim test in male and female C57BL/6J mice.
Topics: Animals; Antidepressive Agents; Depression; Female; Ketamine; Male; Mice; Mice, Inbred C57BL | 2023 |
Anxiolytic-like effects of an mGluR 5 antagonist and a mGluR 2/3 agonist, and antidepressant-like effects of an mGluR 7 agonist in the chick social separation stress test, a dual-drug screening model of treatment-resistant depression.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Clonidine; Depression; Drug Evaluation, Preclinical; Exe | 2023 |
Functional and Molecular Changes in the Prefrontal Cortex of the Chronic Mild Stress Rat Model of Depression and Modulation by Acute Ketamine.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Ketamine; Male; Prefrontal C | 2023 |
The synergistic mechanism of action of Dajianzhong decoction in conjunction with ketamine in the treatment of depression.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Ketamine; Mice; NF-kappa B; Receptors, N-Meth | 2023 |
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
Topics: Aged; Antidepressive Agents; Depression; Double-Blind Method; Humans; Ketamine; Retrospective Studie | 2023 |
A shea butter-based ketamine ointment: The antidepressant effects of transdermal ketamine in rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Ketamine; Male; Ointments; Rats; | 2023 |
Association of Neurofilament Light Chain With the Antidepressant Effects of Low-Dose Ketamine Infusion Among Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intr | 2023 |
[Consider (es)ketamine for treatment-resistant depression].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Psychotherapy | 2023 |
Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report.
Topics: Benzodiazepines; Cohort Studies; Deprescriptions; Depression; Depressive Disorder, Treatment-Resista | 2023 |
Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
Reelin Rescues Behavioral, Electrophysiological, and Molecular Metrics of a Chronic Stress Phenotype in a Similar Manner to Ketamine.
Topics: Animals; Antidepressive Agents; Benchmarking; Corticosterone; Depression; Hippocampus; Ketamine; Mal | 2023 |
Ketamine Metabolites-waiting in the Wings as Therapeutic Candidate for Depression?
Topics: Depression; Ketamine | 2024 |
[IV esketamine for patients with a treatment-resistant depression].
Topics: Antidepressive Agents; Depression; Electroconvulsive Therapy; Humans; Ketamine | 2023 |
Ketamine versus electroconvulsive therapy for treatment-resistant depression: An updated meta-analysis of randomized clinical trials.
Topics: Anesthetics, Dissociative; Depression; Depressive Disorder, Treatment-Resistant; Electroconvulsive T | 2023 |
(S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Ketamine; Rats; Sleep | 2023 |
Nitrous Oxide Reduced Suicidal Ideation in Treatment-Resistant Major Depression in Exploratory Analysis.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Nitrous Oxide; Suicidal Ideation | 2023 |
Esketamine for resistant depression in older people with cognitive impairment: A case report.
Topics: Aged; Antidepressive Agents; Cognitive Dysfunction; Depression; Depressive Disorder, Treatment-Resis | 2023 |
In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Prolonged ketamine therapy differentially rescues psychobehavioural deficits via modulation of nitro-oxidative stress and oxytocin receptors in the gut-brain-axis of chronically-stressed mice.
Topics: Animals; Brain-Gut Axis; Depression; Disease Models, Animal; Female; Hippocampus; Ketamine; Mice; Ox | 2023 |
Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression.
Topics: Bridge Therapy; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
The not so little matter of how to dose ketamine in patients with depression.
Topics: Depression; Humans; Ketamine | 2023 |
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression.
Topics: Adolescent; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Transcranial Mag | 2023 |
Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response.
Topics: Animals; Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Glycogen Synthase Kin | 2024 |
Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Queti | 2023 |
Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb.
Topics: Animals; Antidepressive Agents; Depression; Habenula; Half-Life; Ketamine; Mice; Neurons; Protein Bi | 2023 |
Temporal dynamics of BDNF signaling recruitment in the rat prefrontal cortex and hippocampus following a single infusion of a translational dose of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Hippocampus; Humans; | 2024 |
Aromatase inhibition and ketamine in rats: sex-differences in antidepressant-like efficacy.
Topics: Animals; Antidepressive Agents; Aromatase; Depression; Estrogens; Female; Ketamine; Letrozole; Male; | 2023 |
Ketamine for Depression-Knowns, Unknowns, Possibilities, Barriers, and Opportunities.
Topics: Depression; Humans; Ketamine | 2023 |
Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine?
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Electroconvulsive | 2023 |
Habenular functional connections are associated with depression state and modulated by ketamine.
Topics: Antidepressive Agents; Connectome; Depression; Habenula; Humans; Ketamine; Magnetic Resonance Imagin | 2024 |
Comment on 'A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression'.
Topics: Adult; Aged; Antidepressive Agents; Depression; Humans; Ketamine; Suicidal Ideation | 2024 |
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Infusions, | 2024 |
Nebulized and intraperitoneal ketamine have equivalent antidepressant-like effect in the forced swim and tail suspension tests in mice.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Dexamethasone; Disease Model | 2023 |
Editor's Roundup for Issue #4 of 2023: What Patients and Their Families Are Reading About Electroconvulsive Therapy (ECT) on the Internet; Enhancing Self-efficacy Regarding Managing Cognitive Side Effects of ECT; Rank Order of Change in Depressive Symptom
Topics: Cognition; Depression; Electroconvulsive Therapy; Humans; Internet; Ketamine; Reading; Self Efficacy | 2023 |
Transcriptional signatures of early-life stress and antidepressant treatment efficacy.
Topics: Adverse Childhood Experiences; Animals; Antidepressive Agents; Depression; Escitalopram; Female; Hum | 2023 |
NMDA receptors and L-arginine/nitric oxide/cyclic guanosine monophosphate pathway contribute to the antidepressant-like effect of Yueju pill in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Arginine; Cyclic GMP; Depression; Drugs, Chinese Herbal; Hi | 2019 |
Recovery of cognitive functioning following abstinence from ketamine.
Topics: Adult; Anxiety; Cognition; Cognitive Dysfunction; Depression; Excitatory Amino Acid Antagonists; Fem | 2019 |
The immunomodulatory effect of ketamine in depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2019 |
Suicidality in treatment resistant depression: perspective for ketamine use.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2019 |
Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system.
Topics: Central Nervous System; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2019 |
Magnesium and ketamine in the treatment of depression.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; Humans; K | 2019 |
[Off-label ketamine treatment for treatment-resistant depression: win-win?]
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Off-L | 2019 |
In treatment-resistant depression, adding esketamine nasal spray to an oral antidepressant improved symptoms at 28 days.
Topics: Antidepressive Agents; Depression; Double-Blind Method; Ketamine; Nasal Sprays | 2019 |
Esketamine for treatment resistant depression.
Topics: Administration, Intranasal; Administration, Oral; Antidepressive Agents; Depression; Drug Approval; | 2019 |
Prophylactic (R,S)-ketamine selectively protects against inflammatory stressors.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Conditioning, Classical; Depression; Fear; Inflamm | 2020 |
Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential.
Topics: Depression; Double-Blind Method; Humans; Ketamine; Registries; Suicide | 2019 |
A single coadministration of subeffective doses of ascorbic acid and ketamine reverses the depressive-like behavior induced by chronic unpredictable stress in mice.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Behavior, Animal; Depression; Depressive Disorder, Ma | 2019 |
Association of Craving and Depressive Symptoms in Ketamine-Dependent Patients Undergoing Withdrawal Treatment.
Topics: Adolescent; Adult; Anxiety; Behavior, Addictive; Craving; Depression; Female; Humans; Ketamine; Male | 2020 |
Ketamine reverses the impaired fear memory extinction and accompanied depressive-like behaviors in adolescent mice.
Topics: Age Factors; Animals; Antidepressive Agents; Behavior, Animal; Conditioning, Classical; Depression; | 2020 |
Ketamine rapidly reverses stress-induced impairments in GABAergic transmission in the prefrontal cortex in male rodents.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Inhibit | 2020 |
The Efficacy and Safety of Esketamine for the Treatment-Resistant Depression in Older Adults: Comments on TRANSFORM-3 Trial Results.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2020 |
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2020 |
Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24 h post-treatment) via inducing different brain-derived neurotrophic factor (BDNF) expression level in the hippocampus.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neurot | 2020 |
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Drug Approval; E | 2019 |
Ketamine normalizes subgenual cingulate cortex hyper-activity in depression.
Topics: Depression; Depressive Disorder, Major; Gyrus Cinguli; Humans; Ketamine; Magnetic Resonance Imaging | 2020 |
The Role of Ketamine in Depression #384.
Topics: Antidepressive Agents; Depression; Humans; Infusions, Intravenous; Ketamine | 2020 |
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Ketamine; Male; Narcotic | 2020 |
Overinhibition mediated by parvalbumin interneurons might contribute to depression-like behavior and working memory impairment induced by lipopolysaccharide challenge.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Fl | 2020 |
Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment.
Topics: Antidepressive Agents; Brain; Brain Mapping; Depression; Depressive Disorder, Major; Humans; Ketamin | 2020 |
Low-Dose Ketamine Improves LPS-Induced Depression-like Behavior in Rats by Activating Cholinergic Anti-inflammatory Pathways.
Topics: Animals; Depression; Depressive Disorder, Major; Ketamine; Lipopolysaccharides; Neuroimmunomodulatio | 2020 |
Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Dose-Response | 2020 |
Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis.
Topics: Antidepressive Agents; Depression; Humans; Ketamine; ROC Curve; Suicidal Ideation | 2020 |
Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dizocilpine Maleate; Female; Ket | 2020 |
Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Ketamine; Mice; Mice, Inbred C57 | 2020 |
Approval of esketamine for treatment-resistant depression.
Topics: beta-Cyclodextrins; Depression; Depressive Disorder, Treatment-Resistant; Drug Combinations; Humans; | 2020 |
Approval of esketamine for treatment-resistant depression - Authors' reply.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Approval of esketamine for treatment-resistant depression - Author's reply.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Pregnancy; Suicide, | 2020 |
(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Mod | 2020 |
Ketamine induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Male; MAP Kinase Signaling Syste | 2020 |
Ketamine relieves depression-like behaviors induced by chronic postsurgical pain in rats through anti-inflammatory, anti-oxidant effects and regulating BDNF expression.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Antioxidants; Brain-Derived Neurotrophic F | 2020 |
Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
Topics: Animals; Antidepressive Agents; Depression; Hallucinogens; Ketamine; Rats; Rodentia | 2020 |
Adjunct ketamine treatment of depression in treatment-resistant schizophrenia patients is unsatisfactory in pilot and secondary follow-up studies.
Topics: Depression; Follow-Up Studies; Humans; Ketamine; Pilot Projects; Schizophrenia | 2020 |
Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: A case report.
Topics: Abdominal Neoplasms; Aged; Antidepressive Agents; Depression; Humans; Ketamine; Male; Pain; Terminal | 2020 |
Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.
Topics: Aggression; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Female; K | 2020 |
Are NMDA and opioid receptors involved in the antidepressant actions of ketamine?
Topics: Animals; Antidepressive Agents; Depression; Ketamine; N-Methylaspartate; Receptors, Opioid; Rodentia | 2020 |
Not So Fast: Recent Successes and Failures in Treating Depression.
Topics: beta-Cyclodextrins; Depression; Drug Combinations; Excitatory Amino Acid Antagonists; GABA Modulator | 2020 |
Rapastinel, an NMDAR positive modulator, produces distinct behavioral, sleep, and EEG profiles compared with ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Electroencephalography; Excitatory Ami | 2020 |
Guanosine potentiates the antidepressant-like effect of subthreshold doses of ketamine: Possible role of pro-synaptogenic signaling pathway.
Topics: Animals; Antidepressive Agents; Corticosterone; Depression; Guanosine; Humans; Ketamine; Mice; Prefr | 2020 |
Extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model.
Topics: Animals; Antidepressive Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Depression; Dise | 2020 |
Subanesthetic ketamine exerts antidepressant-like effects in adult rats exposed to juvenile stress.
Topics: Animals; Antidepressive Agents; Cerebral Cortex; Depression; Ketamine; Male; Pyramidal Cells; Rats; | 2020 |
Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression.
Topics: Animals; Depression; Disease Models, Animal; Hippocampus; Immobilization; Ketamine; Long-Term Potent | 2020 |
mGluR5 mediates ketamine antidepressant response in susceptible rats exposed to prenatal stress.
Topics: Animals; Antidepressive Agents; Depression; Fluoxetine; Imipramine; Ketamine; Rats | 2020 |
Molecular mechanisms for the antidepressant-like effects of a low-dose ketamine treatment in a DFP-based rat model for Gulf War Illness.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Calcium | 2020 |
Long-term treatment of depression with intranasal esketamine: Is it justified?
Topics: Administration, Intranasal; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Ketamine contributes to the alteration of Ca
Topics: Analgesics; Animals; Antidepressive Agents; Calcium Signaling; Corticosterone; Depression; Female; K | 2020 |
Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.
Topics: Cost-Benefit Analysis; Depression; Humans; Ketamine; Nasal Sprays; United States | 2020 |
Recent advances in the antidepressant actions of ketamine and agents having ketamine-like antidepressant profiles.
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine | 2020 |
Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-κB/IDO-1 signaling.
Topics: Animals; Antidepressive Agents; Corticosterone; Depression; Disease Models, Animal; Drug Therapy, Co | 2020 |
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Bipolar Disorder; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatm | 2020 |
Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.
Topics: Anesthetics, Dissociative; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Dendrit | 2020 |
Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2020 |
Short - Term Ketamine Administration in Treatment - Resistant Depression: Focus on Cardiovascular Safety.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Immobility-reducing Effects of Ketamine during the Forced Swim Test on 5-HT1A Receptor Activity in the Medial Prefrontal Cortex in an Intractable Depression Model.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Humans; Ketamine; Prefrontal Cortex; | 2020 |
The involvement of PI3K/Akt/mTOR/GSK3β signaling pathways in the antidepressant-like effect of AZD6765.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Drug Combinations; Female; Glycogen Sy | 2020 |
Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Metho | 2020 |
Ketamine, but not guanosine, as a prophylactic agent against corticosterone-induced depressive-like behavior: Possible role of long-lasting pro-synaptogenic signaling pathway.
Topics: Animals; Antidepressive Agents; Corticosterone; Depression; Guanosine; Hindlimb Suspension; Hippocam | 2020 |
Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Humans; Ketamine; Neural Pathways | 2021 |
Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fem | 2021 |
Facilitation of dopamine-dependent long-term potentiation in the medial prefrontal cortex of male rats follows the behavioral effects of stress.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Desipramine; Dopamine; Elevated Plus Maze Test; | 2021 |
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Happiness and Treatment Outcome in Resistant Depression.
Topics: Depression; Happiness; Humans; Ketamine; Psychometrics; Treatment Outcome | 2020 |
Rapid-acting and long-lasting antidepressant-like action of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling.
Topics: Animals; Antidepressive Agents; Azepines; Behavior, Animal; Benzamides; Depression; Disease Models, | 2021 |
Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor.
Topics: Brain-Derived Neurotrophic Factor; Depression; Humans; Ketamine; Plasma; Vascular Endothelial Growth | 2021 |
Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: Reversal by ketamine.
Topics: Analgesics; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models | 2021 |
Copper and anti-anhedonic effect of ketamine in treatment-resistant depression.
Topics: Copper; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ke | 2020 |
Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Imipramine; Ketamine; Male; Memory, S | 2021 |
The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.
Topics: Amino Acids; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Excitatory Amino Ac | 2021 |
Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Topics: Adult; Antidepressive Agents; Anxiety; Anxiety Disorders; Comorbidity; Depression; Depressive Disord | 2021 |
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
Topics: Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Huma | 2021 |
Perspectives of Ketamine Use in COVID-19 Patients.
Topics: Anesthesia; Anxiety; COVID-19; COVID-19 Drug Treatment; Critical Care; Depression; Hemodynamics; Hos | 2021 |
Ketamine for Depression in Older Adults.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Sex- and stress-dependent effects of a single injection of ketamine on open field and forced swim behavior.
Topics: Animals; Depression; Depressive Disorder, Major; Female; Ketamine; Male; Mice; Mice, Inbred C57BL; S | 2021 |
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression.
Topics: Administration, Oral; Depression; Humans; Ketamine; Nasal Sprays; Standard of Care | 2021 |
Comments to Drs. Bahji, Vazquez, and Zarate.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Letter to the editor - Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; | 2021 |
Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression.
Topics: Amygdala; Antidepressive Agents; Depression; Depressive Disorder, Major; Gyrus Cinguli; Humans; Keta | 2021 |
Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine.
Topics: Biomarkers; Clinical Trials as Topic; Depression; Humans; Ketamine; Suicidal Ideation; Suicide, Atte | 2021 |
Proteome profile of telencephalon associates attenuated neurogenesis with chronic stress induced mood disorder phenotypes in zebrafish model.
Topics: Affect; Animals; Antidepressive Agents; Anxiety; Cell Proliferation; Depression; Disease Models, Ani | 2021 |
The Future of Ketamine in the Treatment of Teen Depression.
Topics: Adolescent; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ket | 2021 |
Letter to the editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of lightness are not the same - A comment on Acevedo-Diaz et al.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Single Subcutaneous Ketamine Dose Followed by Oral Ketamine for Depression Symptoms in Hospice Patients: A Case Series.
Topics: Administration, Oral; Antidepressive Agents; Depression; Hospices; Humans; Ketamine | 2021 |
Heart rate as a predictor of ketamine's fast-acting antidepressant response.
Topics: Antidepressive Agents; Depression; Heart Rate; Humans; Ketamine | 2021 |
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Ketamine; Mice | 2021 |
A single administration of ascorbic acid rapidly reverses depressive-like behavior and hippocampal synaptic dysfunction induced by corticosterone in mice.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Corticosterone; Dendritic Spines; Depression; Female; | 2021 |
Ketamine Metabolite (2
Topics: Antidepressive Agents; Depression; Ketamine; Receptors, Opioid, kappa | 2021 |
A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration.
Topics: Depression; Depressive Disorder, Treatment-Resistant; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus | 2021 |
Ketamine, but not fluoxetine, rapidly rescues corticosterone-induced impairments on glucocorticoid receptor and dendritic branching in the hippocampus of mice.
Topics: Animals; Corticosterone; Depression; Fluoxetine; Hippocampus; Ketamine; Mice; Receptors, Glucocortic | 2021 |
Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2021 |
Intranasal administration of transforming growth factor-β1 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: A role of TrkB signaling.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depre | 2021 |
Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model.
Topics: Animals; Antidepressive Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dentate Gyrus; D | 2021 |
Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al.
Topics: Analgesics, Opioid; Antidepressive Agents; Depression; Ketamine | 2021 |
R (-)-methoxetamine exerts rapid and sustained antidepressant effects and fewer behavioral side effects relative to S (+)-methoxetamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclohexanones; Cyclohexylamines; | 2021 |
Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitatory Amino A | 2021 |
A low-dose combination of ketamine and guanosine counteracts corticosterone-induced depressive-like behavior and hippocampal synaptic impairments via mTORC1 signaling.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Corticosterone; Depression; Dose-Re | 2021 |
Ketamine Modulates the Neural Correlates of Reward Processing in Unmedicated Patients in Remission From Depression.
Topics: Antidepressive Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Female; Humans; K | 2022 |
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?
Topics: Adult; Depression; Depressive Disorder, Major; Humans; Ketamine; Sleep; Suicidal Ideation | 2022 |
Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cannabidiol; Depression; Disease Models, Animal; H | 2021 |
Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
Gut microbiota is involved in the antidepressant-like effect of (S)-norketamine in an inflammation model of depression.
Topics: Animals; Antidepressive Agents; Bacteria; Depression; Disease Models, Animal; Gastrointestinal Micro | 2021 |
Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; E | 2021 |
Resting-State Functional Magnetic Resonance Imaging Reveals Neuroplasticity After Repeated Treatment With Ketamine in Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Magnetic Resonance Imaging; | 2021 |
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic.
Topics: Adult; COVID-19; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; H | 2021 |
Novel approaches to estimate prefrontal synaptic strength in vivo in humans: of relevance to depression, schizophrenia, and ketamine.
Topics: Depression; Humans; Ketamine; Prefrontal Cortex; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2022 |
Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Guanosine; Hippocampus; Inflammasome | 2021 |
Ketamine treatment for depression: A model of care.
Topics: Antidepressive Agents; Australia; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2021 |
Ketamine and ECT: better alone than together?
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Electroconvulsive Therapy | 2017 |
The practicalities and ethics of ketamine for depression.
Topics: Depression; Depressive Disorder; Humans; Ketamine | 2017 |
Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [
Topics: Adult; Antidepressive Agents; Brain; Carbon Radioisotopes; Case-Control Studies; Depression; Depress | 2018 |
Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications.
Topics: Adverse Drug Reaction Reporting Systems; Analgesics; Anti-Bacterial Agents; Anti-Inflammatory Agents | 2017 |
Antidepressant drugs for beta amyloid-induced depression: A new standpoint?
Topics: Amyloid beta-Peptides; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Dep | 2017 |
Focused microwave irradiation-assisted immunohistochemistry to study effects of ketamine on phospho-ERK expression in the mouse brain.
Topics: Animals; Antidepressive Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP Respo | 2017 |
Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine.
Topics: Analgesics; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Dis | 2017 |
Ketamine for the Treatment of Depression-Reply.
Topics: Consensus; Depression; Depressive Disorder, Major; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Depression; Depressive Disorder, Major; Diseas | 2017 |
Risk Factors of Lower Urinary Tract Syndrome among Ketamine Users.
Topics: Adult; Analgesics; Comorbidity; Cross-Sectional Studies; Cystitis, Interstitial; Depression; Female; | 2018 |
Ketamine-ECT Study - Author's reply.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Electroconvulsive Therapy | 2017 |
Ketamine-ECT Study.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Electroconvulsive Therapy | 2017 |
Depression in chronic ketamine users: Sex differences and neural bases.
Topics: Anesthetics, Dissociative; Depression; Female; Gyrus Cinguli; Humans; Ketamine; Magnetic Resonance I | 2017 |
Cortical functional hyperconnectivity in a mouse model of depression and selective network effects of ketamine.
Topics: Animals; Antidepressive Agents; Aspartic Acid; Behavior, Animal; Cerebral Cortex; Depression; Diseas | 2017 |
Cortex-wide optical imaging and network analysis of antidepressant effects.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Ketamine; M | 2017 |
What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments?
Topics: Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2017 |
Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Gastrointestinal Microbiome; Ket | 2017 |
Ketamine's antidepressant effect is mediated by energy metabolism and antioxidant defense system.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adenylate Kinase; Animals; Antidepressive Agents; Ant | 2017 |
Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Excitatory | 2018 |
VGF function in depression and antidepressant efficacy.
Topics: Adult; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Dis | 2018 |
Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
Topics: Animals; Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid | 2018 |
Acute Amino Acid d-Serine Administration, Similar to Ketamine, Produces Antidepressant-like Effects through Identical Mechanisms.
Topics: Animals; Antidepressive Agents; Apoptosis; Brain; Brain-Derived Neurotrophic Factor; Cyclic AMP-Depe | 2017 |
Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Ketamine; Magnetic Resonance Spe | 2018 |
Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine.
Topics: Animals; Antidepressive Agents; Depression; Injections, Intraperitoneal; Ketamine; Mice, Inbred C57B | 2017 |
Behavioral and biochemical sensitivity to low doses of ketamine: Influence of estrous cycle in C57BL/6 mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Estradiol; Estrogens; Estrous Cycle; F | 2018 |
The rapid-onset antidepressant effect of ketamine: More surprises?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Drug Discovery; Humans; Ketamine; Rec | 2018 |
Protein kinase Mζ in medial prefrontal cortex mediates depressive-like behavior and antidepressant response.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Excitatory | 2018 |
BDNF release and signaling are required for the antidepressant actions of GLYX-13.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Ketamine; Male; Membr | 2018 |
Sleep as an Underused Target for Rapid Response in the Treatment of Depression and Suicidal Ideation.
Topics: Anesthetics, Dissociative; Deep Brain Stimulation; Depression; Humans; Ketamine; Sleep Deprivation; | 2016 |
Both ketamine and NBQX attenuate alcohol drinking in male Wistar rats.
Topics: Alcohol Drinking; Animals; Depression; Kainic Acid; Ketamine; Male; Quinoxalines; Rats, Wistar; Rece | 2018 |
Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?
Topics: Animals; Antidepressive Agents; Depression; Helplessness, Learned; Ketamine; Rats | 2018 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine.
Topics: Animals; Antidepressive Agents; Brain; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Depressio | 2018 |
What Are the Causes for Discrepancies of Antidepressant Actions of (2R,6R)-Hydroxynorketamine?
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Topics: Action Potentials; Affect; Anhedonia; Animals; Antidepressive Agents; Calcium Channel Blockers; Calc | 2018 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Brain-wide Electrical Spatiotemporal Dynamics Encode Depression Vulnerability.
Topics: Animals; Brain; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Depression; Disease Models, Anim | 2018 |
Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.
Topics: Animals; Antidepressive Agents; Brain; Chromatography, Liquid; Depression; Disease Models, Animal; I | 2018 |
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Blood Pressure; Depression; Depressive Disorder; E | 2018 |
Ketamine: Quo Vadis?
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Suicidal Ideation | 2018 |
Ventral CA3 Activation Mediates Prophylactic Ketamine Efficacy Against Stress-Induced Depressive-like Behavior.
Topics: Animals; Behavior Rating Scale; CA3 Region, Hippocampal; Conditioning, Classical; Depression; Fear; | 2018 |
Can a Framework Be Established for the Safe Use of Ketamine?
Topics: Depression; Depressive Disorder; Double-Blind Method; Humans; Ketamine; Substance-Related Disorders; | 2018 |
Ketamine differentially restores diverse alterations of neuroligins in brain regions in a rat model of neuropathic pain-induced depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2018 |
Adjunctive Intranasal Esketamine in Treatment-Resistant Depression-Reply.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resist | 2018 |
Adjunctive Intranasal Esketamine in Treatment-Resistant Depression.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resist | 2018 |
NMDAR-independent, cAMP-dependent antidepressant actions of ketamine.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cell Line; Cyclic AMP; Cyclic AMP Response | 2019 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Dendritic Spines; Depression; Hip | 2018 |
Ketamine and rapidly acting antidepressants: Breaking the speed of sound or light?
Topics: Antidepressive Agents; Depression; Humans; Ketamine; Time Factors | 2018 |
Anesthetics alleviate learning and memory impairment induced by electroconvulsive shock by regulation of NMDA receptor-mediated metaplasticity in depressive rats.
Topics: Anesthetics; Animals; Behavior, Animal; Cognitive Dysfunction; Depression; Disease Models, Animal; E | 2018 |
Is (S)-norketamine an alternative antidepressant for esketamine?
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine | 2019 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
Rapid antidepressant effect of S-ketamine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Depression; Female; Humans; Ket | 2018 |
The best defense is a strong offense: preventing alcohol abstinence-induced depression.
Topics: Alcohol Abstinence; Depression; Depressive Disorder; Ethanol; Humans; Ketamine | 2018 |
The behavioral study on the interactive aggravation between pruritus and depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Chloroquine; Depression; Depressive Disorder; Dise | 2018 |
Single administration of agmatine reverses the depressive-like behavior induced by corticosterone in mice: Comparison with ketamine and fluoxetine.
Topics: Agmatine; Animals; Antidepressive Agents; Brain; Corticosterone; Depression; Disks Large Homolog 4 P | 2018 |
Early life stress leads to sex differences in development of depressive-like outcomes in a mouse model.
Topics: Age Factors; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; F | 2019 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depre | 2019 |
Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Bipolar Disorder; China; Chromatography, | 2018 |
Ketamine ameliorates depressive-like behaviors by tPA-mediated conversion of proBDNF to mBDNF in the hippocampus of stressed rats.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depres | 2018 |
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Met | 2020 |
Essential roles of neuropeptide VGF regulated TrkB/mTOR/BICC1 signaling and phosphorylation of AMPA receptor subunit GluA1 in the rapid antidepressant-like actions of ketamine in mice.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Gene Knockdown Techni | 2018 |
Lucy in the sky with ketamine: Psychoactive drugs have potential for a major breakthrough in treating depression.
Topics: Antidepressive Agents; Depression; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Off- | 2018 |
Case Report: Ketamine for Pain and Depression in Advanced Cancer.
Topics: Analgesics; Depression; Humans; Ketamine; Male; Middle Aged; Neoplasms; Pain; Treatment Outcome | 2018 |
Ketamine and depression: A special kase for kynurenic acid?
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Kynurenic Acid; K | 2019 |
Ketamine and depression.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Catecholamines; Depression; Humans; Ketamine; Recep | 2018 |
NMDA Antagonists for Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; N-Methylaspartate; Pilot Projects | 2019 |
Ketamine may exert antidepressant effects via suppressing NLRP3 inflammasome to upregulate AMPA receptors.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antidepressive Agents; Depression; Excitatory Amino Acid A | 2019 |
Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Disease Models, A | 2019 |
VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dep | 2019 |
Role of Actinobacteria and Coriobacteriia in the antidepressant effects of ketamine in an inflammation model of depression.
Topics: Actinobacteria; Animals; Antidepressive Agents; Behavior, Animal; Biomarkers; Depression; Depressive | 2019 |
Lack of Opioid System in the Antidepressant Actions of Ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Ketamine; Lipopolysaccharides; Male; M | 2019 |
Choosing the Primary Outcome in Electroconvulsive Therapy Trials and the Art of Asking When, Besides What.
Topics: Anesthesia; Depression; Depressive Disorder; Electroconvulsive Therapy; Humans; Ketamine | 2019 |
Ketamine for suicidal ideation treatment: Available evidence remains convincing.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2019 |
Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.
Topics: Amino Acids; Animals; Antidepressive Agents; Azepines; Benzamides; Depression; Depressive Disorder; | 2019 |
Ketamine improved depressive-like behaviors via hippocampal glucocorticoid receptor in chronic stress induced- susceptible mice.
Topics: Animals; Anxiety; Corticosterone; Depression; Depressive Disorder; Disease Models, Animal; Gene Expr | 2019 |
A response to: Repeated intranasal ketamine for treatment resistant depression: The way to go? Results from a pilot randomised controlled trial.
Topics: Analgesics; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pilot Projects | 2019 |
A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression - the way to go? Results from a pilot randomised controlled trial.
Topics: Analgesics; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pilot Projects | 2019 |
Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora.
Topics: Antidepressive Agents; Depression; Ketamine; Narcotic Antagonists; Receptors, Opioid | 2019 |
Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine.
Topics: Antidepressive Agents; Depression; Ketamine; Narcotic Antagonists; Receptors, Opioid | 2019 |
Depression-like state behavioural outputs may confer beneficial outcomes in risky environments.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Behavior, Animal; Depression; Ketamine; O | 2019 |
Acute ketamine administration attenuates lipopolysaccharide-induced depressive-like behavior by reversing abnormal regional homogeneity in the nucleus accumbens.
Topics: Animals; Antidepressive Agents; Depression; Ketamine; Lipopolysaccharides; Male; Nucleus Accumbens; | 2019 |
Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Depression; Female; Glutamine; Ketamine; Ma | 2019 |
(
Topics: Amino Acids; Animals; Antidepressive Agents; Behavior, Animal; Bridged Bicyclo Compounds, Heterocycl | 2019 |
The Altered-State-of-Consciousness Aspect of a Feeling of Lightness Is Reported to Be Associated with Antidepressant Benefits by Depressed Individuals Receiving Ketamine Infusions: A Systematic Analysis of Internet Video Testimonials.
Topics: Anesthetics, Dissociative; Consciousness; Depression; Humans; Ketamine; Social Media | 2019 |
The novel methoxetamine analogs N-ethylnorketamine hydrochloride (NENK), 2-MeO-N-ethylketamine hydrochloride (2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride (4-MeO-NEK) elicit rapid antidepressant effects via activation of AMPA and 5-HT
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cycloh | 2019 |
Anti-depressant effects of oil from fructus gardeniae via PKA-CREB-BDNF signaling.
Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Pr | 2019 |
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Topics: Anesthetics; Animals; Antidepressive Agents; Behavior, Animal; Depression; Dose-Response Relationshi | 2019 |
Prophylactic Ketamine Treatment Promotes Resilience to Chronic Stress and Accelerates Recovery: Correlation with Changes in Synaptic Plasticity in the CA3 Subregion of the Hippocampus.
Topics: Animals; Antidepressive Agents; Behavior, Animal; CA3 Region, Hippocampal; Depression; Disease Model | 2019 |
Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system.
Topics: Animals; Antidepressive Agents; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Dep | 2019 |
Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.
Topics: Animals; Antidepressive Agents; Biomarkers; Bone Density; Depression; Depressive Disorder; Disease M | 2019 |
Stress-sensitive antidepressant-like effects of ketamine in the mouse forced swim test.
Topics: Animals; Behavior, Animal; Depression; Humans; Ketamine; Male; Mice; Stress, Psychological; Swimming | 2019 |
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive | 2019 |
Rigorous Translational Models Are Key to Studying Ketamine's Antidepressant Mechanism: Response to Wang and Kaplin.
Topics: Antidepressive Agents; Depression; Ketamine; Narcotic Antagonists; Receptors, Opioid | 2019 |
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect-Reply.
Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid | 2019 |
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect.
Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid | 2019 |
Subanesthetic Dose of Ketamine Improved CFA-induced Inflammatory Pain and Depression-like Behaviors Via Caveolin-1 in Mice.
Topics: Analgesics; Animals; Behavior, Animal; Caveolin 1; Depression; Disease Models, Animal; Freund's Adju | 2020 |
A Word to the Wise About Intranasal Esketamine.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Double-Blind Method; Ketamine; Nasal | 2019 |
Potential differences in antidepressant effects of oral ketamine liquid suspension versus compounded capsules.
Topics: Antidepressive Agents; Capsules; Depression; Double-Blind Method; Humans; Ketamine; Outpatients | 2019 |
TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cerebellar Cortex; Depression; De | 2019 |
Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine.
Topics: Animals; Antidepressive Agents; Depression; Dorsal Raphe Nucleus; Glutamic Acid; Ketamine; Male; Mot | 2019 |
Oral ketamine alleviates behavioral despair without cognitive impairment in Wistar rats.
Topics: Administration, Oral; Animals; Antidepressive Agents; Behavior, Animal; Brain; Cognitive Dysfunction | 2019 |
Differences between ketamine's short-term and long-term effects on brain circuitry in depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Cerebrum; Connectome; Depression; | 2019 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Harnessing Neuroimaging to Enhance Our Understanding of the Effects of Ketamine in Depression.
Topics: Brain; Depression; Depressive Disorder; Humans; Ketamine; Neuroimaging | 2019 |
What role does the (2R,6R)-hydronorketamine metabolite play in the antidepressant-like and abuse-related effects of (R)-ketamine?
Topics: Antidepressive Agents; Depression; Ketamine | 2019 |
Potential link between antidepressant-like effects of ketamine and promotion of adult neurogenesis in the ventral hippocampus of mice.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Dentate Gyrus; Depression; Excita | 2019 |
Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Glycine; Inflammation; Ketamine; | 2019 |
Depression researchers rethink popular mouse swim tests.
Topics: Animal Rights; Animals; Animals, Laboratory; Depression; Disease Models, Animal; Ketamine; Learning; | 2019 |
The effects of sub-anesthetic ketamine plus ethanol on behaviors and apoptosis in the prefrontal cortex and hippocampus of adolescent rats.
Topics: Anesthetics, Dissociative; Animals; Anxiety; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal | 2019 |
Considerations for use of ketamine to treat depression in Australia and New Zealand.
Topics: Australia; Depression; Depressive Disorder, Treatment-Resistant; Drug and Narcotic Control; Excitato | 2019 |
The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats.
Topics: Animals; Antidepressive Agents; Depression; Ketamine; Male; Methadone; Rats; Rats, Sprague-Dawley; R | 2020 |
Effect of ketamine combined with DHA on lipopolysaccharide-induced depression-like behavior in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP Resp | 2019 |
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonist | 2013 |
Relationship between cognitive impairment and depressive symptoms in current ketamine users.
Topics: Adolescent; Adult; Analysis of Variance; Case-Control Studies; Cognition Disorders; Cross-Sectional | 2013 |
NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice.
Topics: Animals; Antidepressive Agents; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Cytokines; De | 2013 |
microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents; Computational Biology; Depre | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats.
Topics: Age Factors; Animals; Antidepressive Agents; Anxiety; Depression; Excitatory Amino Acid Antagonists; | 2013 |
Bladder calcification secondary to ketamine.
Topics: Adult; Biopsy; Calcinosis; Cystoscopy; Depression; Diagnosis, Differential; Excitatory Amino Acid An | 2013 |
Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression.
Topics: Animals; Depression; Ketamine; Lipopolysaccharides; Male; Receptors, N-Methyl-D-Aspartate | 2013 |
Cognitive impairments in poly-drug ketamine users.
Topics: Anxiety; Case-Control Studies; Cognition Disorders; Depression; Excitatory Amino Acid Antagonists; E | 2013 |
Scopolamine and ketamine: evidence of convergence?
Topics: Animals; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mal | 2013 |
Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model.
Topics: Animals; Anxiety; Chickens; Depression; Disease Models, Animal; Ketamine | 2013 |
Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: an 11.7 T 1H-MRS study in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Chromatography, High Pressure Liquid; Depressi | 2014 |
Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Fluoxetine; Ketamin | 2014 |
Current drug development for antidepressants and ideas addressing downstream glutamate: the ketamine example.
Topics: Animals; Antidepressive Agents; Depression; Drug Discovery; Glutamic Acid; Humans; Ketamine | 2014 |
Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine.
Topics: Animals; Antidepressive Agents; Brain; Depression; Down-Regulation; gamma-Aminobutyric Acid; Glutama | 2014 |
Rapid antidepressant effects and abuse liability of ketamine.
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate; Subst | 2014 |
Effects of low-dose ketamine combined with propofol on phosphorylation of AMPA receptor GluR1 subunit and GABAA receptor in hippocampus of stressed rats receiving electroconvulsive shock.
Topics: Animals; Antidepressive Agents; Depression; Electroconvulsive Therapy; Hippocampus; Ketamine; Male; | 2015 |
Downregulation of neuregulin 1-ErbB4 signaling and antidepressant properties of ketamine: ErbB4 expressing pyramidal neurons may play a role.
Topics: Animals; Antidepressive Agents; Brain; Depression; Interneurons; Ketamine; Male; Neuregulin-1; Recep | 2015 |
Rapid resolution of suicidal behavior and depression with single low-dose ketamine intravenous push even after 6 months of follow-up.
Topics: Adult; Depression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Injections, Intraven | 2014 |
Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.
Topics: Adaptation, Psychological; Amino Acids; Animals; Antidepressive Agents; Depression; Disease Models, | 2014 |
Combination therapy utilizing ketamine and transcranial magnetic stimulation for treatment-resistant depression: a case report.
Topics: Anesthetics, Dissociative; Combined Modality Therapy; Depression; Female; Humans; Ketamine; Psychiat | 2015 |
Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity.
Topics: Action Potentials; Animals; Antidepressive Agents; Benzazepines; Brain; Depression; Disease Models, | 2014 |
Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Anesthetics, Dissociative; Attention; Cognition; Depression; Female; Follow | 2014 |
Enhancing ketamine translational pharmacology via receptor occupancy normalization.
Topics: Animals; Depression; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Ketamine; Macaca fascic | 2014 |
Effects of single and combined gabapentin use in elevated plus maze and forced swimming tests.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Anxiety; Cyclohexanecarboxylic Acids; Depression; D | 2014 |
GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Depression; Excitatory Postsynapt | 2014 |
Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Female; Interleukin-1; Interleukin-6; Ketamin | 2015 |
Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Arginine; Behavior, Animal; Cyclic GMP; D | 2015 |
How ketamine helps to overcome depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Ketamine; Receptors, N-Methyl-D-Aspart | 2014 |
The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.
Topics: Affect; Animals; Antidepressive Agents; Antimanic Agents; Antioxidants; Behavior, Animal; Brain-Deri | 2014 |
Reasons to be cheerful.
Topics: Anti-Bacterial Agents; Depression; Depsipeptides; Drug Discovery; Drug Resistance, Microbial; Humans | 2015 |
Rave drug tested against depression.
Topics: Antidepressive Agents; Brain; Clinical Trials as Topic; Depression; Glutamic Acid; Humans; Ketamine; | 2015 |
[Inhibition of HCN1 channels by ketamine accounts for its antidepressant actions].
Topics: Animals; Antidepressive Agents; Depression; Hippocampus; Hyperpolarization-Activated Cyclic Nucleoti | 2014 |
Ketamine treatment partly reverses alterations in brain derived- neurotrophic factor, oxidative stress and energy metabolism parameters induced by an animal model of depression.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Creatine Kinase; | 2015 |
Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A₁ and A2A receptor activation.
Topics: Adenosine; Animals; Antidepressive Agents; Creatine; Depression; Excitatory Amino Acid Antagonists; | 2015 |
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Dextromethorphan; | 2015 |
Study of antidepressant drugs in GPR39 (zinc receptor⁻/⁻) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Excitatory Amino Acid A | 2015 |
Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.
Topics: Antidepressive Agents; Benzodiazepines; Clinical Trials as Topic; Depression; Depressive Disorder, T | 2015 |
Ketamine-mediated alleviation of electroconvulsive shock-induced memory impairment is associated with the regulation of neuroinflammation and soluble amyloid-beta peptide in depressive-like rats.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Calcium-Binding Proteins; Depression; Elec | 2015 |
Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior.
Topics: Animals; Antidepressive Agents; Anxiety; Corticosterone; Depression; Fear; Helplessness, Learned; Ke | 2016 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
The effect of imipramine, ketamine, and zinc in the mouse model of depression.
Topics: Animals; Antidepressive Agents, Tricyclic; Depression; Dexamethasone; Dose-Response Relationship, Dr | 2015 |
Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Antidepressive Agents; C-Reactive Protei | 2015 |
The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cytokines; Depression; Disease Models, Animal; Dow | 2015 |
The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN.
Topics: Amino Acids; Animals; Antidepressive Agents; Depression; Dorsal Raphe Nucleus; Fenclonine; Ketamine; | 2016 |
Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a.
Topics: Animals; Carrier Proteins; Depression; Homer Scaffolding Proteins; Humans; Imipramine; Ketamine; Mic | 2015 |
Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Brain; Depression; Dis | 2015 |
Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.
Topics: Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Depression; | 2015 |
Ketamine for depression: the highs and lows.
Topics: Depression; Humans; Ketamine | 2015 |
Despair-associated memory requires a slow-onset CA1 long-term potentiation with unique underlying mechanisms.
Topics: Animals; CA1 Region, Hippocampal; Corticosterone; Depression; Dizocilpine Maleate; Excitatory Amino | 2015 |
Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Hippocampus; Ketamine; Male; Mice; Mic | 2016 |
Brain study seeks roots of suicide.
Topics: Anxiety; Biomarkers; Brain; Case-Control Studies; Depression; Humans; Ketamine; Risk Assessment; Ser | 2015 |
Is ketamine ready to be used clinically for the treatment of depression?
Topics: Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2015 |
Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corticosterone; | 2016 |
Hypoestrogenism alters mood: Ketamine reverses depressive-like behavior induced by ovariectomy in rats.
Topics: Affect; Animals; Antidepressive Agents; Depression; Estrogens; Female; Ketamine; Maze Learning; Ovar | 2016 |
Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking.
Topics: Affect; Alcohol Drinking; Animals; Behavior, Animal; Benzodioxoles; Depression; Endocannabinoids; Et | 2016 |
Time-Course of Depression Improvement With Ketamine Adjunction in Electroconvulsive Therapy.
Topics: Anesthetics, Dissociative; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; Humans | 2016 |
Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder; Female; Humans; Ketamine; Male; Middl | 2016 |
Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation.
Topics: Animals; Antidepressive Agents; Cells, Cultured; Cerebral Cortex; Cysteine; Depression; Disease Mode | 2016 |
Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users.
Topics: Adolescent; Adult; Anxiety; China; Comorbidity; Depression; Excitatory Amino Acid Antagonists; Femal | 2016 |
Instant and Lasting Down-Regulation of NR1 Expression in the Hippocampus is Associated Temporally with Antidepressant Activity After Acute Yueju.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Disease Models, A | 2016 |
Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder.
Topics: Bipolar Disorder; Depression; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Suicidal | 2016 |
Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model.
Topics: Analgesics; Animals; Annexin A2; Antidepressive Agents; Chronic Disease; Depression; Disease Models, | 2016 |
[Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats].
Topics: Animals; Brain; Depression; Depressive Disorder; Disease Models, Animal; Down-Regulation; Imipramine | 2016 |
Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats.
Topics: Anhedonia; Animals; Behavior, Animal; Dendritic Spines; Depression; Disks Large Homolog 4 Protein; E | 2016 |
Hippocampal VEGF is necessary for antidepressant-like behaviors but not sufficient for antidepressant-like effects of ketamine in rats.
Topics: Animals; Antidepressive Agents; Dentate Gyrus; Depression; Excitatory Amino Acid Antagonists; Gene K | 2016 |
Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity.
Topics: Antidepressive Agents; Brain; Depression; Humans; Ketamine | 2016 |
Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats.
Topics: Amino Acids; Animals; Antidepressive Agents; Behavior, Animal; Blotting, Western; Depression; Drug S | 2016 |
N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Respo | 2016 |
Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Depression; Female; Glutamic Acid; Hippocamp | 2016 |
Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Betaine; Depression; Excitatory Amino Acid Antagon | 2016 |
Antinociceptive and Anti-Inflammatory Effects of Ketamine and the Relationship to Its Antidepressant Action and GSK3 Inhibition.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Behavior, Anima | 2016 |
Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Depression; Depressive Disorder, Major; Disease Model | 2016 |
Neurovascular plasticity of the hippocampus one week after a single dose of ketamine in genetic rat model of depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Immobility Response | 2016 |
Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression.
Topics: Amygdala; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Helplessness, Learned; | 2017 |
Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; CA3 Region, Hippocampal; D | 2016 |
Acute single dose of ketamine relieves mechanical allodynia and consequent depression-like behaviors in a rat model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Freund's Adjuv | 2016 |
Interactive effects of ghrelin and ketamine on forced swim performance: Implications for novel antidepressant strategies.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Drug Interactions; Drug Therapy, Co | 2018 |
Ketamine for Depression: An Update.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine | 2016 |
Differential regulation of GluA1 expression by ketamine and memantine.
Topics: Animals; Benzylamines; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Excita | 2017 |
Ketamine's antidepressant action: beyond NMDA receptor inhibition.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Receptors, N-Methyl-D-Aspa | 2016 |
Lack of effect of chronic ketamine administration on depression-like behavior and frontal cortex autophagy in female and male ICR mice.
Topics: Analgesics; Analysis of Variance; Animals; Autophagy; Beclin-1; Depression; Disease Models, Animal; | 2017 |
Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Glycogen Synth | 2017 |
Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Depression; Discrimination Learning; Disease Mo | 2017 |
Hippocampal Perineuronal Nets Are Required for the Sustained Antidepressant Effect of Ketamine.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Chondroitinases and Chondroitin Lyases; Depres | 2017 |
S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression.
Topics: Animals; Depression; Disease Models, Animal; Hippocampus; Immobility Response, Tonic; Ketamine; Male | 2017 |
Breaking Sad: Unleashing the Breakthrough Potential of Ketamine's Rapid Antidepressant Effects.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depression; Drug Discovery; Humans; Ketamine; Recep | 2016 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Sub-anesthetic doses of ketamine exert antidepressant-like effects and upregulate the expression of glutamate transporters in the hippocampus of rats.
Topics: Amino Acid Transport System X-AG; Anesthetics; Animals; Antidepressive Agents; Behavior, Animal; Dep | 2017 |
Antidepressant Potential of (
Topics: Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Hindlimb Suspension; K | 2017 |
Ketamine: Future Treatment For Unresponsive Depression?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ireland; Ketami | 2016 |
Reduction in Suicidal Ideation Following Repeated Doses of Intravenous Ketamine?
Topics: Administration, Intravenous; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Idea | 2017 |
Structural Integrity in the Sustained Antidepressant Effect of Ketamine.
Topics: Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Ketamine; Swimming | 2017 |
Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015.
Topics: Antidepressive Agents; Canada; Depression; Humans; Ketamine; Mass Media; Mental Health; United State | 2017 |
Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Conditioning, Operant; Depression; Disease Models, | 2017 |
Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Disease | 2009 |
Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Brain; Creatine Kinase; Depression; Dose-Response Relatio | 2009 |
Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series.
Topics: Administration, Oral; Adult; Depression; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine | 2010 |
Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine.
Topics: Anesthetics, Dissociative; Antidepressive Agents, Tricyclic; Depression; Desipramine; Dose-Response | 2010 |
Propofol pretreatment increases antidepressant-like effects induced by acute administration of ketamine in rats receiving forced swimming test.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Topics: Animals; Antidepressive Agents; Dendritic Spines; Depression; Intracellular Signaling Peptides and P | 2010 |
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Topics: Animals; Antidepressive Agents; Dendritic Spines; Depression; Intracellular Signaling Peptides and P | 2010 |
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Topics: Animals; Antidepressive Agents; Dendritic Spines; Depression; Intracellular Signaling Peptides and P | 2010 |
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Topics: Animals; Antidepressive Agents; Dendritic Spines; Depression; Intracellular Signaling Peptides and P | 2010 |
The use of a series of ketamine infusions in two patients with treatment-resistant depression.
Topics: Analgesics; Depression; Drug Administration Schedule; Humans; Hypoglycemic Agents; Ketamine; Male; M | 2010 |
Ketamine: a fast-acting antidepressant?
Topics: Analgesics; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Humans; Ketamine; T | 2010 |
Cracking the moody brain: lifting the mood with ketamine.
Topics: Antidepressive Agents; Depression; Glutamic Acid; Humans; Ketamine; Models, Neurological; Protein Bi | 2010 |
Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Elemen | 2011 |
Ketamine alleviates fear, depression, and suicidal ideation in terminally ill patients.
Topics: Analgesics; Depression; Fear; Humans; Ketamine; Suicidal Ideation; Terminally Ill | 2011 |
Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.
Topics: Amino Acid Substitution; Animals; Antidepressive Agents; Cerebral Cortex; Depression; Disease Models | 2011 |
Be prudent of ketamine in treating resistant depression in patients with cancer.
Topics: Analgesics; Depression; Humans; Ketamine; Neoplasms; Patients | 2011 |
Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Respo | 2011 |
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2011 |
Blocking NMDA receptor at rest: a possible alleviation of depression.
Topics: Animals; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine; Rec | 2011 |
Depression and pain: does ketamine improve the quality of life of patients in chronic pain by targeting their mood?
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Depression; Ketamine; Male; Neuralgia | 2011 |
The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; | 2012 |
Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.
Topics: Amino Acids; Analysis of Variance; Animals; Bridged Bicyclo Compounds; Depression; Dicarboxylic Acid | 2011 |
Acute D-serine treatment produces antidepressant-like effects in rodents.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Calcium-Calmodulin-Dependent Protein Kinase Ty | 2012 |
A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Behavior, Animal; Cold Temperature; Corti | 2011 |
Antidepressant-like effects of methanol extract of Hibiscus tiliaceus flowers in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, A | 2012 |
Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Female; Hippoc | 2012 |
Effects of ketamine in treatment-refractory obsessive-compulsive disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2012 |
Involvement of NMDA receptors in the antidepressant-like action of adenosine.
Topics: Adenosine; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Chlorides; Depression; | 2012 |
Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use.
Topics: Adult; Association Learning; Cues; Delusions; Depression; Excitatory Amino Acid Antagonists; Female; | 2013 |
The promise of rapidly acting antidepressants: challenges and opportunities.
Topics: Antidepressive Agents; Depression; Drug Discovery; Humans; Ketamine; N-Methylaspartate | 2012 |
Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients.
Topics: Adult; Antidepressive Agents; Depression; Eukaryotic Initiation Factor-2; Glycogen Synthase Kinase 3 | 2013 |
[Ketamine for treatment of therapy-resistant depression: a case study].
Topics: Anesthetics, Dissociative; Depression; Female; Humans; Ketamine; Middle Aged; Treatment Failure; Tre | 2013 |
GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
Topics: Acoustic Stimulation; Action Potentials; Animals; Antidepressive Agents; Brain; Conditioning, Operan | 2013 |
Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice.
Topics: Animals; Antidepressive Agents; Arginine; Ascorbic Acid; Behavior, Animal; Chlorides; Depression; Di | 2003 |
Behavioral effects of ketamine and toxic interactions with psychostimulants.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Cocaine; Depression; Dose-Res | 2006 |
Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies.
Topics: Adult; Aged; Anesthetics, Dissociative; Depression; Electroconvulsive Therapy; Etomidate; Female; Hu | 2006 |
Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies.
Topics: Adult; Aged; Anesthetics, Dissociative; Depression; Electroconvulsive Therapy; Etomidate; Female; Hu | 2006 |
Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies.
Topics: Adult; Aged; Anesthetics, Dissociative; Depression; Electroconvulsive Therapy; Etomidate; Female; Hu | 2006 |
Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies.
Topics: Adult; Aged; Anesthetics, Dissociative; Depression; Electroconvulsive Therapy; Etomidate; Female; Hu | 2006 |
Depression: comfortably numb.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Child; Controlled Clinical Trials as Topi | 2006 |
Substance use and related problems: a study on the abuse of recreational and not recreational drugs in Northern Italy.
Topics: Accidents, Traffic; Adult; Alcoholism; Amphetamines; Anxiety; Crack Cocaine; Depression; Female; Hal | 2006 |
Ketamine and the potential role for rapid-acting antidepressant medications.
Topics: Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine; Receptors, N | 2007 |
Lack of persistent effects of ketamine in rodent models of depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Apomorphine; Cerebral Cortex; Depr | 2008 |
Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice.
Topics: Animals; Depression; Dizocilpine Maleate; Drug Synergism; Electroshock; Excitatory Amino Acid Antago | 2001 |
Ketamine-facilitated induced anxiety therapy and its effect upon clients' reactions to stressful situations.
Topics: Adaptation, Psychological; Adolescent; Adult; Affect; Anxiety; Arousal; Depression; Female; Humans; | 1979 |
Epilepsy or anesthesia with ketamine.
Topics: Anesthesia; Anesthetics; Animals; Cataplexy; Cats; Central Nervous System; Cyclohexanes; Depression; | 1972 |
Ketamine ("Ketalar"): a safer anaesthetic for ECT.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Anesthesia, Intravenous; Anesthetics; Cyclohexanes; De | 1972 |